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Abstract 
 
The ability of the immune system to discriminate between ‘self’ and ‘non-self’ is critical to ensure 
proper immune responses towards foreign substances while simultaneously maintaining self-
tolerance. Defects in immunological tolerance to self-components are a characteristic for 
autoimmune diseases, which affect numerous people worldwide. In recent years, the role of B cells 
in the pathogenesis of several autoimmune diseases, such as rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE) and multiple sclerosis (MS), has become increasingly apparent. Current 
B cell-directed therapies mainly induce general immune suppression by either inhibiting or 
eliminating the complete B cell compartment, leaving patients at increased risk of infection. Hence, 
the need for more selective B cell therapies that solely target pathogenic autoreactive B cells has 
driven the development of new therapeutic strategies. In this introductory Chapter we provide an 
overview of approaches in the development of antigen-selective immunotherapies selectively 
targeting B cells. At the end of this Chapter, we will focus on B cell-selective targeting strategies 
in rheumatoid arthritis, concluding with the outline of this thesis. 
 
  
1.1 Introduction 
 
One of the cornerstones of the immune system is its ability to discriminate between ‘self’ and ‘non-
self’. This ability ensures the stimulation of proper immune responses towards foreign substances 
while simultaneously maintaining tolerance towards self-components.1,2 Here we will provide an 
introduction on autoimmunity and the involvement of B cells.  
 
B cell development and autoimmunity. B cells are highly specialized cells, functioning in the 
recognition of antigens by binding to cell-surface immunoglobulins, leading to differentiation into 
plasma cells to produce and secrete antibodies to that specific antigen.1, 2 Each B cell expresses 
immunoglobulins to one specific antigen. Additionally, B cells can present antigens (they are also 
classified as antigen-presenting cells (APCs)) and secrete cytokines.  
B cells develop from hematopoietic stem cells originating in the bone marrow (Figure 1). These 
cells differentiate into multipotent progenitor cells and common lymphoid cells, from which B 
cells are derived in several stages.3 During these stages, gene expression patterns are changing as 
are the immunoglobulin heavy and light chain gene rearrangements. Before migrating to the 
periphery, B cells undergo two types of  selection; positive selection, in which the B cell receptor 
(BCR) is tested to recognize a ligand (antigen independent), and negative selection, in which the 
BCR is tested against self-antigens.4 The process of  negative selection is of  great essence for 
central tolerance. Autoreactive B cells which have failed the negative selection can be rescued, 
eliminated or functionally inactivated by various regulatory mechanisms (Figure 1),5 including 
receptor-editing, apoptosis, suppression by regulatory cells and limitations of  survival and growth 
factors, which when defective can lead to a breakdown in tolerance and the development of  
autoimmune diseases.6 The loss of  tolerance is a complex process that involves genetic 
components (e.g. in human leukocyte antigen alleles), most likely combined with environmental 
events (e.g. an infection).7  
 
 
Figure 1. B cell development. Two important checkpoints are implemented to prevent useless or 
autoreactive B cells to move into the periphery. Positive selection includes the checkpoint for the pre-B cell 
receptor (heavy chain rearrangement) and the checkpoint for the BCR, after light chain rearrangement. 
Negative selection includes testing the specificity for self-antigens.  
 
After the negative selection process, the B cells migrate into the spleen and differentiate either into 
follicular (FO) B cells or marginal zone (MZ) B cells. Next, the B cells enter the circulation and 
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bind a specific antigen in lymphoid tissue resulting in mature B cells and differentiation into plasma 
cells.8-10 The immunoglobulin genes of  FO B cells undergo extensive somatic hypermutation and 
isotope switching in germinal centers (GCs), which emerges in the secretion of  different classes 
of  high-affinity antibodies.11 MZ B cells are able to generate antibodies through both T cell-
independent and T cell-dependent pathways.12  
Autoreactive B cells with low-affinity BCRs can escape negative selection and differentiate into 
plasma cells.13 The escaped autoreactive B cells can drive autoimmunity via multiple mechanisms. 
One example is via the formation of  immune complexes in combination with self-antigens. These 
immune complexes can initiate host effector functions via Fc-mediated activation of  the 
complement (soluble proteolytic proteins) cascade.14 An antibody-independent function of  
activated B cells has been revealed by their ability to secrete pro-inflammatory cytokines, such as 
IL-6, IFN-γ, and LTα, in a similar fashion as T cells.15 B cell-derived cytokine release can contribute 
substantially to ongoing autoimmune responses, by regulation of  T cell function and 
inflammation.1 The function of  B cells as antigen-presenting cells is also important, because it 
provides activating and deactivating signals to CD4+ T cells. To do this, B cells express besides 
major histocompatibility complex (MHC) proteins co-stimulatory molecules such as B7 and 
CD40.16 When self-epitopes are presented on MHC class-II, T cells will be activated, expand and 
fulfill their effector functions. B cells contribute to a number of  autoimmune disorders by 
producing autoantibodies. The production of  autoantibodies is suggested to be similar in nature 
to protective antibodies.17 Recognition of  the self-antigen bound by MHC class-II by T cells, co-
stimulatory molecules and the excreted cytokines will activate B cells to differentiate into plasma 
cells and produce the autoantibodies. Binding of  these autoantibodies to tissues or cells will elicit 
an inflammatory response and complement will be activated. This can trigger the destruction of  
these tissues and cells by e.g. the formation of  the membrane-attack complex. Alternatively, the 
cells coated with antibody and complement can be cleared by phagocytes, using either Fc receptors 
or complement receptors. The destruction mechanism of  these tissues will be briefly discussed. 
 
Immunological cell-killing strategies. There are different mechanisms by which the immune 
system induces cell death. One of  these mechanisms is antibody-dependent cellular cytotoxicity 
(ADCC) in which an effector cell actively lyses a target cell (Figure 2A). These effector cells 
recognize the target cells because they are coated with antibodies (a process which is called 
opsonization).16 Although natural killer (NK) cells are the most common cells to clear target cells, 
also eosinophils can mediate ADCC.18 NK cells express FcγRIII, which can bind to the Fc tail of  
the antibody-opsonized cell and induce cell death.19 
Alternatively, the complement system is involved in the elimination of  cells. The complement can 
coat the surface of  bacteria or extracellular virus particles (also called opsonization) which makes 
them more easily phagocytosed. Besides the elimination of  bacterial pathogens, the complement 
is also capable to initiate the elimination of  eukaryotic cells. This occurs by the formation of  a 
membrane-attack complex (MAC), which is initiated by protein C5b. This protein forms a complex 
with proteins C6, C7 and C8. Next, C7 and C8 expose their hydrophobic sites and can subsequently 
be inserted into the membrane. This induces the polymerization of  multiple (up to 16) molecules 
of  C9, resulting in a transmembrane channel which disrupts the plasma membrane and will kill 
the cell (Figure 2B).16 This mechanism is called complement-dependent cytotoxicity (CDC). 
 
 
Figure 2. Immunological cell-killing mechanisms. A) Schematic representation of  ADCC. Antibodies bind 
to an antigen of  the target cells’ membrane. A natural killer cell can bind to the Fc part of  the antibody and 
induce apoptosis; B) Schematic representation of  CDC and MAC formation. Protein C5b binds to C6 and 
C7. C8 is recruited and binds to the membrane. Polymerization of  C9 results in the MAC complex and 
perforates the cell membrane which induces apoptosis. 
 
B cells are considered to play a key role in the pathophysiology of  many autoimmune diseases and 
hence the targeting of  these mechanisms can be beneficial in disease treatment. In this Chapter, 
we will highlight the importance of  the selective targeting of  B cells. The aforementioned 
immunological cell killing strategies can be used for this purpose, but also other strategies will be 
described. We will review the antigen-selective targeting of  B cells as well as the use of  antigen 
conjugates to target the BCR directly. 
 
1.2 Targeting of Autoreactive B Cells 
 
Much research has been performed to elucidate the involvement of  autoreactive B cells in 
autoimmune diseases.20 There is considerable interest in the use of  monoclonal antibodies directed 
against B-cell surface antigens, such as CD20, CD22, CD19 and CD52, as potential therapeutic 
treatment. Monoclonal antibodies to these targets have been investigated for their effectiveness in 
several autoimmune diseases, such as RA, SLE and MS.10 Indirect targeting strategies include 
blocking of  cytokine-signaling as well as intrinsic B cell-activating pathways (such as proteasome 
inhibition). Cytokines provide B cells with signals necessary to maintain their growth and 
differentiation. Deprivation of  these signals, for instance by the anti-BAFF antibody belimumab,21 
affects the function and survival of  B cells. Finally, the agents bortezomib22 and abatacept23 – 
intrinsic proteasome- and co-stimulation inhibitors, respectively – have been clinically approved in 
the treatment of  certain autoimmune disorders.  
All these therapies have one thing in common, their targeting of  general B cell markers and 
properties. No distinction is made between protective and autoreactive B cells, resulting in the loss 
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hence the targeting of  these mechanisms can be beneficial in disease treatment. In this Chapter, 
we will highlight the importance of  the selective targeting of  B cells. The aforementioned 
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described. We will review the antigen-selective targeting of  B cells as well as the use of  antigen 
conjugates to target the BCR directly. 
 
1.2 Targeting of Autoreactive B Cells 
 
Much research has been performed to elucidate the involvement of  autoreactive B cells in 
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inhibition). Cytokines provide B cells with signals necessary to maintain their growth and 
differentiation. Deprivation of  these signals, for instance by the anti-BAFF antibody belimumab,21 
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of  also protective B cells and hence immune deficiency for infectious agents.24 The possibility to 
target specific autoreactive B cells by using the corresponding autoantigen is gaining interest. This 
way of  targeting pathogenic B cells might prevent autoimmune responses without the undesired 
adverse effect of  targeting all B cells.  
 
Targeting of  SIGLEC-G and CD22. Siglecs (sialic acid‐binding immunoglobulin‐like lectins) 
are transmembrane proteins and members of  the immunoglobulin superfamily.25-31 With their 
extracellular ligand binding domain they specifically recognize endogenous sialic acids attached to 
glycoproteins on the cell surface. Multiple Siglecs have been identified, but the only Siglecs 
expressed on B cell surfaces are CD22 and Siglec-G.25, 26 The latter is expressed on mouse B-
lymphocytes and its human orthologue with high sequence homology is Siglec-10.32, 33 These 
Siglecs function as inhibitory co-receptors, when activated they inhibit the BCR signal and promote 
tolerance in B cells (Figure 3).34, 35  
 
 
Figure 3. Influence of  CD22 and Siglec-G/10 on BCR signaling in B cells. A) CD22 homo-oligomers were 
formed by intermolecular sialic acid interactions. Upon BCR activation by antigen binding, CD22 homo-
oligomers are recruited towards the BCR, promoting phosphorylation of  intracellular ITIM domains on 
CD22. SHP-1 recognizes and binds phosphorylated ITIMs, resulting in dampening of  calcium signaling; 
B) A conclusive mechanism for inhibition by Siglec-G/10 is not known. Studies suggest that direct binding 
of  Siglec-G to sialic acids on the BCR promotes recruitment of  Siglecs (CD22) after antigen stimulation. 
Both phosphorylated Siglec-G and Siglec-10 are bound by SHP-1, resulting in suppression of  calcium 
signaling.  
 
The cytoplasmic signaling domain of all three Siglecs carries an immunoreceptor tyrosine-based 
inhibitory motif (ITIM); CD22 even contains several of these motifs.33, 36 These motifs on CD22, 
containing conserved tyrosine residues, are rapidly phosphorylated by the tyrosine kinase Lyn upon 
antigen mediated BCR crosslinking.37 Then SH2-domain-containing tyrosine phosphatase (SHP-
1) is recruited towards phosphorylated ITIMs and becomes activated.38 Subsequently, SHP-1 
dephosphorylates positive activators in the BCR signaling pathway, thereby reducing calcium 
levels, which are the key triggering signals for B cell development and regulation of effector 
functions, in the cell.39-41 For Siglec-G and Siglec-10 similar SHP-1-dependent inhibition 
mechanisms of BCR signaling have been suggested.33, 35 Notably, CD22 is the prominent inhibitory 
co-receptor on B2 cells (conventional B cells, like FO and MZ B cells, developed as described in 
Section 1.1),42 while Siglec-G/10 functions seem to be restricted to the subset of B1 cells (minority 
subset of B cells developed in the prenatal period).35 
Importantly, CD22 in resting B cells is most prominently bound to sialic acids on other, 
neighboring CD22 receptors,43 through which the Siglecs are apparently ‘masked’.44 This so-called 
cis-ligand-binding activity leads to the formation of  homo-oligomers of  CD22 on the cell surface.43 
These oligomers are recruited to the BCR when antigens are bound,45 most likely by protein-
protein interactions.46 The proximity of  CD22 to the BCR seems essential for the inhibitory 
function of  the Siglec,46 as association of  CD22 and BCR promotes phosphorylation of  the 
ITIMs.37 Notably, it has been shown that disruption of  CD22 cis-ligand-binding results in a 
stronger association of  CD22 with the BCR, stronger phosphorylation of  ITIMs and an impaired 
BCR-induced Ca2+ response.45, 47, 48 Additionally, engagement of  CD22 in trans-interactions with 
sialic acids on other cells, seems to enforce ligation of  the Siglecs to the BCR and suppresses BCR 
signaling.49 Co-expression of  self-antigen and sialic acids on target cells thereby promotes tolerance 
towards the respective antigens.50 The role of  competition between both mechanisms – cis- and 
trans-interactions – is not fully understood and remains to be elucidated.51, 52 Furthermore, much 
less is known about the activating mechanism of  Siglec-G.52 It has recently been shown that Siglec-
G is already associated with the BCR in resting B cells.53 Siglec-G has been suggested to directly 
bind to sialic acids on the BCR. Supposedly, this interaction can be further increased upon BCR 
activation.53 
Siglecs are constitutively active on B cells in order to maintain control over immunity and 
tolerance.51, 54 Both CD22-deficient34, 55, 56 and Siglec-G-deficient35 mice do not develop 
autoimmune disease. However, CD22 x Siglec-G double-deficient mice do show an SLE-like 
phenotype and develop glomerulonephritis.57 This clearly demonstrates a complementary role for 
Siglec-G and CD22 in preventing immunity towards self-antigens. CD22 and Siglec-G are 
expressed during all stages of  B cell development.25 Hence, these are potential B cell targets for 
inhibition of  the BCR-mediated response in autoimmune diseases. 
Kelm et al.58 were the first to show that binding of  a ligand to the lectin domain of  CD22 has a 
direct influence on the intracellular inhibitory domain.58 They showed, using synthetic sialosides 
as inhibitors for the lectin domain of  CD22, that tyrosine-phosphorylation of  CD22 and SHP-1 
recruitment was decreased similar to CD22-deficient B cells. In addition, trans-ligand interactions 
have been reported to strongly dampen B cell activation when the target cell, displaying the antigen, 
co-expresses sialoglycoconjugates.50 Courtney et al.59 and Duong et al.60 firstly employed this 
relationship and synthetically designed multivalent carriers, with self-antigens as well as CD22 or 
Siglec-G ligands, to dampen autoantigen specific B cells. Courtney et al.59 used ring-opening 
metathesis polymerization (ROMP) to generate polymers bearing the antigen 2,4-dinitrophenyl 
(DNP), a sialic acid-terminated trisaccharide – a CD22 ligand –, or both recognition elements. The 
density and valency of  both homopolymers and copolymers was chosen to elicit BCR binding and 
signaling.61 Monitoring the intracellular Ca2+ ion concentration in living cells showed that 
stimulation with polymers substituted with only DNP antigens caused a fast rise in calcium 
concentration, whereas polymers substituted with only CD22 ligands had no effect. The 
substituted copolymer, with both CD22 ligand and DNP antigens, did not evoke a calcium 
response, indicating an inhibiting effect by the CD22 ligands. In additional experiments the authors 
showed that co-expression of  both recognition elements on polymers is essential to block B cell-
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subset of B cells developed in the prenatal period).35 
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function of  the Siglec,46 as association of  CD22 and BCR promotes phosphorylation of  the 
ITIMs.37 Notably, it has been shown that disruption of  CD22 cis-ligand-binding results in a 
stronger association of  CD22 with the BCR, stronger phosphorylation of  ITIMs and an impaired 
BCR-induced Ca2+ response.45, 47, 48 Additionally, engagement of  CD22 in trans-interactions with 
sialic acids on other cells, seems to enforce ligation of  the Siglecs to the BCR and suppresses BCR 
signaling.49 Co-expression of  self-antigen and sialic acids on target cells thereby promotes tolerance 
towards the respective antigens.50 The role of  competition between both mechanisms – cis- and 
trans-interactions – is not fully understood and remains to be elucidated.51, 52 Furthermore, much 
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G is already associated with the BCR in resting B cells.53 Siglec-G has been suggested to directly 
bind to sialic acids on the BCR. Supposedly, this interaction can be further increased upon BCR 
activation.53 
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tolerance.51, 54 Both CD22-deficient34, 55, 56 and Siglec-G-deficient35 mice do not develop 
autoimmune disease. However, CD22 x Siglec-G double-deficient mice do show an SLE-like 
phenotype and develop glomerulonephritis.57 This clearly demonstrates a complementary role for 
Siglec-G and CD22 in preventing immunity towards self-antigens. CD22 and Siglec-G are 
expressed during all stages of  B cell development.25 Hence, these are potential B cell targets for 
inhibition of  the BCR-mediated response in autoimmune diseases. 
Kelm et al.58 were the first to show that binding of  a ligand to the lectin domain of  CD22 has a 
direct influence on the intracellular inhibitory domain.58 They showed, using synthetic sialosides 
as inhibitors for the lectin domain of  CD22, that tyrosine-phosphorylation of  CD22 and SHP-1 
recruitment was decreased similar to CD22-deficient B cells. In addition, trans-ligand interactions 
have been reported to strongly dampen B cell activation when the target cell, displaying the antigen, 
co-expresses sialoglycoconjugates.50 Courtney et al.59 and Duong et al.60 firstly employed this 
relationship and synthetically designed multivalent carriers, with self-antigens as well as CD22 or 
Siglec-G ligands, to dampen autoantigen specific B cells. Courtney et al.59 used ring-opening 
metathesis polymerization (ROMP) to generate polymers bearing the antigen 2,4-dinitrophenyl 
(DNP), a sialic acid-terminated trisaccharide – a CD22 ligand –, or both recognition elements. The 
density and valency of  both homopolymers and copolymers was chosen to elicit BCR binding and 
signaling.61 Monitoring the intracellular Ca2+ ion concentration in living cells showed that 
stimulation with polymers substituted with only DNP antigens caused a fast rise in calcium 
concentration, whereas polymers substituted with only CD22 ligands had no effect. The 
substituted copolymer, with both CD22 ligand and DNP antigens, did not evoke a calcium 
response, indicating an inhibiting effect by the CD22 ligands. In additional experiments the authors 
showed that co-expression of  both recognition elements on polymers is essential to block B cell-
17
Antigen-Selective B cell-Targeting in Autoimmune Diseases
529590-L-bw-Lelieveldt
Processed on: 13-3-2019 PDF page: 18
activation. As a result, the co-cluster of  the BCR and CD22 on the B cell surface suggests that 
trans-ligand interactions of  CD22 diminish the calcium signal. Alternatively, Duong et al.60 
conjugated multiple nitrophenol (NP) haptens, T cell-independent type 2 antigens, and glycan 
ligands for both CD22 and Siglec-G to a polyacrylamide (PA) polymer. They also prepared 
corresponding carriers with glycans lacking a sialic acid residue (NP-PA). As anticipated, robust in 
vivo generation of  NP-specific plasma cells as well as antibodies against NP were observed in mice 
immunized with NP-PA. Copolymers with Siglec ligands dramatically reduced plasma cell and 
antibody counts, indicating that co-presentation of  Siglec ligands prevents the immunogenic 
response to selective antigens. Remarkably, mice injected with high affinity Siglec ligands attached 
to NP antigens even established antigen-selective tolerance for about a month, as challenges with 
non-sialylated antigen conjugates afterwards failed to evoke an antibody response. However, when 
an adjuvant was administered simultaneously with the injection, full tolerance was not observed. 
This raised doubt as to whether this approach would be effective towards T cell-dependent 
antigens, since a second stimulating signal from T helper cells could counteract dampening by 
CD22.  
In order to reduce the drawback of  previous antigen conjugates, Macauley et al.62 designed 
liposomal nanoparticles as carriers for protein antigens and CD22 ligands. In vivo use of  these 
particles has been validated and robust methods exist for conjugation of  peptides and glycans to 
lipids for incorporation in the lipid bilayer of  liposomes.63-65 Accordingly, the authors constructed 
Siglec-engaging tolerance-inducing antigenic liposomes (STALs) displaying both a protein antigen 
and CD22 ligands (Figure 4). Siglec ligands with a 200-fold higher affinity than natural ligands 
were used, as was the T cell-independent antigen NP. Immunization of  mice with STALs showed 
a dramatically lower anti-NP response than with immunogenic liposomes, and upon two 
subsequent challenges the mice did not evoke a response at all. Tolerance to NP was induced 
CD22-dependently. Also STALs with multiple different T cell-dependent antigens proved to 
induce a tolerogenic effect, showing significantly lower antigen-selective antibody response upon 
subsequent challenges with corresponding antigens. Noteworthy, it was shown that the mechanism 
of  tolerance induction appears to be intrinsic to depletion of  antigen-reactive B cells, by CD22 
dependent apoptosis,62 in which the pro-apoptotic factor BIM appeared to play a critical role.66 
Moreover, this effect on viability was even shown in human naive and memory B cells in vitro, 
suggesting that STALs may additionally be beneficial for suppression of  a memory B cell response. 
Tolerance induction was mainly obtained via CD22 inhibitory effects, due to ligand specificity. 
Since an independent role for Siglec-G had not been demonstrated before, Pfrengle et al.67 
developed a high-affinity ligand with specificity for Siglec-G. Comparable results were obtained in 
experiments conducted with STALs bearing these Siglec-G ligands. Inhibition of  BCR signaling 
and a reduction in the number of  living B cells was observed upon enforced ligation of  Siglec-G 
with the BCR, not only in B1 cells, but surprisingly also in splenic B2 cells. Therefore, it will be of  
specific interest to determine the manner in which Siglec-G and CD22 act cooperatively in 
preventing immunogenic reactivity towards autoantigens. 
The tolerogenic effect of  STALs was further improved by encapsulation of  an 
immunosuppressive agent in the lipid membrane, which had previously been shown successful in 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles for tolerance induction in various immunological 
compartments.68, 69 Pang et al.70 constructed STALs with encapsulated rapamycin (RAPA), a natural 
compound which prevents B and T cell proliferation by blocking IL-2 and IL-15 signaling, and is 
used to prevent the rejection of  organ transplants.71 
 
Figure 4. The influence of STALs on BCR signaling in autoimmune B cells. STALs display autoantigens 
on their membrane surface. Upon interaction of antigen with the BCR, Siglec-G/10 and CD22 are recruited 
towards activated BCR. Both Siglecs recognize and bind sialic acid ligands present on STALs, forming trans-
interactions, resulting in suppressed calcium signaling. The B cell becomes tolerant towards the specific 
auto-antigen presented by STALs and might undergo apoptotic cell death. 
 
The STALs with RAPA showed enhanced antigen-selective tolerance upon in vivo immunization 
in naive mice, compared to STALs without RAPA. To investigate the tolerogenic effect of  STALs 
with RAPA on the memory B cell response in vivo, antigen-sensitized mice were immunized 
accordingly. Neither STALs nor STALs with RAPA were able to completely prevent a memory B 
cell response towards soluble ovalbumin (OVA) antigens, although a significant reduction of  anti-
OVA antibodies was observed in the STALs with RAPA group compared to control mice. The 
authors hypothesized that the lack of  complete tolerance induction is the result of  relatively low 
doses of  RAPA.70 In conclusion, these findings demonstrate the potential of  STALs as an antigen-
selective tolerogenic platform, possibly combined with immunomodulatory agents, in treatment 
of  autoimmune diseases. As CD22 and Siglec-G are displayed on the cell surface of  all B cells and 
have distinct, yet overlapping, affinities for their sialylated glycan ligands, they prove to be suitable 
B cell targets in achieving antigen-selective B cell tolerance. Recently, a human CD22 transgenic 
mouse model, showing similar CD22-dependent effects on BCR signaling and tolerance, has been 
developed.72 This might be a new valuable model to assess mechanisms of  action and future 
optimization of  CD22 targeted therapies in a preclinical setting.  
 
Targeting of ICAM. For a humoral immune response against T cell-dependent antigens, 
additional stimulation by T helper cells is critical to evoke full B cell activation and differentiation, 
as binding of the BCR to a single protein antigen is insufficient.73 Peptide epitopes are presented 
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were used, as was the T cell-independent antigen NP. Immunization of  mice with STALs showed 
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of  tolerance induction appears to be intrinsic to depletion of  antigen-reactive B cells, by CD22 
dependent apoptosis,62 in which the pro-apoptotic factor BIM appeared to play a critical role.66 
Moreover, this effect on viability was even shown in human naive and memory B cells in vitro, 
suggesting that STALs may additionally be beneficial for suppression of  a memory B cell response. 
Tolerance induction was mainly obtained via CD22 inhibitory effects, due to ligand specificity. 
Since an independent role for Siglec-G had not been demonstrated before, Pfrengle et al.67 
developed a high-affinity ligand with specificity for Siglec-G. Comparable results were obtained in 
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on MHC class-II complexes on the surface of B cells after uptake and processing of antigens that 
bind the BCR. Then CD4+ T helper cells can engage and the T cell receptor (TCR) will specifically 
recognize and interact with the MHC class II-peptide complex. Subsequent activation of T cells 
requires additional co-stimulatory signals, which can be provided by intercellular adhesion 
molecule-1 (ICAM-1/CD45), among others.73 This is the major receptor for lymphocyte function-
associated antigen-1 (LFA-1), an integrin found on T cells.74 Interaction of LFA-1 with ICAM-1 
on APCs is essential for stabilization of cell-cell interactions and induction of a pro-inflammatory 
response, as well as for transmigration of leukocytes into tissue, since ICAM-1 is also present on 
endothelial cells.74, 75 
This adhesion interaction also provides co-stimulation in the immunological synapse (IS) formed 
between T cells and other APCs, such as dendritic cells (DCs) and macrophages.76 The mature IS 
is defined by supramolecular activation clusters (SMACs),77-79 the center of  which is enriched for 
TCR-peptide-MHC complexes (signal-1), while the outer ring contains the adhesion molecules 
LFA-1/ICAM-1 (signal-2) (Figures 5A, B). Adhesion molecules first localize in the center of  
SMACs, whereas the engaged TCRs form a peripheral ring, translocation and segregation follow 
to form the mature IS. Importantly, in case the co-stimulation by the adhesion ligand ICAM-1 is 
lacking, T cell-activation is reduced and this might even induce selective tolerance towards the 
peptides presented. Besides, evidence shows that these adhesion molecules play an important role 
in the pathogenesis and progression of  autoimmune diseases.74, 80 Formation of  the IS between 
APCs and either CD4+ helper or CD8+ cytotoxic T cells is a critical step in the activation of  
antigen-selective T cells and subsequent immune responses, as well as B cell-activation and 
humoral immunity towards T cell-dependent antigens. Hence, the LFA-1/ICAM-1 interaction is a 
potential target in inducing antigen-selective tolerance in autoimmune diseases. 
 
 
Figure 5. The proposed mechanism of  BPI action in preventing formation of  the immunological synapse. 
A) The initial stage of  IS formation shows interaction of  LFA-1/ICAM-1 at the center and TCR/MHC-
antigen complexes at the outer ring; B) Both pairs are transmigrated and segregated to form the mature IS; 
C) In the presence of  BPI, antigen peptide will bind to MHC class-II complexes while LABL peptide will 
bind ICAM-1 on APCs, forming a bridge in between and partly preventing T cell and APC interactions; D) 
Since transmigration and segregation are unable to occur properly, the mature IS cannot be formed.  
 
Targeting of  ICAM-1 was first employed by the development of  a bifunctional peptide inhibitor 
(BPI). Kobayashi et al.81 developed a spacer peptide conjugated to an antigen epitope peptide as 
well as an ICAM-1 binding peptide. In this study they used the epitope peptide PLP139–151,82 derived 
from the self-antigen myelin proteolipid protein (PLP), which is an important antigenic protein in 
the pathogenesis of  MS. The previously discovered ICAM-1 blocking peptide (LABL)83, 84 was 
attached on the other end of  the peptide spacer. LABL has been shown to block T cell adhesion 
to epithelial cells by binding ICAM-1.83-86 The authors hypothesized that the PLP peptide 
conjugated to LABL simultaneously binds MHC class-II, the antigen can bind to empty active 
MHC-II,87, 88 and ICAM-1 on APCs (Figures 5C, D). By forming a bridge between the target 
molecules, the BPI disables the translocation and segregation of  both receptors, which is needed 
to form the mature IS.81 Another possible mechanism is inhibition of  signal clustering by steric 
hindrance when either solely PLP binds MHC class-II or only LABL binds ICAM-1, alternatively 
a combination of  all mechanisms is suggested. Notably, if  only LABL binds ICAM-1, this would 
not be an antigen specific strategy. Altogether, this should result in inhibition of  T cell-activation 
and suppression of  an autoimmune response towards PLP. The therapeutic activity of  PLP-PBI 
was evaluated in mice induced with experimental autoimmune encephalomyelitis (EAE), which is 
a model for human MS. 
Disease progression and severity were significantly reduced in an antigen-selective manner. 
Additional experiments suggest that the unique structure of  the BPI is important for its 
suppressing activity and that suppression of  EAE is the result of  induced regulatory T cells. This 
approach was also applied to treat type 1 diabetes (T1D) by using the diabetes-associated antigen 
glutamic acid decarboxylase (GAD).89, 90 A BPI bearing GAD peptide was employed to test its 
suppressing activity on T1D, by injection in non-obese diabetes (NOD) mice, a model for human 
T1D.91 Positive effects on the suppression of  insulitis and disease progression were observed. 
Multiple follow-up studies have been reported in order to improve BPI efficacy for future 
treatment of  MS patients.92-97 Firstly, optimization of  PLP-BPI led to newly synthesized derivatives 
showing more effective suppression of  disease severity and morbidity in vivo in EAE mice, prior 
to and after onset of  the disease.92 To reduce the number of  treatment injections, a vaccine-like 
approach was applied.93, 94 A colloidal gel was prepared consisting of  PLGA nanoparticles coated 
with either positively or negatively charged polysaccharides. Controlled-release of  the BPI from 
the colloidal gel was obtained and suppression of  EAE in mice by a one-time injection was 
comparable with the effect of  three injections from previous BPIs.93, 94 Furthermore, multivalent 
BPIs (MVB)96 were developed to address the problem of  epitope spreading, a process by which 
autoimmunity extends to multiple different self-epitopes, that occurs in later stages of  the disease.98  
Targeting B799, 100 co-stimulators on APCs instead of  ICAM-1, using novel BPIs displaying B7 
antisense peptide (B7AP), has also shown to be effective.97 The B7 receptor is expressed on APCs 
and can either bind to CD28 to activate naive T cells, or can bind to CTLA-4 on activated T cells 
to downregulate the activation and proliferation. Stewart et al. showed by synthesizing a BPI-
containing B7AP with a MS antigenic peptide, that EAE was suppressed in an animal model.97 
Finally, since the short half-life of  BPI in vivo appeared to be a potential problem,101 novel BPIs 
were synthesized in which the two peptides were fused via a fragment crystallizable (Fc) region of  
a human IgG1 antibody. This proof-of-concept has shown that preparation of  such a BPI-Fc 
fusion is possible and that it still functions to protect mice against EAE.95 
With respect to previously mentioned epitope spreading in later stages of  MS, I-Domain-Antigen 
Conjugates (IDACs) were developed.102, 103 The I-domain binds to ICAM and is similar to the 
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on MHC class-II complexes on the surface of B cells after uptake and processing of antigens that 
bind the BCR. Then CD4+ T helper cells can engage and the T cell receptor (TCR) will specifically 
recognize and interact with the MHC class II-peptide complex. Subsequent activation of T cells 
requires additional co-stimulatory signals, which can be provided by intercellular adhesion 
molecule-1 (ICAM-1/CD45), among others.73 This is the major receptor for lymphocyte function-
associated antigen-1 (LFA-1), an integrin found on T cells.74 Interaction of LFA-1 with ICAM-1 
on APCs is essential for stabilization of cell-cell interactions and induction of a pro-inflammatory 
response, as well as for transmigration of leukocytes into tissue, since ICAM-1 is also present on 
endothelial cells.74, 75 
This adhesion interaction also provides co-stimulation in the immunological synapse (IS) formed 
between T cells and other APCs, such as dendritic cells (DCs) and macrophages.76 The mature IS 
is defined by supramolecular activation clusters (SMACs),77-79 the center of  which is enriched for 
TCR-peptide-MHC complexes (signal-1), while the outer ring contains the adhesion molecules 
LFA-1/ICAM-1 (signal-2) (Figures 5A, B). Adhesion molecules first localize in the center of  
SMACs, whereas the engaged TCRs form a peripheral ring, translocation and segregation follow 
to form the mature IS. Importantly, in case the co-stimulation by the adhesion ligand ICAM-1 is 
lacking, T cell-activation is reduced and this might even induce selective tolerance towards the 
peptides presented. Besides, evidence shows that these adhesion molecules play an important role 
in the pathogenesis and progression of  autoimmune diseases.74, 80 Formation of  the IS between 
APCs and either CD4+ helper or CD8+ cytotoxic T cells is a critical step in the activation of  
antigen-selective T cells and subsequent immune responses, as well as B cell-activation and 
humoral immunity towards T cell-dependent antigens. Hence, the LFA-1/ICAM-1 interaction is a 
potential target in inducing antigen-selective tolerance in autoimmune diseases. 
 
 
Figure 5. The proposed mechanism of  BPI action in preventing formation of  the immunological synapse. 
A) The initial stage of  IS formation shows interaction of  LFA-1/ICAM-1 at the center and TCR/MHC-
antigen complexes at the outer ring; B) Both pairs are transmigrated and segregated to form the mature IS; 
C) In the presence of  BPI, antigen peptide will bind to MHC class-II complexes while LABL peptide will 
bind ICAM-1 on APCs, forming a bridge in between and partly preventing T cell and APC interactions; D) 
Since transmigration and segregation are unable to occur properly, the mature IS cannot be formed.  
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suppressing activity on T1D, by injection in non-obese diabetes (NOD) mice, a model for human 
T1D.91 Positive effects on the suppression of  insulitis and disease progression were observed. 
Multiple follow-up studies have been reported in order to improve BPI efficacy for future 
treatment of  MS patients.92-97 Firstly, optimization of  PLP-BPI led to newly synthesized derivatives 
showing more effective suppression of  disease severity and morbidity in vivo in EAE mice, prior 
to and after onset of  the disease.92 To reduce the number of  treatment injections, a vaccine-like 
approach was applied.93, 94 A colloidal gel was prepared consisting of  PLGA nanoparticles coated 
with either positively or negatively charged polysaccharides. Controlled-release of  the BPI from 
the colloidal gel was obtained and suppression of  EAE in mice by a one-time injection was 
comparable with the effect of  three injections from previous BPIs.93, 94 Furthermore, multivalent 
BPIs (MVB)96 were developed to address the problem of  epitope spreading, a process by which 
autoimmunity extends to multiple different self-epitopes, that occurs in later stages of  the disease.98  
Targeting B799, 100 co-stimulators on APCs instead of  ICAM-1, using novel BPIs displaying B7 
antisense peptide (B7AP), has also shown to be effective.97 The B7 receptor is expressed on APCs 
and can either bind to CD28 to activate naive T cells, or can bind to CTLA-4 on activated T cells 
to downregulate the activation and proliferation. Stewart et al. showed by synthesizing a BPI-
containing B7AP with a MS antigenic peptide, that EAE was suppressed in an animal model.97 
Finally, since the short half-life of  BPI in vivo appeared to be a potential problem,101 novel BPIs 
were synthesized in which the two peptides were fused via a fragment crystallizable (Fc) region of  
a human IgG1 antibody. This proof-of-concept has shown that preparation of  such a BPI-Fc 
fusion is possible and that it still functions to protect mice against EAE.95 
With respect to previously mentioned epitope spreading in later stages of  MS, I-Domain-Antigen 
Conjugates (IDACs) were developed.102, 103 The I-domain binds to ICAM and is similar to the 
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binding region in LFA-1,104 hence the I-domain is comparable to the LABL peptide. Antigenic 
peptides are conjugated to the I-domain to form IDACs. Multivalent BPIs display two antigenic 
peptides, whereas IDACs enable the conjugation of  multiple protein epitopes. The authors 
hypothesized that when the I-domain of  IDAC binds ICAM-1 on the surface of  APCs, antigen 
peptides can simultaneously bind MHC class-II molecules. Since IDACs can present multiple 
different peptides to APCs, they might inhibit antigen-selective T cell activation for several 
different T cell subsets simultaneously and prevent epitope spreading in MS. To proof  the concept, 
IDACs were prepared by conjugation of  several PLP peptides. The multivalent IDACs proved 
effective in suppressing EAE in mice.102, 103 Besides, it was shown that delivery of  antigenic peptides 
by the I-domain resulted in immunotolerance when mice were treated both in a prophylactic and 
vaccine-like manner.103 The potential of  IDACs in prevention of  antigenic spreading is yet to be 
determined.  
Similarly, Berkland et al.105 developed so-called multivalent soluble antigen arrays (SAgA), a 
hyaluronic acid (HA) polymer conjugated with multiple PLP and LABL peptides (SAgAPLP:LABL) 
(Figure 6). HA is a natural glycosaminoglycan that is characterized by highly flexible and water 
soluble behavior.106, 107 It has recently been reported that controlling the molecular weight of  HA 
facilitates specific lymphatic uptake of  the polymers.108 Before ligation of  the peptides, they were 
end-functionalized with hydroxylamine,109-111 which allowed for easy grafting onto the polymers by 
a one-pot, single-step oxime addition.105 The different peptides were successfully attached 
approximately in the desired 1:1 ratio. Simultaneous delivery of  both PLP antigens and ICAM-1 
ligands (LABL) on the HA graft polymers significantly suppressed EAE disease in mice, compared 
to multiple controls, such as a mixture of  the free components; PLP, LABL and HA.105 These in 
vivo effects were further investigated by comparing SAgAPLP:LABL with a 1:1 mixture of  HA polymer 
displaying either PLP antigen (HAPLP) or LABL peptide (HALABL) (Figure 6).112  
 
 
Figure 6. Schematic overview of  the various scaffolds used to antigen-selectively target B cells. All scaffolds 
display both the antigenic peptide PLP and the ICAM-1 ligand LABL. The bifunctional peptide inhibitor 
(BPIPLP:LABL) displays only one entity of  both peptides, whereas multivalent soluble antigen arrays 
(SAgAPLP:LABL) and PLGA nanoparticles (NPPLP:LABL) are conjugated with a number of  both peptides. 
Linear HA polymers are also depicted with either solely PLP peptides (HAPLP) or only LABL (HALABL).115  
Interestingly, clinical data proved that similar in vivo protection against EAE was obtained. 
However, when splenocytes isolated from EAE mice were similarly treated ex vivo, cytokine 
expression profiles appeared to be very different, suggesting that exact mechanisms of  protection 
and the role of  co-delivery should be further elucidated.112 In addition, SAgA carriers were also 
equipped with both PLP autoantigen and one of  the three different B7-binding peptides which 
specifically targets the B7 co-stimulatory receptor.113 As binding peptides, either one of  the two 
inhibitory CD28 mimic peptides or a stimulating peptide mimic of  CTLA-4 was used. Surprisingly, 
all three independent SAgAs were found to inhibit disease progression. Berkland et al. 
hypothesized, based on previous reports,114 that the CTLA-4 mimic is inhibitory instead of  
stimulatory due to the dampening of  T cell inactivation and hence overstimulation of  T-cells. This 
mechanism is therefore possibly inducing anergy.113 
Various consecutive studies investigated the effect of  the physical characteristics of  the different 
scaffolds on their inhibitory potency,115-117 the preferred routes of  administration118, 119 and the 
potential mechanism leading to tolerance induction.35, 39 Sestak et al.115 compared clinical effects of  
BPIs, 45 kDa SAgA, 65 kDa SAgA and PLGA nanoparticles, all displaying PLP and LABL 
peptides (Figure 6). They observed that the soluble, small scaffolds – BPI and SAgA – were the 
most effective treatments, compared to large, insoluble nanoparticles. Overall, the SAgA with a 
size of  45 kDa showed the best clinical results with respect to disease onset and the maintenance 
of  murine weight.115 Finally, Hartwell et al.120 used human Raji B cells, B lymphocytes of  a Burkitt’s 
lymphoma patient and which harbor the Epstein–Barr virus,121 as a model for APCs to investigate 
specificity and binding mode of  SAgAs in vitro. By competitive dissociation studies using flow 
cytometry they showed that the addition of  antigen-peptides increased an antigen-selective 
response. The authors hypothesized that PLP peptides on SAgA would bind either MHC class-II 
complexes or the BCR on the cellular surface of  B cells. Also, it has been shown that engagement 
and clustering of  the BCR with an inhibitory co-receptor can cause reduction in IgM-stimulated 
signaling in the Raji B cells. Furthermore, IgM blocking experiments suggest that the BCR is a 
target for SAgAPLP:LABL. Altogether, they have shown that SAgAPLP:LABL binding dampens BCR-
mediated signaling.120 Replacement of  the hydrolyzable oxime bonds between the peptides and the 
HA scaffold by a hydrolytically stable linkage using a Cu-catalyzed Azide−Alkyne Cycloaddition 
(CuAAC), greatly enhanced binding avidity as well as calcium flux signaling inhibition.116 
Continuous BCR engagement and clustering was observed in vitro, which pointed to a likely 
therapeutic cellular mechanism in which the click-conjugated SAgAPLP:LABL induces B cell anergy. 
Lastly, in vivo efficacy against EAE was vastly enhanced compared to previous hydrolyzable 
SAgAPLP:LABL, demonstrating its promising potential in the treatment of  autoimmune diseases, MS 
in particular.116  
In conclusion, BPIs, IDACs and SAgAs have all been proven successful in preventing EAE 
disease symptoms in mice, and therefore are considered as potential therapeutic strategies in the 
treatment of MS patients. Currently, the biggest challenge is to elucidate the mechanism by which 
these peptide carriers effect autoimmune responses and the individual contributions of the 
antigenic peptide and LABL therein. It has become evident that co-delivery of an auto-antigenic 
peptide and a secondary signal is critical. The ICAM-1 binding peptide LABL has proven to be an 
effective secondary signal. Whether this signal prevents the adhesion of APCs with T cells via 
blocking of the ICAM-1/LFA-1 interaction, or solely functions to support the engagement of the 
peptide carriers onto the cellular surface of APCs, is yet uncertain. As for interactions of the 
conjugated autoantigen with APCs, different mechanisms are proposed for different peptide 
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binding region in LFA-1,104 hence the I-domain is comparable to the LABL peptide. Antigenic 
peptides are conjugated to the I-domain to form IDACs. Multivalent BPIs display two antigenic 
peptides, whereas IDACs enable the conjugation of  multiple protein epitopes. The authors 
hypothesized that when the I-domain of  IDAC binds ICAM-1 on the surface of  APCs, antigen 
peptides can simultaneously bind MHC class-II molecules. Since IDACs can present multiple 
different peptides to APCs, they might inhibit antigen-selective T cell activation for several 
different T cell subsets simultaneously and prevent epitope spreading in MS. To proof  the concept, 
IDACs were prepared by conjugation of  several PLP peptides. The multivalent IDACs proved 
effective in suppressing EAE in mice.102, 103 Besides, it was shown that delivery of  antigenic peptides 
by the I-domain resulted in immunotolerance when mice were treated both in a prophylactic and 
vaccine-like manner.103 The potential of  IDACs in prevention of  antigenic spreading is yet to be 
determined.  
Similarly, Berkland et al.105 developed so-called multivalent soluble antigen arrays (SAgA), a 
hyaluronic acid (HA) polymer conjugated with multiple PLP and LABL peptides (SAgAPLP:LABL) 
(Figure 6). HA is a natural glycosaminoglycan that is characterized by highly flexible and water 
soluble behavior.106, 107 It has recently been reported that controlling the molecular weight of  HA 
facilitates specific lymphatic uptake of  the polymers.108 Before ligation of  the peptides, they were 
end-functionalized with hydroxylamine,109-111 which allowed for easy grafting onto the polymers by 
a one-pot, single-step oxime addition.105 The different peptides were successfully attached 
approximately in the desired 1:1 ratio. Simultaneous delivery of  both PLP antigens and ICAM-1 
ligands (LABL) on the HA graft polymers significantly suppressed EAE disease in mice, compared 
to multiple controls, such as a mixture of  the free components; PLP, LABL and HA.105 These in 
vivo effects were further investigated by comparing SAgAPLP:LABL with a 1:1 mixture of  HA polymer 
displaying either PLP antigen (HAPLP) or LABL peptide (HALABL) (Figure 6).112  
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display both the antigenic peptide PLP and the ICAM-1 ligand LABL. The bifunctional peptide inhibitor 
(BPIPLP:LABL) displays only one entity of  both peptides, whereas multivalent soluble antigen arrays 
(SAgAPLP:LABL) and PLGA nanoparticles (NPPLP:LABL) are conjugated with a number of  both peptides. 
Linear HA polymers are also depicted with either solely PLP peptides (HAPLP) or only LABL (HALABL).115  
Interestingly, clinical data proved that similar in vivo protection against EAE was obtained. 
However, when splenocytes isolated from EAE mice were similarly treated ex vivo, cytokine 
expression profiles appeared to be very different, suggesting that exact mechanisms of  protection 
and the role of  co-delivery should be further elucidated.112 In addition, SAgA carriers were also 
equipped with both PLP autoantigen and one of  the three different B7-binding peptides which 
specifically targets the B7 co-stimulatory receptor.113 As binding peptides, either one of  the two 
inhibitory CD28 mimic peptides or a stimulating peptide mimic of  CTLA-4 was used. Surprisingly, 
all three independent SAgAs were found to inhibit disease progression. Berkland et al. 
hypothesized, based on previous reports,114 that the CTLA-4 mimic is inhibitory instead of  
stimulatory due to the dampening of  T cell inactivation and hence overstimulation of  T-cells. This 
mechanism is therefore possibly inducing anergy.113 
Various consecutive studies investigated the effect of  the physical characteristics of  the different 
scaffolds on their inhibitory potency,115-117 the preferred routes of  administration118, 119 and the 
potential mechanism leading to tolerance induction.35, 39 Sestak et al.115 compared clinical effects of  
BPIs, 45 kDa SAgA, 65 kDa SAgA and PLGA nanoparticles, all displaying PLP and LABL 
peptides (Figure 6). They observed that the soluble, small scaffolds – BPI and SAgA – were the 
most effective treatments, compared to large, insoluble nanoparticles. Overall, the SAgA with a 
size of  45 kDa showed the best clinical results with respect to disease onset and the maintenance 
of  murine weight.115 Finally, Hartwell et al.120 used human Raji B cells, B lymphocytes of  a Burkitt’s 
lymphoma patient and which harbor the Epstein–Barr virus,121 as a model for APCs to investigate 
specificity and binding mode of  SAgAs in vitro. By competitive dissociation studies using flow 
cytometry they showed that the addition of  antigen-peptides increased an antigen-selective 
response. The authors hypothesized that PLP peptides on SAgA would bind either MHC class-II 
complexes or the BCR on the cellular surface of  B cells. Also, it has been shown that engagement 
and clustering of  the BCR with an inhibitory co-receptor can cause reduction in IgM-stimulated 
signaling in the Raji B cells. Furthermore, IgM blocking experiments suggest that the BCR is a 
target for SAgAPLP:LABL. Altogether, they have shown that SAgAPLP:LABL binding dampens BCR-
mediated signaling.120 Replacement of  the hydrolyzable oxime bonds between the peptides and the 
HA scaffold by a hydrolytically stable linkage using a Cu-catalyzed Azide−Alkyne Cycloaddition 
(CuAAC), greatly enhanced binding avidity as well as calcium flux signaling inhibition.116 
Continuous BCR engagement and clustering was observed in vitro, which pointed to a likely 
therapeutic cellular mechanism in which the click-conjugated SAgAPLP:LABL induces B cell anergy. 
Lastly, in vivo efficacy against EAE was vastly enhanced compared to previous hydrolyzable 
SAgAPLP:LABL, demonstrating its promising potential in the treatment of  autoimmune diseases, MS 
in particular.116  
In conclusion, BPIs, IDACs and SAgAs have all been proven successful in preventing EAE 
disease symptoms in mice, and therefore are considered as potential therapeutic strategies in the 
treatment of MS patients. Currently, the biggest challenge is to elucidate the mechanism by which 
these peptide carriers effect autoimmune responses and the individual contributions of the 
antigenic peptide and LABL therein. It has become evident that co-delivery of an auto-antigenic 
peptide and a secondary signal is critical. The ICAM-1 binding peptide LABL has proven to be an 
effective secondary signal. Whether this signal prevents the adhesion of APCs with T cells via 
blocking of the ICAM-1/LFA-1 interaction, or solely functions to support the engagement of the 
peptide carriers onto the cellular surface of APCs, is yet uncertain. As for interactions of the 
conjugated autoantigen with APCs, different mechanisms are proposed for different peptide 
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carriers. Autoantigens on BPIs are considered to interact with MHC class-II complexes on APCs. 
However, antigenic peptides are usually loaded onto MHC class-II complexes within APCs before 
being presented on the cellular surface.122 Also, unloaded MHC complexes are often unstable and 
in particular abundantly present on immature DCs.123 Besides, evidence of the mechanism 
involving MHC class-II has not been provided by the authors to date. Nevertheless, BPIs may 
exert their function in vivo by alteration of the fate of naive T cells. As T cells normally gain an 
inflammatory phenotype, such as differentiation into CD4+ helper or CD8+ cytotoxic T cells, BPI 
mediation leads to an increase in the presence of suppressor or regulatory phenotypes. In this case, 
BPIs might also inhibit an antigen-selective humoral immune response towards T cell-dependent 
antigens. On the contrary, autoantigens on SAgAs have been suggested to engage and cluster the 
BCRs on B cells, reducing BCR-mediated signaling. Considering this mechanism, the multivalency 
of the linear polymers benefits effective receptor clustering. If this is true, it could affect B cell 
activation towards both T cell-dependent and T cell-independent antigens. Moreover, the in vivo 
effect of SAgAPLP:LABL may completely be a result of B cell-targeting via the BCR, as the possible 
interaction with MHC class-II remains to be determined. Therefore, SAgA polymers might even 
specifically target B cells. Altogether, BPI, IDAC and SAgA scaffolds targeting ICAM-1 hold great 
promise to promote antigen-selective immune tolerance in autoimmune disease. 
 
FcγRIIb. FcγRIIb (CD32) is an inhibitory immunoglobulin G (IgG) co-receptor on B 
lymphocytes, which is the only IgG Fc-recognizing receptor present on the B cell extracellular 
surface.124, 125 IgG immune complexes represent the inhibitory-ligand of this receptor,125 which 
were already recognized as such more than 30 years ago.126 The single-chain FcγRIIb protein holds 
an ITIM on its cytoplasmic domain, of which the tyrosine residue gets phosphorylated upon co-
ligation of the receptor with the BCR.127, 128 Co-ligation occurs when IgG-antigen complexes 
interact simultaneously with the BCR and the FcγRIIb receptor.125 The receptor can effectuate its 
inhibitory effect via three separable pathways, resulting in either inhibition of both calcium-
signaling and cellular proliferation – via ITIM-dependent mechanisms129-131 – or in induction of 
apoptosis – via an ITIM-independent mechanism.132 Calcium-signaling as well as B cell 
proliferation are reduced via downstream-signaling starting with recruitment of SH2-containing 
inositol polyphosphate 5-phosphatase (SHIP) to phosphorylated ITIM motifs. SHIP hydrolyzes 
the membrane phosphatidylinositol 3,4,5-trisphosphate (PIP3), eventually preventing the influx of 
extracellular calcium and thereby inhibiting BCR signaling.133, 134 Recruitment and activation of 
p62dok and subsequent inactivation of mitogen-activated protein (MAP) kinases leads to arrest of 
the BCR-triggered proliferation of B cells (Figure 7A).135, 136 This inhibitory function is of 
importance in the downregulation of a B cell response. The inhibitory FcγRIIb receptor has been 
implicated in the development of autoimmune disease, as FcγRIIb deficient mice showed 
imbalanced immune responses, increased antibody production to both T cell-dependent and T 
cell-independent antigens, as well as developmental autoimmune pathology.137-139 
Recently, a novel method using chimeric molecules has been designed to mimic this physiological 
inhibitory mechanism in order to develop an immune inhibitory therapy targeting B cells in an 
antigen-selective manner. Tchorbanov et al.140 and Mihaylova et al.141 almost simultaneously 
reported on the first chimeric molecules mimicking the IgG-containing immune complexes. These 
chimeric molecules were hypothesized to be able to crosslink the BCR and the FcγRIIb receptor, 
thereby suppressing an on-going antibody response to the autoantigen of  interest (Figure 7B). The 
authors constructed the chimeric molecules by conjugation of  either a DNA-mimicking peptide140 
or a histone-1 peptide141 to rat monoclonal anti-mouse FcγRIIb antibody. These antigens were of  
interest since IgG autoantibodies targeting double-stranded (ds) DNA142 or histones143 are 
characteristic in SLE pathogenesis. Silencing of  the ds-DNA- or histone-1-specific B-lymphocytes 
in vitro and in vivo in lupus-prone MRLlpr mice144 resulted in apoptosis of  the corresponding B 
lymphocytes and a reduced number of  ds-DNA or histone-1 antibody levels. Nevertheless, 
constant antibody levels were observed in sick, old mice, probably since pre-existing long-lived 
antibody secreting plasma cells were unaffected by this treatment. B lymphocytes and antibody 
levels with other antigen specificities were not affected. Additionally, the progression of  lupus 
disease symptoms were delayed in both young and old mice,140, 141 although prolonged overall 
survival of  old mice was only observed when treated with the chimeric construct bearing the ds-
DNA mimicking peptide.140 Interestingly, chimeric histone-1 conjugates also partly suppressed the 
production of  ds-DNA antibodies, which might be the result of  ‘tolerance-spreading’, according 
to the authors.141 
 
 
Figure 7. Mechanism and inhibition of  FcγRIIb. A) FcγRIIb recognizes the Fc tail of  IgG molecules and 
the IgG-antigen complex can interact simultaneously with this receptor and the BCR to inhibit B cell 
activity; B) By synthesizing a chimeric construct in which an autoantigen is conjugated to a FcγRIIb-specific 
monoclonal antibody, simultaneous binding was achieved and selective B cells were inactivated. Co-
crosslinking of  the respective inhibitory receptor with the antigen-selective BCR on disease-associated 
autoreactive B cells provided B cell tolerance. 
 
A limitation of  this approach was the appearance of  an immunogenic response towards the 
chimeric construct, the rat anti-mouse FcγRIIb antibody in particular, as a result of  anti-chimeric 
immunoglobulin antibody production. To circumvent the immunogenic response towards the 
chimeric construct, mouse IgG2a, which is able to bind the FcγRIIb receptor, was used as the 
antibody backbone. Tri-specific chimeric constructs were created, targeting simultaneously the 
FcγRIIb receptor, the co-inhibitory receptor CD22, and the BCR.145 This induced two independent 
inhibitory pathways, effectively suppressing both IgG and IgM anti-DNA antibody levels in lupus 
prone mice. Despite the use of  mouse IgG2a antibodies, the mice still produced antibodies to the 
mouse antibody scaffold after 15 weeks.145 To address the resistance of  long-lived plasma cells to 
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carriers. Autoantigens on BPIs are considered to interact with MHC class-II complexes on APCs. 
However, antigenic peptides are usually loaded onto MHC class-II complexes within APCs before 
being presented on the cellular surface.122 Also, unloaded MHC complexes are often unstable and 
in particular abundantly present on immature DCs.123 Besides, evidence of the mechanism 
involving MHC class-II has not been provided by the authors to date. Nevertheless, BPIs may 
exert their function in vivo by alteration of the fate of naive T cells. As T cells normally gain an 
inflammatory phenotype, such as differentiation into CD4+ helper or CD8+ cytotoxic T cells, BPI 
mediation leads to an increase in the presence of suppressor or regulatory phenotypes. In this case, 
BPIs might also inhibit an antigen-selective humoral immune response towards T cell-dependent 
antigens. On the contrary, autoantigens on SAgAs have been suggested to engage and cluster the 
BCRs on B cells, reducing BCR-mediated signaling. Considering this mechanism, the multivalency 
of the linear polymers benefits effective receptor clustering. If this is true, it could affect B cell 
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lymphocytes, which is the only IgG Fc-recognizing receptor present on the B cell extracellular 
surface.124, 125 IgG immune complexes represent the inhibitory-ligand of this receptor,125 which 
were already recognized as such more than 30 years ago.126 The single-chain FcγRIIb protein holds 
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Figure 7. Mechanism and inhibition of  FcγRIIb. A) FcγRIIb recognizes the Fc tail of  IgG molecules and 
the IgG-antigen complex can interact simultaneously with this receptor and the BCR to inhibit B cell 
activity; B) By synthesizing a chimeric construct in which an autoantigen is conjugated to a FcγRIIb-specific 
monoclonal antibody, simultaneous binding was achieved and selective B cells were inactivated. Co-
crosslinking of  the respective inhibitory receptor with the antigen-selective BCR on disease-associated 
autoreactive B cells provided B cell tolerance. 
 
A limitation of  this approach was the appearance of  an immunogenic response towards the 
chimeric construct, the rat anti-mouse FcγRIIb antibody in particular, as a result of  anti-chimeric 
immunoglobulin antibody production. To circumvent the immunogenic response towards the 
chimeric construct, mouse IgG2a, which is able to bind the FcγRIIb receptor, was used as the 
antibody backbone. Tri-specific chimeric constructs were created, targeting simultaneously the 
FcγRIIb receptor, the co-inhibitory receptor CD22, and the BCR.145 This induced two independent 
inhibitory pathways, effectively suppressing both IgG and IgM anti-DNA antibody levels in lupus 
prone mice. Despite the use of  mouse IgG2a antibodies, the mice still produced antibodies to the 
mouse antibody scaffold after 15 weeks.145 To address the resistance of  long-lived plasma cells to 
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this chimeric approach, the treatment was combined with partial plasma cell depletion by 
simultaneous administration of  bortezomib.146 This combination therapy significantly showed 
beneficial effects with respect to disease appearance and survival. Similar chimeric conjugates were 
also employed to target nicotinic acetylcholine receptor-reactive B cells in myasthenia gravis 
disease, successful antigen-selective depletion of  B cells has been shown in vitro147 and in vivo.148 To 
further decrease an immunogenic response Gesheva et al.149 generated a chimeric gene-engineered 
DNA molecule, encoding a ds-DNA-like peptide and a single-chain variable fragment (scFv) of  
the FcγRIIb-specific antibody. The immunogenic Fc fragment was lacking in the corresponding 
fusion protein, reducing a chimeric immune response in lupus prone mice.149  
In conclusion, the FcγRIIb is an interesting target for B cell inhibition and the antigen-combined 
strategies have proven beneficial in vitro and in vivo. Moreover, in contrast to CD20, FcγRIIb is 
expressed on plasma cells and may control their activity as well.150 
 
Complement receptor 1. Complement receptor 1 (CR1, CD35) represents another interesting 
target to deliver an inhibitory signal to a selective subset of  B cells.151 This receptor induces 
cleavage and hence complement activation of  C3b into iC3b and C3d. This naturally causes the 
binding of  the pathogen to CR2 and the BCR, resulting in B cell activation. It has been shown 
that the CR1 can also have an inhibitory function by binding to C3b to prevent overreaction 
towards an opsonized pathogen.151 This results in suppression of  BCR signaling as well as the 
dampening of  proliferation and differentiation of  activated B cells (Figure 8A).152 Although the 
expression of  CR1 on B lymphocytes in SLE and RA patients is markedly reduced,153 its inhibitory 
capacity has been demonstrated to be maintained on B cells from RA patients.154 Voynova et al.155 
created chimeric constructs carrying ds-DNA-mimicking peptide and monoclonal anti-CR1 
antibody, aiming to selectively silence autoreactive B cells from SLE patients (Figure 8B).  
 
 
Figure 8. Complement receptor 1. A) Schematic representation of  the function of  CR1. When CR1 binds 
to C3b fragments, it makes them susceptible to cleavage by complement factor I (green triangle). Cleavage 
results in C3d, which can bind to the CR2 component of  the B cell co-receptor; B) Suggested strategy to 
target CR1, which showed to also have an inhibitory function to the BCR. 
 
By employing this strategy, similar as to the FcγRIIb receptor targeting approach, they showed 
that crosslinking of CR1 with cell surface BCR also effectively provides an inhibitory signal. The 
peptide chimera reduced the number of anti-dsDNA antibody secreting cells in a culture of lupus 
patients’ PBMCs.155 This effect has also been demonstrated in humanized SCID mice, transferred 
with lymphocytes from lupus patients, where it resulted in re-established autoreactive B cell 
tolerance and prevented the appearance of disease symptoms.156 In conclusion, the CR1 receptors, 
which provide negative feedback regulation to activated B cells in natural context, are promising 
targets in delivering inhibitory signals to autoreactive B cells.157-159  
 
The use of antigen-drug conjugates to target autoreactive B cells. Besides using autoantigens 
combined with inhibitory signals to induce antigen-selective inhibition as described above, 
autoantigens can also be conjugated directly to a cytotoxic molecule. Since BCRs internalize after 
the binding to an antigen, the toxin can be specifically delivered to the B cells recognizing the 
autoantigen.160 
A truncated form of  Pseudomonas aeruginosa exotoxin A (ETA’) has been used as highly potent 
toxin conjugated to target and eliminate allergen-specific B cells. ETA’ halts protein synthesis in 
target cells by inhibition of  elongation factor 2, a protein involved in translational elongation in 
the ribosome. Without polypeptide elongation, protein synthesis is stalled. Stöcker et al.161 fused 
this toxin to epitopes of  the Ph1 p 5b allergen specific for timothy grass pollen. They showed that 
this allergen toxin (AT) was internalized and resulted in antigen-selective cell death in vitro (Figure 
9A). They predicted that depletion of  allergen-specific B cell populations will finally reduce the 
number of  corresponding IgE-producing B cells. A similar approach using diphtheria toxin (DT) 
and an OVA-DT antigen proved to be effective for OVA-induced allergy in mice. The authors 
observed selective killing of  B cells bearing OVA-specific IgE and decreasing levels of  OVA-
specific IgE.162 These methods might be relevant as a therapeutic approach to allergies. 
The effectivity of  ETA’ fusion proteins was demonstrated on human memory B cells as well. The 
tetanus toxoid fragment C (TTC) was used as a model antigen since it is relatively easy to obtain 
TT-expressing B cells from human PBMCs. Using a TTC-ETA’ fusion construct, an antigen-
selective depletion was shown in TTC-reactive human memory B cells from TT-vaccinated 
donors.163 
Nachreiner et al.164 focused on the autoreactive B cells producing antibodies targeting the central 
nervous system in MS. These specific antibodies have a strong demyelinating potential. This 
damage impairs the conduction of  signals in the affected nerves and results in deficiency in for 
example sensation and movement. The recognition antigen, an extracellular Ig-like domain of  
human myelin oligodendrocyte glycoprotein (MOG), was fused to ETA’ and tested in a MOG-
sensitive murine hybridoma cell line or on freshly isolated splenocytes from mice with high 
numbers of  MOG-expressing B cells and high levels of  MOG antibodies (TH mice). The authors 
showed that the chimeric immunotoxin targeted MOG-reactive B-lymphocytes by binding to the 
appropriate receptors selectively, which led to apoptosis of  the target cells.  
The ETA’ toxin is derived from bacteria, hence these fusion toxins have the disadvantage of  high 
immunogenicity.165 Therefore, Zochner et al.166 conjugated the CH2 and CH3 domains of  the human 
IgG1 heavy chain to MOG (MOG-Fc) (Figure 9B). The Ig isotype chosen for this conjugate 
functions well for antibody-dependent cellular cytotoxicity and complement-dependent 
cytotoxicity by effector cells. The advantage of  using the CH2 and CH3 domains is that two MOG 
antigens can be attached which increases the avidity. The toxicity of  this MOG-Fc was achieved 
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damage impairs the conduction of  signals in the affected nerves and results in deficiency in for 
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human myelin oligodendrocyte glycoprotein (MOG), was fused to ETA’ and tested in a MOG-
sensitive murine hybridoma cell line or on freshly isolated splenocytes from mice with high 
numbers of  MOG-expressing B cells and high levels of  MOG antibodies (TH mice). The authors 
showed that the chimeric immunotoxin targeted MOG-reactive B-lymphocytes by binding to the 
appropriate receptors selectively, which led to apoptosis of  the target cells.  
The ETA’ toxin is derived from bacteria, hence these fusion toxins have the disadvantage of  high 
immunogenicity.165 Therefore, Zochner et al.166 conjugated the CH2 and CH3 domains of  the human 
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by binding of  MOG to the specific B cell and crosslinking thereof  with effector cells. The co-
incubation in vitro of  target cells with human PBMCs showed the complete elimination of  target 
cells. TH mice were used for in vivo testing and the authors showed significant depletion of  MOG-
expressing B cells both ex vivo and in vivo, even though the MOG reactive antibody titer is high. 
They showed that not only the number of  MOG-expressing B cells was reduced, but that also the 
serum titer of  anti-MOG was decreased.  
 
 
Figure 9. Antigen-toxin conjugation. A) An autoantigen can be fused with a toxin which is active inside 
the cell. After BCR internalization, elimination of  the cell takes place; B) If  an autoantigen is fused to a Fc 
part of  IgG1, effector cells are needed for the antibody dependent cellular cytotoxicity. 
 
Alternatively, Reiners et al.167 produced a fusion protein containing a toxin and the mutated and 
inactive antigen proteinase 3 (PR3). PR3 is a neutrophil and monocyte-derived neutral serine 
protease. This antigen is the main target of  anti-neutrophil cytoplasmic autoantibodies which are 
present in Wegener’s granulomatosis (WG). WG is a rare disease and is a form of  vasculitis. The 
importance of  autoreactive B cells in this disease has been established. The toxin fused to PR3 
was the ribonuclease angiogenin, a human toxin with low immunogenicity. Using FACS analysis, 
the authors showed that autoantigen-selective cell death was induced for the WG cell line while a 
control cell line was unaffected.167 
 
Targeting of CD138 and CD44. Autoantibodies are often drivers of consistent autoimmune 
pathology and chronic inflammation.20, 168-172 After activation, B cells differentiate into either short-
lived plasmablasts or long-lived plasma cells, amongst others.172-174 The major function of both B 
cell subsets is to consistently produce and secrete antibodies. Plasmablasts represent a direct result 
of B cell activity and circulate through the peripheral blood, being consistently regenerated after B 
cell activation.175, 176 On the contrary, long-lived plasma cells arise from pre-existing plasmablasts 
upon a secondary immune response towards a specific antigen. They migrate to and reside in 
survival niches within the bone marrow or inflamed tissue, and persistently secrete high-affinity 
antibodies for years, perhaps even decades.174, 177 They are able to secrete antibodies independently 
of antigen recognition as well as B or T cell help,178-180 providing maintenance of humoral memory 
in response to infection and vaccination.175, 181 In autoimmune disease, autoreactive long-lived 
memory plasma cells have been implicated in disease pathology173, 182 and constitute a major 
therapeutic challenge.172, 173 While short-lived plasmablasts are indirectly addressed via B cell-
targeted therapies, long-lived plasma cells are invulnerable to conventional immunosuppression 
methods as well as regular B and T cell-targeted therapies,172, 183 as they do not display BCRs and 
other B cell markers on their extracellular surface.12 Antigen-selective depletion of long-lived 
memory plasma cells would be a valuable addition to the treatment spectrum to achieve B cell 
tolerance to autoantigens.  
 
 
Figure 10. Depletion of  autoreactive memory plasma cells by novel affinity matrix (AM) technology. A) 
CD138 of  autoreactive plasma cells are coated with anti-CD138 F(ab)2 fragments conjugated to an 
autoantigen. Secreted autoantibodies are captured by the AM and the cells are targets for complement-
dependent lysis; B) Protective plasma cells are similarly coated with anti-CD138 F(ab)2 fragments 
conjugated to an autoantigen, since they also express CD138 proteins. Secreted protective antibodies will 
not recognize nor bind the autoantigen on the AM. Protective plasma cells will not be lysed.  
 
A potential approach to distinguish the autoreactive from protective long-lived plasma cells is 
based on the antibodies that the cells secrete. This methodology was originally shown to be 
effective by Köhler et al,184, 185 who showed that coating of  a hybridoma cell line with their 
respective antigen, led to the attachment of  its secreted antibodies onto the cell surface. As a result, 
the complement system was activated and the hybridoma cells were killed by complement-
mediated lysis.184, 185 This novel strategy was later employed in a similar fashion to enable analysis 
and isolation of  live hybridoma cells and T lymphocytes.186 The cells of  interest were coated with 
a specific affinity matrix (AM), by using a construct containing both an antibody and a high-affinity 
ligand of  the secreted molecule. The antibody specifically binds a molecular target on the 
extracellular surface of  the secreting cells, after which the high-affinity ligands bind the secreted 
molecules.186 Then this AM technology was utilized to specifically target autoreactive long-lived 
plasma cells in mice, by targeting CD138 or CD44, both surface markers on plasma cells (Figure 
10).187 Anti-CD138 and anti-CD44 F(ab)2 fragments were conjugated to antigens of  interest, in 
this study either ovalbumin or the acetylcholine receptor was used. In principle, all plasma cells 
will be coated with the AM, however, the matrix will only capture any antigen-selective antibodies 
if  those are secreted by the cell. Subsequently the cells will undergo complement-mediated lysis. 
This technique was successfully applied to deplete autoreactive long-lived plasma cells from a 
murine model of  experimental autoimmune myasthenia gravis ex vivo. In addition, by testing the 
AM technology with a mixture of  different antibody secreting plasma cells, the matrix significantly 
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showed a high level of  specificity for the antigen used in the matrix.187 Lastly, preliminary 
experiments in mice suggested the in vivo therapeutic potential.172 
In conclusion, this strategy might be an elegant approach to antigen-selectively target and deplete 
autoreactive long-lived memory plasma cells involved in autoimmune disease pathogenesis, while 
keeping the protective humoral memory untouched.172 Potential limitations of  this approach in vivo 
might be the presence of  circulating autoantibodies, which could bind the AM of  protective 
plasma cells.172 Besides, clinical translation of  this approach may prove difficult when various 
autoantibodies are involved in disease pathology.168 Also, the effect of  the AM on the surface of  
protective plasma cells has to be investigated.  
 
1.3 Targeting of ACPA-Specific Autoreactive B Cells in Rheumatoid Arthritis  
 
One of the most frequently occurring autoimmune diseases is rheumatoid arthritis. Although the 
complete mechanism of this disease remains to be elucidated, autoantibodies are known to sustain 
inflammation. The B cells producing these antibodies are therefore a relevant target to treat RA. 
 
Rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease affecting ~1% of the 
Western population, with women outnumbering men by three to one. This autoimmune disease 
involves inflammation, which eventually leads to the destruction of joints and cartilage. RA is 
hallmarked by the presence of anti-citrullinated protein antibodies (ACPA) and/or rheumatoid 
factor (antibodies targeting the Fc region of human IgG, RF) in 50-80% of the patients. Although 
the exact mechanism is not fully understood, it is known that genetic and environmental factors 
affect the risk for RA. 
Antibodies to citrullinated proteins are sustaining the destructive inflammation. Protein 
citrullination is a posttranslational modification, in which an arginine is converted into a citrulline 
by a calcium-dependent enzyme called peptidylarginine deiminase (PAD).188 Within the cell, PADs 
reside mostly in an inactive state as the minimal calcium concentration for PAD activity is 10-5 
mol/L while the intracellular concentration is 10-7 mol/L. Upon cell death, the integrity of the 
plasma membrane is lost, allowing extracellular calcium (concentration 10-3 mol/L) to enter the 
cell and activate the PADs. Alternatively, PADs might leak out of the cell and become activated 
extracellularly. The conversion of arginine to citrulline results in the loss of a positive charge 
(Figure 11A), which might affect protein folding or protein-protein interactions. Activation of 
PADs and citrullination of proteins is a general process in inflammation; however, RA patients 
develop an immune response to these citrullinated proteins. B cells that produce ACPA are 
thought to be the key factor for the chronicity of the inflammation.189 ACPA can be detected up 
to several years before the onset of the disease.190 In addition, ACPA are correlated to the severity 
of the disease and are therefore an interesting marker to predict the development of the disease.191  
ACPA recognize citrullinated vimentin on osteoclast precursor cells,192 which stimulate TNF 
production and differentiate to bone-resorbing osteoclasts. Osteoclasts express high levels of PAD 
type 2, which in turn increases local citrullination, including vimentin on the precursor cells. This 
initial bone loss may initiate recruitment of B and T cells by the bone marrow adjacent to the joint. 
The synovitis leads to the production of proinflammatory cytokines which in turn stimulates 
osteoclastogenesis, aided by T-helper cells,193 and subsequently enhances bone erosion (Figure 
11B). Hence, established RA is marked by bone erosion combined with inflamed tissue.194 
Since these ACPA-producing B cells are known to be pathogenic and ACPA are highly disease-
specific biomarkers that are associated with joint destruction, B-cell depletion strategies like 
Rituximab (targeting CD20) are effective.195 This treatment destroys B cells through the 
mechanism of ADCC. However, the lack of specificity causes serious side-effects due to the 
concomitant loss of protective memory cells. Therefore, new strategies in which only autoreactive 
B cells are targeted are of great interest. 
 
 
Figure 11. Development of RA. A) The guanidinium functional group from a peptidyl-arginine is converted 
into an ureido moiety by PADs, creating a peptidyl-citrulline; B) Schematic representation of the postulated 
different stages of disease onset. Bone resorbing osteoclasts differentiate from their precursor cells due to 
TNF production stimulated by surface ACPA binding on for example citrullinated vimentin. Immune cells 
are attracted and inflammation is initiated. Expanding cells establish a chronic inflammation and bone and 
cartilage degradation is sustained. 
 
B cell receptor targeting. Autoreactive B cells from RA patients have been selectively detected 
and depleted in vitro by targeting the BCR.6, 196 The majority of RA patients express ACPA that are 
disease-specific biomarkers and associated with disease pathogenesis.197 In order to study ACPA-
expressing B cells, Kerkman et al.198 developed autoantigen tetramers as tool to isolate them from 
the peripheral blood of RA patients (Figure 12A). The tetramers were constructed by conjugation 
of biotinylated cyclic citrullinated peptide 2 (CCP2) to streptavidin, labeled with a fluorescent dye. 
These conjugates allowed the detection and selection of ex vivo ACPA-producing B cells.198 
Pozsgay et al.196 employed an analogous technique to selectively target and deplete citrullinated 
protein-specific B cells from ACPA-positive RA patients (Figure 12B). They synthesized PLGA 
nanoparticles displaying multiple copies of  β60-74Cit peptide, the major epitope of  citrullinated 
fibrinogen,199, 200 as well as a complement-activating lytic peptide derived from gp120 of  HIV-1.201 
By using these bifunctional nanoparticles, the authors showed that they could significantly reduce 
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showed a high level of  specificity for the antigen used in the matrix.187 Lastly, preliminary 
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the β60-74Cit specific ACPA production. They were able to specifically deplete citrullinated 
protein-specific B cells in ex vivo cultures of  patient’s blood. Lysis of  β60-74Cit epitope-specific 
autoreactive B cells was selectively induced via complement-dependent cytotoxicity, achieved by 
the formation of  the complement membrane attack complex, C5b-9. Both ACPA and ACPA-
producing B cells were effectively reduced.196 
 
 
Figure 12. Detection, isolation and depletion of  autoreactive B cells by targeting of  the BCR. A) 
Biotinylated citrullinated peptides (blue circles) are conjugated to fluorescently labeled streptavidin. 
Antigen-selective targeting of  B cells via the BCR enables detection and isolation of  B cells of  interest; B) 
Multiple citrullinated peptides as well as complement-activating peptides are conjugated to a PLGA 
nanoparticle. Antigen-selective targeting of  autoreactive B cells using this peptide combination induced the 
formation of  the complement membrane attack complex and hence depletion of  these B cells.  
 
In conclusion, this strategy is an elegant approach to target and deplete autoreactive B cells in an 
antigen-selective manner.196 Protective B cells would remain untouched, while the B cells involved 
in autoimmune disease pathogenesis can be depleted. On a critical note, the BCR is well-known 
to internalize when bound to an antigen.202 An interesting question is whether the BCR is 
internalized when bound by the PLGA nanoparticles, and whether the nanoparticles are 
internalized when bound to the receptor. If  this happens, it would probably affect the efficacy of  
the treatment strategy. The possibility of  BCR internalization is not discussed by the authors.196 
However, this internalization also gives new possibilities, such as antigen-selective internalization 
of  cytotoxic molecules. Moreover, since the β60-74Cit peptide is not the only epitope targeted by 
ACPA in RA patients, clinical translation of  this treatment method should involve simultaneous 
administration of  a number of  different lytic nanoparticles, displaying various autoantigenic 
epitopes.196 Although this approach has only been applied in in vitro studies so far, it holds potential 
in the development of  antigen-selective B cell-targeted therapies by targeting the BCR on 
autoreactive B cells.  
 
1.4 Conclusions and Outlook 
 
Current B cell-directed therapies mainly induce immune suppression by either inhibiting or 
eliminating the complete B cell compartment, leaving patients at increased risk of  infection.2 
Ideally, therapeutics would only target autoreactive B cells involved in disease pathogenesis, while 
leaving healthy B cells intact. Although antigen-selective immunotherapies targeting the B cell 
compartment have only emerged during recent years, many promising approaches have been 
developed. The display of  autoantigen peptides is important for B cell specificity and efficacy of  
targeted therapies. Therefore, the identification of  autoantigens and respective epitopes involved 
in disease pathology remains an important issue.2 For RA, much research has been performed on 
the autoantigens already.203 To improve targeting strategies described here, reduction of  
autoantigen clearance by free circulating autoantibodies could be beneficial. Not much is known 
about the possible interference of  autoantibodies with the strategies reviewed in this Chapter. 
However, the ACPA serum titer of  RA patients can be as high as 10-200 µg/mL.204 To improve B 
cell binding in these strategies, we suggest that circumventing autoantibody-mediated clearance of  
the autoantigen could be beneficial. Also, the possibilities to target B cells via their BCR are limited 
and hence this is the focus of  this thesis; strategies to target and eliminate autoreactive B cells 
while circumventing the clearance by circulating autoantibodies.  
 
1.5 Outline of  this Thesis 
 
The goal of  the work described in this thesis is to improve antigen-selective B cell targeting and 
thereby creating specificity of  autoreactive B cells over autoantibodies. We envision that by caging 
of  an autoantigen-conjugate binding to both autoreactive B cells and autoantibodies can be 
circumvented. We envision that selective activation in close proximity of  a B cell, by using B cell-
specific markers, can result in optimal binding of  the antigen conjugate with the autoreactive B 
cell instead of  the autoantibody. 
In the studies described in Chapter 2 we explore the possibility to cage a cyclic citrullinated 
peptide (CCP) with a carboxynitrobenzyl group and the subsequent removal using the enzyme 
nitroreductase. In Chapter 3 we describe a chemical approach to selectively activate the 
autoantigen, by using an iminosydnone click-to-release reaction. In Chapter 4 we describe the 
development of  a new click-to-release reaction, using phenylvinyl boronic acids (VBA), and we 
utilized this reaction to cage a lymphocyte-specific toxin. In the studies described in Chapter 5 we 
explore the use poly(isocyanopeptides) (PICs) as alternative multivalent scaffold for the frequently 
used streptavidin. In Chapter 6 we describe the discovery of  a new synthetic antigen peptide, 
which can bind to anti-carbamylated antibodies (anti-CarP).  
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Abstract 
 
Autoreactive B cells are thought to play a pivotal role in many autoimmune diseases. Rheumatoid 
arthritis (RA) is an autoimmune disease affecting ~1% of the Western population and is 
hallmarked by the presence of anti-citrullinated proteins antibodies (ACPA) produced by 
autoreactive B cells. We intend to develop a method to target and selectively eliminate these 
autoreactive B cells using a sequential antigen prodrug targeting strategy. As ACPA-expressing B 
cells are thought to play essential roles in RA-disease pathogenesis, we used this B cell response as 
a prototype to analyze the feasibility to generate a construct consisting of a biologically silenced, 
i.e. caged, antigen connected to a cytotoxic prodrug. Caging of the antigen is considered relevant 
as it is anticipated that circulating autoantibodies will otherwise clear the antigen-prodrug before 
it can reach the target cell. The antigen-prodrug can only bind to the autoantigen-specific B cell 
receptor (BCR) upon enzymatic removal of the caging group in close proximity of the B cell 
surface. BCR binding ultimately induces antigen-selective cytotoxicity after internalization of the 
antigen. We have synthesized a cyclic citrullinated peptide (CCP) antigen suitable for BCR binding, 
and demonstrated that binding by ACPA was impaired upon introduction of a carboxy-p-
nitrobenzyl (CNBz) caging group at the side chain of the citrulline residue. Enzymatic reduction 
of the CNBz moiety by nitroreductase fully restored citrulline-selective recognition by both ACPA 
and ACPA-expressing B cells and showed targeted cell death of CCP-recognizing B cells only. 
These results mark an important step towards antigen-selective B cell targeting in general and more 
specifically in RA, as successful caging and activation of citrullinated antigens forms the basis for 
subsequent use of such construct as a prodrug in the context of autoimmune diseases.  
  
2.1 Introduction 
 
Many autoimmune diseases are characterized by the presence of antibodies that are directed to 
self-antigens.1 The importance of autoreactive B cells in autoimmunity is well recognized, however, 
the exact mechanisms of their involvement have not been fully established. Rheumatoid arthritis 
(RA) is an inflammatory autoimmune disease that is characterized by chronic synovitis and erosive 
destruction of articular cartilage and bone. RA affects 0.5-1% of adults in the developed world.2 
Of these patients, 70-80% harbor anti-citrullinated protein antibodies (ACPA).3  
Protein citrullination, the process in which a peptidylarginine is enzymatically converted into a 
peptidylcitrulline by peptidylarginine deiminase (PAD), is a posttranslational modification 
commonly observed in inflammation.4 Antibodies directed to citrullinated proteins can be detected 
several years before the onset of RA, are associated with severity of the disease and are therefore 
an interesting marker to predict the development of RA.5 Cyclic citrullinated peptides (CCPs) are 
often used as a test substrate for the detection of ACPA.6  
Depletion of CD20-expressing B cells (e.g. using rituximab) is effective in treating RA.7 The 
therapeutic effect is greater in ACPA-positive RA patients than in the ACPA-negative 
counterpart.8 These observations suggest that autoreactive ACPA-expressing B cells may play 
central roles in driving and maintaining the inflammatory processes in RA. As CD20-expression 
by B cells is not restricted to the autoreactive B cell compartment, depletion of the entire CD20-
positive population by rituximab leads to immune deficiency against infectious agents.9 Hence, a 
strategy to specifically deplete autoreactive B cells is of great interest. For example, the use of an 
autoantigen-toxin conjugate that selectively targets the BCR can be beneficial.  
So far, researchers have used autoantigens as part of selective targeting strategies for autoreactive 
B cells (outlined in more detail in Chapter 1). For example, Reiners and coworkers showed that by 
using proteinase 3, an autoantigen in Wegener’s granulomatosis, conjugated to an angiogenin toxin, 
proteinase 3-selective B cell hybridomas could be selectively targeted.10 Similar approaches using 
alternative toxins have also been described for the selective targeting of B cells involved in multiple 
sclerosis11, 12 or B cells producing antibodies against a tetanus toxoid fragment.13 However, since 
specific B cells can differentiate into plasma cells excreting the same immunoglobulin, antigen-
conjugates might be cleared by these free circulating autoantibodies. Especially since the ACPA 
serum titer of RA patients can be as high as 10-200 µg/mL.14 To improve B cell binding in these 
strategies, we suggest that circumventing autoantibody-mediated clearance of the autoantigen 
could be beneficial.  
Here, we aimed to develop a sequential antigen-prodrug targeting strategy using the RA-selective 
autoimmune response as example, where a specific citrullinated peptide (CP) is conjugated to a 
cytotoxic entity (Figure 1). As a CP is able to bind to ACPA-expressing B cells and to soluble, free-
circulating ACPA, we introduced a protecting group to circumvent undesired antigen binding to 
soluble ACPA upon administration. We envisioned that the exposure of the citrullinated epitope 
of the antigen can be locally restored to ensure high concentrations of the antigen-drug conjugate 
in close proximity of ACPA-expressing B cells (Figure 1). Antigen binding via the specific B cell 
receptor followed by internalization of the toxin conjugate should subsequently result in selective 
ACPA-positive B cell death.  
We based our approach on the concept of an antibody-directed enzyme prodrug therapy 
(ADEPT) as our ultimate goal for the activation of a CP. This strategy has been explored 
extensively for local activation of cytotoxic prodrugs for tumor treatment.15 In an ADEPT strategy, 
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2.1 Introduction 
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therapeutic effect is greater in ACPA-positive RA patients than in the ACPA-negative 
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by B cells is not restricted to the autoreactive B cell compartment, depletion of the entire CD20-
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B cells (outlined in more detail in Chapter 1). For example, Reiners and coworkers showed that by 
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conjugates might be cleared by these free circulating autoantibodies. Especially since the ACPA 
serum titer of RA patients can be as high as 10-200 µg/mL.14 To improve B cell binding in these 
strategies, we suggest that circumventing autoantibody-mediated clearance of the autoantigen 
could be beneficial.  
Here, we aimed to develop a sequential antigen-prodrug targeting strategy using the RA-selective 
autoimmune response as example, where a specific citrullinated peptide (CP) is conjugated to a 
cytotoxic entity (Figure 1). As a CP is able to bind to ACPA-expressing B cells and to soluble, free-
circulating ACPA, we introduced a protecting group to circumvent undesired antigen binding to 
soluble ACPA upon administration. We envisioned that the exposure of the citrullinated epitope 
of the antigen can be locally restored to ensure high concentrations of the antigen-drug conjugate 
in close proximity of ACPA-expressing B cells (Figure 1). Antigen binding via the specific B cell 
receptor followed by internalization of the toxin conjugate should subsequently result in selective 
ACPA-positive B cell death.  
We based our approach on the concept of an antibody-directed enzyme prodrug therapy 
(ADEPT) as our ultimate goal for the activation of a CP. This strategy has been explored 
extensively for local activation of cytotoxic prodrugs for tumor treatment.15 In an ADEPT strategy, 
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an enzyme is conjugated to a targeting antibody after which a nontoxic prodrug is administered. 
The prodrug is then locally activated by the enzyme, releasing the toxin specifically at the directed 
site. Several enzymes have been explored for this strategy including alkaline phosphatase,16 beta-
lactamase17 and carboxypeptidase G2.18  
 
 
Figure 1. Schematic representation of the sequential prodrug strategy. A) Antigen activation mechanism. 
NTR reduction of the aromatic nitro group to the (hydroxyl)amine and subsequent 1,6-elimination; in 
future applications, enzymatic reduction will have to be included in an ADEPT strategy so that antigen 
activation takes place locally, in the vicinity of the BCR; B) CArgP and CCP(CNBz) will not bind to the 
BCR. After reduction with NTR, the activated CCP-toxin can selectively bind the BCR followed by BCR-
mediated internalization and initiation of cell death; C) Schematic representation of the CXP (with X being 
different amino acids) peptides used. CCP contains citrulline, CArgP contains arginine and CCP(CNBz) 
contains the carboxynitrobenzyl caged citrulline. Together with the toxin, this shows the proposed structure 
of the sequential antigen-prodrug.  
 
In our studies, we focused on using nitroreductase (NTR), which reduces an aromatic nitro group 
into an amine (or hydroxylamine).19 This enzyme has been explored before in ADEPT strategies, 
where a potent cytotoxic drug was liberated in vivo upon reduction of the aromatic nitro group.20, 
21 In this and other studies, a nitrobenzyl alcohol protecting group was used as self-immolative 
linker upon reduction.22-24 We therefore envisioned that a carboxy-p-nitrobenzyl (CNBz) would 
serve as a good protecting group for citrulline and that reduction by NTR would initiate 1,6-
elimination and CO2 release, resulting in a free ureido group at the citrulline side chain (Figure 1A). 
In our study, we used NTR as a proof of concept for selective activation of a prototype 
autoantigen, acting on the assumption that this concept can in the future be implemented into an 
ADEPT strategy. 
2.2 Results and Discussion 
 
Autoantigen selection. We started our studies by exploring different possible autoantigens for 
the ACPA-expressing immortalized B cells and their monoclonal antibodies used as model system. 
These B cells were previously isolated from an ACPA-positive RA patient and transduced with 
BCL-XL, BCL-6 and GFP genes resulting in ACPA-secreting and -expressing, GFP-positive 
immortalized B cell line.25 
We selected a set of known peptide epitopes and evaluated binding to ACPA for future use as 
prodrug antigen for ACPA-expressing B cells.26-28 Figure 2 shows the results from an ELISA 
experiment with nine different peptides, tested against the monoclonal ACPA. Fibronectin and 
cyclic citrullinated peptide-1 (CCP1) showed to be the best hits in this assay. We selected a CCP1 
analogue (CCP), a well-known ACPA antigen,29, 30 as initial antigen for our conjugate assembly, 
since this peptide epitope contains only one citrulline, whereas fibronectin does have two sides of 
citrullination. 
 
 
Figure 2. ELISA screening of different peptide epitopes for monoclonal ACPA produced by immortalized 
B cells which were used as a model system. Both fibronectin and CCP1 gave high signals.  
 
Synthesis of (caged) citrullinated antigens. We next explored a synthetic strategy to generate 
a caged cyclic citrullinated peptide antigen. As the citrulline residue is key for recognition by ACPA 
and citrulline-directed BCRs, we envisioned that the urea moiety of the citrulline residue itself 
would be the best position to introduce the CNBz caging group. The incorporation of CO2 as a 
driving force in antigen activation can be advantageous, however, only a few reactions with ureas 
to produce N-(carbamoyl)carbamates have been reported in literature.31, 32  
 
 
Scheme 1. Citrulline caging with carboxy-p-nitrobenzyl. i) p-Nitrobenzyl chloroformate, THF, 19 h, 40 °C, 
77% yield based on recovered starting material. 
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Citrulline caging was finally achieved by reacting Fmoc-citrulline with para-nitrobenzyl 
chloroformate in THF in reasonable yield after recovery of the unreacted starting material (Scheme 
1). The carboxy-p-nitrobenzyl caged Fmoc-citrulline (1) proved very stable towards 20% piperidine 
as well as TFA and could thus be used in standard peptide synthesis to produce the full CCP 
antigen. 
CCP is recognized by 37-62% of ACPA-positive sera,29 whereas the arginine containing variant 
of the peptide (CArgP) does not have affinity for ACPA and can therefore serve as a negative 
control. We synthesized CXP peptides (with X being different amino acids) using standard Fmoc 
solid phase peptide synthesis with arginine (2, CArgP) as the negative control, citrulline (3, CCP) 
as the positive control and caged citrulline 1 (4, CCP(CNBz)) (Figure 3A). A biotin moiety was 
installed at the single free amine functionality on resin for further experimental evaluation. The 
CXP peptides were covalently cyclized by first reacting the N-terminus with chloroacetic anhydride 
followed by deprotection of the full peptide and substitution of the chloride by the internal 
cysteine. 
 
 
Figure 3. ACPA binding to caged CCP and the activation using NTR. A) Structures of CArgP (2), CCP 
(3) and the CNBz caged CCP (4). Biotin was used for conjugation purposes; B) CCP ELISA using caged 
antigens detected by monoclonal ACPA. 1 h incubation of the caged peptide with different NTR 
concentrations fully restored ACPA binding. Experiment was performed twice in triplicate.  
This covalently cyclized CCP variant (CCP) showed slightly higher affinity to monoclonal ACPA 
compared to original CCP1 which is cyclized via a thiol-bridge including a second cysteine on our 
alanine position (Figure SI-1). The CNBz-caged variant of CCP proved to be stable for at least 7 
days in acidic to neutral pH (Figure SI-2).  
 
NTR-mediated activation of CCP(CNBz). Having the biotinylated controls and caged CXP 
antigens 2-4 in hand, we explored the rate of CNBz reduction by NTR. We first established that 
activation of the CNBz-caged citrulline building block 1 using NTR and NADH as cofactor was 
fast and full activation was observed within 5 minutes using 0.3 equivalents of NTR (Figure SI-3). 
Next, we evaluated whether the CNBz caging group retained the CCP antigen from binding to 
ACPA in an enzyme-linked immunosorbent assay (ELISA) using monoclonal ACPA obtained 
from the supernatant of ACPA-producing immortalized B cells. Biotinylated and caged peptide 4 
as well as control peptides 2 and 3 were coupled to a streptavidin-coated ELISA plate and 
incubated with monoclonal ACPA-containing supernatant. Reduction of the CNBz group by NTR 
was performed before coupling of the peptide to the ELISA plate. Figure 3B shows that 
monoclonal ACPA-recognized CCP, as expected. More importantly, CNBz caging of CCP 
retained monoclonal ACPA from binding to the level observed for the negative control peptide 
(CArgP, 2). Treatment of CCP(CNBz) with NTR and NADH (for 1 h at 37 °C in PBS pH 7.4) 
showed a concentration-dependent antigen activation, as evidenced by restoration of the binding 
to the monoclonal ACPA. Full restoration of antigen binding was already achieved within 5 
minutes using 0.3 equivalents NTR (Figure SI-4).  
As ACPA present in blood of RA-patients are not monoclonal,33 the recognition of these peptides 
by patient sera was investigated. We selected sera of five different patients that were highly positive 
for antibodies to CCP2, the common antigen used for the detection of ACPA in a clinical 
diagnostic setting. Four of these RA patients were highly positive and one weakly positive for CCP 
recognition (Figure 4). The CArgP negative control was not bound by patient ACPA, and, 
similarly, no recognition of CCP(CNBz) antigen was observed. Antigen activation using 0.3 
equivalents of NTR resulted in the full recovery of initial binding to the polyclonal ACPA for all 
five patients showing that both caging and activation of CCP for recognition by patient derived 
polyclonal ACPA is feasible. 
 
 
Figure 4. ELISA with the CXP antigens incubated with ACPA-positive patient sera. 0.3 equiv. 
nitroreductase was used for antigen activation. This experiment was performed in duplicate. 
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Antigen-dependent selective cellular targeting and toxicity. Application of the sequential 
antigen prodrug targeting strategy presented here requires efficient antigen activation in the 
proximity of cells. To this end, biotinylated CXP antigens were conjugated to fluorescently labelled 
streptavidin tetramers to visualize antigen binding to B cells by flow cytometry.34 Two B cell clones 
derived from immortalized ACPA-expressing and anti-tetanus toxoid (TT)-specific B cells were 
used for this purpose. The antigen specificity of the immortalized B cell clones is shown in Figure 
SI-5.  
 
 
Figure 5. Flow cytometric binding studies of streptavidin-coupled, biotinylated CCP, CArgP, and 
(activated) CCP(CNBz) to A) an ACPA-expressing B cell clone and B) an anti-TT-specific B cell clone. 
This experiment was performed in duplicate.  
 
Figure 5A shows staining of CCP-streptavidin-APC conjugates (y-axis) to clonal ACPA-expressing 
immortalized B cells (GFP-positive, x-axis), indicating binding of CCP-streptavidin tetramers to 
cell surface BCRs. No binding was observed for the CArgP and CCP(CNBz) antigen variants, 
demonstrating specificity of the signals observed for CCP. Notably, addition of 0.3 equivalents 
NTR for 1 hour almost completely recovered antigen-binding to ACPA-expressing B cells (last 
panel), while no binding was observed to anti-TT-specific control B cell clones (Figure 5B). 
Together, these data indicate that caging and activation of CCP can be achieved for antigen-specific 
recognition by both soluble antibodies and surface-expressed B cell receptors.  
To demonstrate that we can not only deprotect and restore antigen-recognition by B cells but 
also achieve selective killing of ACPA-expressing B cells, we next conjugated the biotinylated 
antigen variants to a streptavidin-saporin conjugate (SA-ZAP).35, 36 Saporin is a cytotoxic ribosome 
inhibitor that induces cell death by apoptosis,37 which has been used in many in vivo studies as 
antibody-drug conjugate and was found to be stable and well-tolerated.35, 38-41 Equal numbers (1 x 
104) of ACPA-expressing and anti-TT-specific immortalized B cells were cultured with 0, 0.1, 1, 
10 and 100 nM antigen-SA-ZAP conjugates. After 4 days of incubation, a XTT cell viability assay 
was performed to assess the amount of remaining viable cells. The percentage of living cells was 
calculated by dividing the optical density value of cells treated with antigen-SA-ZAP by the optical 
density of cells treated in parallel with the corresponding antigen-SA complex. Figures 6A and B 
schematically show the structure of the prodrug and controls, and propose the expected outcome 
of this experiment, while Figures 6C and D show the percentage of living ACPA-expressing B 
cells or anti-TT-expressing B cells, respectively, after treatment with SA-ZAP conjugated to CXP 
either treated or non-treated with NTR. 
 
 
Figure 6. Selective cytotoxicity by caging and activation of CCP. A) Schematic representation of 
streptavidin-ZAP bound to the CXP peptides; B) schematic representation of the expected toxicity of the 
different SA-ZAP conjugates to ACPA-expressing B cells. Percentage of living ACPA-expressing B cells 
(C) and anti-TT-specific B cells (D) after four days of treatment with antigen-toxin conjugates.  
 
The exposure of cells to CCP-SA-ZAP at 1 nM as well as the activated CCP(CNBz) induced death 
of up to 60% of ACPA-expressing B cells. At this SA-ZAP concentration, 86% of ACPA-
expressing B cells survived the treatment when bound to CCP(CNBz), comparable to CArgP-SA-
ZAP or SA-ZAP without peptide. Increasing the concentration resulted in more cell death, 
although increasing cellular toxicity was then also noted for SA-ZAP that was not conjugated to 
any antigen (Figure 6C). The lack of 100% death of ACPA-expressing B cell clone by either CCP-
SA-ZAP or NTR-treated CCP(CNBz)-SA-ZAP could relate to the transfection of these cells with 
anti-apoptotic genes, which might make them less susceptible to toxic agents than conventional B 
cells would be.  
As the antigen-toxin conjugate, once it is activated by nitroreductase, can bind to both the B cell 
receptor of ACPA-expressing cells and to secreted ACPA molecules we consider it important that 
antigen activation eventually occurs in close vicinity to the B cell receptor that we envision to be 
achieved by an ADEPT approach. Nonetheless, binding of secreted ACPA molecules to the 
conjugate could lead to the formation of immune complexes. Circulating ACPA-immune 
complexes have been reported to be capable of stimulating effector cells in vitro via binding to Fc 
receptors.42 Thus, unwanted Fc receptor-mediated effects such as antibody dependent cellular 
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antigen activation eventually occurs in close vicinity to the B cell receptor that we envision to be 
achieved by an ADEPT approach. Nonetheless, binding of secreted ACPA molecules to the 
conjugate could lead to the formation of immune complexes. Circulating ACPA-immune 
complexes have been reported to be capable of stimulating effector cells in vitro via binding to Fc 
receptors.42 Thus, unwanted Fc receptor-mediated effects such as antibody dependent cellular 
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cytotoxicity cannot be fully excluded and future in vivo studies will have to be performed to evaluate 
this possibility.  
Finally, selectivity of the approach was demonstrated by the lack of toxicity of the conjugates for 
anti-TT-specific B cells (Figure 6D), and also NTR by itself did not show toxic effects on the B 
cells used (Figure SI-6). These results indicate that CCP-SA-ZAP and NTR-treated CCP(CNBz)-
SA-ZAP can be used for the selective depletion of ACPA-expressing B cells ex vivo. 
 
2.3 Conclusions 
 
The therapeutic efficacy of CD20 depletion in the treatment of RA, the risks of long-lasting 
systemic immunosuppression associated with this treatment, and the high specificity of the ACPA 
immune response for this disease have fueled efforts aimed at the selective elimination of ACPA-
expressing memory B cells as a prospect of targeted therapy in RA. Here, we demonstrate a 
sequential two-step prodrug strategy to selectively eliminate autoreactive B cells. By exploiting the 
essential requirement of the citrulline residue in the antigen for recognition by ACPA-BCR and 
soluble ACPA molecules, we showed that caging this amino acid with CNBz resulted in complete 
loss of binding to ACPA and ACPA-expressing B cells. Furthermore, the CNBz group could be 
removed by nitroreductase to restore binding of the antigen. Using this strategy, we selectively 
induced cell death in immortalized ACPA-expressing B cell clones using an antigen coupled to a 
streptavidin-toxin, while anti-TT expressing B cells were insensitive to these conjugates.  
We expect that antigen activation in close proximity to the B cell membrane, e.g. by using NTR, 
can circumvent binding of antigen to free circulating ACPA, thereby decreasing the risk for rapid 
clearance of the drug from tissue and the circulation. The CNBz reduction using NTR may be 
beneficial as elevated levels of reductases are found in hypoxic inflamed tissue.43 In addition, NTR 
has been explored previously in ADEPT21 and enzyme-selective cofactors for E. coli NTR are 
reported circumventing the use of serum-sensitive cofactors such as NAD(P)H.44 
In conclusion, we show that we can selectively cage and activate CCP, thereby tuning the affinity 
to ACPA and ACPA-expressing B cells. Using this approach, we expect that it will be possible to 
circumvent CCP(CNBz) from binding to ACPA and after selective activation by NTR in the 
proximity of B cells, using a possible ADEPT construct, regain binding to the BCR and thereby 
the internalization of a cytotoxin. Since not all autoreactive B cells reside in inflamed tissue, but 
also in lymph nodes, we currently investigate additional approaches for the selective activation of 
target antigens including click-to-release chemistry (Chapter 3).45  
In this study, we demonstrated caging and activation of CCP in the context of the citrulline-
specific B cell response, and we expect that this modular strategy will be applicable interchangeably 
for other (auto)antigens as well. The selectivity of the antigen and the possibility to retain binding 
to circulation ACPA brings us a step closer to the selective elimination of autoreactive B cells for 
the treatment of patients with ACPA-positive RA.  
 
2.4 Materials and Methods 
 
General methods and materials. Unless stated otherwise, all chemicals were used without 
further purification. Amino acids were obtained from Bachem (Bubendorf, Switzerland) or 
Novabiochem (EMD Chemicals, Gibbstown, USA). Solvents were purchased from J.T. Baker, 
Biosolve, Fisher Scientific and Merck Millipore and used as received. If no further details are given 
the reaction was performed under ambient atmosphere and temperature. Analytical thin layer 
chromatography (TLC) was performed on silica gel-coated plates (Merck, 60 F254) with the 
indicated solvent mixture, visualization was done using ultraviolet (UV) irradiation (λ = 254 nm) 
and/or staining with aqueous KMnO4. Purification by column chromatography was carried out 
using silica gel 60 (Merck, 0.040-0.063 mm). 1H-NMR chemical shifts (δ), recorded on a Bruker 
500 MHz Avance III spectrometer equipped with a Prodigy BB cryoprobe, are reported in parts 
per million (ppm) relative to a residual proton peak of the solvent, δ = 7.26 for CDCl3. 13C-NMR 
chemical shifts (δ), are reported in parts per million (ppm) relative to CDCl3 (δ = 77.16). Coupling 
constants are reported as a J-value in Hertz (Hz). Low-resolution mass spectra (LRMS) were 
recorded on Thermo LCQ Advantage Max (ESI). A Thermo Finnigan LCQ Fleet ESI ion-trap 
mass spectrometer, which is equipped with a Shimadzu HPLC (C18-column, particle size 3 μm, 
acetonitrile/water gradient 5 - 100%, in 16 minutes and a flow of 0.2 ml/min) and a PDA detector, 
was used to separate organic compounds and record low-resolution mass spectra. High-resolution 
mass spectra (HRMS) of small molecules were recorded on a JEOL AccuTOF JMS-T100CS (ESI). 
Preparative HPLC was performed on a Shimadzu LC-20A Prominence system (Shimadzu, ’s-
Hertogenbosch, The Netherlands) equipped with a Gemini NX-C18 column, 150 × 21.2 mm, 
particle size 10 μm (Phenomenex, Utrecht, The Netherlands). Gradient used was 
acetonitrile/water 5-50%, in 30 minutes and a flow of 6 ml/min. Analytical HPLC measurements 
were performed on a Shimadzu LC-20A Prominence system (Shimadzu, ‘s-Hertogenbosch, The 
Netherlands) equipped with a Gemini NX-C18 column, 150 × 3 mm, particle size 3 μm 
(Phenomenex, Utrecht, The Netherlands). Gradient used is acetonitrile/water 5 - 100%, in 30 
minutes and a flow of 0.4 ml/min. Injected peptides were monitored at 254 nm and 215 nm and 
the desired peaks were integrated manually using a LabSolutions software package (Shimadzu, ‘s-
Hertogenbosch, The Netherlands). 
 
14-(9H-Fluoren-9-yl)-1-(4-nitrophenyl)-3,5,12-trioxo-2,13-dioxa-4,6,11-triazatetradecane-
10-carboxylic acid (1). Fmoc-Cit-OH (2.00 g, 5.0 mmol, 1 equiv.) was 
dissolved in THF (115 ml) and heated to 40 °C. 4-Nitrobenzyl 
chloroformate (1.63 g, 7.6 mmol, 1.5 equiv.) was dissolved in THF (5 
mL) and added to Fmoc-Cit-OH. The reaction mixture was stirred for 
19 h. The mixture was concentrated in vacuo and the mixture was 
purified over silica (2.5-5% MeOH in CH2Cl2), yielding a yellow solid 
product (1) (948 mg, 77% after regaining starting material). Rf = 0.49 
(5% MeOH in EtOAc). 1H NMR (500 MHz, chloroform-d) δ 9.08 (s, 1H), 8.15 (d, J = 8.3 Hz, 
2H), 7.93 (s, 1H), 7.73 (d, J = 7.5 Hz, 2H), 7.63 – 7.52 (m, 2H), 7.43 (d, J = 8.1 Hz, 2H), 7.37 (t, J 
= 7.3 Hz, 2H), 7.31 – 7.26 (m, 2H), 5.58 (d, J = 6.2 Hz, 1H), 5.17 (s, 2H), 4.43 (s, 1H), 4.39 (d, J 
= 6.6 Hz, 2H), 4.19 (t, J = 6.6 Hz, 1H), 3.46 – 3.11 (m, 2H), 1.98 – 1.69 (m, 2H), 1.66 – 1.55 (m, 
2H). 13C NMR (126 MHz, chloroform-d) δ 176.01, 156.18, 154.74, 153.97, 147.97, 143.75, 142.18, 
141.42, 128.40, 127.87, 127.19, 125.19, 123.99, 120.14, 67.07, 66.30, 53.49, 47.32, 39.45, 29.64, 
25.51. HRMS (ESI+) m/z calcd for C29H28N4NaO9+ [M+Na]+ 599.17485, found: 599.17540. 
 
General peptide synthesis. The first amino acid, Fmoc-Lys(Mtt)-OH, (2 equiv.) was added to 
the Wang resin with DIPCDI (2 equiv.), HOBt (4 equiv.) and DMAP (2 equiv.) in DMF. The 
mixture was shaken for 16 h at room temperature. After washing, the Mtt group was cleaved off 
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cytotoxicity cannot be fully excluded and future in vivo studies will have to be performed to evaluate 
this possibility.  
Finally, selectivity of the approach was demonstrated by the lack of toxicity of the conjugates for 
anti-TT-specific B cells (Figure 6D), and also NTR by itself did not show toxic effects on the B 
cells used (Figure SI-6). These results indicate that CCP-SA-ZAP and NTR-treated CCP(CNBz)-
SA-ZAP can be used for the selective depletion of ACPA-expressing B cells ex vivo. 
 
2.3 Conclusions 
 
The therapeutic efficacy of CD20 depletion in the treatment of RA, the risks of long-lasting 
systemic immunosuppression associated with this treatment, and the high specificity of the ACPA 
immune response for this disease have fueled efforts aimed at the selective elimination of ACPA-
expressing memory B cells as a prospect of targeted therapy in RA. Here, we demonstrate a 
sequential two-step prodrug strategy to selectively eliminate autoreactive B cells. By exploiting the 
essential requirement of the citrulline residue in the antigen for recognition by ACPA-BCR and 
soluble ACPA molecules, we showed that caging this amino acid with CNBz resulted in complete 
loss of binding to ACPA and ACPA-expressing B cells. Furthermore, the CNBz group could be 
removed by nitroreductase to restore binding of the antigen. Using this strategy, we selectively 
induced cell death in immortalized ACPA-expressing B cell clones using an antigen coupled to a 
streptavidin-toxin, while anti-TT expressing B cells were insensitive to these conjugates.  
We expect that antigen activation in close proximity to the B cell membrane, e.g. by using NTR, 
can circumvent binding of antigen to free circulating ACPA, thereby decreasing the risk for rapid 
clearance of the drug from tissue and the circulation. The CNBz reduction using NTR may be 
beneficial as elevated levels of reductases are found in hypoxic inflamed tissue.43 In addition, NTR 
has been explored previously in ADEPT21 and enzyme-selective cofactors for E. coli NTR are 
reported circumventing the use of serum-sensitive cofactors such as NAD(P)H.44 
In conclusion, we show that we can selectively cage and activate CCP, thereby tuning the affinity 
to ACPA and ACPA-expressing B cells. Using this approach, we expect that it will be possible to 
circumvent CCP(CNBz) from binding to ACPA and after selective activation by NTR in the 
proximity of B cells, using a possible ADEPT construct, regain binding to the BCR and thereby 
the internalization of a cytotoxin. Since not all autoreactive B cells reside in inflamed tissue, but 
also in lymph nodes, we currently investigate additional approaches for the selective activation of 
target antigens including click-to-release chemistry (Chapter 3).45  
In this study, we demonstrated caging and activation of CCP in the context of the citrulline-
specific B cell response, and we expect that this modular strategy will be applicable interchangeably 
for other (auto)antigens as well. The selectivity of the antigen and the possibility to retain binding 
to circulation ACPA brings us a step closer to the selective elimination of autoreactive B cells for 
the treatment of patients with ACPA-positive RA.  
 
2.4 Materials and Methods 
 
General methods and materials. Unless stated otherwise, all chemicals were used without 
further purification. Amino acids were obtained from Bachem (Bubendorf, Switzerland) or 
Novabiochem (EMD Chemicals, Gibbstown, USA). Solvents were purchased from J.T. Baker, 
Biosolve, Fisher Scientific and Merck Millipore and used as received. If no further details are given 
the reaction was performed under ambient atmosphere and temperature. Analytical thin layer 
chromatography (TLC) was performed on silica gel-coated plates (Merck, 60 F254) with the 
indicated solvent mixture, visualization was done using ultraviolet (UV) irradiation (λ = 254 nm) 
and/or staining with aqueous KMnO4. Purification by column chromatography was carried out 
using silica gel 60 (Merck, 0.040-0.063 mm). 1H-NMR chemical shifts (δ), recorded on a Bruker 
500 MHz Avance III spectrometer equipped with a Prodigy BB cryoprobe, are reported in parts 
per million (ppm) relative to a residual proton peak of the solvent, δ = 7.26 for CDCl3. 13C-NMR 
chemical shifts (δ), are reported in parts per million (ppm) relative to CDCl3 (δ = 77.16). Coupling 
constants are reported as a J-value in Hertz (Hz). Low-resolution mass spectra (LRMS) were 
recorded on Thermo LCQ Advantage Max (ESI). A Thermo Finnigan LCQ Fleet ESI ion-trap 
mass spectrometer, which is equipped with a Shimadzu HPLC (C18-column, particle size 3 μm, 
acetonitrile/water gradient 5 - 100%, in 16 minutes and a flow of 0.2 ml/min) and a PDA detector, 
was used to separate organic compounds and record low-resolution mass spectra. High-resolution 
mass spectra (HRMS) of small molecules were recorded on a JEOL AccuTOF JMS-T100CS (ESI). 
Preparative HPLC was performed on a Shimadzu LC-20A Prominence system (Shimadzu, ’s-
Hertogenbosch, The Netherlands) equipped with a Gemini NX-C18 column, 150 × 21.2 mm, 
particle size 10 μm (Phenomenex, Utrecht, The Netherlands). Gradient used was 
acetonitrile/water 5-50%, in 30 minutes and a flow of 6 ml/min. Analytical HPLC measurements 
were performed on a Shimadzu LC-20A Prominence system (Shimadzu, ‘s-Hertogenbosch, The 
Netherlands) equipped with a Gemini NX-C18 column, 150 × 3 mm, particle size 3 μm 
(Phenomenex, Utrecht, The Netherlands). Gradient used is acetonitrile/water 5 - 100%, in 30 
minutes and a flow of 0.4 ml/min. Injected peptides were monitored at 254 nm and 215 nm and 
the desired peaks were integrated manually using a LabSolutions software package (Shimadzu, ‘s-
Hertogenbosch, The Netherlands). 
 
14-(9H-Fluoren-9-yl)-1-(4-nitrophenyl)-3,5,12-trioxo-2,13-dioxa-4,6,11-triazatetradecane-
10-carboxylic acid (1). Fmoc-Cit-OH (2.00 g, 5.0 mmol, 1 equiv.) was 
dissolved in THF (115 ml) and heated to 40 °C. 4-Nitrobenzyl 
chloroformate (1.63 g, 7.6 mmol, 1.5 equiv.) was dissolved in THF (5 
mL) and added to Fmoc-Cit-OH. The reaction mixture was stirred for 
19 h. The mixture was concentrated in vacuo and the mixture was 
purified over silica (2.5-5% MeOH in CH2Cl2), yielding a yellow solid 
product (1) (948 mg, 77% after regaining starting material). Rf = 0.49 
(5% MeOH in EtOAc). 1H NMR (500 MHz, chloroform-d) δ 9.08 (s, 1H), 8.15 (d, J = 8.3 Hz, 
2H), 7.93 (s, 1H), 7.73 (d, J = 7.5 Hz, 2H), 7.63 – 7.52 (m, 2H), 7.43 (d, J = 8.1 Hz, 2H), 7.37 (t, J 
= 7.3 Hz, 2H), 7.31 – 7.26 (m, 2H), 5.58 (d, J = 6.2 Hz, 1H), 5.17 (s, 2H), 4.43 (s, 1H), 4.39 (d, J 
= 6.6 Hz, 2H), 4.19 (t, J = 6.6 Hz, 1H), 3.46 – 3.11 (m, 2H), 1.98 – 1.69 (m, 2H), 1.66 – 1.55 (m, 
2H). 13C NMR (126 MHz, chloroform-d) δ 176.01, 156.18, 154.74, 153.97, 147.97, 143.75, 142.18, 
141.42, 128.40, 127.87, 127.19, 125.19, 123.99, 120.14, 67.07, 66.30, 53.49, 47.32, 39.45, 29.64, 
25.51. HRMS (ESI+) m/z calcd for C29H28N4NaO9+ [M+Na]+ 599.17485, found: 599.17540. 
 
General peptide synthesis. The first amino acid, Fmoc-Lys(Mtt)-OH, (2 equiv.) was added to 
the Wang resin with DIPCDI (2 equiv.), HOBt (4 equiv.) and DMAP (2 equiv.) in DMF. The 
mixture was shaken for 16 h at room temperature. After washing, the Mtt group was cleaved off 
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using 2% TFA in DCM repeatable for 2 minutes. After washing with DCM and DMF, biotin was 
coupled using DIPCDI (3.3 equiv.) and HOBt (3.6 equiv.). Upon completion, the resin was flushed 
three times with DMF and piperidine was then added for 30 min to cleave off the Fmoc protecting 
group. The resin was subsequently flushed three times with DMF. A mixture of 3 equiv. Fmoc-
AA-OH, 3.6 equiv. HOBt and 3.3 equiv. DIPCDI was added to the resin to bind the subsequent 
amino acid. This reaction was incubated at room temperature. After coupling of the next amino 
acid, the remaining free amines were capped with acetic anhydride (1 mL) and pyridine (1 mL) in 
DMF (12 mL). After washing three times with DMF, piperidine was added again and the cycles 
continued. After the last amino acid, chloroacetic anhydride (5 equiv.) and DIPEA (5 equiv.) were 
added in DMF and shaken for 45 min. Finally, a mixture of 92.5% TFA, 2.5% H2O, 2.5% EDT 
and 2.5% TIPS was made. This mixture was added to the resin and incubated for 3 h at room 
temperature to cleave off the peptide from the resin and to deprotect the amino acid residues. The 
peptide was precipitated in diethyl ether, filtered and dried. Kaiser tests were performed to follow 
the coupling reactions.  
 
General peptide cyclisation. The crude peptides were dissolved in a 50 mM NH4HCO3 buffer 
pH 8.4: MeCN 1:1, at a concentration of 2 mg/mL and stirred for 24 h. MeCN was evaporated 
and the remaining H2O was lyophilized. The peptides were purified using preparative reversed-
phase HPLC and analyzed using analytical HPLC. 
 
CArgP (2). CArgP was synthesized following the procedures described in the general peptide 
synthesis. Next, this peptide was cyclized and purified as described in the general cyclisation 
method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for C100H172N42O33S22+ [M+2H]2+ 
1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 852.28. C100H173N41O34S24+ 
[M+4H]4+ 639.06, found 640.20. 
 
CCP(3). CCP was synthesized following the procedures described in the general peptide synthesis. 
Next, this peptide was cyclized and purified as described in the general cyclisation method. HPLC: 
Rt. 12.753 min. LCMS (ESI+) m/z calcd for C100H171N41O34S22+ [M+2H]2+ 1277.61, found 
1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 852.68. C100H173N41O34S24+ [M+4H]4+ 639.31, 
found 641.16. 
 
CCP(CNBz) (4). CCP(CNBz) was synthesized following the procedures described in the general 
peptide synthesis. Next, this peptide was cyclized and purified as described in the general 
cyclisation method. HPLC: Rt. 14.854 min. LCMS (ESI+) m/z calcd for C108H176N42O38S22+ 
[M+2H]2+ 1367.12, found 1367.52. C108H177N42O38S23+ [M+3H]3+ 911.75, found 912.20. 
C108H178N42O38S24+ [M+4H]4+ 684.06, found 685.20. 
 
CCP(CNBz) stability measurements at various pH. The peptide was dissolved in 1% DMSO 
/ McIlvaine buffer (pH 4-9 at a concentration of 0.2 mg/ml). The reaction was set at 37°C at 600 
rpm for 1-7 days. A sample was taken and was measured by LCMS. The area under the curve of 
the chromatogram shows the percentage of starting material or degradation material (CCP). 
 
Cell culture and monoclonal antibodies. Immortalized B cell clones recognizing CCP and 
tetanus toxoid (TT) were generated by transducing antigen-specific human memory B cells with 
retroviruses encoding BCL-6 and BCL-XL, as previously described.46, 47 Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 8% heat-inactivated fetal calf 
serum, penicillin/streptomycin (PS, 100 U/ml), 2 mM Glutamax and 1 µg/ml puromycin in the 
presence of irradiated CD40L-expressing cells and mouse interleukin-21-Fc (mIL21-Fc). These B 
cell clones maintained the expression of membrane bound ACPA or anti-TT antibody and also 
secreted antibodies recognizing CCP or TT, respectively. Supernatants of the cell cultures which 
contained secreted monoclonal antibodies against CCP or TT were harvested after three days of 
culture.  
 
RA plasma. Peripheral blood was obtained from ACPA-positive RA patients who visited the 
outpatient clinic of the Department of Rheumatology at Leiden University Medical Centre 
(LUMC). The patients met the 2010 ACR/EULAR criteria for RA at the time of diagnosis and 
gave written informed consent to participate in the study. Permission to conduct the study was 
obtained from the ethical review board of LUMC. Blood plasma was obtained by centrifuging 
heparin-treated peripheral blood.  
 
ELISA measurements. The ability of the CNBz moiety to protect CCP epitopes from the 
recognition of both monoclonal and polyclonal ACPA and the capacity of NTR to remove the 
CNBz group and recover CCP reactivity were assessed by ELISA. All reactants were dissolved in 
PBS pH = 7.4. 10 µM (1 equiv.) of biotinylated CCP(CNBz) was treated with 3 µM (0.3 equiv.), 1 
µM (0.1 equiv.), 0.3 µM (0.03 equiv.) and 0.1 µM (0.01 equiv.) NTR and 50 equiv. NADH (both 
from Sigma Aldrich) to test the NTR capacity for 1 hour at 37 oC. Next, biotinylated CCP, CArgP, 
CCP(CNBz) and NTR-pretreated CCP(CNBz) were coupled to streptavidin-coated ELISA plates 
(C96 Maxisorp Nunc-immuno plate, Thermo-Scientific). Undiluted supernatants of the 
immortalized B cell clones and 1:50 diluted patient’s plasma samples were incubated with the 
respective antigens; antigen-bound IgG was detected by polyclonal rabbit anti-human IgG HRP 
(DAKO) and stained with ABTS.H2O2 (Sigma-Aldrich) or TMB-UP (Biomerieux). The 
absorbance of the colorimetric signal was measured with iMark TM Microplate Reader (BioRad) 
at 415nm or 450nm, resp. 
 
FACS measurements. Biotinylated CCP(CNBz), CCP and CArgP were coupled with APC-
labelled streptavidin (Lifetechnologies), as previously described.48 One equivalent of APC-labelled 
CCP(CNBz) tetramer was treated with 0.3 equiv. NTR and 50 equiv. NADH for 1 hour at 37 oC 
in cell cultures containing either ACPA-expressing or anti-TT-expressing immortalized B cells in 
a 96 well plate. Subsequently, the cells were kept on ice for 30 minutes, washed, resuspended with 
1% paraformaldehyde and measured by flow cytometry using BD LSRFortessa (BD Biosciences). 
 
Cell viability assay. Biotinylated CCP, CArgP and CCP(CNBz) were conjugated with 
streptavidin-saporin (Advanced Targeting systems) in a 4:1 ratio to make peptide-drug conjugates. 
1 x 104 ACPA-expressing and/or anti-TT-specific B cell clones were cultured with medium, 
mIL21-Fc and soluble CD40L (from Biolegend) in the presence of 0, 0.1, 1, 10, 100 nM peptide-
drug conjugates in a 96-well plate. After 4 days, supernatants were collected and XTT labelling and 
electron-coupling reagents (Roche) were added to the culture according to the manufacturer’s 
protocol and incubated for 6 hours. Cell viability was measured on an iMark TM Microplate Reader 
(from BioRad). 
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using 2% TFA in DCM repeatable for 2 minutes. After washing with DCM and DMF, biotin was 
coupled using DIPCDI (3.3 equiv.) and HOBt (3.6 equiv.). Upon completion, the resin was flushed 
three times with DMF and piperidine was then added for 30 min to cleave off the Fmoc protecting 
group. The resin was subsequently flushed three times with DMF. A mixture of 3 equiv. Fmoc-
AA-OH, 3.6 equiv. HOBt and 3.3 equiv. DIPCDI was added to the resin to bind the subsequent 
amino acid. This reaction was incubated at room temperature. After coupling of the next amino 
acid, the remaining free amines were capped with acetic anhydride (1 mL) and pyridine (1 mL) in 
DMF (12 mL). After washing three times with DMF, piperidine was added again and the cycles 
continued. After the last amino acid, chloroacetic anhydride (5 equiv.) and DIPEA (5 equiv.) were 
added in DMF and shaken for 45 min. Finally, a mixture of 92.5% TFA, 2.5% H2O, 2.5% EDT 
and 2.5% TIPS was made. This mixture was added to the resin and incubated for 3 h at room 
temperature to cleave off the peptide from the resin and to deprotect the amino acid residues. The 
peptide was precipitated in diethyl ether, filtered and dried. Kaiser tests were performed to follow 
the coupling reactions.  
 
General peptide cyclisation. The crude peptides were dissolved in a 50 mM NH4HCO3 buffer 
pH 8.4: MeCN 1:1, at a concentration of 2 mg/mL and stirred for 24 h. MeCN was evaporated 
and the remaining H2O was lyophilized. The peptides were purified using preparative reversed-
phase HPLC and analyzed using analytical HPLC. 
 
CArgP (2). CArgP was synthesized following the procedures described in the general peptide 
synthesis. Next, this peptide was cyclized and purified as described in the general cyclisation 
method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for C100H172N42O33S22+ [M+2H]2+ 
1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 852.28. C100H173N41O34S24+ 
[M+4H]4+ 639.06, found 640.20. 
 
CCP(3). CCP was synthesized following the procedures described in the general peptide synthesis. 
Next, this peptide was cyclized and purified as described in the general cyclisation method. HPLC: 
Rt. 12.753 min. LCMS (ESI+) m/z calcd for C100H171N41O34S22+ [M+2H]2+ 1277.61, found 
1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 852.68. C100H173N41O34S24+ [M+4H]4+ 639.31, 
found 641.16. 
 
CCP(CNBz) (4). CCP(CNBz) was synthesized following the procedures described in the general 
peptide synthesis. Next, this peptide was cyclized and purified as described in the general 
cyclisation method. HPLC: Rt. 14.854 min. LCMS (ESI+) m/z calcd for C108H176N42O38S22+ 
[M+2H]2+ 1367.12, found 1367.52. C108H177N42O38S23+ [M+3H]3+ 911.75, found 912.20. 
C108H178N42O38S24+ [M+4H]4+ 684.06, found 685.20. 
 
CCP(CNBz) stability measurements at various pH. The peptide was dissolved in 1% DMSO 
/ McIlvaine buffer (pH 4-9 at a concentration of 0.2 mg/ml). The reaction was set at 37°C at 600 
rpm for 1-7 days. A sample was taken and was measured by LCMS. The area under the curve of 
the chromatogram shows the percentage of starting material or degradation material (CCP). 
 
Cell culture and monoclonal antibodies. Immortalized B cell clones recognizing CCP and 
tetanus toxoid (TT) were generated by transducing antigen-specific human memory B cells with 
retroviruses encoding BCL-6 and BCL-XL, as previously described.46, 47 Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 8% heat-inactivated fetal calf 
serum, penicillin/streptomycin (PS, 100 U/ml), 2 mM Glutamax and 1 µg/ml puromycin in the 
presence of irradiated CD40L-expressing cells and mouse interleukin-21-Fc (mIL21-Fc). These B 
cell clones maintained the expression of membrane bound ACPA or anti-TT antibody and also 
secreted antibodies recognizing CCP or TT, respectively. Supernatants of the cell cultures which 
contained secreted monoclonal antibodies against CCP or TT were harvested after three days of 
culture.  
 
RA plasma. Peripheral blood was obtained from ACPA-positive RA patients who visited the 
outpatient clinic of the Department of Rheumatology at Leiden University Medical Centre 
(LUMC). The patients met the 2010 ACR/EULAR criteria for RA at the time of diagnosis and 
gave written informed consent to participate in the study. Permission to conduct the study was 
obtained from the ethical review board of LUMC. Blood plasma was obtained by centrifuging 
heparin-treated peripheral blood.  
 
ELISA measurements. The ability of the CNBz moiety to protect CCP epitopes from the 
recognition of both monoclonal and polyclonal ACPA and the capacity of NTR to remove the 
CNBz group and recover CCP reactivity were assessed by ELISA. All reactants were dissolved in 
PBS pH = 7.4. 10 µM (1 equiv.) of biotinylated CCP(CNBz) was treated with 3 µM (0.3 equiv.), 1 
µM (0.1 equiv.), 0.3 µM (0.03 equiv.) and 0.1 µM (0.01 equiv.) NTR and 50 equiv. NADH (both 
from Sigma Aldrich) to test the NTR capacity for 1 hour at 37 oC. Next, biotinylated CCP, CArgP, 
CCP(CNBz) and NTR-pretreated CCP(CNBz) were coupled to streptavidin-coated ELISA plates 
(C96 Maxisorp Nunc-immuno plate, Thermo-Scientific). Undiluted supernatants of the 
immortalized B cell clones and 1:50 diluted patient’s plasma samples were incubated with the 
respective antigens; antigen-bound IgG was detected by polyclonal rabbit anti-human IgG HRP 
(DAKO) and stained with ABTS.H2O2 (Sigma-Aldrich) or TMB-UP (Biomerieux). The 
absorbance of the colorimetric signal was measured with iMark TM Microplate Reader (BioRad) 
at 415nm or 450nm, resp. 
 
FACS measurements. Biotinylated CCP(CNBz), CCP and CArgP were coupled with APC-
labelled streptavidin (Lifetechnologies), as previously described.48 One equivalent of APC-labelled 
CCP(CNBz) tetramer was treated with 0.3 equiv. NTR and 50 equiv. NADH for 1 hour at 37 oC 
in cell cultures containing either ACPA-expressing or anti-TT-expressing immortalized B cells in 
a 96 well plate. Subsequently, the cells were kept on ice for 30 minutes, washed, resuspended with 
1% paraformaldehyde and measured by flow cytometry using BD LSRFortessa (BD Biosciences). 
 
Cell viability assay. Biotinylated CCP, CArgP and CCP(CNBz) were conjugated with 
streptavidin-saporin (Advanced Targeting systems) in a 4:1 ratio to make peptide-drug conjugates. 
1 x 104 ACPA-expressing and/or anti-TT-specific B cell clones were cultured with medium, 
mIL21-Fc and soluble CD40L (from Biolegend) in the presence of 0, 0.1, 1, 10, 100 nM peptide-
drug conjugates in a 96-well plate. After 4 days, supernatants were collected and XTT labelling and 
electron-coupling reagents (Roche) were added to the culture according to the manufacturer’s 
protocol and incubated for 6 hours. Cell viability was measured on an iMark TM Microplate Reader 
(from BioRad). 
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Figure SI-2. The stability of the CNBz linker of the caged CCP in pH 4-9 (McIlvaine buffer) for 1-7 days 
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Figure SI-3. Activation of Fmoc-Cit(CNBz)-OH using nitroreductase at t = 5 min. Y-axis represents the 
percentage of material, either Fmoc-Cit(CNBz)-OH starting material (purple) or Fmoc-Cit-OH, activated 
product (orange). Different amounts of nitroreductase (concentration on the x-axis) were added and all 
conditions were measured after 5 minutes. Using 100 µg/ml NTR showed almost complete citrulline 
activation. 
 
 
 
Figure SI-4. Activation of CCP(CNBz) followed over time. The activation using NTR was stopped by 
adding nicotinic acid (20 equiv. compared to NADH, which was used in a 50 times excess over 
CCP(CNBz)) at various time points, to replace the NADH necessary for NTR activity. Error bars are 
standard deviations calculated using GraphPad Prism. 
  
 
 
Figure SI-5. Antigen specificity of ACPA-expressing and anti-TT-specific B cell clones. Primary ACPA+ 
and anti-TT+ MBC were sorted and immortalized using lentiviral transduction with BCL-6 and BCL-XL. 
The immortalized ACPA-expressing B cell clone stained positive for CCP2-APC- and CCP2-BV605-
tetramers and the signal can be blocked by pre-incubation with an excess of CCP2-PE-tetramer. 
Immortalized anti-TT-specific B cells stained positive for directly labelled TT-APC and TT-PE; the signal 
can be blocked by pre-incubation with an excess of unlabeled TT. 
 
 
 
Figure SI-6. Less than one percent of ACPA-expressing B cells was positive for dead cell staining when 
incubated with NTR at 37 °C for 1 h. As a positive control, over fifty percent of the CD40L cells (cultured 
with ACPA-expressing cells) stained positive for death cells. This shows that NTR on its own is not toxic 
for B cells within 1 hour. 
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Abstract 
 
Rheumatoid arthritis (RA) is an autoimmune disease affecting ca. 1% of the Western population. 
Autoantibodies against citrullinated proteins (ACPA) are prevalent in RA patients and eliminating 
the ACPA-producing B cells would be a promising strategy for the treatment of RA. Here we aim 
to develop an antigen-drug conjugate which is caged to prevent undesired binding to circulating 
antibodies. By selective activation of the recognizing antigen at the autoreactive B cell membrane, 
we envision to enhance B cell receptor (BCR) binding only. After binding and internalization of 
the BCR, we envisioned that a conjugated toxin, monomethyl auristatin E (MMAE), becomes 
activated and induces apoptosis in an antigen selective manner. We showed in Chapter 2 that 
antigen-selective silencing and activation could be achieved using a specific enzyme-substrate 
combination. While enzymes are promising for activating multiple substrates, it is challenging to 
find orthogonal and non-immunogenic enzymes that can be used for in vivo applications. In this 
Chapter, we describe the possibility of using an alternative antigen activation strategy based on a 
so-called click-to-release reaction. We show that iminosydnones (Im) function as a potent caging 
group for the citrullines in antigen peptides, and that activation and liberation of the autoantigen 
can be achieved after the cycloaddition with dibenzocyclooctyne (DBCO). We conjugated the 
cyclic citrullinated peptide (CCP) antigen to MMAE and compared the cytotoxicity with CCP(Im)-
MMAE and MMAE alone and observed no difference. As MMAE is a highly potent toxin, this 
suggests that monovalent antigen binding is not sufficient to induce receptor internalization that 
is required to induce MMAE-dependent cell death. The use of multivalent systems therefore seems 
essential for internalization- and antigen-dependent cell death strategies when applied to B cells.  
 
  
3.1 Introduction 
 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of 
joint tissue and is more prevalent in women than in men.1 Autoantibodies against citrullinated 
proteins are the key factor to sustained inflammation. Citrullination is a post-translational 
modification and results from the conversion of peptidyl arginine by peptidyl arginine deiminase 
(PAD) enzymes. Although this is a common process, many RA patients develop antibodies against 
these citrullinated proteins (ACPA). These ACPA are present years before the disease onset and 
therefore function as a relevant clinical marker to predict the development of RA.2  
RA treatment is currently directed at decreasing inflammation, preventing joint and organ damage 
and reducing pain. Nonsteroidal anti-inflammatory drugs are drugs which ease RA symptoms, 
whereas disease-modifying antirheumatic drugs (DMARDs) such as methotrexate or 
hydroxychloroquin are drugs that reduces disease progression. These drugs however do no treat 
the origin of the disease, but are directed at addressing the symptoms. 
Approximately 70-80% of RA patients are positive for ACPA, antibodies which are involved in 
chronic inflammation and cartilage damage. ACPA can bind to osteoclasts precursor cells and help 
them differentiate into bone-resorbing osteoclasts. These osteoclasts produce PAD enzymes, 
which are responsible for the citrullination of tissue in joints, especially vimentin.3 More effector 
cells are attracted to this site and the inflammation becomes sustained. ACPA stimulate 
osteoclastogenesis and osteoclasts induce citrulline modifications, so the removal of ACPA can 
likely decrease bone resorption and cartilage loss. Since ACPA are produced by autoreactive B 
cells, they are a relevant target for specific RA therapy. Depletion of the entire B cell population 
by rituximab is beneficial,4 however, as targeting is not restricted to the autoreactive B cell 
compartment this treatment leads to severe side effects such as immune deficiency against 
infectious agents.5 
In Chapter 2 we described a strategy to target and eliminate autoreactive B cells selectively by 
using an autoantigen-drug conjugate. Since free circulating ACPA are present in very high 
concentrations (up to hundreds of µg/mL)6 these can neutralize the autoantigen. We therefore 
suggested an approach to physically cage the autoantigen, to prevent binding to circulating ACPA, 
which can then be enzymatically removed in close proximity of B cells. Although we observed 
antigen-selective cell death using this approach, the use of an enzymatic activation strategy may be 
challenging in vivo. For example, to circumvent nonselective antigen activation by endogenous 
enzymes, orthogonal enzyme-substrate pairs are needed, and as these are often derived from other 
species, they may cause unwanted immune responses. To circumvent the use of enzymes, we here 
explore the use of a chemical activation strategy, which is bioorthogonal and provides full control 
of antigen-drug activation. 
 
 
Figure 1. Proposed click-to-release antigen activation mechanism using an iminosydnone and a 
cyclooctyne.  
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The interest in so-called bioorthogonal click-to-release reactions for activation of protected (caged) 
biologically relevant molecules in vivo has increased significantly in the last years. Several 
bioorthogonal bond cleavage reactions have been developed,7 including the tetrazine ligation with 
trans-cyclooctenes followed by a retro Diels-Alder reaction releasing an amine,8 and the tetrazine 
ligation using vinyl ethers releasing an alkoxy moiety.9, 10  
Very recently, Bernard et al. published an article on the use of iminosydnones in a fast-reacting 
bioorthogonal click-to-release reaction.11 In this reaction, a cyclooctyne reacts in a [3+2] 
cycloaddition with an iminosydnone yielding an unstable tricyclic adduct, which rapidly dissociated 
into a cyclooctane-fused pyrazole and an isocyanate after a retro Diels-Alder reaction (Figure 1). 
Due to the reaction with water, this isocyanate degrades rapidly into CO2 and a stable ureido 
moiety. 
In this Chapter we describe the use of an iminosydnone as a caging group for citrulline to mask 
the binding to ACPA and ACPA-expressing B cells. We hypothesize that with the use of a 
cyclooctyne, such as DBCO, we can activate the citrulline-containing antigen peptide (cyclic 
citrullinated peptide, CCP). As suggested in Chapter 2, we aim to employ an antibody-directed 
targeting strategy, for example directed to CD20, to activate the ACPA antigen in close proximity 
to the B cell membrane (Figure 2).  
 
 
Figure 2. Schematic representation of the caging and activation strategy using iminosydnones. 
Iminosydnone (Im) functions as a linker between a targeting anti-CD20 Fab fragment and CCP. The caged 
antigen-drug conjugates do not have affinity for the BCR or ACPA, but after cycloaddition using DBCO 
the CCP peptide is liberated. After binding of the antigen-drug conjugate to the BCR, it will be internalized, 
cleaved in the cell and the liberated toxin can induce apoptosis. 
To this end, we aim to use a Fab (antigen-binding site-containing) fragment for the targeting of 
CD20 instead of a full antibody, since Fab fragments are known to be less immunogenic than a 
full antibody, as the Fc part is lacking.12 Our final aim is to prepare a conjugate containing both a 
CD20-targeting Fab fragment and the CCP peptide, linked via a cleavable iminosydnone. The 
iminosydnone-conjugated antigen is targeted to the B cell membrane and is cleaved upon addition 
of DBCO. The advantage of this strategy is that a large excess of DBCO can be used to cleave the 
iminosydnone and liberate the antigen. The antigen subsequently binds to the B cell receptor, 
which it is then internalized. As our first aim, we tested the approach in unconjugated form. For 
this, we prepared a CCP antigen that was caged on the citrulline with an iminosydnone moiety and 
modified on the C-terminus with a potent toxin. For activation purposes DBCO was used, which 
should lead to internalization and cleavage of the toxin and thereby inducing apoptosis. 
 
3.2 Results and Discussion 
 
Synthesis of Fmoc-Cit(Im)-OH and CCP(Im). We started the synthesis of the caged non-
natural amino acid Fmoc-Cit(Im)-OH (6) with the preparation of the iminosydnone according to 
the reported literature procedure.11 Aniline was reacted under basic conditions and elevated 
temperature with chloroacetonitrile providing 2-(phenylamino)acetonitrile (1) in quantitative yield 
(Scheme 1). This compound was reacted with isoamyl nitrite and subsequently cyclized with HCl 
in dioxane to yield sydnone 2. Next, Fmoc-Orn(Cbz)-OH was converted into a tert-butyl ester and 
the Cbz moiety was removed from the δ-amine using hydrogen and Pd/C. In one pot, the free 
amine was reacted with triphosgene to create an isocyanate followed by the addition of 
iminosydnone 2 to form an ureido linkage between ornithine 4 and iminosydnone 2. After removal 
of the tert-butyl ester of 5 using TFA in DCM, the target caged Fmoc-Cit(Im)-OH (6) was obtained 
and subsequently used in solid phase peptide synthesis (SPPS). 
 
 
Scheme 1. Synthesis of Fmoc-Orn(Im)-OH (6). i) Chloroacetonitrile, acetonitrile, NaI, K2CO3, 3 h, reflux, 
quantitative; ii) amyl nitrite, diethyl ether, 20h, r.t.; iii) 4M HCl in dioxane, 24 h, 32% over two steps; iv) 
tert-butyl 2,2,2-trichloroacetimidate, BF3 etherate, THF/hexane (1:1), overnight, 0 °C  r.t.; v) Pd/C, H2, 
MeOH, 2 h, r.t., 80% over two steps; vi) 1. triphosgene, sat. NaHCO3/DCM (1:1), 10 min, 0 °C. 2. Sydnone 
2 was added, 3 h, 0 °C, 28% yield; vii) TFA/DCM (1:1), 2 h, r.t., quant. 
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We synthesized CCP(Im) (Figure 3A) using standard Fmoc-based SPPS while Fmoc-Cit(Im)-OH 
(6) was treated as a regular amino acid. After completion of the synthesis, chloroacetic anhydride 
was reacted with the N-terminus prior to cleavage from the resin. The peptide was then covalently 
cyclized by a substitution reaction of the internal cysteine onto the chloride in a basic solution. 
Biotin was coupled to the side chain of the C-terminal lysine for enzyme-linked immunosorbent 
assay (ELISA) purposes (Figure 3A). In a similar fashion, CArgP (7) and CCP (8) were synthesized 
as negative and positive control, respectively.  
 
DBCO-mediated activation of CCP(Im). Having the biotinylated caged CCP and control 
peptides in hand (Figure 3A), we next explored the binding for ACPA with and without the 
addition of DBCO.  
 
 
Figure 3. ACPA binding of caged CCP and the activation using DBCO. A) Structures of CArgP (7), CCP 
(8) and the iminosydnone-caged CCP (9). Biotin is used for conjugation purposes; B, C) ELISA using caged 
antigens detected by monoclonal ACPA. Incubation of the caged peptide over a time range at 37 °C with 
B) 1 equiv. DBCO or C) 10 equiv. DBCO. Absorbance at 450 nm.  
 
To evaluate the rate of the iminosydnone cycloaddition, we treated CCP(Im) 9 with 1 equiv. or 10 
equiv. of DBCO and measured the conversion over time at 37 °C. At specific time points, an 
excess benzyl azide (100 equiv. compared to DBCO) was added to quench the DBCO and thereby 
the reaction with the iminosydnone. The activated or untreated peptides were then added to a 
streptavidin-coated ELISA plate and incubated with monoclonal ACPA obtained from the 
supernatant of ACPA-producing immortalized B cells. Next, horseradish peroxidase (HRP)-
conjugated secondary antibodies and a HRP substrate were added to provide information on the 
relative binding efficiency of the different peptides by measuring absorption. 
Figure 3B shows the results of the ELISA of CCP(Im) when subjected to 1 and 10 equiv. of 
DBCO over time. Monoclonal ACPA did not bind CCP(Im) showing a similar absorption level as 
observed for the negative control peptide (CArgP, 7). Immobilizing CCP confirmed ACPA 
binding, as expected. Addition of 1 equiv. of DBCO provided a time-dependent increase in 
binding within 2 hours at 37 °C, whereas the iminosydnone click-to-release reaction seemed 
complete after 5-10 minutes when using 10 equiv. of DBCO (Figure 3C).  
To validate that the observed binding is specific to the activation by DBCO, we investigated the 
stability of the iminosydnone caged CCP (9) by dissolving the peptide in McIlvaine buffer13 (a 
mixture of aqueous Na2HPO4 and citric acid) in the range from pH 4 to pH 9. We measured the 
sample using analytical HPLC up to 7 days, and calculated the area under the curve. Slight 
degradation was observed at pH 8 and 9, but the iminosydnone-caged CCP (9) proved to be stable 
for at least 7 days in acidic to neutral pH (Figure 4). 
 
 
Figure 4. The stability of the iminosydnone caged CCP. Stability was tested in pH 4-9 (McIlvaine buffer) 
for 1-7 days at 37 °C and 600 rpm. The amount of CCP(Im) was determined by HPLC and was quantified 
by the area under the curve. The graph shows the relative amount compared to the amount of starting 
material. 
 
To test whether the caging and activation of CCP(Im) (9) also worked in de proximity of B cells, 
we conjugated the biotinylated CXP antigens (with X being different amino acids) to fluorescently 
labelled streptavidin tetramers to visualize antigen binding to B cells by flow cytometry.14 Two B 
cell clones derived from immortalized ACPA-expressing and anti-tetanus toxoid (TT) specific B 
cells were used for this purpose. The antigen specificity of the immortalized B cell clones is shown 
in Chapter 2 (Section 2.6, SI-5). Click-to-release activation was performed for 1 hour at 37 °C prior 
to the incubation with cells. 
Figure 5 shows the data from the flow cytometric binding studies with all different peptide-
streptavidin conjugates. Streptavidin contains allophycocyanin (APC) as a fluorophore and hence 
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binding of the antigen-streptavidin complex will result in a positive APC signal. All cells express 
also GFP and are therefore always GFP positive. For ACPA-expressing B cells (Figure 5A), no 
binding for TT is observed as expected, similar to CArgP and CCP(Im). All ACPA-expressing cells 
become positive for APC when CCP is bound, and this effect is seen for the CCP(Im) 
preincubated with 5 mM of DBCO (see Figure SI-1 for all DBCO concentrations). This shows 
that caging and activation of CCP(Im) is effective for ACPA-expressing B cells.  
We further demonstrated that binding is specific for ACPA-expressing B cells, as no binding of 
either CCP or the activated CCP(Im) is observed for anti-TT-expressing B cells (Figure 5B). As 
expected, these cells are only positive for TT, the cognate antigen for these immortalized B cells. 
 
 
Figure 5. Flow cytometric binding studies of streptavidin-coupled, biotinylated CCP, CArgP, and 
(activated) CCP(Im) to A) an ACPA-expressing B cell clone and B) an anti-TT-specific B cell clone. 
Activation of CCP(Im) was performed using 5 mM DBCO for 1 h at 37 °C, before addition to the cells. 
 
Synthesis and activity of MMAE-conjugated ACPA antigens. To show that we can induce 
selective cell death depending on the antigen used, we next attached a toxin, monomethyl auristatin 
E (MMAE), to the C-terminal lysine of the peptides. MMAE is a highly potent antimitotic drug, 
which inhibits cell division by caging the polymerization of tubulin.15 Due to its potency, MMAE 
is often used as drug conjugated to monoclonal antibodies (mAb) for selective cell targeting, 
showing effectiveness in preclinical studies against certain tumors.16 MMAE is often conjugated to 
mAb via a maleimide coupling, containing a Val-Cit motif and a cleavable linker (Figure 6). Due 
to this Val-Cit motif, cathepsin B can cleave this linker inside lysosomes and induce 1,6-elimination 
of the para-aminobenzyl carbamate (PAB) spacer thereby releasing the conjugated cargo.17, 18 
Here, we aim to exploit the same cleavage mechanism by attaching the commercially available 
maleimide-functionalized MMAE toxin (maleimide-Val-Cit-PAB-MMAE) to CXP antigens. The 
binding of this antigen will then induce B cell receptor (BCR) internalization and hence access to 
cathepsin B to liberate MMAE. 
 
 
Figure 6. Structure of maleimide-Val-Cit-PAB-MMAE.  
 
Since our CXP antigens do not contain a free thiol group needed for the reaction with a maleimide, 
we first synthesized a small thiol-containing linker that could be attached to the C-terminal lysine. 
For this, thioglycolic acid was first protected with a trityl group (compound 10) and the carboxylic 
acid was subsequently activated with a hydroxysuccinimide.19 (11, Scheme 2)  
 
 
Scheme 2. Reaction scheme for the synthesis of NHS ester 11.19 i) Trityl chloride, BF3 etherate, 
DCM/AcOH (1:1), 30 min, r.t., 85%; ii) NHS, EDC-HCl, MeCN, 2 h, r.t., 70%.  
 
We synthesized the CXP peptides as described previously, while retaining the C-terminal lysine 
for further modification. After cleavage from the resin, the peptides were cyclized, purified 
(antigen peptides 12a-14a, Figure 7) and subjected to NHS ester 11. While CArgP was used as a 
negative control in Chapter 2, we here use CNleP because we observed lower background using 
this norleucine peptide compared to arginine (see Chapter 5). After reaction with NHS ester 11, 
the trityl group was removed using TFA and the peptides were subsequently purified by 
preparative HPLC (antigen peptides 12b-14b). Next, the purified peptides were treated for 1 hour 
with TCEP on resin to reduce potential oxidized cysteines, and finally incubated with maleimide-
Val-Cit-PAB-MMAE for 24 hours at room temperature to yield the MMAE-conjugated CXP 
antigens (antigen peptides 12c-14c).  
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B cells (Figure 8B). The results demonstrate that the observed cytotoxicity is independent of the 
conjugated antigen, which may be due to the monovalent structure of the peptide-MMAE 
conjugates or to the mechanism of MMAE toxin itself.  
 
 
Figure 8. Cytotoxicity assay using antigen-MMAE conjugates for A) ACPA-positive B cells, and B) anti-
TT-positive B cells. Different concentrations of peptide-MMAE conjugates were tested for cytotoxicity. 
MMAE alone was also tested as the control for no antigen-specificity. Cell viability was measured using an 
XTT assay. MMAE showed to be cytotoxic in a dose-dependent manner, but no difference was observed 
when any of the antigen peptides was added. 
 
3.3 Conclusions and Outlook 
 
In this Chapter we have shown the synthesis of an iminosydnone-modified citrulline building block 
and the incorporation of this non-natural amino acid into a peptide. The iminosydnone functioned 
as a caging group for the citrulline-containing CCP antigen, which was validated by its lack of 
binding to both ACPA and ACPA-expressing B cells. By the addition of DBCO, we showed that 
a cycloaddition and subsequent release reaction liberated the CCP antigen. By the use of 10 equiv. 
of DBCO, the reaction was already complete within 5-10 minutes at 37 °C. After the release of 
CCP we showed that binding to ACPA and ACPA-expressing B cells was restored, to the same 
extent as the regular CCP peptide, demonstrating that full activation was achieved using this click-
to-release reaction.  
We next synthesized a set of antigen peptides conjugated to the MMAE toxin, with the ultimate 
goal to activate the antigens in close proximity of the B cell membrane for enhanced specificity. 
However, the cytotoxicity of peptide-MMAE conjugates proved not antigen-selective and similar 
cytotoxicity was observed for the positive and negative control peptides. It seems that the 
monovalent antigen binds insufficiently to the BCR or that the BCR was not internalized due to 
the lack of receptor clustering. The minimum level of BCR signaling required for antigen 
internalization is still unclear.21 Although it was shown that inducing BCR clustering is possible 
using a monovalent peptide in a specific case,22 possibly more signals are needed in general to 
overcome a threshold to elicit downstream BCR signaling and BCR clustering.21 One example to 
bypass this specificity threshold concerning our autoantigen is by using agents capable of BCR 
crosslinking. Reagents directed to the constant region of IgG (such as anti-IgG) crosslink the BCR 
by bringing BCRs in close proximity.21 Such strategies may be adopted in future studies.  
Alternatively the use of a multivalent system (such as streptavidin described in Chapter 2) would 
induce receptor clustering and selective targeting of the antigen-MMAE conjugates. Hence, we 
 
Figure 7. Synthesis of MMAE containing peptides 12-14. A) The side chains are depicted with CCP as 
positive control, CNleP as negative control and CCP(Im) as the caged and activatable antigen; B) Schematic 
representation of the synthesis steps towards the toxin-functionalized antigen peptides. All lysine peptides 
12a-14a were reacted with NHS ester 11. The trityl linker was removed using TFA to yield thiol-containing 
peptides 12b-14b after purification. Treatment with TCEP was performed for 1 hour before the maleimide-
Val-Cit-PAB-MMAE was added yielding the final antigen-drug conjugates 12c-14c.  
 
Antigen-dependent selective cellular targeting and cytotoxicity. Having the antigen-drug 
conjugates in hand, we examined the cytotoxicity and selective activation of CXP in close 
proximity of B cells. We first measured the selective cytotoxicity to ACPA- and anti-TT-positive 
B cells with peptides 12c-14c and MMAE alone. We mixed the cells with varying CXP-MMAE 
concentrations and incubated the cells at 37 °C for 3 days before evaluating cell viability in a XTT 
assay.  
Figure 8A shows the dose response curves for all peptide-MMAE conjugates incubated with 
ACPA-positive B cells. MMAE shows dose-dependent toxicity to ACPA-positive B cells. 
Unexpectedly, no difference was observed when MMAE was conjugated to CCP (12c, positive 
control) as compared to CNleP (13c, negative control). Since MMAE is only toxic after 
internalization and cleavage of the Val-Cit sequence,20 we expected a lower cytotoxicity for the 
CNleP-MMAE conjugate due to the lack of BCR binding. The addition of iminosydnone to CCP 
(14c) also did not affect the cytotoxicity of MMAE. Moreover, all peptide conjugates showed 
similar cytotoxicity as MMAE alone, meaning that the cytotoxicity is not antigen-dependent, but 
may be due to unselective uptake of MMAE. A similar result was observed for the anti-TT-positive 
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aim to produce multivalent antigen-MMAE conjugates in the future, to test the DBCO activation 
in the vicinity of ACPA-positive B cells. Local antigen activation can be achieved when DBCO is 
localized to the B cell membrane using e.g. Fab fragment conjugates. Since more DBCO might be 
needed locally to deprotect the multimeric CCP(Im), we will also explore the possibility to make a 
multivalent Fab-DBCO conjugate. Other possibilities to create high local DBCO concentrations 
may be achieved, for example, by using DBCO-infused polymeric gels.23, 24 For such a strategy, 
hydrogels excreting DBCO can be injected locally in the site of inflammation or in lymph nodes, 
locations where autoreactive B cells are found, to activate antigens (see Chapter 7).  
Finally, we are interested in using a single conjugate of the anti-CD20 Fab fragment attached to 
the iminosydnone caging group on the CCP antigen peptide. When a biotin is attached to the CCP 
antigen, this conjugate can bind a streptavidin-toxin thereby creating a multivalent dual targeting 
strategy. We have successfully demonstrated in Chapter 2 that a similar strategy ensures antigen-
selective B cell cytotoxicity. By creating such a streptavidin anti-CD20 Fab-CCP conjugate, the 
Fab fragment and CCP are simultaneously targeted to the B cell membrane allowing selective 
antigen activation in close proximity of the B cell membrane by using an excess of DBCO (see 
also Chapter 7).  
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3.5 Materials and Methods 
 
For general methods, see the materials and methods section of Chapter 2 (paragraph 2.4). 
 
2-(Phenylamino)acetonitrile (1). To a mixture of aniline (4.56 mL, 50 mmol, 1.0 equiv.) in dry 
acetonitrile  (50 mL) NaI (7.5 g, 50 mmol, 1.0 equiv.), K2CO3 (6.9 g, 50 mmol, 
1 equiv.) and chloroacetonitrile (3.36 mL, 53 mmol, 1.1 equiv.) were added. 
This mixture was refluxed under nitrogen for 3 h. The solids were filtered off 
and the filtrate was partitioned between ethyl acetate/water. The organic layer 
was separated, washed with brine, dried with MgSO4 and purified on a silica column (30% EtOAc 
in heptane) yielding compound 1 as a yellow oil (6.46 g, quant.). Rf = 0.42 (30% EtOAc in heptane). 
1H-NMR (400 MHz, DMSO-d6) δ 7.18-7.16 (m, 2H), 6.72-6.69 (m, 3H), 4.24 (s, 2H). 13C-NMR 
(100 MHz, DMSO-d6) δ 146.55, 129.03(2C), 118.62, 117.85, 113.00 (2C), 31.42. LRMS (ESI+): 
m/z calcd for C8H9N2+ [M+H]+ 133.1, found: 133.2. The data corresponds to the reported 
literature values.11  
 
5-Amino-3-phenyl-1,2,3-oxadiazol-3-ium chloride (2). Compound 1 (2.36 g, 20 mmol, 1.0 
equiv.) was added to diethyl ether (40 mL). To this mixture, amyl nitrite (4.04 
mL, 60 mmol, 3.0 equiv.) was slowly added. This was stirred for 20 h at room 
temperature. Afterwards, 4M HCl in dioxane (38 mL) was added and stirred 
for 24 h. The product was obtained via filtration and trituration in methanol 
by addition of diethyl ether yielding compound 2 as a salt (1.26 g, 32%). 1H-NMR (400 MHz, 
DMSO-d6) δ 10.08 (s, 2H), 8.68 (s, 1H), 8.07-8.05 (m, 2H), 7.84-7.74 (m, 3H). 13C-NMR (100 MHz, 
DMSO- d6) δ 169.90, 134.02, 133.28, 130.84 (2C), 123.14 (2C), 102.72. LRMS (ESI+): m/z calcd 
for C8H8N3O [M-Cl-] 162.1, found: 162.1. The data corresponds to the reported literature values.11  
 
Fmoc-Orn(Cbz)-OtBu (3). Fmoc-Orn(Cbz)-OH (1.73 g, 3.7 mmol, 1.0 equiv.) was dissolved in 
THF/Hexane (30 mL, 1:1). This was cooled down to 0 °C and 
afterwards tert-butyl 2,2,2-trichloroacetimidate (1.32 mL, 7.4 mmol, 
2.0 equiv.) was added. This was stirred for 15 min and then BF3 
etherate (228 uL, 1.8 mmol, 0.5 equiv.) was added to the mixture and 
the reaction was stirred overnight at room temperature. The product was obtained via column 
chromatography using a gradient of EtOAc in heptane (0% to 40%). Rf = 0.30 (30% EtOAc in 
heptane). 1H NMR (500 MHz, MeOH-d4) δ 7.79 (d, J = 7.5 Hz, 2H), 7.67 (t, J = 7.0 Hz, 2H), 7.39 
(t, J = 7.4 Hz, 2H), 7.37 – 7.26 (m, 7H), 5.49 (s, 2H), 5.08 (s, 2H), 4.37 (qd, J = 10.6, 7.1 Hz, 2H), 
4.22 (t, J = 6.8 Hz, 1H), 4.06 (dd, J = 8.6, 5.0 Hz, 1H), 3.15 (t, J = 6.7 Hz, 2H), 1.89 – 1.61 (m, 
2H), 1.59 (d, J = 6.5 Hz, 2H), 1.46 (s, 9H). 13C NMR (126 MHz, MeOH-d4) δ 171.88, 157.50, 
157.19, 143.92, 143.76, 141.18 (2C), 137.01, 128.06 (2C), 127.54 (2C), 127.38 (3C), 126.77 (2C), 
124.86 (2C), 119.53 (2C), 81.36, 66.49, 65.96, 54.57, 47.04, 39.92, 28.55, 26.90 (3C), 26.00. HRMS 
(ESI+) m/z calcd for C32H36N2NaO6+ [M+Na]+ 567.24711, found 567.24580. 
 
Fmoc-Orn-OtBu (4). Fmoc-Orn(Cbz)-OtBu was dissolved in methanol (40 mL). To this 
palladium on activated carbon (40 mg, 0.14 mmol) was added. The flask 
was then closed and H2 was bubbled through while stirring till 
completion. The product was filtrated over celite and obtained via 
column chromatography in 10% methanol in DCM (1.20 g, 80% yield over two steps). Rf = 0.23 
(10% MeOH in DCM). 1H NMR (500 MHz, MeOH-d4) δ 7.78 (d, J = 7.5 Hz, 2H), 7.66 (t, J = 7.8 
Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.25 (s, 1H), 4.89 (s, 2H), 4.42 (dd, J = 
10.6, 6.8 Hz, 1H), 4.31 (dd, J = 10.6, 6.8 Hz, 10H), 4.20 (t, J = 6.9 Hz, 1H), 4.06 (t, J = 8.8 Hz, 
1H), 2.95 (t, J = 7.1 Hz, 1H), 1.95 – 1.83 (m, 1H), 1.74 (dt, J = 16.6, 8.9 Hz, 3H), 1.46 (s, 9H). 13C 
NMR (126 MHz, MeOH-d4) δ 171.36, 157.29, 143.75 (2C), 141.20 (2C), 127.42 (2C), 126.79 (2C), 
124.80 (2C), 119.57 (2C), 81.66, 66.59, 54.28, 46.99, 38.92, 28.15, 26.89 (3C), 23.85. HRMS (ESI+) 
m/z calcd for C24H31N2O4+ [M+H]+ 411.228383, found 411.22757. C24H30N2NaO4+ [M+Na]+ 
433.21033, found 433.20943. 
 
Fmoc-Cit(Im)-OtBu (5). Compound 4 (721 mg, 1.8 mmol, 1.0 equiv.) was dissolved in 8 mL 
DCM and sat. NaHCO3 (1:1) and cooled down to 0 
°C. Whilst stirring vigorously, triphosgene (174 mg, 
0.59 mmol, 0.3 equiv.) was added and stirred was 
continued for 10 minutes. Afterwards, compound 2 
(348 mg, 1.8 mmol, 1 equiv.) was added and the 
reaction was stirred at 0 °C until completion. The reaction was quenched with brine and the 
compound was purified by column chromatography (60% EtOAc/heptane to 100% EtOAC) to 
yield compound 5 (290 mg, 28% yield). Rf = 0.30 (100% EtOAc). 1H NMR (500 MHz, MeOH-d4) 
δ 8.00 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.83 – 7.61 (m, 6H), 7.34 (dq, J = 35.2, 7.4 Hz, 
5H), 4.41 – 4.32 (m, 2H), 4.22 (t, J = 7.0 Hz, 1H), 4.07 (dd, J = 8.6, 4.9 Hz, 1H), 3.47 – 3.35 (m, 
76
Chapter 3
529590-L-bw-Lelieveldt
Processed on: 13-3-2019 PDF page: 77
3
aim to produce multivalent antigen-MMAE conjugates in the future, to test the DBCO activation 
in the vicinity of ACPA-positive B cells. Local antigen activation can be achieved when DBCO is 
localized to the B cell membrane using e.g. Fab fragment conjugates. Since more DBCO might be 
needed locally to deprotect the multimeric CCP(Im), we will also explore the possibility to make a 
multivalent Fab-DBCO conjugate. Other possibilities to create high local DBCO concentrations 
may be achieved, for example, by using DBCO-infused polymeric gels.23, 24 For such a strategy, 
hydrogels excreting DBCO can be injected locally in the site of inflammation or in lymph nodes, 
locations where autoreactive B cells are found, to activate antigens (see Chapter 7).  
Finally, we are interested in using a single conjugate of the anti-CD20 Fab fragment attached to 
the iminosydnone caging group on the CCP antigen peptide. When a biotin is attached to the CCP 
antigen, this conjugate can bind a streptavidin-toxin thereby creating a multivalent dual targeting 
strategy. We have successfully demonstrated in Chapter 2 that a similar strategy ensures antigen-
selective B cell cytotoxicity. By creating such a streptavidin anti-CD20 Fab-CCP conjugate, the 
Fab fragment and CCP are simultaneously targeted to the B cell membrane allowing selective 
antigen activation in close proximity of the B cell membrane by using an excess of DBCO (see 
also Chapter 7).  
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3.5 Materials and Methods 
 
For general methods, see the materials and methods section of Chapter 2 (paragraph 2.4). 
 
2-(Phenylamino)acetonitrile (1). To a mixture of aniline (4.56 mL, 50 mmol, 1.0 equiv.) in dry 
acetonitrile  (50 mL) NaI (7.5 g, 50 mmol, 1.0 equiv.), K2CO3 (6.9 g, 50 mmol, 
1 equiv.) and chloroacetonitrile (3.36 mL, 53 mmol, 1.1 equiv.) were added. 
This mixture was refluxed under nitrogen for 3 h. The solids were filtered off 
and the filtrate was partitioned between ethyl acetate/water. The organic layer 
was separated, washed with brine, dried with MgSO4 and purified on a silica column (30% EtOAc 
in heptane) yielding compound 1 as a yellow oil (6.46 g, quant.). Rf = 0.42 (30% EtOAc in heptane). 
1H-NMR (400 MHz, DMSO-d6) δ 7.18-7.16 (m, 2H), 6.72-6.69 (m, 3H), 4.24 (s, 2H). 13C-NMR 
(100 MHz, DMSO-d6) δ 146.55, 129.03(2C), 118.62, 117.85, 113.00 (2C), 31.42. LRMS (ESI+): 
m/z calcd for C8H9N2+ [M+H]+ 133.1, found: 133.2. The data corresponds to the reported 
literature values.11  
 
5-Amino-3-phenyl-1,2,3-oxadiazol-3-ium chloride (2). Compound 1 (2.36 g, 20 mmol, 1.0 
equiv.) was added to diethyl ether (40 mL). To this mixture, amyl nitrite (4.04 
mL, 60 mmol, 3.0 equiv.) was slowly added. This was stirred for 20 h at room 
temperature. Afterwards, 4M HCl in dioxane (38 mL) was added and stirred 
for 24 h. The product was obtained via filtration and trituration in methanol 
by addition of diethyl ether yielding compound 2 as a salt (1.26 g, 32%). 1H-NMR (400 MHz, 
DMSO-d6) δ 10.08 (s, 2H), 8.68 (s, 1H), 8.07-8.05 (m, 2H), 7.84-7.74 (m, 3H). 13C-NMR (100 MHz, 
DMSO- d6) δ 169.90, 134.02, 133.28, 130.84 (2C), 123.14 (2C), 102.72. LRMS (ESI+): m/z calcd 
for C8H8N3O [M-Cl-] 162.1, found: 162.1. The data corresponds to the reported literature values.11  
 
Fmoc-Orn(Cbz)-OtBu (3). Fmoc-Orn(Cbz)-OH (1.73 g, 3.7 mmol, 1.0 equiv.) was dissolved in 
THF/Hexane (30 mL, 1:1). This was cooled down to 0 °C and 
afterwards tert-butyl 2,2,2-trichloroacetimidate (1.32 mL, 7.4 mmol, 
2.0 equiv.) was added. This was stirred for 15 min and then BF3 
etherate (228 uL, 1.8 mmol, 0.5 equiv.) was added to the mixture and 
the reaction was stirred overnight at room temperature. The product was obtained via column 
chromatography using a gradient of EtOAc in heptane (0% to 40%). Rf = 0.30 (30% EtOAc in 
heptane). 1H NMR (500 MHz, MeOH-d4) δ 7.79 (d, J = 7.5 Hz, 2H), 7.67 (t, J = 7.0 Hz, 2H), 7.39 
(t, J = 7.4 Hz, 2H), 7.37 – 7.26 (m, 7H), 5.49 (s, 2H), 5.08 (s, 2H), 4.37 (qd, J = 10.6, 7.1 Hz, 2H), 
4.22 (t, J = 6.8 Hz, 1H), 4.06 (dd, J = 8.6, 5.0 Hz, 1H), 3.15 (t, J = 6.7 Hz, 2H), 1.89 – 1.61 (m, 
2H), 1.59 (d, J = 6.5 Hz, 2H), 1.46 (s, 9H). 13C NMR (126 MHz, MeOH-d4) δ 171.88, 157.50, 
157.19, 143.92, 143.76, 141.18 (2C), 137.01, 128.06 (2C), 127.54 (2C), 127.38 (3C), 126.77 (2C), 
124.86 (2C), 119.53 (2C), 81.36, 66.49, 65.96, 54.57, 47.04, 39.92, 28.55, 26.90 (3C), 26.00. HRMS 
(ESI+) m/z calcd for C32H36N2NaO6+ [M+Na]+ 567.24711, found 567.24580. 
 
Fmoc-Orn-OtBu (4). Fmoc-Orn(Cbz)-OtBu was dissolved in methanol (40 mL). To this 
palladium on activated carbon (40 mg, 0.14 mmol) was added. The flask 
was then closed and H2 was bubbled through while stirring till 
completion. The product was filtrated over celite and obtained via 
column chromatography in 10% methanol in DCM (1.20 g, 80% yield over two steps). Rf = 0.23 
(10% MeOH in DCM). 1H NMR (500 MHz, MeOH-d4) δ 7.78 (d, J = 7.5 Hz, 2H), 7.66 (t, J = 7.8 
Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.25 (s, 1H), 4.89 (s, 2H), 4.42 (dd, J = 
10.6, 6.8 Hz, 1H), 4.31 (dd, J = 10.6, 6.8 Hz, 10H), 4.20 (t, J = 6.9 Hz, 1H), 4.06 (t, J = 8.8 Hz, 
1H), 2.95 (t, J = 7.1 Hz, 1H), 1.95 – 1.83 (m, 1H), 1.74 (dt, J = 16.6, 8.9 Hz, 3H), 1.46 (s, 9H). 13C 
NMR (126 MHz, MeOH-d4) δ 171.36, 157.29, 143.75 (2C), 141.20 (2C), 127.42 (2C), 126.79 (2C), 
124.80 (2C), 119.57 (2C), 81.66, 66.59, 54.28, 46.99, 38.92, 28.15, 26.89 (3C), 23.85. HRMS (ESI+) 
m/z calcd for C24H31N2O4+ [M+H]+ 411.228383, found 411.22757. C24H30N2NaO4+ [M+Na]+ 
433.21033, found 433.20943. 
 
Fmoc-Cit(Im)-OtBu (5). Compound 4 (721 mg, 1.8 mmol, 1.0 equiv.) was dissolved in 8 mL 
DCM and sat. NaHCO3 (1:1) and cooled down to 0 
°C. Whilst stirring vigorously, triphosgene (174 mg, 
0.59 mmol, 0.3 equiv.) was added and stirred was 
continued for 10 minutes. Afterwards, compound 2 
(348 mg, 1.8 mmol, 1 equiv.) was added and the 
reaction was stirred at 0 °C until completion. The reaction was quenched with brine and the 
compound was purified by column chromatography (60% EtOAc/heptane to 100% EtOAC) to 
yield compound 5 (290 mg, 28% yield). Rf = 0.30 (100% EtOAc). 1H NMR (500 MHz, MeOH-d4) 
δ 8.00 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.83 – 7.61 (m, 6H), 7.34 (dq, J = 35.2, 7.4 Hz, 
5H), 4.41 – 4.32 (m, 2H), 4.22 (t, J = 7.0 Hz, 1H), 4.07 (dd, J = 8.6, 4.9 Hz, 1H), 3.47 – 3.35 (m, 
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1H), 3.23 (t, J = 6.9 Hz, 1H), 1.90 – 1.79 (m, 1H), 1.76 – 1.65 (m, 2H), 1.65 – 1.57 (m, 1H), 1.45 
(s, 9H) (1 proton missing). 13C-NMR (100 MHz, MeOH-d4) 171.98, 157.22, 143.89 (2C), 141.16 
(2C), 132.63, 130.09 (2C), 127.36 (2C), 126.65 (2C), 124.85 (2C), 121.72 (2C), 119.43 (2C), 104.99, 
81.29, 66.50, 54.64, 47.04, 39.39, 28.60, 26.86 (3C), 26.18 (2 carbons missing). HRMS (ESI+) m/z 
calcd for C33H36N5O6+ [M+H]+ 598.266560, found 598.26471. 
 
Fmoc-Cit(Im)-OH (6). Compound 5 (500 mg, 0.84 mmol) was dissolved in 5 mL DCM. TFA 
(5 mL) was slowly added and the resulting solution was 
stirred for 2 h. The solvents were removed via 
evaporation and complete removal of TFA was realized 
by co-evaporation with DCM (3 x). The product was 
then lyophilized and obtained as a pure dark yellow solid 
(452 mg, quant.). Rf = 0.40 (5% MeOH, 1% AcOH in DCM). 1H NMR (500 MHz, MeOH-d4) δ 
8.01 (d, J = 7.8 Hz, 1H), 7.84 (t, J = 7.0 Hz, 1H), 7.79 – 7.71 (m, 4H), 7.65 (t, J = 7.0 Hz, 2H), 
7.32 (dt, J = 34.3, 7.4 Hz, 5H), 4.33 (dd, J = 15.5, 7.2 Hz, 2H), 4.25 – 4.13 (m, 2H), 3.32 (d, J = 
5.8 Hz, 1H), 3.17 (dq, J = 37.1, 7.1 Hz, 1H), 2.01 – 1.88 (m, 1H), 1.81 – 1.62 (m, 2H). (1 proton 
missing). 13C NMR (126 MHz, MeOH-d4) δ 174.27, 157.27, 143.85 (2C), 141.12 (2C), 134.00, 
132.99, 130.45 (2C), 127.38 (2C), 126.77 (2C), 124.87 (2C), 122.30 (2C), 119.50 (2C), 106.74, 83.51, 
66.72, 53.51, 47.00, 39.44, 28.52, 25.72. (1 carbon missing). HRMS (ESI+) m/z calcd for 
C29H28N5O6+ [M+H]+ 542.203960, found 542.20316. m/z calcd for C29H27N5NaO6+ [M+Na]+ 
620.24850, found 620.24681. 
 
2-(Tritylthio)acetic acid (10). Thioglycolic acid (1.8 mL, 26 mmol, 1 equiv.) was dissolved in 
DCM/AcOH (1:1, 24 mL) and trityl chloride (7.20 g, 26 mmol, 1 equiv.) was 
added. BF3 etherate (2 mL, 13 mmol, 0.5 equiv.) was added dropwise and the  
reaction was stirred for 30 minutes at room temperature. Afterwards, the volatiles 
were evaporated and water (10 mL) was added. The product was obtained by extraction with 
EtOAc (3 x 30 mL), drying with MgSO4 and removing the EtOAc in vacuo to yield a white powder 
(7.29 g, 85%). Rf = 0.36 (10% MeOH in DCM). 1H NMR (400 MHz, chloroform-d) δ 7.46 – 7.36 
(m, 6H), 7.32 – 7.26 (m, 6H), 7.25 – 7.19 (m, 3H), 3.02 (s, 2H). 13C-NMR(100 MHz, chloroform-
d) δ 173.05, 145.60(3C), 130.68 (6C), 129.02 (6C), 127.99 (3C), 68.09, 35.69. LRMS (ESI+): cannot 
be found with ESI. The data corresponds to reported literature values.19 
 
2,5-Dioxopyrrolidin-1-yl 2-(tritylthio)acetate (11). Compound 10 (5.00 g, 15 mmol, 1.0 equiv.) 
was dissolved in acetonitrile (20 mL) and to this N-hydroxysuccinimide (1.72 
g, 15 mmol, 1.0 equiv.) and EDC-HCl (3.16 g, 17 mmol, 1.1 equiv.) were 
added. The mixture was stirred for 2 h at room temperature. The mixture was 
then left at -20 °C for 1 h to form crystal seeds and transferred to the fridge 
to precipitate overnight. The precipitate was collected to yield a white powder (4.58 g, 70% yield). 
Rf = 0.50 (50% EtOAc in heptane). 1H NMR (400 MHz, chloroform-d) δ 7.43 – 7.39 (m, 6H), 
7.34 – 7.28 (m, 6H), 7.26 – 7.21 (m, 3H), 3.18 (s, 2H), 2.80 (s, 4H). 13C-NMR (100 MHz, 
chloroform-d) δ 168.60, 165.08, 143.56 (3C), 129.51 (6C), 128.25 (6C), 127.16 (3C), 68.06, 31.44, 
25.56 (2C). LRMS (ESI+): cannot be found with ESI. The data corresponds to the reported 
literature values.19 
General peptide synthesis and cyclization method. See the materials and methods section of 
Chapter 2 (paragraph 2.4). 
 
CArgP-biotin (7). CArgP was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for 
C100H172N42O33S22+ [M+2H]2+ 1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 
852.28. C100H173N41O34S24+ [M+4H]4+ 639.06, found 640.20. 
 
CCP-biotin (8). CCP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 12.753 min. LCMS (ESI+) m/z calcd for C100H171N41O34S22+ 
[M+2H]2+ 1277.61, found 1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 852.68. 
C100H173N41O34S24+ [M+4H]4+ 639.31, found 641.16. 
 
CCP(Im)-biotin (9). CCP(Im) was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 13.867 min. LCMS (ESI+) m/z calcd for C108H176N43O35S22+ 
[M+2H]2+ 1349.63, found 1349.64. C108H177N43O35S23+ [M+3H]3+ 900.09, found 900.20. 
C108H178N43O35S24+ [M+4H]4+675.32, found 675.72. 
 
CCP-Lys (12a). CCP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 10.209 min. LCMS (ESI+) m/z calcd for C90H157N39O32S2+ 
[M+2H]2+ 1164.08, found 1163.00. C90H158N39O32S3+ [M+3H]3+ 776.39, found 776.92. 
C90H159N39O32S4+ [M+4H]4+ 582.54, found 583.00. 
 
CNleP-Lys (13a). CNleP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.054 min. LCMS (ESI+) m/z calcd for C90H157N37O31S2+ 
[M+2H]2+ 1142.08, found 1142.88. C90H158N37O31S3+ [M+3H]3+ 761.72, found 762.68. 
C90H159N37O31S4+ [M+4H]4+ 571.54, found 573.68. 
 
CCP(Im)-Lys (14a). CCP(Im)-Lys was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in 
the general cyclization method. HPLC: Rt. 12.185. LCMS (ESI+) m/z calcd for C98H161N41O33S2+ 
[M+2H]2+ 1236.83, found 1236.72. C98H162N41O33S3+ [M+3H]3+ 824.88, found 825.16. 
C98H163N41O33S4+ [M+4H]4+ 618.92, found 619.12. C98H164N41O33S5+ [M+5H]5+ 495.33, found 
495.60. C98H165N41O33S6+ [M+6H]6+ 412.94, found 412.96. 
 
General linker attachment protocol. The peptide (12a-14a) (1 equiv.) was dissolved in DMF (2 
mL) and DIPEA (100 equiv.). To this mixture was added 11 (1 equiv.) in DMF and the resulting 
mixture was stirred for 2 h. The peptide was then precipitated in diethyl ether, collected and dried. 
A cleavage mixture of TFA/TIS/EDT/H2O (92.5:2.5:2.5:2.5) was added and left to shake for 2 
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1H), 3.23 (t, J = 6.9 Hz, 1H), 1.90 – 1.79 (m, 1H), 1.76 – 1.65 (m, 2H), 1.65 – 1.57 (m, 1H), 1.45 
(s, 9H) (1 proton missing). 13C-NMR (100 MHz, MeOH-d4) 171.98, 157.22, 143.89 (2C), 141.16 
(2C), 132.63, 130.09 (2C), 127.36 (2C), 126.65 (2C), 124.85 (2C), 121.72 (2C), 119.43 (2C), 104.99, 
81.29, 66.50, 54.64, 47.04, 39.39, 28.60, 26.86 (3C), 26.18 (2 carbons missing). HRMS (ESI+) m/z 
calcd for C33H36N5O6+ [M+H]+ 598.266560, found 598.26471. 
 
Fmoc-Cit(Im)-OH (6). Compound 5 (500 mg, 0.84 mmol) was dissolved in 5 mL DCM. TFA 
(5 mL) was slowly added and the resulting solution was 
stirred for 2 h. The solvents were removed via 
evaporation and complete removal of TFA was realized 
by co-evaporation with DCM (3 x). The product was 
then lyophilized and obtained as a pure dark yellow solid 
(452 mg, quant.). Rf = 0.40 (5% MeOH, 1% AcOH in DCM). 1H NMR (500 MHz, MeOH-d4) δ 
8.01 (d, J = 7.8 Hz, 1H), 7.84 (t, J = 7.0 Hz, 1H), 7.79 – 7.71 (m, 4H), 7.65 (t, J = 7.0 Hz, 2H), 
7.32 (dt, J = 34.3, 7.4 Hz, 5H), 4.33 (dd, J = 15.5, 7.2 Hz, 2H), 4.25 – 4.13 (m, 2H), 3.32 (d, J = 
5.8 Hz, 1H), 3.17 (dq, J = 37.1, 7.1 Hz, 1H), 2.01 – 1.88 (m, 1H), 1.81 – 1.62 (m, 2H). (1 proton 
missing). 13C NMR (126 MHz, MeOH-d4) δ 174.27, 157.27, 143.85 (2C), 141.12 (2C), 134.00, 
132.99, 130.45 (2C), 127.38 (2C), 126.77 (2C), 124.87 (2C), 122.30 (2C), 119.50 (2C), 106.74, 83.51, 
66.72, 53.51, 47.00, 39.44, 28.52, 25.72. (1 carbon missing). HRMS (ESI+) m/z calcd for 
C29H28N5O6+ [M+H]+ 542.203960, found 542.20316. m/z calcd for C29H27N5NaO6+ [M+Na]+ 
620.24850, found 620.24681. 
 
2-(Tritylthio)acetic acid (10). Thioglycolic acid (1.8 mL, 26 mmol, 1 equiv.) was dissolved in 
DCM/AcOH (1:1, 24 mL) and trityl chloride (7.20 g, 26 mmol, 1 equiv.) was 
added. BF3 etherate (2 mL, 13 mmol, 0.5 equiv.) was added dropwise and the  
reaction was stirred for 30 minutes at room temperature. Afterwards, the volatiles 
were evaporated and water (10 mL) was added. The product was obtained by extraction with 
EtOAc (3 x 30 mL), drying with MgSO4 and removing the EtOAc in vacuo to yield a white powder 
(7.29 g, 85%). Rf = 0.36 (10% MeOH in DCM). 1H NMR (400 MHz, chloroform-d) δ 7.46 – 7.36 
(m, 6H), 7.32 – 7.26 (m, 6H), 7.25 – 7.19 (m, 3H), 3.02 (s, 2H). 13C-NMR(100 MHz, chloroform-
d) δ 173.05, 145.60(3C), 130.68 (6C), 129.02 (6C), 127.99 (3C), 68.09, 35.69. LRMS (ESI+): cannot 
be found with ESI. The data corresponds to reported literature values.19 
 
2,5-Dioxopyrrolidin-1-yl 2-(tritylthio)acetate (11). Compound 10 (5.00 g, 15 mmol, 1.0 equiv.) 
was dissolved in acetonitrile (20 mL) and to this N-hydroxysuccinimide (1.72 
g, 15 mmol, 1.0 equiv.) and EDC-HCl (3.16 g, 17 mmol, 1.1 equiv.) were 
added. The mixture was stirred for 2 h at room temperature. The mixture was 
then left at -20 °C for 1 h to form crystal seeds and transferred to the fridge 
to precipitate overnight. The precipitate was collected to yield a white powder (4.58 g, 70% yield). 
Rf = 0.50 (50% EtOAc in heptane). 1H NMR (400 MHz, chloroform-d) δ 7.43 – 7.39 (m, 6H), 
7.34 – 7.28 (m, 6H), 7.26 – 7.21 (m, 3H), 3.18 (s, 2H), 2.80 (s, 4H). 13C-NMR (100 MHz, 
chloroform-d) δ 168.60, 165.08, 143.56 (3C), 129.51 (6C), 128.25 (6C), 127.16 (3C), 68.06, 31.44, 
25.56 (2C). LRMS (ESI+): cannot be found with ESI. The data corresponds to the reported 
literature values.19 
General peptide synthesis and cyclization method. See the materials and methods section of 
Chapter 2 (paragraph 2.4). 
 
CArgP-biotin (7). CArgP was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for 
C100H172N42O33S22+ [M+2H]2+ 1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 
852.28. C100H173N41O34S24+ [M+4H]4+ 639.06, found 640.20. 
 
CCP-biotin (8). CCP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 12.753 min. LCMS (ESI+) m/z calcd for C100H171N41O34S22+ 
[M+2H]2+ 1277.61, found 1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 852.68. 
C100H173N41O34S24+ [M+4H]4+ 639.31, found 641.16. 
 
CCP(Im)-biotin (9). CCP(Im) was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 13.867 min. LCMS (ESI+) m/z calcd for C108H176N43O35S22+ 
[M+2H]2+ 1349.63, found 1349.64. C108H177N43O35S23+ [M+3H]3+ 900.09, found 900.20. 
C108H178N43O35S24+ [M+4H]4+675.32, found 675.72. 
 
CCP-Lys (12a). CCP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 10.209 min. LCMS (ESI+) m/z calcd for C90H157N39O32S2+ 
[M+2H]2+ 1164.08, found 1163.00. C90H158N39O32S3+ [M+3H]3+ 776.39, found 776.92. 
C90H159N39O32S4+ [M+4H]4+ 582.54, found 583.00. 
 
CNleP-Lys (13a). CNleP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.054 min. LCMS (ESI+) m/z calcd for C90H157N37O31S2+ 
[M+2H]2+ 1142.08, found 1142.88. C90H158N37O31S3+ [M+3H]3+ 761.72, found 762.68. 
C90H159N37O31S4+ [M+4H]4+ 571.54, found 573.68. 
 
CCP(Im)-Lys (14a). CCP(Im)-Lys was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in 
the general cyclization method. HPLC: Rt. 12.185. LCMS (ESI+) m/z calcd for C98H161N41O33S2+ 
[M+2H]2+ 1236.83, found 1236.72. C98H162N41O33S3+ [M+3H]3+ 824.88, found 825.16. 
C98H163N41O33S4+ [M+4H]4+ 618.92, found 619.12. C98H164N41O33S5+ [M+5H]5+ 495.33, found 
495.60. C98H165N41O33S6+ [M+6H]6+ 412.94, found 412.96. 
 
General linker attachment protocol. The peptide (12a-14a) (1 equiv.) was dissolved in DMF (2 
mL) and DIPEA (100 equiv.). To this mixture was added 11 (1 equiv.) in DMF and the resulting 
mixture was stirred for 2 h. The peptide was then precipitated in diethyl ether, collected and dried. 
A cleavage mixture of TFA/TIS/EDT/H2O (92.5:2.5:2.5:2.5) was added and left to shake for 2 
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h. The peptide was precipitated in diethyl ether, collected and lyophilized. The crude peptide was 
then purified using preparative HPLC (see Chapter 2 for specifics).  
 
CCP-SH (12b). HPLC: Rt. 12.405. LCMS (ESI+) m/z calcd for C92H159N39O33S22+ [M+2H]2+ 
1201.82, found 1201.60. C98H162N41O33S3+ [M+3H]3+ 801.54, found 801.48. C98H163N41O33S4+ 
[M+4H]4+ 601.41, found 601.52. C98H164N41O33S5+ [M+5H]5+ 481.33, found 481.48 
 
CNleP-SH (13b). HPLC: Rt. 13.166. LCMS (ESI+) m/z calcd for C92H159N37O32S22+ [M+2H]2+ 
1179.76, found 1179.68. C92H160N37O32S23+ [M+3H]3+ 786.84, found 786.84. C92H161N37O32S24+ 
[M+4H]4+ 590.38, found 590.40. C92H162N37O32S25+ [M+5H]5+ 472.52, found 472.76.  
  
CCP(Im)-SH (14b). HPLC: Rt. 13.719. LCMS (ESI+) m/z calcd for C100H163N41O34S22+ 
[M+2H]2+ 1273.88, found 1273.44. C98H164N41O33S2+ [M+3H]3+ 849.59, found 849.64. 
C98H165N41O33S2+ [M+4H]4+ 637.44, found 637.32. C98H166N41O33S2+ [M+5H]5+ 510.15, found 
510.36. 
 
General maleimide coupling protocol. Peptides 12b-14b were treated with PiercerTM TCEP 
reducing gel for 1 h at room temperature in milliQ (750 µL). The gel was centrifuged and the 
supernatant was collected. The gel was washed two times with milliQ (250 µL), and this was 
combined with the first supernatant. To the peptide solution MC-Val-Cit-PAB-MMAE dissolved 
in DMSO (10 mM, 0.75 equiv.) was added. The suspension was shaken overnight at room 
temperature. The peptides were purified using a reversed phase preparative HPLC using an 
acetonitrile/water gradient (5-100%, 1-45 min).  
 
CCP-MMAE (12c) HPLC: Rt. 19.187. LCMS (ESI+) m/z calcd for C160H265N50O48S23+ [M+3H]3+ 
1240.43, found 1240.16. C160H266N50O48S24+ [M+4H]4+ 930.57, found 930.48. C160H267N50O48S25+ 
[M+5H]5+ 744.66, found 744.44. 
 
CNleP-MMAE (13c) HPLC: Rt. 19.018. LCMS (ESI+) m/z calcd for C160H265N48O47S23+ 
[M+3H]3+ 1225.76, found 1225.52. C160H266N48O47S24+ [M+4H]4+ 919.57, found 919.52. 
C160H267N48O47S25+ [M+5H]5+ 735.85, found 735.60. 
 
CCP(Im)-MMAE (14c) HPLC: Rt. 19.108. LCMS (ESI+) m/z calcd for C168H269N52O49S23+ 
[M+3H]3+ 1288.47, found 1288.16. C168H270N52O49S24+ [M+4H]4+ 966.60, found 966.52. 
C168H271N52O49S25+ [M+5H]5+ 773.48, found 773.28. C168H272N52O49S26+ [M+5H]6+ 644.74, found 
644.52. 
 
CCP(Im) stability measurements at various pH. The peptide was dissolved in 1% 
DMSO/McIlvaine buffer (pH 4-9 at a concentration of 0.2 mg/mL). Aqueous Na2HPO4 was used 
for pH 9. The reaction was set at 37 °C at 600 rpm for 1-7 days. A sample was taken and measured 
by HPLC. The area under the curve of the chromatogram shows the percentage of starting material 
or degradation material (CCP). 
 
 
 
ELISA experiments. In general, the CCP(Im)-biotin peptide (9) was dissolved in MilliQ with a 
final concentration of 1.25 mg/mL. The solution was divided in parts of 400 µL and transferred 
to 6 vials. A DBCO stock solution (10 equiv.) was prepared and a dilution was made to make a 
second stock solution (1 equiv.). In a similar manner, the benzyl azide stock solutions were made 
(1000 or 100 equiv.), after which aliquots of 50 µL of the benzyl azide stock solutions were put in 
small vials.  
To the 400 µL peptide solution 100 µL of the DBCO stock solution was added. The reaction was 
performed at 37 °C. After 0 min, 1 min, 5 min, 10 min, 30 min, 1 h, 2 h, the reaction was quenched 
by taking 50 µL of sample and adding it to the vial containing the 100 equiv. of benzyl azide 
(relative to DBCO). The sample was then kept at -20 °C overnight until use in ELISA. 
The sample solutions (0.5 mg/mL) and the solutions containing peptides 7-9 were then diluted 
to 10 µg/mL using 0.1% BSA/PBS. The solutions (100 µL) were added to the ELISA plate, coated 
with streptavidin, and incubated for 1 hour at 37 °C. The plate was washed three times with 
PBS/0.1% Tween, followed by and incubation step with ACPA-positive or anti-TT-positive serum 
(100 µL) for 1 hour at 37 °C. The plate was then again washed three times with PBS/0.1% Tween. 
Afterwards, the wells were incubated with 100 µL of rabbit anti-human-HRP (1:2000 dilution) for 
1 hour at 37 °C and washed. Finally, the wells were incubated with 100 µL of a mixture of 
TMB/UP (1:1) at room temperature for 5 minutes. The coloring reaction was quenched by 
addition of 100 µL of 2M H2SO4. The absorbance was measured at 450 nm.  
 
FACS experiments. The streptavidin-peptide complexes were prepared as described in 
literature.25 Briefly, the CXP-biotin peptide derivatives (7-9) were dissolved in PBS to make a 2 
mg/mL stock solution. This solution was further diluted to make 14 µL of 1 mg/mL peptide 
solution in PBS buffer. In a vial 37.5 µL of Streptavidin-APC solution (S32362, LUMC), 12.5 µL 
CCP-biotin derivative solution (1 mg/mL) was added and these were incubated overnight at 4 °C.  
A Bio-Spin 30 column was resuspended and centrifuged for 2 min at 1000 g twice with the 
removal of buffer. The column was then placed in a vial and the sample was loaded. The column 
was centrifuged for 4 minutes at 1000 g to get the APC tetramer samples in vials. These samples 
were stored at 4 °C. 
CCP(Im) tetramers (1 µL, 0.9 µg/mL) were incubated in the dark for 1 hour with 0 µL, 1 µL, 2 
µL, 3 µL, 4 µL, 5 µL, 6 µL, 7 µL, 8 µL, 9 µL or 10 µL of a 10 mM DBCO-CO2H solution (final 
volume 20 µL). The peptide tetramers were all 1000 times diluted and 30 µL was added to both 
ACPA-expressing B cells or anti-TT-expressing B cells in a 48 well plate. The cells were put on ice 
for 30 min. 100 µl of PBA was added per well, the plate was centrifuged and the supernatant 
discarded. This was repeated once. Then, 100 µl of 1% paraformaldehyde was added and the cell 
suspensions were transferred to micronic tubes and measured by flow cytometry using BD 
LSRFortessa (BD Biosciences). 
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h. The peptide was precipitated in diethyl ether, collected and lyophilized. The crude peptide was 
then purified using preparative HPLC (see Chapter 2 for specifics).  
 
CCP-SH (12b). HPLC: Rt. 12.405. LCMS (ESI+) m/z calcd for C92H159N39O33S22+ [M+2H]2+ 
1201.82, found 1201.60. C98H162N41O33S3+ [M+3H]3+ 801.54, found 801.48. C98H163N41O33S4+ 
[M+4H]4+ 601.41, found 601.52. C98H164N41O33S5+ [M+5H]5+ 481.33, found 481.48 
 
CNleP-SH (13b). HPLC: Rt. 13.166. LCMS (ESI+) m/z calcd for C92H159N37O32S22+ [M+2H]2+ 
1179.76, found 1179.68. C92H160N37O32S23+ [M+3H]3+ 786.84, found 786.84. C92H161N37O32S24+ 
[M+4H]4+ 590.38, found 590.40. C92H162N37O32S25+ [M+5H]5+ 472.52, found 472.76.  
  
CCP(Im)-SH (14b). HPLC: Rt. 13.719. LCMS (ESI+) m/z calcd for C100H163N41O34S22+ 
[M+2H]2+ 1273.88, found 1273.44. C98H164N41O33S2+ [M+3H]3+ 849.59, found 849.64. 
C98H165N41O33S2+ [M+4H]4+ 637.44, found 637.32. C98H166N41O33S2+ [M+5H]5+ 510.15, found 
510.36. 
 
General maleimide coupling protocol. Peptides 12b-14b were treated with PiercerTM TCEP 
reducing gel for 1 h at room temperature in milliQ (750 µL). The gel was centrifuged and the 
supernatant was collected. The gel was washed two times with milliQ (250 µL), and this was 
combined with the first supernatant. To the peptide solution MC-Val-Cit-PAB-MMAE dissolved 
in DMSO (10 mM, 0.75 equiv.) was added. The suspension was shaken overnight at room 
temperature. The peptides were purified using a reversed phase preparative HPLC using an 
acetonitrile/water gradient (5-100%, 1-45 min).  
 
CCP-MMAE (12c) HPLC: Rt. 19.187. LCMS (ESI+) m/z calcd for C160H265N50O48S23+ [M+3H]3+ 
1240.43, found 1240.16. C160H266N50O48S24+ [M+4H]4+ 930.57, found 930.48. C160H267N50O48S25+ 
[M+5H]5+ 744.66, found 744.44. 
 
CNleP-MMAE (13c) HPLC: Rt. 19.018. LCMS (ESI+) m/z calcd for C160H265N48O47S23+ 
[M+3H]3+ 1225.76, found 1225.52. C160H266N48O47S24+ [M+4H]4+ 919.57, found 919.52. 
C160H267N48O47S25+ [M+5H]5+ 735.85, found 735.60. 
 
CCP(Im)-MMAE (14c) HPLC: Rt. 19.108. LCMS (ESI+) m/z calcd for C168H269N52O49S23+ 
[M+3H]3+ 1288.47, found 1288.16. C168H270N52O49S24+ [M+4H]4+ 966.60, found 966.52. 
C168H271N52O49S25+ [M+5H]5+ 773.48, found 773.28. C168H272N52O49S26+ [M+5H]6+ 644.74, found 
644.52. 
 
CCP(Im) stability measurements at various pH. The peptide was dissolved in 1% 
DMSO/McIlvaine buffer (pH 4-9 at a concentration of 0.2 mg/mL). Aqueous Na2HPO4 was used 
for pH 9. The reaction was set at 37 °C at 600 rpm for 1-7 days. A sample was taken and measured 
by HPLC. The area under the curve of the chromatogram shows the percentage of starting material 
or degradation material (CCP). 
 
 
 
ELISA experiments. In general, the CCP(Im)-biotin peptide (9) was dissolved in MilliQ with a 
final concentration of 1.25 mg/mL. The solution was divided in parts of 400 µL and transferred 
to 6 vials. A DBCO stock solution (10 equiv.) was prepared and a dilution was made to make a 
second stock solution (1 equiv.). In a similar manner, the benzyl azide stock solutions were made 
(1000 or 100 equiv.), after which aliquots of 50 µL of the benzyl azide stock solutions were put in 
small vials.  
To the 400 µL peptide solution 100 µL of the DBCO stock solution was added. The reaction was 
performed at 37 °C. After 0 min, 1 min, 5 min, 10 min, 30 min, 1 h, 2 h, the reaction was quenched 
by taking 50 µL of sample and adding it to the vial containing the 100 equiv. of benzyl azide 
(relative to DBCO). The sample was then kept at -20 °C overnight until use in ELISA. 
The sample solutions (0.5 mg/mL) and the solutions containing peptides 7-9 were then diluted 
to 10 µg/mL using 0.1% BSA/PBS. The solutions (100 µL) were added to the ELISA plate, coated 
with streptavidin, and incubated for 1 hour at 37 °C. The plate was washed three times with 
PBS/0.1% Tween, followed by and incubation step with ACPA-positive or anti-TT-positive serum 
(100 µL) for 1 hour at 37 °C. The plate was then again washed three times with PBS/0.1% Tween. 
Afterwards, the wells were incubated with 100 µL of rabbit anti-human-HRP (1:2000 dilution) for 
1 hour at 37 °C and washed. Finally, the wells were incubated with 100 µL of a mixture of 
TMB/UP (1:1) at room temperature for 5 minutes. The coloring reaction was quenched by 
addition of 100 µL of 2M H2SO4. The absorbance was measured at 450 nm.  
 
FACS experiments. The streptavidin-peptide complexes were prepared as described in 
literature.25 Briefly, the CXP-biotin peptide derivatives (7-9) were dissolved in PBS to make a 2 
mg/mL stock solution. This solution was further diluted to make 14 µL of 1 mg/mL peptide 
solution in PBS buffer. In a vial 37.5 µL of Streptavidin-APC solution (S32362, LUMC), 12.5 µL 
CCP-biotin derivative solution (1 mg/mL) was added and these were incubated overnight at 4 °C.  
A Bio-Spin 30 column was resuspended and centrifuged for 2 min at 1000 g twice with the 
removal of buffer. The column was then placed in a vial and the sample was loaded. The column 
was centrifuged for 4 minutes at 1000 g to get the APC tetramer samples in vials. These samples 
were stored at 4 °C. 
CCP(Im) tetramers (1 µL, 0.9 µg/mL) were incubated in the dark for 1 hour with 0 µL, 1 µL, 2 
µL, 3 µL, 4 µL, 5 µL, 6 µL, 7 µL, 8 µL, 9 µL or 10 µL of a 10 mM DBCO-CO2H solution (final 
volume 20 µL). The peptide tetramers were all 1000 times diluted and 30 µL was added to both 
ACPA-expressing B cells or anti-TT-expressing B cells in a 48 well plate. The cells were put on ice 
for 30 min. 100 µl of PBA was added per well, the plate was centrifuged and the supernatant 
discarded. This was repeated once. Then, 100 µl of 1% paraformaldehyde was added and the cell 
suspensions were transferred to micronic tubes and measured by flow cytometry using BD 
LSRFortessa (BD Biosciences). 
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3.7 Supplementary Figure 
 
 
Figure SI-1. Flow cytometric binding studies of streptavidin-coupled, biotinylated CCP, CArgP, and 
(activated) CCP(Im) to A) an ACPA-expressing B cell clone and B) an anti-TT-specific B cell clone. 
Activation of CCP(Im) was performed using DBCO for 1 h at 37 °C before addition to the cells. 
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Abstract 
 
Bioorthogonal reactions can be performed selectively in the presence of any biological functional 
group and are widely used to achieve site-selective chemical modifications of biomolecules. The 
click-to-release reaction is a variant that has gained much interest over the last few years. The 
bioorthogonal reaction between tetrazines and trans-cyclooctenes or vinyl ethers for example, 
initiate the release of a small molecule immediately after the cycloaddition. Recently, our group 
reported that vinyl boronic acids (VBAs) gave exceptionally high reaction rates in the 
bioorthogonal inverse electron-demand Diels-Alder reaction with pyridyl tetrazines. In the present 
study, we explore whether VBAs can be used in the click-to-release variant and demonstrate the 
use with a VBA-protected cladribine prodrug. We show that the cytotoxicity of cladribine is 
dampened by the attachment of the VBA, and activity can be largely restored upon the reaction 
with a tetrazine, inducing cell death.  
  
4.1 Introduction  
 
Chemical site-selective protein modifications have become increasingly popular for modification 
and control over protein functions in vitro and in living systems. Over the last few years, more 
reactions have been developed and used to ‘decorate’ biomolecules with a desired functionality 
such as fluorophores, affinity probes or reactive tags. All these reactions have some properties in 
common; ideally, they must be selective over other functional groups in biomolecules, have fast 
reaction rates and progress in aqueous media around physiological pH.1 Reactions such as the 
Staudinger ligation2 or the strain-promoted alkyne–azide cycloaddition (SPAAC)3-4 have been used 
extensively for modifying purposes. Our group has recently reported a new bioorthogonal reaction 
based on a vinylboronic acid (VBA) tetrazine ligation. It was shown that by introducing a boronic 
acid moiety on an alkene, reaction rates of an iEDDA (inverse electron demand Diels-Alder) click 
reaction were improved several orders of magnitude compared to the non-modified linear alkene.5 
The hydrophilic properties and the small size of VBAs compared to other bioorthogonal reactants 
make them attractive for the use in biomolecular labeling experiments. VBAs were shown to be 
biocompatible, non-toxic, and highly stable in aqueous media and cell lysates. Moreover, VBAs 
can be used orthogonally to the SPAAC reaction for protein modification, making them attractive 
complements to the bioorthogonal molecular toolbox.5-7  
While the number of bioorthogonal reactions used in vivo is limited due to the need of toxic 
reagents (e.g. copper, in copper (I)-catalyzed alkyne-azide cycloaddition8-9) or possible side reactions 
of the reactants (strained alkenes or alkynes react with cysteines), VBAs appeared useful in cellular 
experiments. No side reactions with vicinal diols (present in carbohydrates for example) were 
observed when performing reactions in living cells.6  
It was shown that the reactivity of VBAs depends on the tetrazine and its substituents. Since the 
boronic acid coordinates to the pyridyl ring of dipyridyl tetrazine, reaction rates were enhanced in 
comparison to tetrazines lacking such potent Lewis base.10 The orthogonal use of this 
bioorthogonal reaction was shown by using two different tetrazines favoring the reaction with 
either a VBA or norbornene. This was demonstrated using a subunit-specific proteasome inhibitor 
conjugated to norbornene and a proteasome inhibitor bearing a VBA. When adding both a phenyl 
pyrimidyl tetrazine and a dipyridyl tetrazine, containing different fluorophores, it was shown that 
due to different reaction rates subunit-specific labeling occurred.7 
The interest in bioorthogonal click-to-release reactions for activation of protected biologically 
relevant molecules in vivo has increased significantly in the last years. Therefore, a significant 
number of bioorthogonal bond cleavage reactions have been developed.11 The combination of a 
tetrazine ligation and a release reaction enables new applications in vitro and in vivo, such as the 
activation of prodrugs or fluorogenic compounds. Alkenes bearing a leaving group directly 
attached to the double bond undergo a subsequent release reaction after the iEDDA, yielding both 
the leaving group and the pyridazine product.12 A substituent on the allylic position of the alkene 
also confers a release reaction, although the amount is dependent on the tautomer and the 
substituents of the dihydropyridazine product. Positioning the release substituent at the allylic 
position, though, may be advantageous for the cylcoaddition due to decreased steric hindrance.12-
13 
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Figure 1. Tetrazine click-to-release reaction. A) Reagents for click-to-release reactions, trans-cyclooctene I, 
vinyl ether II, vinyl boronic acids III and IV; B) Proposed click-to-release mechanism, liberating boric acid 
and a leaving group; C) Schematic overview of click-to-release reaction with cladribine-VBA. Cell death is 
only expected when the cladribine-VBA is activated by a tetrazine cycloaddition; D) Structure of cladribine.  
In 2013, the group of Robillard reported the first bioorthogonal click-to-release reaction based on 
the reaction of tetrazines with trans-cyclooctenes (TCOs) that possess a carbamate substituent at 
the allylic position (Figure 1A).14 After the iEDDA of the tetrazine and TCO, the 4,5-
dihydropyridazine eliminates the leaving group to liberate both CO2 and the amine. Unfortunately, 
part of the dihydropyridazine tautomerizes to the 1,4-dihydropyidazine, which does not lead to a 
release reaction. Although this click-to-release process does not give complete elimination, it has 
been frequently applied in biological systems for activation of prodrugs15-16 or caged proteins.17-18 
Recently, it was noted that this click-to-release reaction is environmentally sensitive and 
improvements on both the TCO and tetrazine resulted in ultrafast click-to-release reaction rates 
and the complete elimination of the leaving group.19  
In 2016, the groups of Deveraj and Bernardes reported both the bioorthogonal click-to-release 
reaction of tetrazines and vinyl ethers (Figure 1A).20-21 These alkenes bear their leaving group 
directly on the alkene and give therefore full release of the alcohol after the iEDDA. The vinyl 
ethers appeared stable in aqueous solutions for at least 8 hours and were suitable for applications 
in living cells. The vinyl ethers have the advantage to be small in size, but have disappointingly low 
rate constants when reacting with tetrazines. 
Since VBAs have proven to be useful in bioorthogonal conjugation, we envisioned that by 
introducing a boronic acid group on the vinyl ethers, we could increase the rate of these click-to-
release reactions. In addition, similar to vinyl ethers,20-21 we expect that VBA ethers give full release 
of the alcohol, or amine when linked via a carbamate, after the iEDDA. The proposed iEDDA 
click-to-release reaction mechanism of boronic acids with tetrazines is shown in Figure 1B. Upon 
cycloaddition and retro-Diels-Alder reaction liberating N2, the boric acid and the leaving group, 
which can be a linked via an alcohol or carbamate, are released.  
To proof the applicability of the VBA click-to-release strategy we developed a VBA protected 
cladribine, which can be released using tetrazine (Figure 1C) in the proximity of cells. Cladribine 
(2-chlorodeoxyadenosine; 2CdA; Figure 1D) is a purine analogue and resembles deoxyadenosine. 
Cladribine contains a chlorine atom and is, unlike adenosine, resistant to breakdown by adenosine 
deaminase. In the cell, cladribine gets activated upon phosphorylation, and is then incorporated 
into the DNA synthesis pathway, leading to strand breaks in the newly synthesized DNA. The 
consequence of this is that the cell will go into apoptosis. The high level of deoxycytidine kinase, 
responsible for the phosphorylation of cladribine, and the low level of 5’-nucleotidase activity in 
lymphocytes, compared to other cells, results in accumulation of the activated cladribine, 
specifically in lymphocytes. Therefore, cladribine is already used as a synthetic chemotherapeutic 
agent in B cell chronic lymphocytic leukemia and multiple sclerosis.22-24 Lymphocytes also play a 
major role in disease progression of rheumatoid arthritis (RA), where autoreactive antibodies (such 
as anti-citrullinated protein antibodies, ACPA) are produced in high numbers by B cell-derived 
plasma cells. Treatment of RA patients with rituximab, leading to the killing of B-lymphocytes, has 
been shown to give a therapeutic benefit.25 Here we show that we can turn cladribine into a prodrug 
through VBA protection which can be liberated using a VBA-tetrazine click-to-release reaction to 
selectively target lymphocytes, including autoreactive ACPA-positive B cells.  
 
4.2 Results and Discussion 
 
Synthesis and comparison of vinylboronic acid (6) and vinyl ether (9). Vinyl ethers are 
relevant for click-to-release reactions due to their relatively small size. However, rather low reaction 
rates have been observed in reaction with tetrazines.20 By the introduction of a boronic acid 
functional group we expect to increase the reaction rates with tetrazines and we expect full release 
as has been seen for the vinyl ethers. 
To make a comparison with the vinyl ethers and later on for the attachment of a toxin, we 
synthesized VBA 6, containing the ether moiety, and its primary alkene derivative 9 (Scheme 1). 
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The synthesis of VBA 6 started with the etherification of 4-hydroxybenzyl alcohol 1 with 
trichloroethylene and subsequent protection of the primary alcohol. Next, dichlorovinyl ether 3 
was treated with n-BuLi to eliminate hydrogen chloride and to provide alkynyl ether 4. 
Deprotection of the primary alcohol and hydroboration of alkyne 5 with pinacolborane yielded 
VBA pinacol ester 6. In our kinetic experiments, we used the pinacol ester as precursor for the 
free boronic acid as it hydrolyzes quickly in aqueous media (see Figure SI-1). The synthesis of vinyl 
ether 9 started with 4-hydroxybenzaldehyde (7). First, reaction with 1,2-dibromoethane was 
performed yielding compound 8 and subsequently elimination using t-BuOK was carried out. 
Lastly, NaBH4 was used to reduce the aldehyde to the corresponding benzyl alcohol. All reactions 
towards the vinyl ether 9 were performed conform a literature procedure.16 
 
 
 
Scheme 1. Synthesis of VBA ether 6 and vinyl ether 9. i) Trichloroethylene, K2CO3, DMF, 70 °C, 16 h, 
87%. ii) TBSCl, imidazole, DMF, 2 h, quant. iii) n-BuLi, Et2O, -78 to -40 °C, 87%. iv) TBAF, THF, 0 °C, 
91%. v) Pinacolborane, RuHClCO(PPh3)3, toluene, 50 °C, 16 h, 76%. vi) Dibromoethane, K2CO3, MeCN, 
reflux, 20 h, 79%. vii) t-BuOK, DMSO, r.t., 10 min. viii) NaBH4, MeOH, r.t., 1.5 h, 18%. 
 
Having alkenes 6 and 9 in hand, we next examined the second-order rate constants with 3,6-
dipyridyl-s-tetrazine 10 in 75% MeOH in PBS at a controlled temperature of 20 °C. As we used 
the pinacol ester as precursor, we incubated ester 6 for 2 h in the solvent mixture to achieve full 
hydrolysis to the free boronic acid before measuring its k2 value. Second-order rate constants were 
obtained by following the decrease of the tetrazine UV absorbance in the visible region (Figure 
SI-2). The pseudo first-order constant kobs was first determined by plotting the decay of tetrazine 
absorbance against time (minutes) for five different amounts of excess of alkene. By fitting an 
exponential nonlinear regression curve, the Kobs could be extracted (see also Materials and 
Methods). Next, the Kobs was plotted against the five different alkene concentrations and a linear 
regression fit gave a linear function, of which the slope corresponded to the k2 (Figure SI-2). The 
second-order rate constant for VBA 6 was a 4-fold higher than the rate constant of vinyl ether 9, 
clearly indicating a positive effect of the boronic acid on the reactivity of the alkene (Figure 2A).  
The observed rate constant of VBA ether 6 was lower than expected as we previously observed 
rate enhancements of up to 100-fold compared to the unsubstituted alkene derivatives.5 We 
hypothesize that the moderate rate enhancement is due to the ether on the vinylic position. Since 
this alcohol is slightly electron-donating, we assume that the alkene becomes more electron-rich 
and therefore lowers the Lewis acidity of the boronic acid, which becomes less coordinating to the 
pyridyl rings of the tetrazine.  
 
 
Figure 2. Click-to-release reactions and reaction rates. A) Scheme of  the reaction of  3,6-dipyridyl-s-
tetrazine 10 with VBA ether 6 and vinyl ether 9. k2 values were measured in 3:1 MeOH/PBS; B) 1H-NMR 
study of  the reaction between tetrazine 10 (∎) and VBA ether 6 (▲) yielding pyridazine 11 () and 4-
hydroxybenzyl alcohol 1 (♦) in 3:1 CD3OD/deuterated PBS; C) Same as B, but then the reaction of  10 with 
vinyl ether 9 (▼). 
 
Next, we looked in more detail into the click-to-release reaction of 3,6-dipyridyl-s-tetrazine 10 and 
alkenes 6 and 9 by 1H NMR in 75% CD3OD in deuterated PBS over time (Figures 2B, C). A near 
to complete conversion of VBA ether 6 was observed after 7 days, while vinyl ether 9 gave only 
around 50% conversion. Both reactions yielded the formation of pyridazine 11 and 4-
hydroxybenzyl alcohol 1, while no intermediates were observed, showing that the release reaction 
was fast for both vinyl ether 9 as well as VBA ether 6.  
 
Synthesis of cladribine-VBA as a click-to-release prodrug. To apply the click-to-release 
reaction with VBA, we next synthesized cladribine-VBA 16. The VBA is intended to function as 
a caging group to inactivate cladribine, and upon click-to-release with tetrazine, cladribine would 
be released and become active again. Figure 3A schematically shows the click-to-release reaction 
yielding the liberated cladribine toxin. 
We commenced the synthesis from VBA alcohol 6 (Scheme 2). Activation of the alcohol using 
bis(pentafluorophenyl)carbonate and Et3N as a base was successful to yield VBA 14. Cladribine 
92
Chapter 4
529590-L-bw-Lelieveldt
Processed on: 13-3-2019 PDF page: 93
4
The synthesis of VBA 6 started with the etherification of 4-hydroxybenzyl alcohol 1 with 
trichloroethylene and subsequent protection of the primary alcohol. Next, dichlorovinyl ether 3 
was treated with n-BuLi to eliminate hydrogen chloride and to provide alkynyl ether 4. 
Deprotection of the primary alcohol and hydroboration of alkyne 5 with pinacolborane yielded 
VBA pinacol ester 6. In our kinetic experiments, we used the pinacol ester as precursor for the 
free boronic acid as it hydrolyzes quickly in aqueous media (see Figure SI-1). The synthesis of vinyl 
ether 9 started with 4-hydroxybenzaldehyde (7). First, reaction with 1,2-dibromoethane was 
performed yielding compound 8 and subsequently elimination using t-BuOK was carried out. 
Lastly, NaBH4 was used to reduce the aldehyde to the corresponding benzyl alcohol. All reactions 
towards the vinyl ether 9 were performed conform a literature procedure.16 
 
 
 
Scheme 1. Synthesis of VBA ether 6 and vinyl ether 9. i) Trichloroethylene, K2CO3, DMF, 70 °C, 16 h, 
87%. ii) TBSCl, imidazole, DMF, 2 h, quant. iii) n-BuLi, Et2O, -78 to -40 °C, 87%. iv) TBAF, THF, 0 °C, 
91%. v) Pinacolborane, RuHClCO(PPh3)3, toluene, 50 °C, 16 h, 76%. vi) Dibromoethane, K2CO3, MeCN, 
reflux, 20 h, 79%. vii) t-BuOK, DMSO, r.t., 10 min. viii) NaBH4, MeOH, r.t., 1.5 h, 18%. 
 
Having alkenes 6 and 9 in hand, we next examined the second-order rate constants with 3,6-
dipyridyl-s-tetrazine 10 in 75% MeOH in PBS at a controlled temperature of 20 °C. As we used 
the pinacol ester as precursor, we incubated ester 6 for 2 h in the solvent mixture to achieve full 
hydrolysis to the free boronic acid before measuring its k2 value. Second-order rate constants were 
obtained by following the decrease of the tetrazine UV absorbance in the visible region (Figure 
SI-2). The pseudo first-order constant kobs was first determined by plotting the decay of tetrazine 
absorbance against time (minutes) for five different amounts of excess of alkene. By fitting an 
exponential nonlinear regression curve, the Kobs could be extracted (see also Materials and 
Methods). Next, the Kobs was plotted against the five different alkene concentrations and a linear 
regression fit gave a linear function, of which the slope corresponded to the k2 (Figure SI-2). The 
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Synthesis of cladribine-VBA as a click-to-release prodrug. To apply the click-to-release 
reaction with VBA, we next synthesized cladribine-VBA 16. The VBA is intended to function as 
a caging group to inactivate cladribine, and upon click-to-release with tetrazine, cladribine would 
be released and become active again. Figure 3A schematically shows the click-to-release reaction 
yielding the liberated cladribine toxin. 
We commenced the synthesis from VBA alcohol 6 (Scheme 2). Activation of the alcohol using 
bis(pentafluorophenyl)carbonate and Et3N as a base was successful to yield VBA 14. Cladribine 
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was acetylated using Ac2O and pyridine to protect the alcohols from reacting with VBA 14. The 
acetylated cladribine 13 was deprotonated with NaH to couple with VBA 14. Deacetylation of 
cladribine yielded the final compound 16 in which the toxin was linked via a self-cleavable linker26 
to the VBA.  
 
 
Scheme 2. Synthesis of cladribine-VBA 16. i) Ac2O, pyridine, r.t., 1.5 h, quant. ii) 
Bis(pentafluorophenyl)carbonate, Et3N, r.t., 1 h, 84%. iii) 11 + 12, NaH, r.t., 7 h, 42%. iv) NaOMe in 
MeOH, MeCN, r.t., 1 h, 59% .  
 
To gain an indication of the release rate of cladribine prior to performing click-to-release reactions 
with cells, we tested the cycloaddition with tetrazine and subsequent release over time in a buffer 
system. Before reacting VBA 16 with tetrazine 17, pinacol hydrolysis was performed in PBS at 
room temperature for 2 hours. Either 1 or 10 equivalents of tetrazine were added and the reaction 
was followed over time with LCMS. Deprotection in PBS at 37 °C, using 1 equivalent of tetrazine 
was complete in 24 hours, while using 10 equivalents completion was already achieved within 2 
hours (Figure 3B). No intermediate products were observed, indicating that the cleavage of the 
linker occurs instantaneously after the cycloaddition. While the click-to-release of 4-hydroxybenzyl 
alcohol 1 took 7 days, the release of cladribine with the same amount of tetrazine was finished in 
only 24 hours. Protic solvents have been described to accelerate the iEDDA reaction and this 
effect is even more pronounced when reactions are performed in water.27 The click-to-release using 
VBA 6 was achieved after 7 days in 75% MeOH in PBS (this compound is less water soluble than 
VBA 16) and after only one day using 1% DMSO in PBS as a solvent for VBA 16.  
As shown in Figure 3A, the addition of tetrazine liberates cladribine upon cycloaddition. In the 
absence of tetrazine, cladribine is protected and should not be toxic to cells. To test this effect on 
living cells, we incubated immortalized ACPA-positive B cells, a model cell line for autoreactive B 
cells in RA, with cladribine-VBA. Cladribine alone was incubated with the cells as a control and 
showed to be toxic for immortalized B cells in a dose dependent manner (Figure SI-3). The VBA 
modification on cladribine inactivated the compound, as the observed toxicity was dampened. 
However, full inactivation was not obtained (Figure 4A). To examine whether this partial toxicity 
was due to stability issues, we incubated protected cladribine 16 for up to 3 days in PBS at 37 °C. 
A significant degree of instability was observed for this compound after 3 days, as 
protodeborylation (17%) and unmodified cladribine (67%) were observed (Figure SI-4).  
 
 
Figure 3. Click-to-release of VBA 16 to yield the free drug cladribine 12. A) Schematic overview of click-
to-release reaction with cladribine-VBA; B) The release of cladribine after the reaction with either 1 (pink) 
or 10 (yellow) equivalents of tetrazine 17. The amount of cladribine was determined by LCMS and was 
quantified by the area under the curve. The graph shows the relative amount compared to the amount of 
starting material. 
 
Although active cladribine was already observed after 24 h, we continued our studies for activation 
purposes. We preincubated cladribine-VBA 16 with tetrazine 17 (10 equivalents) for 24 hours 
before adding the mixture to the cells. After 3 days of incubation, we observed that the toxicity 
level of tetrazine-activated cladribine was similar to that of cladribine alone (Figure 4A). However, 
cladribine activation with 10 equivalents of tetrazine in the direct vicinity of cells did not show the 
anticipated results as shown for the pre-incubated cell cytotoxicity experiment (Figure SI-5). 
Although significant amounts of cladribine-VBA were liberated compared to the control, only a 
minority of cells died at 100 nM. This appeared concentration dependent, since the toxicity 
increased during the experiment with higher concentrations (1 µM). Increasing the amount of 
tetrazine to 100 equivalents, however, induced toxicity to the same level as observed for cladribine 
(Figure SI-5). On the other hand, using 100 equivalents of tetrazine without cladribine also induced 
toxicity, making it impossible to tell whether the cells died because of the liberated cladribine or 
because of tetrazine toxicity.  
As cladribine is more toxic for lymphoid cells (explained above), we tested toxicity on HEK293-
TM cells, expressing a transmembrane (TM) domain-containing ACPA receptor. Figure 4B shows 
that with up to 400 nM of cladribine no toxicity was observed on HEK293-TM cells, while only 
13% of the immortalized B cells survived at the same concentration. This shows that cladribine is 
indeed less toxic for these HEK cells compared to the immortalized B cells. Although deprotection 
and lymphocyte toxicity of cladribine-VBA were observed over time, hardly any cell death was 
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seen for HEK cells after 3 days of incubation, indicating a potential therapeutic window using 
these compounds.  
 
 
Figure 4. Cytotoxicity of (activated) cladribine-VBA on lymphoid and non-lymphoid cells after 3 days. 
Cladribine-VBA and tetrazine 17 (10 equiv.) were preincubated for 24h before the addition to the cells. A) 
Cytotoxicity for autoreactive immortalized B cells, 30,000 cells were used; B) Cytotoxicity for HEK cells 
expressing ACPA receptors, 10,000 cells were used.  
 
4.3 Conclusion 
 
In this Chapter we have shown that VBAs can be used in click-to-release reactions. The release 
was instantaneous after the tetrazine cycloaddition as no reaction intermediates were observed by 
NMR experiments. We assume that the slight electron-donating nature of the ether at the vinylic 
position reduces the reaction rate as compared to regular VBAs lacking the ether function.  
We used the VBA click-to-release strategy on a cytotoxic drug that is initially caged, but released 
and activated upon reaction with tetrazine. Cladribine-VBA slowly degraded over 3 days so that 
partial deprotection was observed when cladribine-VBA was incubated, without the addition of 
tetrazine, with cells. Overall, incubation optimization is required to achieve optimal deprotection 
of the cladribine-VBA and minimal toxicity of the caged cladribine. Since the used VBA prodrug 
degrades slowly over time, it is not suited for experiments requiring long incubation times. 
Exploring other VBA-prodrug linkages or another toxin-VBA conjugate can be beneficial for this 
purpose and used to dissect the origin of the VBA prodrug instability. Even then, slow degradation 
of a protected drug does not have to be problematic if prodrug activation and toxicity induction 
is faster. Hence, it would be interesting to attach a more potent drug which requires a shorter 
incubation time to induce toxicity, and to further evaluate this strategy as a viable release 
mechanism. 
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4.5 Materials and Methods 
 
For general methods, see the materials and methods section of Chapter 2 (paragraph 2.4). 
 
(Z)-(4-((1,2-Dichlorovinyl)oxy)phenyl)methanol (2). 4-Hydroxybenzyl alcohol 1 (2.0 g, 16 
mmol, 1.0 equiv.) was dissolved in DMF (16 mL) under ambient atmosphere 
and K2CO3 (2.7 g, 19 mmol, 1.2 equiv.) was added. Next, the mixture was 
heated at 70 °C and trichloroethylene (1.8 mL, 19 mmol, 1.2 equiv.) was 
added dropwise. After the mixture was heated at 70 °C overnight, it was cooled down to r.t., H2O 
(20 mL) was added and the mixture was extracted with EtOAc (3 × 15 mL). The combined organic 
layers were washed with brine and dried over Na2SO4, and the volatiles were removed under 
reduced pressure. As there was still water present, the product was resuspended in H2O and 
extracted with Et2O (3 × 15 mL). The combined organic layers were washed with brine and dried 
over Na2SO4. The volatiles were removed under reduced pressure yielding vinyl ether 2 (3.1 g, 
87%) as a dark orange oil. Rf = 0.57 (50% EtOAc in heptane). 1H NMR (400 MHz, chloroform-
d) δ 7.40 – 7.34 (m, 2H), 7.09 – 7.04 (m, 2H), 5.96 (s, 1H), 4.67 (s, 2H). 13C NMR (100 MHz, 
chloroform-d) δ 153.3, 140.0, 137.1, 128.6, 117.2, 103.8, 64.7. GCMS 6.68 min, m/z = 218 (M+, 
calcd. for C9H8Cl2O2 = 218, 100%), 107 [(M-C7H7O)+, 55%], 77 [(M-C6H5)+, 85%]. 
 
(Z)-tert-Butyl((4-((1,2-dichlorovinyl)oxy)benzyl)oxy)dimethylsilane (3). Alcohol 2 (2.0 g, 
9.1 mmol, 1.0 equiv.) was dissolved in dry DMF (16 mL) and the mixture 
was cooled to 0 °C. Then, imidazole (750 mg, 11 mmol, 1.2 equiv.) and 
TBDMSCl (1.7 g, 11 mmol, 1.2 equiv.) were added and the reaction was 
stirred for 2 h at r.t. The mixture was diluted with Et2O (20 mL), washed with sat. NH4Cl and 
brine and dried over Na2SO4. The volatiles were removed under reduced pressure yielding TBDMS 
ether 8 (3.1 g, quant.) as a slightly yellow oil. Rf = 0.32 (10% EtOAc in heptane). 1H NMR (400 
MHz, chloroform-d) δ 7.36 – 7.29 (m, 2H), 7.06 – 6.99 (m, 2H), 5.94 (s, 1H), 4.72 (s, 2H), 0.94 (s, 
9H), 0.10 (s, 6H). 13C NMR (100 MHz, chloroform-d) δ 152.7, 140.2, 137.8, 127.4, 116.9, 103.5, 
64.4, 25.9, 18.4, -5.3. GCMS 8.36 min, m/z = 332 (M+, calcd. for C15H22Cl2O2Si = 332, <1%), 275 
[(M-C11H13O2Si)+, 65%]. 
 
tert-Butyl((4-(ethynyloxy)benzyl)oxy)dimethylsilane (4). Dichlorovinyl ether 3 (2.0 g, 6.0 
mmol, 1.0 equiv.) was dissolved in dry Et2O (50 mL) and n-BuLi (15 mL 
of 1.6 M in hexanes, 23.8 mmol, 4.0 equiv.) was added dropwise to the 
mixture. The solution was then stirred for 1 h at -78 °C, before the mixture 
was warmed to -40 °C over the course of 1 h and stirred for another 1 h at -40 °C. Next, the 
mixture was quenched with H2O (10 mL) and extracted with Et2O (3× 15mL). The combined 
organic layers were washed with sat. NH4Cl and brine and dried over Na2SO4. The volatiles were 
removed under reduced pressure and the crude product was purified using column 
chromatography (1% EtOAc in heptane), yielding alkyne 4 (1.4 g, 87%) as a dark brown oil. Rf = 
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seen for HEK cells after 3 days of incubation, indicating a potential therapeutic window using 
these compounds.  
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position reduces the reaction rate as compared to regular VBAs lacking the ether function.  
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purpose and used to dissect the origin of the VBA prodrug instability. Even then, slow degradation 
of a protected drug does not have to be problematic if prodrug activation and toxicity induction 
is faster. Hence, it would be interesting to attach a more potent drug which requires a shorter 
incubation time to induce toxicity, and to further evaluate this strategy as a viable release 
mechanism. 
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added dropwise. After the mixture was heated at 70 °C overnight, it was cooled down to r.t., H2O 
(20 mL) was added and the mixture was extracted with EtOAc (3 × 15 mL). The combined organic 
layers were washed with brine and dried over Na2SO4, and the volatiles were removed under 
reduced pressure. As there was still water present, the product was resuspended in H2O and 
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(Z)-tert-Butyl((4-((1,2-dichlorovinyl)oxy)benzyl)oxy)dimethylsilane (3). Alcohol 2 (2.0 g, 
9.1 mmol, 1.0 equiv.) was dissolved in dry DMF (16 mL) and the mixture 
was cooled to 0 °C. Then, imidazole (750 mg, 11 mmol, 1.2 equiv.) and 
TBDMSCl (1.7 g, 11 mmol, 1.2 equiv.) were added and the reaction was 
stirred for 2 h at r.t. The mixture was diluted with Et2O (20 mL), washed with sat. NH4Cl and 
brine and dried over Na2SO4. The volatiles were removed under reduced pressure yielding TBDMS 
ether 8 (3.1 g, quant.) as a slightly yellow oil. Rf = 0.32 (10% EtOAc in heptane). 1H NMR (400 
MHz, chloroform-d) δ 7.36 – 7.29 (m, 2H), 7.06 – 6.99 (m, 2H), 5.94 (s, 1H), 4.72 (s, 2H), 0.94 (s, 
9H), 0.10 (s, 6H). 13C NMR (100 MHz, chloroform-d) δ 152.7, 140.2, 137.8, 127.4, 116.9, 103.5, 
64.4, 25.9, 18.4, -5.3. GCMS 8.36 min, m/z = 332 (M+, calcd. for C15H22Cl2O2Si = 332, <1%), 275 
[(M-C11H13O2Si)+, 65%]. 
 
tert-Butyl((4-(ethynyloxy)benzyl)oxy)dimethylsilane (4). Dichlorovinyl ether 3 (2.0 g, 6.0 
mmol, 1.0 equiv.) was dissolved in dry Et2O (50 mL) and n-BuLi (15 mL 
of 1.6 M in hexanes, 23.8 mmol, 4.0 equiv.) was added dropwise to the 
mixture. The solution was then stirred for 1 h at -78 °C, before the mixture 
was warmed to -40 °C over the course of 1 h and stirred for another 1 h at -40 °C. Next, the 
mixture was quenched with H2O (10 mL) and extracted with Et2O (3× 15mL). The combined 
organic layers were washed with sat. NH4Cl and brine and dried over Na2SO4. The volatiles were 
removed under reduced pressure and the crude product was purified using column 
chromatography (1% EtOAc in heptane), yielding alkyne 4 (1.4 g, 87%) as a dark brown oil. Rf = 
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0.33 (1% EtOAc in heptane). 1H NMR (400 MHz, chloroform-d) δ 7.35 – 7.29 (m, 2H), 7.26 – 
7.23 (m, 2H), 4.71 (s, 2H), 2.07 (s, 1H), 0.94 (s, 9H), 0.09 (s, 6H). 13C NMR (100 MHz, chloroform-
d) δ 154.5, 137.9, 127.4, 114.7, 84.7, 64.3, 33.2, 25.9, 18.4, -5.2. GCMS 6.71 min, m/z = 262 (M+, 
calcd. for C15H22O2Si = 262, < 1%), 205 [(M-C11H13O2Si)+, 100%], 131 [(M-C9H7O)+, 100%], 77 
[(M-C6H5)+, 30%]. 
 
(4-(Ethynyloxy)phenyl)methanol (5). TBMDS ether 4 (1.0 g, 3.8 mmol, 1.0 equiv.) was 
dissolved in dry THF (20 mL) and the mixture was cooled to 0 °C. 1 M TBAF 
in THF (4.2 mL, 4.2 mmol, 1.1 equiv.) was added and the mixture was stirred 
for 30 mins at 0 °C before the reaction was quenched with H2O (15 mL). The 
product was extracted with EtOAc (3 × 15mL) and the combined organic layers were washed with 
brine and dried over MgSO4. The volatiles were removed under reduced pressure and the crude 
product was purified using column chromatography (30% EtOAc in heptane), yielding alcohol 5 
(506 mg, 91%) as a dark green solid. Rf = 0.3 (30% EtOAc in heptane). 1H NMR (400 MHz, 
chloroform-d) δ 7.40 – 7.36 (m, 2H), 7.30 – 7.27 (m, 2H), 4.68 (s, 2H), 2.10 (s, 1H). 13C NMR (100 
MHz, chloroform-d) δ 155.0, 137.3, 128.5, 115.1, 84.5, 64.6, 33.5. GCMS 4.64 min, m/z = 148 
(M+, calcd. for C9H8O2 = 148, 100%), 77 [(M- C6H5)+, 70%]. 
 
(E)-(2-(4-(Hydroxymethyl)phenoxy)vinyl)boronic acid pinacol ester (6). Alkyne 5 (100 mg, 
0.68 mmol, 1.0 equiv.) was dissolved in dry toluene (2 mL) and sparged 
with N2 for 10 minutes. Pinacolborane (490 µL, 3.4 mmol, 5.0 equiv.) 
and RuHClCO(PPh3)3 (38 mg, 34 µmol, 0.05 equiv.) were added and the 
mixture was stirred at 50 °C overnight. The mixture was cooled down to r.t. before the volatiles 
were removed under reduced pressure. The crude product was dissolved in Et2O (10 mL) and 
washed with sat. NaHCO3 and brine, and dried over Na2SO4. The volatiles were removed under 
reduced pressure and the crude product was purified using column chromatography (30 to 40% 
EtOAc in heptane), yielding VBA 6 (141 mg, 76%) as a dark brown oil. Rf = 0.33 (40% EtOAc in 
heptane). 1H NMR (400 MHz, chloroform-d) δ 7.36 – 7.31 (m, 2H), 7.23 (d, J = 13.8 Hz, 1H), 7.07 
– 7.02 (m, 2H), 4.88 (d, J = 13.9 Hz, 1H), 4.66 (d, J = 5.7 Hz, 2H), 1.60 (t, J = 5.9 Hz, 1H), 1.27 
(s, 12H). 13C NMR (100 MHz, chloroform-d) δ 159.4, 136.6, 128.5, 118.4, 83.0, 64.8, 24.7, 21.1. 
No signal was observed for the carbon attached to boron. GCMS 8.90 min, m/z = 275 (M+, calcd. 
for C15H21BO4 = 275, 100%), 77 [(M-C6H5)+, 28%]. 
 
4-(2-Bromoethoxy)benzaldehyde (8). 4-Hydroxybenzaldehyde 7 (1.0 g, 8.2 mmol, 1.0 equiv.) 
was dissolved in MeCN (63 mL) under ambient atmosphere. 
Dibromoethane (7.1 mL, 82 mmol, 10.0 equiv.) and K2CO3 (2.1 g, 14.9 
mmol, 1.8 equiv.) were added and the mixture was stirred at 80 °C 
overnight. The mixture was cooled down to r.t., H2O (50 mL) was added 
and the product was extracted with Et2O (3 × 20 mL). The combined organic layers were washed 
with brine, dried over MgSO4 and the volatiles were removed under reduced pressure. The crude 
product was purified using column chromatography (30% EtOAc in heptane), yielding ether 8 (1.5 
g, 79%) as a white solid. Rf = 0.38 (30% EtOAc in heptane). 1H NMR (400 MHz, chloroform-d) 
δ 9.90 (s, 1H), 7.92 – 7.81 (m, 2H), 7.06 – 6.98 (m, 2H), 4.38 (t, J = 6.2 Hz, 2H), 3.67 (t, J = 6.2 
Hz, 2H). 13C NMR (100 MHz, chloroform-d) δ 190.7, 163.0, 132.0, 130.5, 114.9, 68.0, 28.4. GCMS 
6.87 min, m/z = 228 (M+, calcd. for C9H9BrO2 = 228.0, 67%), 201 [(M-C8H8BrO)+, 70%], 107 
[(M-C2H4Br)+, 5%]. 
 
(4-(Vinyloxy)phenyl)methanol (9). Benzaldehyde 8 (400 mg, 1.8 mmol, 1.0 equiv.) was 
dissolved in dry DMSO (7 mL) and purged with N2 for 10 minutes. t-BuOK 
(239 mg, 2.1 mmol, 1.2 equiv.) was slowly added in portions and the mixture 
was stirred for 10 minutes. Then, the mixture was diluted with EtOAc (35 mL) 
and quenched with ice water (1 mL). The layers were separated and the organic layers was washed 
with H2O (3 × 10 mL), brine and dried over MgSO4. The volatiles were removed under reduced 
pressure and the crude mixture was dissolved in MeOH (20 mL). NaBH4 (132 mg, 3.5 mmol, 2.0 
equiv.) was added in portions and the mixture was stirred for 1.5 h. The reaction was quenched 
with H2O (20 mL) and the pH was adjusted with 0.1 M HCl until pH = 7. The mixture was 
extracted with EtOAc (3 × 15 mL), washed with brine and dried over MgSO4. The volatiles were 
removed and the crude product was purified using column chromatography (20 to 30% EtOAc in 
heptane) yielding benzyl alcohol 9 (48 mg, 18%) as a colorless oil. Rf = 0.56 (30% EtOAc in 
heptane). 1H NMR (400 MHz, chloroform-d) δ 7.36 – 7.30 (m, 2H), 7.03 – 6.97 (m, 2H), 6.64 (dd, 
J = 13.7, 6.1 Hz, 1H), 4.76 (dd, J = 13.7, 1.7 Hz, 1H), 4.65 (d, J = 4.2 Hz, 2H), 4.44 (dd, J = 6.1, 
1.7 Hz, 1H). 13C NMR (100 MHz, chloroform-d) δ 156.3, 148.2, 135.7, 128.6, 117.2, 95.2, 64.9. 
GCMS 4.55 min, m/z = 150 (M+, calcd. for C9H10O2 = 150, 100%), 107 [(M-C7H7O)+, 70%], 77 
[(M-C6H5)+, 50%]. 
 
2-Chloro-2′-deoxy-3′,5′-di-O-acetyladenosine (13). Cladribine 12 (25 mg, 88 µmol, 1.0 equiv.) 
was suspended in acetic anhydride (175 µl) and pyridine (263 µl). The 
mixture was stired for 1.5 h under N2. The solvents were evaporated 
to yield acetylated cladribine 13 as a white solid (33 mg, quant.). Rf = 
0.23 (5% MeOH in DCM). 1H NMR (500 MHz, chloroform-d) δ 7.97 
(s, 1H), 6.41 (dd, J = 8.1, 5.8 Hz, 1H), 5.86 (s, 2H), 5.41 – 5.36 (m, 
1H), 4.38 (t, J = 3.9 Hz, 2H), 4.34 (td, J = 4.1, 3.6, 1.9 Hz, 1H), 2.80 (ddd, J = 14.4, 8.2, 6.3 Hz, 
1H), 2.64 (ddd, J = 14.1, 5.8, 2.3 Hz, 1H), 2.14 (s, 3H), 2.11 (s, 3H). 13C NMR (126 MHz, 
chloroform-d) δ 170.37, 170.29, 155.99, 154.35, 150.69, 138.76, 118.90, 84.46, 82.63, 74.39, 63.71, 
37.99, 20.94, 20.82. HRMS (ESI+) m/z calcd for C14H17ClN5O5+ [M+H]+ 370.09127, found: 
370.09182. m/z calcd for C14H16ClN5NaO5+ [M+Na]+ 392.07322, found: 392.07377. 
 
(E)-(2-(4-(Perfluorophenyl carbonate)phenoxy)vinyl)boronic acid pinacol ester (14). 
Alcohol 6 (100 mg, 0.36 mmol, 1.0 equiv.) was dissolved 
in DCM (3 mL) under ambient atmosphere. 
Bis(pentafluorophenyl)carbonate (214 mg, 0.54 mmol, 1.5 
equiv.) and Et3N (252 µl, 1.8 mmol, 5.0 equiv.) were added 
and the mixture was stirred for 1 h. The volatiles were 
removed under reduced pressure and the crude product was purified using column 
chromatography (1 to 5% EtOAc in heptane), yielding VBA 14 (111 mg, 84%) as a colorless oil. 
Rf = 0.13 (5% EtOAc in heptane). 1H NMR (500 MHz, chloroform-d 3) δ 7.40 (d, J = 8.6 Hz, 2H), 
7.23 (d, J = 13.8 Hz, 1H), 7.08 (d, J = 8.6 Hz, 2H), 5.29 (s, 2H), 4.93 (d, J = 13.8 Hz, 1H), 1.28 (s, 
12H). 13C NMR (126 MHz, chloroform-d) δ 158.68, 156.78, 151.26, 142.25, 140.80, 140.20, 138.77, 
136.85, 130.46, 130.25, 129.26, 118.41, 83.13, 71.59, 24.72. No signal was observed for the carbon 
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0.33 (1% EtOAc in heptane). 1H NMR (400 MHz, chloroform-d) δ 7.35 – 7.29 (m, 2H), 7.26 – 
7.23 (m, 2H), 4.71 (s, 2H), 2.07 (s, 1H), 0.94 (s, 9H), 0.09 (s, 6H). 13C NMR (100 MHz, chloroform-
d) δ 154.5, 137.9, 127.4, 114.7, 84.7, 64.3, 33.2, 25.9, 18.4, -5.2. GCMS 6.71 min, m/z = 262 (M+, 
calcd. for C15H22O2Si = 262, < 1%), 205 [(M-C11H13O2Si)+, 100%], 131 [(M-C9H7O)+, 100%], 77 
[(M-C6H5)+, 30%]. 
 
(4-(Ethynyloxy)phenyl)methanol (5). TBMDS ether 4 (1.0 g, 3.8 mmol, 1.0 equiv.) was 
dissolved in dry THF (20 mL) and the mixture was cooled to 0 °C. 1 M TBAF 
in THF (4.2 mL, 4.2 mmol, 1.1 equiv.) was added and the mixture was stirred 
for 30 mins at 0 °C before the reaction was quenched with H2O (15 mL). The 
product was extracted with EtOAc (3 × 15mL) and the combined organic layers were washed with 
brine and dried over MgSO4. The volatiles were removed under reduced pressure and the crude 
product was purified using column chromatography (30% EtOAc in heptane), yielding alcohol 5 
(506 mg, 91%) as a dark green solid. Rf = 0.3 (30% EtOAc in heptane). 1H NMR (400 MHz, 
chloroform-d) δ 7.40 – 7.36 (m, 2H), 7.30 – 7.27 (m, 2H), 4.68 (s, 2H), 2.10 (s, 1H). 13C NMR (100 
MHz, chloroform-d) δ 155.0, 137.3, 128.5, 115.1, 84.5, 64.6, 33.5. GCMS 4.64 min, m/z = 148 
(M+, calcd. for C9H8O2 = 148, 100%), 77 [(M- C6H5)+, 70%]. 
 
(E)-(2-(4-(Hydroxymethyl)phenoxy)vinyl)boronic acid pinacol ester (6). Alkyne 5 (100 mg, 
0.68 mmol, 1.0 equiv.) was dissolved in dry toluene (2 mL) and sparged 
with N2 for 10 minutes. Pinacolborane (490 µL, 3.4 mmol, 5.0 equiv.) 
and RuHClCO(PPh3)3 (38 mg, 34 µmol, 0.05 equiv.) were added and the 
mixture was stirred at 50 °C overnight. The mixture was cooled down to r.t. before the volatiles 
were removed under reduced pressure. The crude product was dissolved in Et2O (10 mL) and 
washed with sat. NaHCO3 and brine, and dried over Na2SO4. The volatiles were removed under 
reduced pressure and the crude product was purified using column chromatography (30 to 40% 
EtOAc in heptane), yielding VBA 6 (141 mg, 76%) as a dark brown oil. Rf = 0.33 (40% EtOAc in 
heptane). 1H NMR (400 MHz, chloroform-d) δ 7.36 – 7.31 (m, 2H), 7.23 (d, J = 13.8 Hz, 1H), 7.07 
– 7.02 (m, 2H), 4.88 (d, J = 13.9 Hz, 1H), 4.66 (d, J = 5.7 Hz, 2H), 1.60 (t, J = 5.9 Hz, 1H), 1.27 
(s, 12H). 13C NMR (100 MHz, chloroform-d) δ 159.4, 136.6, 128.5, 118.4, 83.0, 64.8, 24.7, 21.1. 
No signal was observed for the carbon attached to boron. GCMS 8.90 min, m/z = 275 (M+, calcd. 
for C15H21BO4 = 275, 100%), 77 [(M-C6H5)+, 28%]. 
 
4-(2-Bromoethoxy)benzaldehyde (8). 4-Hydroxybenzaldehyde 7 (1.0 g, 8.2 mmol, 1.0 equiv.) 
was dissolved in MeCN (63 mL) under ambient atmosphere. 
Dibromoethane (7.1 mL, 82 mmol, 10.0 equiv.) and K2CO3 (2.1 g, 14.9 
mmol, 1.8 equiv.) were added and the mixture was stirred at 80 °C 
overnight. The mixture was cooled down to r.t., H2O (50 mL) was added 
and the product was extracted with Et2O (3 × 20 mL). The combined organic layers were washed 
with brine, dried over MgSO4 and the volatiles were removed under reduced pressure. The crude 
product was purified using column chromatography (30% EtOAc in heptane), yielding ether 8 (1.5 
g, 79%) as a white solid. Rf = 0.38 (30% EtOAc in heptane). 1H NMR (400 MHz, chloroform-d) 
δ 9.90 (s, 1H), 7.92 – 7.81 (m, 2H), 7.06 – 6.98 (m, 2H), 4.38 (t, J = 6.2 Hz, 2H), 3.67 (t, J = 6.2 
Hz, 2H). 13C NMR (100 MHz, chloroform-d) δ 190.7, 163.0, 132.0, 130.5, 114.9, 68.0, 28.4. GCMS 
6.87 min, m/z = 228 (M+, calcd. for C9H9BrO2 = 228.0, 67%), 201 [(M-C8H8BrO)+, 70%], 107 
[(M-C2H4Br)+, 5%]. 
 
(4-(Vinyloxy)phenyl)methanol (9). Benzaldehyde 8 (400 mg, 1.8 mmol, 1.0 equiv.) was 
dissolved in dry DMSO (7 mL) and purged with N2 for 10 minutes. t-BuOK 
(239 mg, 2.1 mmol, 1.2 equiv.) was slowly added in portions and the mixture 
was stirred for 10 minutes. Then, the mixture was diluted with EtOAc (35 mL) 
and quenched with ice water (1 mL). The layers were separated and the organic layers was washed 
with H2O (3 × 10 mL), brine and dried over MgSO4. The volatiles were removed under reduced 
pressure and the crude mixture was dissolved in MeOH (20 mL). NaBH4 (132 mg, 3.5 mmol, 2.0 
equiv.) was added in portions and the mixture was stirred for 1.5 h. The reaction was quenched 
with H2O (20 mL) and the pH was adjusted with 0.1 M HCl until pH = 7. The mixture was 
extracted with EtOAc (3 × 15 mL), washed with brine and dried over MgSO4. The volatiles were 
removed and the crude product was purified using column chromatography (20 to 30% EtOAc in 
heptane) yielding benzyl alcohol 9 (48 mg, 18%) as a colorless oil. Rf = 0.56 (30% EtOAc in 
heptane). 1H NMR (400 MHz, chloroform-d) δ 7.36 – 7.30 (m, 2H), 7.03 – 6.97 (m, 2H), 6.64 (dd, 
J = 13.7, 6.1 Hz, 1H), 4.76 (dd, J = 13.7, 1.7 Hz, 1H), 4.65 (d, J = 4.2 Hz, 2H), 4.44 (dd, J = 6.1, 
1.7 Hz, 1H). 13C NMR (100 MHz, chloroform-d) δ 156.3, 148.2, 135.7, 128.6, 117.2, 95.2, 64.9. 
GCMS 4.55 min, m/z = 150 (M+, calcd. for C9H10O2 = 150, 100%), 107 [(M-C7H7O)+, 70%], 77 
[(M-C6H5)+, 50%]. 
 
2-Chloro-2′-deoxy-3′,5′-di-O-acetyladenosine (13). Cladribine 12 (25 mg, 88 µmol, 1.0 equiv.) 
was suspended in acetic anhydride (175 µl) and pyridine (263 µl). The 
mixture was stired for 1.5 h under N2. The solvents were evaporated 
to yield acetylated cladribine 13 as a white solid (33 mg, quant.). Rf = 
0.23 (5% MeOH in DCM). 1H NMR (500 MHz, chloroform-d) δ 7.97 
(s, 1H), 6.41 (dd, J = 8.1, 5.8 Hz, 1H), 5.86 (s, 2H), 5.41 – 5.36 (m, 
1H), 4.38 (t, J = 3.9 Hz, 2H), 4.34 (td, J = 4.1, 3.6, 1.9 Hz, 1H), 2.80 (ddd, J = 14.4, 8.2, 6.3 Hz, 
1H), 2.64 (ddd, J = 14.1, 5.8, 2.3 Hz, 1H), 2.14 (s, 3H), 2.11 (s, 3H). 13C NMR (126 MHz, 
chloroform-d) δ 170.37, 170.29, 155.99, 154.35, 150.69, 138.76, 118.90, 84.46, 82.63, 74.39, 63.71, 
37.99, 20.94, 20.82. HRMS (ESI+) m/z calcd for C14H17ClN5O5+ [M+H]+ 370.09127, found: 
370.09182. m/z calcd for C14H16ClN5NaO5+ [M+Na]+ 392.07322, found: 392.07377. 
 
(E)-(2-(4-(Perfluorophenyl carbonate)phenoxy)vinyl)boronic acid pinacol ester (14). 
Alcohol 6 (100 mg, 0.36 mmol, 1.0 equiv.) was dissolved 
in DCM (3 mL) under ambient atmosphere. 
Bis(pentafluorophenyl)carbonate (214 mg, 0.54 mmol, 1.5 
equiv.) and Et3N (252 µl, 1.8 mmol, 5.0 equiv.) were added 
and the mixture was stirred for 1 h. The volatiles were 
removed under reduced pressure and the crude product was purified using column 
chromatography (1 to 5% EtOAc in heptane), yielding VBA 14 (111 mg, 84%) as a colorless oil. 
Rf = 0.13 (5% EtOAc in heptane). 1H NMR (500 MHz, chloroform-d 3) δ 7.40 (d, J = 8.6 Hz, 2H), 
7.23 (d, J = 13.8 Hz, 1H), 7.08 (d, J = 8.6 Hz, 2H), 5.29 (s, 2H), 4.93 (d, J = 13.8 Hz, 1H), 1.28 (s, 
12H). 13C NMR (126 MHz, chloroform-d) δ 158.68, 156.78, 151.26, 142.25, 140.80, 140.20, 138.77, 
136.85, 130.46, 130.25, 129.26, 118.41, 83.13, 71.59, 24.72. No signal was observed for the carbon 
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attached to boron. 19F NMR (471 MHz, chloroform-d) δ -152.93 – -153.03 (m), -157.41 (t, J = 21.7 
Hz), -161.90 – -162.05 (m). 11B NMR (160 MHz, chloroform-d) δ 30.59. GCMS 12.91 min, m/z = 
486 (M+, C22H20BF5O6 = 486, 0%), 427 [(M-C19H13 BF5O5)+, 2%], 259 [(M-C15H20 BO3)+, 50%].  
 
(E)-(2-(4-(O-Diacetylated cladribine carbamate)phenoxy)vinyl)boronic acid pinacol ester 
(15). Acetylated cladribine 13 (19 mg, 50 µmol, 1.0 
equiv.) was dissolved in DMF (1 ml) and cooled to 0 
°C. NaH (2.5 mg, 60 µmol, 1.2 equiv, 60% dispersion 
in oil) was added. The mixture was stirred for 30 
minutes before compound 14 (25 mg, 50 µmol, 1.0 
equiv) was added. The reaction was stirred for 7 h 
and subsequently quenched with H2O on ice. The 
water layer was extracted with EtOAc (3 x 5 ml). The combined organic layers were washed with 
brine and dried over Na2SO4. The solvents were removed under reduced pressure. Purification by 
flash chromatography (50-60% EtOAc in heptane) yielded the desired 15 (14 mg, 42%) as a white 
oil. Rf = 0.20 (60% EtOAC in heptane). 1H NMR (500 MHz, chloroform-d) δ 8.25 (s, 1H), 8.15 
(s, 1H), 7.42 (d, J = 8.6 Hz, 2H), 7.22 (d, J = 13.8 Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 6.44 (dd, J = 
8.0, 5.9 Hz, 1H), 5.39 (dt, J = 6.1, 2.2 Hz, 1H), 5.26 (s, 2H), 4.90 (d, J = 13.8 Hz, 1H), 4.37 (td, J 
= 5.4, 5.0, 2.1 Hz, 3H), 2.80 (ddd, J = 14.3, 8.1, 6.3 Hz, 1H), 2.67 (ddd, J = 14.2, 5.9, 2.3 Hz, 1H), 
2.14 (s, 3H), 2.09 (s, 3H), 1.26 (s, 12H). 13C NMR (126 MHz, chloroform-d) δ 170.48, 170.41, 
159.09, 156.47, 154.26, 152.54, 150.64, 150.20, 141.18, 130.91, 130.44, 121.53, 118.45, 84.80, 83.21, 
82.97, 74.45, 67.82, 63.78, 38.18, 24.88, 21.06, 20.95. No signal was observed for the carbon 
attached to boron. 11B NMR (160 MHz, CDCl3) δ 22.42. HRMS (ESI+) m/z calcd for 
C30H35BClN5NaO10+ [M+Na]+ 694.20577, found: 694.20565.  
 
(E)-(2-(4-(Cladribine carbamate)phenoxy)vinyl)boronic acid pinacol ester (16). Cladribine-
VBA 15 (9.5 mg, 14 µmol, 1.0 equiv) was dissolved in 
MeCN (500 µL) and NaOMe (7.1 µL, 5M solution in 
MeOH, 2.5 equiv) was added. After 1 h, the solvents 
were evaporated and the product was dissolved in 10% 
H2O in MeCN to yield pure cladribine-VBA 16 as a 
yellow solid (5 mg, 59%). Rf = 0.40 (10% MeOH in 
DCM). 1H NMR (500 MHz, MeOH-d4) δ 8.03 (s, 1H), 
7.26 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.32 – 6.19 (m, 3H), 5.00 (s, 2H), 4.90 (d, J = 
13.6 Hz, 1H), 4.46 (dt, J = 5.6, 2.7 Hz, 1H), 3.94 (q, J = 3.0 Hz, 1H), 3.69 (ddd, J = 55.6, 12.3, 3.3 
Hz, 2H), 2.72 – 2.62 (m, 1H), 2.31 – 2.24 (m, 1H), 1.10 (s, 12H). 13C NMR (126 MHz, MeOH-d4) 
δ 157.77, 153.36, 149.92, 144.80, 139.30, 130.67, 129.13, 115.67, 88.29, 85.47, 74.42, 71.58, 66.04, 
62.29, 40.03, 23.62. No signal was observed for the carbon attached to boron. Pinacol is no longer 
attached, due to the NMR solvent. 11B NMR (160 MHz, MeOH-d4) δ 4.38. HRMS (ESI+) m/z 
calcd for C26H31BClN5NaO8+ [M+Na]+ 610,18519, found: 610,18615.  
 
 
6-(6-(Pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazin-3-yl)pyridine-3-amine (S1). 
5-Amino-2-pyridinecarbonitrile (1.0 g, 8.39 mmol, 1.0 equiv.) and 2-cyanopyridine 
(0.87 g, 8.39 mmol, 1.0 equiv.) were heated in hydrazine monohydrate (1.6 mL, 33.57 
mmol, 4.0 equiv.) overnight at 90 °C under nitrogen. The solvent was evaporated and 
the mixture was purified twice using column chromatography, first a column using 40-
80% EtOAc in heptane and then 0-5% MeOH in DCM yielding dihydrotetrazine S1 
as a yellow solid (520 mg, 2.05 mmol, 24%). Rf = 0.25 (50% EtOAc in heptane). 1H 
NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.65 (s, 1H), 8.62 (ddd, J = 4.9, 1.7, 1.0 Hz, 
1H), 7.98-7.88 (m, 3H), 7.64 (dd, J = 8.6, 0.7 Hz, 1H), 7.51 (ddd, J = 7.2, 4.9, 1.5 Hz, 
1H), 6.99 (dd, J = 8.6, 2.7 Hz, 1H), 5.88 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 148.6, 147.5, 
146.7, 146.64, 146.60, 137.3, 134.2, 134.1, 125.2, 121.8, 120.8, 120.3. LRMS (ESI+) m/z calcd for 
C12H12N7+ [M+H]+ 254.1, found: 254.1. The data agrees with the reported literature values.28-29 
 
2-(Boc-amino)-N-(6-(6-(pyridine-2-yl)-1,4-dihydro-1,2,4,5-tetrazin-3yl)pyridine-3-
yl)acetamide (S2).  Boc-glycine (622 mg, 3.55 mmol, 2.0 equiv.) was dissolved 
in dry THF (9 mL) under nitrogen and cooled to 0 °C. N-Methylmorpholine 
(977 µL, 8.88 mmol, 5.0 equiv.) and isobutyl chloroformate (464 µL, 3.55 mmol, 
2.0 equiv.) were added and the mixture was stirred for 5 min. Then amine S1 
(450 mg, 1.78 mmol, 1.0 equiv.) was added and the mixture was stirred 
overnight. Water and EtOAc were added, the layers were separated and the 
water layer was extracted with EtOAc (2 x). The combined organic layers were 
washed with sat. NaHCO3 (aq.), dried over Na2SO4, and the solvent was 
removed under reduced pressure. The product was purified using column 
chromatography (70-100% EtOAc in heptane) yielding amide S2 as a yellow solid (575 mg, 79%). 
Rf = 0.37 (70% EtOAc in heptane). 1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.93 (s, 1H), 
8.88 (s, 1H), 8.82 (d, J = 2.5 Hz, 1H), 8.67-8.57 (m, 1H), 8.15 (dd, J = 8.7, 2.5 Hz, 1H), 8.00-7.87 
(m, 3H), 7.53 (ddd, J = 7.2, 4.9, 1.5 Hz, 1H), 7.13 (t, J = 6.1 Hz, 1H), 3.78 (d, J = 6.1 Hz, 2H), 1.40 
(s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 169.2, 155.9, 148.6, 147.3, 146.3, 146.1, 141.3, 138.9, 
137.4, 137.0, 126.8, 125.3, 121.4, 121.0, 78.2, 43.8, 28.2. LRMS (ESI+) m/z calcd for C19H23N8O3+ 
[M+H]+ 411.2, found: 411.1. The data agrees with the reported literature values. 28 
 
2-(Boc-amino)-N-(6-(6-(pyridine-2-yl)-1,2,4,5-tetrazin-3-yl)pyridine-3-yl)acetamide (S3). 
Dihydrotetrazine S2 (300 mg, 0.73 mmol, 1.0 equiv.) was dissolved in acetic acid 
(15 mL). Sodium nitrite (93 mg, 1.10 mmol, 1.1 equiv.) was added and the 
solution was stirred for 10 min. The mixture was diluted with DCM, and washed 
3 times with sat. NaHCO3 (aq.). The organic layer was dried with Na2SO4 and the 
volatiles were removed under reduced pressure. The product was purified using 
column chromatography (0-8% MeOH in DCM) yielding tetrazine S3 as a pink 
solid (151 mg, 51%). Rf = 0.45 (10% MeOH in DCM). 1H NMR (400 MHz, 
DMSO-d6) δ 10.62 (s, 1H), 9.05 (d, J = 2.5 Hz, 1H), 8.97-8.90 (m, 1H), 8.64 (d, J 
= 8.7 Hz, 1H), 8.59 (td, J = 8.0, 1.1 Hz, 1H), 8.43 (dd, J = 8.7, 2.5 Hz, 1H), 8.16 
(dt, J = 7.7, 1.7 Hz, 1H), 7.73 (ddd, J = 7.7, 4.7, 1.2 Hz, 1H), 7.18 (t, J = 6.1 Hz, 1H), 3.84 (d, J = 
6.1, 2H), 1.41 (s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 169.5, 163.0, 162.8, 156.0, 150.6, 150.2, 
144.0, 141.3, 138.2, 137.8, 126.6, 126.3, 124.9, 124.2, 78.2, 43.9, 28.2. LRMS (ESI+) m/z calcd for 
C19H21N8O3+ [M+H]+ 409.2, found: 409.1. The data agrees with the reported literature values. 28 
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attached to boron. 19F NMR (471 MHz, chloroform-d) δ -152.93 – -153.03 (m), -157.41 (t, J = 21.7 
Hz), -161.90 – -162.05 (m). 11B NMR (160 MHz, chloroform-d) δ 30.59. GCMS 12.91 min, m/z = 
486 (M+, C22H20BF5O6 = 486, 0%), 427 [(M-C19H13 BF5O5)+, 2%], 259 [(M-C15H20 BO3)+, 50%].  
 
(E)-(2-(4-(O-Diacetylated cladribine carbamate)phenoxy)vinyl)boronic acid pinacol ester 
(15). Acetylated cladribine 13 (19 mg, 50 µmol, 1.0 
equiv.) was dissolved in DMF (1 ml) and cooled to 0 
°C. NaH (2.5 mg, 60 µmol, 1.2 equiv, 60% dispersion 
in oil) was added. The mixture was stirred for 30 
minutes before compound 14 (25 mg, 50 µmol, 1.0 
equiv) was added. The reaction was stirred for 7 h 
and subsequently quenched with H2O on ice. The 
water layer was extracted with EtOAc (3 x 5 ml). The combined organic layers were washed with 
brine and dried over Na2SO4. The solvents were removed under reduced pressure. Purification by 
flash chromatography (50-60% EtOAc in heptane) yielded the desired 15 (14 mg, 42%) as a white 
oil. Rf = 0.20 (60% EtOAC in heptane). 1H NMR (500 MHz, chloroform-d) δ 8.25 (s, 1H), 8.15 
(s, 1H), 7.42 (d, J = 8.6 Hz, 2H), 7.22 (d, J = 13.8 Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 6.44 (dd, J = 
8.0, 5.9 Hz, 1H), 5.39 (dt, J = 6.1, 2.2 Hz, 1H), 5.26 (s, 2H), 4.90 (d, J = 13.8 Hz, 1H), 4.37 (td, J 
= 5.4, 5.0, 2.1 Hz, 3H), 2.80 (ddd, J = 14.3, 8.1, 6.3 Hz, 1H), 2.67 (ddd, J = 14.2, 5.9, 2.3 Hz, 1H), 
2.14 (s, 3H), 2.09 (s, 3H), 1.26 (s, 12H). 13C NMR (126 MHz, chloroform-d) δ 170.48, 170.41, 
159.09, 156.47, 154.26, 152.54, 150.64, 150.20, 141.18, 130.91, 130.44, 121.53, 118.45, 84.80, 83.21, 
82.97, 74.45, 67.82, 63.78, 38.18, 24.88, 21.06, 20.95. No signal was observed for the carbon 
attached to boron. 11B NMR (160 MHz, CDCl3) δ 22.42. HRMS (ESI+) m/z calcd for 
C30H35BClN5NaO10+ [M+Na]+ 694.20577, found: 694.20565.  
 
(E)-(2-(4-(Cladribine carbamate)phenoxy)vinyl)boronic acid pinacol ester (16). Cladribine-
VBA 15 (9.5 mg, 14 µmol, 1.0 equiv) was dissolved in 
MeCN (500 µL) and NaOMe (7.1 µL, 5M solution in 
MeOH, 2.5 equiv) was added. After 1 h, the solvents 
were evaporated and the product was dissolved in 10% 
H2O in MeCN to yield pure cladribine-VBA 16 as a 
yellow solid (5 mg, 59%). Rf = 0.40 (10% MeOH in 
DCM). 1H NMR (500 MHz, MeOH-d4) δ 8.03 (s, 1H), 
7.26 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.32 – 6.19 (m, 3H), 5.00 (s, 2H), 4.90 (d, J = 
13.6 Hz, 1H), 4.46 (dt, J = 5.6, 2.7 Hz, 1H), 3.94 (q, J = 3.0 Hz, 1H), 3.69 (ddd, J = 55.6, 12.3, 3.3 
Hz, 2H), 2.72 – 2.62 (m, 1H), 2.31 – 2.24 (m, 1H), 1.10 (s, 12H). 13C NMR (126 MHz, MeOH-d4) 
δ 157.77, 153.36, 149.92, 144.80, 139.30, 130.67, 129.13, 115.67, 88.29, 85.47, 74.42, 71.58, 66.04, 
62.29, 40.03, 23.62. No signal was observed for the carbon attached to boron. Pinacol is no longer 
attached, due to the NMR solvent. 11B NMR (160 MHz, MeOH-d4) δ 4.38. HRMS (ESI+) m/z 
calcd for C26H31BClN5NaO8+ [M+Na]+ 610,18519, found: 610,18615.  
 
 
6-(6-(Pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazin-3-yl)pyridine-3-amine (S1). 
5-Amino-2-pyridinecarbonitrile (1.0 g, 8.39 mmol, 1.0 equiv.) and 2-cyanopyridine 
(0.87 g, 8.39 mmol, 1.0 equiv.) were heated in hydrazine monohydrate (1.6 mL, 33.57 
mmol, 4.0 equiv.) overnight at 90 °C under nitrogen. The solvent was evaporated and 
the mixture was purified twice using column chromatography, first a column using 40-
80% EtOAc in heptane and then 0-5% MeOH in DCM yielding dihydrotetrazine S1 
as a yellow solid (520 mg, 2.05 mmol, 24%). Rf = 0.25 (50% EtOAc in heptane). 1H 
NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.65 (s, 1H), 8.62 (ddd, J = 4.9, 1.7, 1.0 Hz, 
1H), 7.98-7.88 (m, 3H), 7.64 (dd, J = 8.6, 0.7 Hz, 1H), 7.51 (ddd, J = 7.2, 4.9, 1.5 Hz, 
1H), 6.99 (dd, J = 8.6, 2.7 Hz, 1H), 5.88 (s, 2H). 13C NMR (100 MHz, DMSO-d6) δ 148.6, 147.5, 
146.7, 146.64, 146.60, 137.3, 134.2, 134.1, 125.2, 121.8, 120.8, 120.3. LRMS (ESI+) m/z calcd for 
C12H12N7+ [M+H]+ 254.1, found: 254.1. The data agrees with the reported literature values.28-29 
 
2-(Boc-amino)-N-(6-(6-(pyridine-2-yl)-1,4-dihydro-1,2,4,5-tetrazin-3yl)pyridine-3-
yl)acetamide (S2).  Boc-glycine (622 mg, 3.55 mmol, 2.0 equiv.) was dissolved 
in dry THF (9 mL) under nitrogen and cooled to 0 °C. N-Methylmorpholine 
(977 µL, 8.88 mmol, 5.0 equiv.) and isobutyl chloroformate (464 µL, 3.55 mmol, 
2.0 equiv.) were added and the mixture was stirred for 5 min. Then amine S1 
(450 mg, 1.78 mmol, 1.0 equiv.) was added and the mixture was stirred 
overnight. Water and EtOAc were added, the layers were separated and the 
water layer was extracted with EtOAc (2 x). The combined organic layers were 
washed with sat. NaHCO3 (aq.), dried over Na2SO4, and the solvent was 
removed under reduced pressure. The product was purified using column 
chromatography (70-100% EtOAc in heptane) yielding amide S2 as a yellow solid (575 mg, 79%). 
Rf = 0.37 (70% EtOAc in heptane). 1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.93 (s, 1H), 
8.88 (s, 1H), 8.82 (d, J = 2.5 Hz, 1H), 8.67-8.57 (m, 1H), 8.15 (dd, J = 8.7, 2.5 Hz, 1H), 8.00-7.87 
(m, 3H), 7.53 (ddd, J = 7.2, 4.9, 1.5 Hz, 1H), 7.13 (t, J = 6.1 Hz, 1H), 3.78 (d, J = 6.1 Hz, 2H), 1.40 
(s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 169.2, 155.9, 148.6, 147.3, 146.3, 146.1, 141.3, 138.9, 
137.4, 137.0, 126.8, 125.3, 121.4, 121.0, 78.2, 43.8, 28.2. LRMS (ESI+) m/z calcd for C19H23N8O3+ 
[M+H]+ 411.2, found: 411.1. The data agrees with the reported literature values. 28 
 
2-(Boc-amino)-N-(6-(6-(pyridine-2-yl)-1,2,4,5-tetrazin-3-yl)pyridine-3-yl)acetamide (S3). 
Dihydrotetrazine S2 (300 mg, 0.73 mmol, 1.0 equiv.) was dissolved in acetic acid 
(15 mL). Sodium nitrite (93 mg, 1.10 mmol, 1.1 equiv.) was added and the 
solution was stirred for 10 min. The mixture was diluted with DCM, and washed 
3 times with sat. NaHCO3 (aq.). The organic layer was dried with Na2SO4 and the 
volatiles were removed under reduced pressure. The product was purified using 
column chromatography (0-8% MeOH in DCM) yielding tetrazine S3 as a pink 
solid (151 mg, 51%). Rf = 0.45 (10% MeOH in DCM). 1H NMR (400 MHz, 
DMSO-d6) δ 10.62 (s, 1H), 9.05 (d, J = 2.5 Hz, 1H), 8.97-8.90 (m, 1H), 8.64 (d, J 
= 8.7 Hz, 1H), 8.59 (td, J = 8.0, 1.1 Hz, 1H), 8.43 (dd, J = 8.7, 2.5 Hz, 1H), 8.16 
(dt, J = 7.7, 1.7 Hz, 1H), 7.73 (ddd, J = 7.7, 4.7, 1.2 Hz, 1H), 7.18 (t, J = 6.1 Hz, 1H), 3.84 (d, J = 
6.1, 2H), 1.41 (s, 9H). 13C NMR (100 MHz, DMSO-d6) δ 169.5, 163.0, 162.8, 156.0, 150.6, 150.2, 
144.0, 141.3, 138.2, 137.8, 126.6, 126.3, 124.9, 124.2, 78.2, 43.9, 28.2. LRMS (ESI+) m/z calcd for 
C19H21N8O3+ [M+H]+ 409.2, found: 409.1. The data agrees with the reported literature values. 28 
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2-Amino-N-(6-(6-(pyridine-2-yl)-1,2,4,5-tetrazin-3-yl)pyridine-3-yl)acetamide 
hydrochloride (17). Boc-protected amine S3 (40 mg, 98 µmol, 1.0 equiv.) was 
dissolved in dry DCM (2.2 mL) under nitrogen. 4M HCl in dioxane (735 µL, 
2.94 mmol, 30 equiv.) was slowly added and the mixture was stirred for 30 min. 
The solvent was removed under reduced pressure, whereupon the pink solid 
was lyophilized yielding amine 17 (34 mg, quant.). 1H NMR (400 MHz, DMSO-
d6) δ 11.57 (s, 1H), 9.16 (d, J = 2.4 Hz, 1H), 8.98-8.91 (m, 1H), 8.68 (d, J = 8.7 
Hz, 1H), 8.61 (dt, J = 8.0, 1.1 Hz, 1H), 8.44 (dd, J = 8.7, 2.5 Hz, 1H), 8.35 (br. 
t, J = 5.6 Hz, 2H), 8.18 (dt, J = 7.7, 1.8 Hz, 1H), 7.75 (ddd, J = 7.7, 4.7, 1.2 Hz, 
1H), 3.99-3.91 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 166.1, 163.0, 162.7, 
150.5, 150.0, 144.6, 141.3, 138.0, 137.6, 126.7, 126.6, 125.1, 124.3, 41.3. LRMS (ESI+) m/z calcd 
for C14H13N8O+ [M+H]+ 309.1, found: 309.1. The data agrees with the reported literature values.28 
 
1H NMR study of the click-to-release reaction. The reactions between tetrazine 10 and the 
alkenes 6 and 9 in 3:1 CD3OD/deuterated PBS were followed using 1H NMR (500 MHz). Prior 
to the start of the tetrazine ligation, pinacol ester 6 (5 mM) was incubated in 3:1 MeOD-
d4/deuterated PBS. The hydrolysis of the pinacol ester was followed over time and showed full 
conversion to the free boronic acid within 2 h (Figure SI-1). Next, tetrazine 17 (5.0 mM) and the 
deprotected VBA 6 or the vinyl ether 9 (5.0 mM) were mixed 1:1 for a final concentration of 2.5 
mM and the reactions were followed over time up to 14 days at room temperature.  
 
Second order rate constant experiment. The reactions between the alkenes and dipyridyl 
tetrazine derivative 10 in 75% MeOH/PBS were followed on a plate reader (Spark M10 microplate 
reader (Tecan)) at a controlled temperature of 20 °C, by measuring the absorbance of the tetrazine 
at 540 nm. The tetrazine and alkene were both dissolved in methanol, and then diluted with PBS. 
After addition of the tetrazine to the alkene solution, the measurement was started directly. The 
final concentration of the tetrazine was 500 μM and of the excess of alkene was 5, 6.25, 7.50, 8.75 
μM or 10mM. The time between the addition of the tetrazine and the start of the measurement 
was ± 20s. All reactions were performed in quadruplo. The kinetics were normalized and plotted 
in Figure SI-2A and 2B. The observed reactions were normalized by setting the absorbance at t = 
0 s as 100%. Since the reactions did not end in a plateau after the set time, the plateau was set 
equal to the background absorbance of the dihydropyridazine absorption at the given wavelength. 
It was taken into account that the measurement was started after a certain time.  
 
Pseudo-first-order rate constant determination. The pseudo first-order rate constants kobs for 
the tetrazine reactions with an excess of alkene was determined. The decay of the absorbance of 
the tetrazine was plotted against time (min) for the 5 different concentrations of the alkene. The 
kobs was determined by fitting an exponential ‘one phase decay’ (nonlinear regression) using 
PrismGraphPad Software whereby Y = (Y0 -plateau)*exp(-kobs*time(s)) + plateau.  
 
Second-order rate constant determination. To determine the second-order rate constant, the 
kobs of the reactions was plotted against the concentration of the alkenes. The line was fitted using 
a linear regression and the slope gave k2. The goodness of the fit is shown by the coefficient of 
determination (R2). The data is shown in Figure SI-2A and 2B. 
 
Click-to-release LCMS measurements. The reaction between tetrazine 17 and cladribine-VBA 
16 in 1% DMSO/PBS was followed using LCMS. Prior to the start of the tetrazine ligation, pinacol 
ester 16 (0.2 mM) was incubated in 1% DMSO/PBS. The hydrolysis of the pinacol ester was 
followed over time and tetrazine 17 (0.2 mM or 2.0 mM) was subsequently added. The reaction 
was followed over 24 hours at 37 °C. The amount of cladribine was determined and was quantified 
by the area under the curve. The graph shows the relative amount compared to the amount of 
starting material. 
 
Cell toxicity assays. ACPA-expressing B cell clones or HEK-TM cells were cultured with 
medium, and mIL21-Fc and soluble CD40L (from Biolegend) for the B cell clones. Stock solutions 
of tetrazine (500 mM), cladribine (10 µM) and cladribine-VBA (10 µM) were prepared in DMSO. 
Different concentrations were diluted in medium and cladribine-VBA was premixed with tetrazine 
in different amounts. All conditions were incubated overnight at 37 °C (except for the experiment 
in Figure SI-5, in there everything was mixed with the cells and directly incubated for 3 days) and 
added to 3x104 ACPA-expressing B cell clones or 1 x 104 HEK-TM cells in a 96-well plate. The 
cells were incubated for 3 days, after which XTT labelling and electron-coupling reagents (Roche) 
were added to the culture according to the manufacturer’s protocol and incubated for 4 hours. 
After the addition of a 5% Tween solution, cell viability was measured on a iMark TM Microplate 
Reader (from BioRad). Values measured at 630-690 nm were subtracted from 450-500 nm. 
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2-Amino-N-(6-(6-(pyridine-2-yl)-1,2,4,5-tetrazin-3-yl)pyridine-3-yl)acetamide 
hydrochloride (17). Boc-protected amine S3 (40 mg, 98 µmol, 1.0 equiv.) was 
dissolved in dry DCM (2.2 mL) under nitrogen. 4M HCl in dioxane (735 µL, 
2.94 mmol, 30 equiv.) was slowly added and the mixture was stirred for 30 min. 
The solvent was removed under reduced pressure, whereupon the pink solid 
was lyophilized yielding amine 17 (34 mg, quant.). 1H NMR (400 MHz, DMSO-
d6) δ 11.57 (s, 1H), 9.16 (d, J = 2.4 Hz, 1H), 8.98-8.91 (m, 1H), 8.68 (d, J = 8.7 
Hz, 1H), 8.61 (dt, J = 8.0, 1.1 Hz, 1H), 8.44 (dd, J = 8.7, 2.5 Hz, 1H), 8.35 (br. 
t, J = 5.6 Hz, 2H), 8.18 (dt, J = 7.7, 1.8 Hz, 1H), 7.75 (ddd, J = 7.7, 4.7, 1.2 Hz, 
1H), 3.99-3.91 (m, 2H). 13C NMR (100 MHz, DMSO-d6) δ 166.1, 163.0, 162.7, 
150.5, 150.0, 144.6, 141.3, 138.0, 137.6, 126.7, 126.6, 125.1, 124.3, 41.3. LRMS (ESI+) m/z calcd 
for C14H13N8O+ [M+H]+ 309.1, found: 309.1. The data agrees with the reported literature values.28 
 
1H NMR study of the click-to-release reaction. The reactions between tetrazine 10 and the 
alkenes 6 and 9 in 3:1 CD3OD/deuterated PBS were followed using 1H NMR (500 MHz). Prior 
to the start of the tetrazine ligation, pinacol ester 6 (5 mM) was incubated in 3:1 MeOD-
d4/deuterated PBS. The hydrolysis of the pinacol ester was followed over time and showed full 
conversion to the free boronic acid within 2 h (Figure SI-1). Next, tetrazine 17 (5.0 mM) and the 
deprotected VBA 6 or the vinyl ether 9 (5.0 mM) were mixed 1:1 for a final concentration of 2.5 
mM and the reactions were followed over time up to 14 days at room temperature.  
 
Second order rate constant experiment. The reactions between the alkenes and dipyridyl 
tetrazine derivative 10 in 75% MeOH/PBS were followed on a plate reader (Spark M10 microplate 
reader (Tecan)) at a controlled temperature of 20 °C, by measuring the absorbance of the tetrazine 
at 540 nm. The tetrazine and alkene were both dissolved in methanol, and then diluted with PBS. 
After addition of the tetrazine to the alkene solution, the measurement was started directly. The 
final concentration of the tetrazine was 500 μM and of the excess of alkene was 5, 6.25, 7.50, 8.75 
μM or 10mM. The time between the addition of the tetrazine and the start of the measurement 
was ± 20s. All reactions were performed in quadruplo. The kinetics were normalized and plotted 
in Figure SI-2A and 2B. The observed reactions were normalized by setting the absorbance at t = 
0 s as 100%. Since the reactions did not end in a plateau after the set time, the plateau was set 
equal to the background absorbance of the dihydropyridazine absorption at the given wavelength. 
It was taken into account that the measurement was started after a certain time.  
 
Pseudo-first-order rate constant determination. The pseudo first-order rate constants kobs for 
the tetrazine reactions with an excess of alkene was determined. The decay of the absorbance of 
the tetrazine was plotted against time (min) for the 5 different concentrations of the alkene. The 
kobs was determined by fitting an exponential ‘one phase decay’ (nonlinear regression) using 
PrismGraphPad Software whereby Y = (Y0 -plateau)*exp(-kobs*time(s)) + plateau.  
 
Second-order rate constant determination. To determine the second-order rate constant, the 
kobs of the reactions was plotted against the concentration of the alkenes. The line was fitted using 
a linear regression and the slope gave k2. The goodness of the fit is shown by the coefficient of 
determination (R2). The data is shown in Figure SI-2A and 2B. 
 
Click-to-release LCMS measurements. The reaction between tetrazine 17 and cladribine-VBA 
16 in 1% DMSO/PBS was followed using LCMS. Prior to the start of the tetrazine ligation, pinacol 
ester 16 (0.2 mM) was incubated in 1% DMSO/PBS. The hydrolysis of the pinacol ester was 
followed over time and tetrazine 17 (0.2 mM or 2.0 mM) was subsequently added. The reaction 
was followed over 24 hours at 37 °C. The amount of cladribine was determined and was quantified 
by the area under the curve. The graph shows the relative amount compared to the amount of 
starting material. 
 
Cell toxicity assays. ACPA-expressing B cell clones or HEK-TM cells were cultured with 
medium, and mIL21-Fc and soluble CD40L (from Biolegend) for the B cell clones. Stock solutions 
of tetrazine (500 mM), cladribine (10 µM) and cladribine-VBA (10 µM) were prepared in DMSO. 
Different concentrations were diluted in medium and cladribine-VBA was premixed with tetrazine 
in different amounts. All conditions were incubated overnight at 37 °C (except for the experiment 
in Figure SI-5, in there everything was mixed with the cells and directly incubated for 3 days) and 
added to 3x104 ACPA-expressing B cell clones or 1 x 104 HEK-TM cells in a 96-well plate. The 
cells were incubated for 3 days, after which XTT labelling and electron-coupling reagents (Roche) 
were added to the culture according to the manufacturer’s protocol and incubated for 4 hours. 
After the addition of a 5% Tween solution, cell viability was measured on a iMark TM Microplate 
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4.7 Supplementary Figures 
 
 
Figure SI-1. Pinacol hydrolysis in PBS. A) Schematic representation of the pinacol hydrolysis; B) Studies 
were performed with 5mM VBA 6 dissolved in 75% MeOD/deuteurated PBS at room temperature and 
analyzed at different time points by 1H NMR. 
 
Figure SI-2. Kinetics of the click-to-release reaction with tetrazine 10 (500 μM) with 10 - 20 equiv. of the 
alkene in 75% MeOH/PBS. The left graph is the normalized absorbance at 540 nm of the reaction 
between tetrazine 10 and the alkene (A: VBA 6 and B: vinyl ether 9) at different concentrations against 
time (min). The right graph shows the plot of the kobs values against the alkene (A: VBA 6 and B: vinyl 
ether 9) concentration. The slope of the linear fit is the second - order rate constant, the goodness of the 
fit is shown by R2.  
 
 
Figure SI-3. Dose dependency of ACPA-positive B cell clone for cladribine. Immortalized ACPA-positive 
B cells were incubated with cladribine for 3 days before an XTT assay was performed. Experiment was 
performed in triplo.  
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Figure SI-4. Stability of cladribine-VBA 16. Studies were performed at 37 °C in PBS and analyzed at 
different time points by LCMS. A) Day 0 is not 100% since the stock solution (12mg/mL) in DMSO, was 
stored at -20 °C for approximately 10 weeks, and contained some unprotected cladribine; B) LCMS 
spectrum after 1 day of incubation. 
 
 
 
Figure SI-5. Incubation and click-to-release with ACPA-positive B cell clones (50.000 cells per well). For 
0.1 µM cladribine significant deprotection was observed, however, the toxicity was only a small percentage 
of the control. For 1 µM cladribine, which showed clear cytotoxicity, the addition 1 and 10 equiv. tetrazine 
were not toxic, but 100 equiv. (100 µM) was as toxic as cladribine (1 µM). Click-to-release of cladribine-
VBA 16 with 1 or 10 equiv. tetrazine showed a significant result to liberate cladribine, however, full 
deprotection was the goal. Statistics were calculated using a student t-Test using two-sample assuming 
unequal variances (confirmed by F-Test) and a two-tailed distribution. 
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Abstract 
 
Rheumatoid arthritis (RA) is characterized by the production of anti-citrullinated protein 
antibodies (ACPA) in the majority of the patients. To obtain more knowledge about the origin and 
role of autoreactive B cells in RA, isolation of ACPA-producing B cells is required. Recently, a 
method was developed to target and isolate B cells using a tetravalent streptavidin (SA) protein 
conjugated to biotinylated antigens. Here we explore the possibility of using a higher multivalent 
scaffold for B cell targeting to increase binding avidity and the number of potential binding sites 
for cargo loading. The scaffold used for this purpose consists of poly(isocyanopeptides) (PIC). 
This polymer with a length of approximately 400 nm has more than 100 binding sites available 
compared to only 4 for SA. We synthesized this PIC scaffold containing a fluorophore and 
different antigen peptides. It was shown that both the citrullinated peptide-containing PIC and SA 
scaffold bound equally effective to ACPA-positive cells as evidenced by flow cytometry binding 
studies. However, a major difference between these two scaffolds was observed with respect to 
non-specific binding. For the antigens conjugated to the PIC scaffold hardly any non-specific 
binding was observed, whereas high background levels were detected for antigens conjugated to 
SA. It was also noted that the antigen used as negative control, CArgP, gave high background 
signals, whereas this was not observed for cyclic norleucine peptide (CNleP). Lastly, we indirectly 
showed that PICs were not internalized upon binding to the BCR, making them a suitable scaffold 
for carrying extracellular apoptotic signals. 
  
5.1 Introduction 
 
Rheumatoid arthritis (RA) is characterized by chronic inflammation causing cartilage and bone 
loss and occurs in ca. 1% of the western population. The inflammation results in deformed and 
painful joints and is sustained by antibody development of autoreactive B cells. These autoreactive 
antibodies are directed to citrullinated proteins and are present at the early onset of the disease.1 
Although anti-citrullinated protein antibodies (ACPA) have been extensively studied, much is 
unknown about the autoantibody-producing B cells. ACPA-positive B cells do display an activated 
and proliferative phenotype, however, they are present in low abundancy.2 It has also been 
described that ACPA have low avidity compared to antibodies to ‘recall’ antigens.3 These two 
features make it difficult to isolate ACPA-positive B cells for studies and to target these specific B 
cells for therapy.  
A streptavidin (SA)-based method for enhanced isolation of these rare B cells was developed by 
Scherer et al.4 They used fluorophore-containing SA tetramers conjugated to biotinylated citrulline-
containing antigens to specifically detect ACPA-expressing B cells. However, it remains unclear 
whether they were able to isolate all ACPA-expressing B cells from circulation. Hence, we envision 
that a higher avidity for ACPA-positive B cells can be achieved by using a highly multivalent 
scaffold compared to the tetravalent SA system. In addition, while SA has only four possible 
binding sites, the use of a highly multivalent system provides more options for functionalization 
as for example multiple different antigens or a combination of antigens and drugs can be attached.  
A good candidate for a multivalent system is the poly(isocyanopeptides) (PIC) scaffold. This 
polymer is semi-flexible and has already been shown to be effective in T cell activation because of 
proper arrangement and clustering of receptors by the attached components.5 Mandal and 
coworkers showed that they could synthesize a filamentous synthetic dendritic cell (sDC) for T 
cell activation.6 They were able to functionalize the isocyanopeptide polymer with anti-CD3 
antibodies towards T-cell activation. In addition, they hypothesized and showed that, since the 
polymer is semi-flexible and contains multiple antibodies, the sDC was effective in T-cell binding 
and initiation of receptor clustering for T-cell activation. By comparing the sDCs to free anti-CD3 
it was shown that the sDC increased T-cell activation by approximately 2.5 times and that these 
T-cells released 2-3 fold more IFNγ, a marker characterizing a late activation event.7 This also 
underlines the benefit of multivalent scaffolds over monovalent compounds, in which the PICs 
mimic the protein mobility of natural plasma membranes.8 
Due to low avidity of the citrullinated antigen targeting B cells we were curious to see whether 
enhanced binding to these B cells could be achieved using multivalent and flexible PICs to ACPA 
antigens. Moreover, in case successful binding is observed, this scaffold would be of great interest 
for future multivalent B cell targeting therapeutics.  
 
5.2 Results and Discussion 
 
Synthesis of multivalent antigen-containing SA and PIC scaffolds. To test the avidity for 
antigen-containing SA and PICs, we synthesized scaffolds containing the cyclic citrullinated 
peptide (CCP) antigen as well as a fluorophore for visualization. We used the cyclic citrullinated 
peptide 1 (CCP1) analogue, a well-known ACPA antigen,9-10 as described in Chapter 2. The 
peptides CCP (1), CArgP (2) and CNleP (3, Figure 1), containing a biotin at the C-terminal lysine, 
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that a higher avidity for ACPA-positive B cells can be achieved by using a highly multivalent 
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mimic the protein mobility of natural plasma membranes.8 
Due to low avidity of the citrullinated antigen targeting B cells we were curious to see whether 
enhanced binding to these B cells could be achieved using multivalent and flexible PICs to ACPA 
antigens. Moreover, in case successful binding is observed, this scaffold would be of great interest 
for future multivalent B cell targeting therapeutics.  
 
5.2 Results and Discussion 
 
Synthesis of multivalent antigen-containing SA and PIC scaffolds. To test the avidity for 
antigen-containing SA and PICs, we synthesized scaffolds containing the cyclic citrullinated 
peptide (CCP) antigen as well as a fluorophore for visualization. We used the cyclic citrullinated 
peptide 1 (CCP1) analogue, a well-known ACPA antigen,9-10 as described in Chapter 2. The 
peptides CCP (1), CArgP (2) and CNleP (3, Figure 1), containing a biotin at the C-terminal lysine, 
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were conjugated to SA as described in Chapter 2 (Figure 1).4 Prior to antigen conjugation, UV-Vis 
measurements were performed and the absorbance of SA and the absorbance of the respective 
fluorophore (AF647) were used to calculate the concentration of both (using the corresponding 
extinction coefficients and path length, see Section 5.5, Materials and Methods). The outcome of 
the calculations showed that on average every SA contained two fluorophores. Since SA can 
conjugate to four biotin molecules, the estimated fluorophore:antigen ratio was 1:2 (Note SI-1). 
 
 
Figure 1. Overview of multivalent antigen-containing SA scaffolds. Three different conjugates were 
prepared, using NHS-AF647 and biotinylated peptides CCP, CArgP and CNleP.  
 
The PIC scaffold is based on a water-soluble polyisocyano co-polymer bearing a non-functional 
methoxy and functional azide groups (Figure 2B). All PIC polymers were synthesized according 
to previously published methods.5-6 The corresponding methoxy and azide isocyanide monomers 
were polymerized using a nickel catalyst to obtain azide-functionalized PICs with an average length 
of 383 nm. This resulted in a methoxy:azide ratio of 1:30, statistically yielding a polymer with a 
functional azide group every 3.5 nm. Considering the average polymer length, every scaffold 
contains approximately 110 available azides. Roughly half of the azides were utilized in a strain-
promoted azide-alkyne cycloaddition by DBCO-PEG4-biotin.11-12 These polymers were further 
functionalized with a DIBO-AF647 (approximately 4% of the azides) prior to functionalization 
with an ACPA antigen peptide with the remaining azides. 
For conjugation of CCP to PIC, we introduced a C-terminal lysine and reacted this peptide, after 
cyclization and purification, with NHS-PEG4-DBCO (Figure 2A). This DBCO was subsequently 
used for the cycloaddition with the remaining azides on the PIC, in a final ratio of 1:10 
fluorophore:CCP on the PICs (Figure 2B). 
 
 
Figure 2. Overview of multivalent antigen-containing PIC scaffolds. A) The structure of CXP, with X 
being citrulline (CCP), arginine (CArgP) or norleucine (CNleP). CXP was synthesized with a lysine at the 
C-terminus which can be modified using a NHS-PEG4-DBCO for cycloaddition purposes to the PIC 
polymers; B) Schematic overview of the synthesis approach of CXP loaded PICs. All PICs were first reacted 
with DBCO-biotin (not shown) and subsequently with DIBO-fluorophores and with one of the antigen 
peptides to form the multivalent antigen structure. 
 
Flow cytometric binding studies of  scaffold background. To evaluate the binding efficiencies 
of  the different scaffolds to ACPA-expressing cells, we used HEKACPA-TM as the antigen binding 
cells and non-transfected HEK cells as a negative control. These HEKACPA-TM cells express trans-
membrane ACPA and GFP, and are known to bind to CCP.4  
First, we examined the background signal of  the unmodified scaffolds. For this, we used the SA 
and PIC scaffold conjugated to AF647, but without any antigen peptides. Scaffold concentrations 
were corrected to the amount of  potentially bound antigens: while the PICs can contain 5 times 
more peptides than SA, 5 times lower scaffold concentrations were used to maintain the alleged 
peptide concentration throughout all experiments. This also means that the fluorophore 
concentration was lower for the PICs than for the SA scaffold. A starting concentration of  around 
1 µM was prepared for PIC and SA and serial dilutions were created from there. We next incubated 
the cell lines with the scaffolds at different concentrations for 30 minutes on ice, after which the 
cells were washed and fixed using 1% paraformaldehyde. The staining of  cells was measured by 
flow cytometry. Since the ACPA-expressing cell line is GFP positive, double positive cells, stained 
for both GFP and AF647, were considered positive for scaffold binding. For the non-ACPA-
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peptide concentration throughout all experiments. This also means that the fluorophore 
concentration was lower for the PICs than for the SA scaffold. A starting concentration of  around 
1 µM was prepared for PIC and SA and serial dilutions were created from there. We next incubated 
the cell lines with the scaffolds at different concentrations for 30 minutes on ice, after which the 
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flow cytometry. Since the ACPA-expressing cell line is GFP positive, double positive cells, stained 
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expressing cell line, no increased AF647 signal was expected, meaning that double negative cells 
were expected for the non-transfected HEK cells.  
 
 
Figure 3. Flow cytometric binding studies of scaffold background for SA- and PIC-AF647. A) Schematic 
overview of experimental set-up; Percentage of positive cells was plotted against the alleged peptide antigen 
concentration for B) HEKACPA-TM cells, C) non-transfected HEK cells, D) ACPA-positive B cells and E) 
anti-TT-positive B cells. 
 
Figure 3A shows a schematic overview of  the experimental set-up looking at background signal 
for both scaffolds. For both cell lines, no AF647 positive signal was expected due to the lack of  
antigen peptides. After measuring the fluorescence intensity for the different cell lines, we plotted 
the percentage of  AF647 positive cells (see Figure SI-2 for HEK cell FACS plots) against the 
alleged peptide concentration on the scaffold. Figures 3B and C show that for both cell types high 
fluorescence signals were measured for SA-AF647, whereas hardly any signal was observed for 
PIC-AF647. This shows that the non-specific binding of  SA for the different cell types was much 
higher than for the PIC scaffold. Although 5 times higher fluorophore concentrations were used 
in the SA samples to keep the peptide concentration constant, the observed background effect 
was more than 5 times higher. This suggests that the non-specific binding is dependent on SA and 
not on the fluorophore itself.  
In a follow-up experiment, we used immortalized B cells to evaluate binding. These B cells were 
previously isolated from an ACPA-positive RA patient and transduced with BCL-XL, BCL-6 and 
GFP genes resulting in an ACPA-secreting and -expressing, GFP-positive immortalized B cell 
line.13 Similarly, immortalized B cells recognizing tetanus toxoid (TT) antigens were created. Both 
of  these cells were used in experiments with both scaffolds with the ACPA-expressing B cells as 
target cells and the anti-TT-expressing B cells as the negative control cells. A similar experiment 
compared to both HEK cell lines was performed for the immortalized B cells. Since both cell lines 
are GFP positive, but no antigen is attached to the scaffold, GFP positive and AF647 negative 
signals were expected for both cell lines. Figures 3D and E (see Figure SI-3 for immortalized B 
cell FACS plots) show that indeed no AF647 positive cells were observed for the PIC scaffold. For 
the SA scaffold, however, increasing AF647 signals were observed with increasing scaffold 
concentrations. The background signal for SA was higher for the immortalized B cells compared 
to the HEK cell lines. So far, we do not have an explanation for this effect. Overall, the PICs do 
not show any background to all four cell types while increasing SA background with increasing 
concentrations was observed (Figure 3). 
 
Flow cytometric binding studies of antigen loaded scaffolds. To see whether we could induce 
a higher binding avidity for the higher multivalent PIC scaffolds, we loaded the scaffolds with the 
peptide antigen CCP. The CCP antigens were synthesized with a C-terminal lysine and 
subsequently modified using NHS-PEG4-DBCO (Figure 2A). The DBCO was reacted with the 
azides on the PICs, which were previously modified with the AF647 fluorophore (Figure 2B). The 
amounts of PIC-CCP and the SA-CCP for cell-binding experiments were based on equal peptide 
concentrations as described above. After incubation with the different cell types, we analyzed the 
data using flow cytometry (Figure 4A). Figure 4B depicts the increase in AF647 positive cells with 
the increase in peptide (and hence scaffold) concentration. Binding to non-transfected HEK cells 
was only observed at very high scaffold concentrations (Figure 4C). Since no ACPA receptor was 
present, this signal must be due to non-specific binding. Similar to what was observed for the non-
loaded scaffolds (Figure 3), the SA scaffold gave a higher background signal than the PIC scaffold.  
For the ACPA-expressing B cells (Figure 4D) almost all cells were positive for AF647, even at the 
lowest concentration (1.2 nM), for both scaffolds. The difference between binding at the same 
concentration for ACPA-positive B cells and the HEKACPA-WT cells is most likely due to the higher 
affinity for CCP of the immortalized B cells. Similarly, as observed for the non-transfected HEK 
cells, the anti-TT-positive B cells (Figure 4E) showed a background signal which was higher for 
SA than for the PIC scaffold. Figures SI-4 and SI-5 show the FACS plots corresponding to the 
HEK cells and the immortalized B cells, respectively.  
Next, we evaluated the binding specificity for PIC and SA scaffolds loaded with control peptides 
CArgP and CNleP. High signals were observed for scaffolds containing CArgP. This peptide 
contains five positively charged arginine residues, which might explain the high binding to the 
negatively charged cell-membrane. Therefore, we evaluated whether a norleucine residue, an 
amino acid without a positive charge, at the variable position of CXP would diminish non-specific 
binding.  
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loaded scaffolds (Figure 3), the SA scaffold gave a higher background signal than the PIC scaffold.  
For the ACPA-expressing B cells (Figure 4D) almost all cells were positive for AF647, even at the 
lowest concentration (1.2 nM), for both scaffolds. The difference between binding at the same 
concentration for ACPA-positive B cells and the HEKACPA-WT cells is most likely due to the higher 
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Figure 4. Flow cytometric binding titration of CCP loaded SA and PIC. A) Schematic overview of 
experimental set-up; Percentage of positive cells was plotted against the peptide antigen concentration for 
B) HEKACPA-TM cells, C) non-transfected HEK cells, D) ACPA-positive B cells and E) anti-TT-positive 
B cells. 
 
To test if the removal of one positive charge would indeed reduce the background signal, we used 
the PIC-scaffolds loaded with either CArgP or CNleP and incubated them with the different cell 
types for 30 minutes on ice (Figure 5A). After analyzing the data we observed that the CArgP gave 
high background levels for all cell lines, while CNleP hardly showed any binding (Figures 5 B-E, 
SI-6 and SI-7 for FACS plots). Therefore, we suggest to use CNleP as a proper negative control 
for future cell studies. 
 
 
Figure 5. Flow cytometric binding studies and comparison of PIC loaded with either CNleP or CArgP. A) 
Schematic overview of experimental set-up; Percentage of positive cells was plotted against the peptide 
antigen concentration for B) HEKACPA-TM cells, C) non-transfected HEK cells, D) ACPA-positive B cells 
and E) anti-TT-positive B cells. *data not representative 
 
Internalization studies with the PIC scaffolds. The advantage of using the PIC scaffold is that 
there are multiple binding sites, which can be modified accordingly. Besides the addition of 
multiple (different) antigens, functional molecules can also be attached. One interesting example 
for the use of a multivalent scaffold is the possibility to target specific B cells using an autoantigen 
and simultaneously bind to regulatory molecules on the B cell membrane, to dampen B cell 
activation and proliferation.14 Recently, PLGA particles have been used for the attachment of an 
autoantigen and a complement activating peptide to induce antigen-selective cytotoxicity.15 More 
examples of multivalent structures used in the targeting of B cells have been described in Chapter 
1.  
Also, besides conjugation of a functional molecule interfering with processes on the outside of a 
B cell, the attachment of a toxin can induce antigen-selective cell death, e.g. when a toxin becomes 
activated after internalization into the B cell. The applicability of PICs for either of these purposes 
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autoantigen and a complement activating peptide to induce antigen-selective cytotoxicity.15 More 
examples of multivalent structures used in the targeting of B cells have been described in Chapter 
1.  
Also, besides conjugation of a functional molecule interfering with processes on the outside of a 
B cell, the attachment of a toxin can induce antigen-selective cell death, e.g. when a toxin becomes 
activated after internalization into the B cell. The applicability of PICs for either of these purposes 
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is, however, dependent on the mode of binding and possibility of the PICs to enter the cells after 
binding to the BCR. 
 
 
Figure 6. Internalization studies via indirect staining. A) Schematic representation of the experimental 
setup and expected outcome; B) Indirect internalization tested for ACPA-positive B cells. Staining for both 
AF647 and AF594 was measured; C) Indirect internalization tested for anti-TT-positive B cells. All signals 
were negative as expected due to the lack of the CCP binding to the BCR. 
 
To test whether PICs were internalized into a B cell, we incubated the CCP loaded PICs with the 
immortalized B cells for 1 hour at 37 °C, after which the cells were washed thoroughly to remove 
non-specific PIC binding. In case the all PICs were internalized, no PICs would be present on the 
surface of the cell, but when internalization is hampered the PICs will stay bound to the BCR on 
the cell surface. Since the PICs do also contain biotin molecules, we could indirectly stain the PICs 
with SA containing AF647. For this experiment, we synthesized PICs containing AF594, in order 
to detect both the PIC and SA in a different channel during flow cytometry measurements. After 
SA-AF647 was added and incubated for 30 minutes, the cell fluorescence was measured (Figure 
6A).  
Figure 6B (left-most panels) shows that the cells are positive for both AF594 and for AF647, 
meaning that SA was bound to the PIC scaffolds on the outside of the cell and that not all, if any, 
PICs were internalized. Since BCR internalization is an active process, we incubated the PIC 
scaffold with the cells also for 1 hour at 4 °C as a negative control. The second panel in Figure 6B 
shows that the cells were positive for both fluorophores, as expected, and that the fluorescent level 
was the same as observed at 37 °C. To show that the signal from AF647 was not a result of non-
specific binding of SA, we omitted PIC in the first incubation step. Indeed, no fluorescent signal 
was observed indicating that SA could not bind to the cells without the PIC particles (panel 3, 
Figure 6B). It is still possible however, that a small amount of PICs is internalized, but we were 
not able to detect this. Microscopy studies will have to show this in the future. Finally, we 
evidenced in Figure 6C that the staining with PIC and SA was specific for the ACPA-expressing 
B cells, due to the antigen involved, as no fluorescent signal in both channels was observed for 
anti-TT-expressing B cells.  
 
5.3 Conclusions 
 
In this Chapter we have shown that PICs function as a promising multivalent scaffold for the 
binding to ACPA-positive cells. The data presented here shows that peptide loaded PIC and SA 
are comparable in binding avidity towards different B cell lines. The advantage of PIC over SA, 
however, is the low background observed for all cell types, with and without peptides loaded. We 
also showed that we could reduce the background signal caused by the CArgP peptide, which was 
used as a negative control. Most likely due to the high number of positive charges in CArgP high 
background signals were observed, which is probably related to electrostatic interactions with the 
cell membrane. Since PICs contain more CArgP peptides compared to SA, even more positive 
charges were combined on the polymers. A significant binding difference was observed when one 
arginine was replaced by norleucine, suggesting that the loss of one positive charge in the peptide 
was sufficient to dampen the background signal. We assume that the PICs decorated with the 
CNleP peptides benefit even more from this loss in positive charge, because of the higher loading 
of peptides on the polymer. 
We indirectly showed that most or all PICs are still bound to the BCR, on the cell surface, within 
1 h of incubation at 37 °C. Therefore, the PICs are of potential relevance to function as a scaffold 
to target B cells and to induce antigen selective toxicity by the additional conjugation of an 
inhibiting molecule. CD22 ligand is a good candidate, as it is already used to dampen the B cell 
activation by binding to Siglecs.14 Alternatively, the attachment of a Fas ligand, which trimerizes 
the Fas receptor on the B cell membrane, can induce cell selective apoptosis. Further research into 
the influence of polymer length and spacing between peptides will complement our understanding 
for future application possibilities.  
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scaffold with the cells also for 1 hour at 4 °C as a negative control. The second panel in Figure 6B 
shows that the cells were positive for both fluorophores, as expected, and that the fluorescent level 
was the same as observed at 37 °C. To show that the signal from AF647 was not a result of non-
specific binding of SA, we omitted PIC in the first incubation step. Indeed, no fluorescent signal 
was observed indicating that SA could not bind to the cells without the PIC particles (panel 3, 
Figure 6B). It is still possible however, that a small amount of PICs is internalized, but we were 
not able to detect this. Microscopy studies will have to show this in the future. Finally, we 
evidenced in Figure 6C that the staining with PIC and SA was specific for the ACPA-expressing 
B cells, due to the antigen involved, as no fluorescent signal in both channels was observed for 
anti-TT-expressing B cells.  
 
5.3 Conclusions 
 
In this Chapter we have shown that PICs function as a promising multivalent scaffold for the 
binding to ACPA-positive cells. The data presented here shows that peptide loaded PIC and SA 
are comparable in binding avidity towards different B cell lines. The advantage of PIC over SA, 
however, is the low background observed for all cell types, with and without peptides loaded. We 
also showed that we could reduce the background signal caused by the CArgP peptide, which was 
used as a negative control. Most likely due to the high number of positive charges in CArgP high 
background signals were observed, which is probably related to electrostatic interactions with the 
cell membrane. Since PICs contain more CArgP peptides compared to SA, even more positive 
charges were combined on the polymers. A significant binding difference was observed when one 
arginine was replaced by norleucine, suggesting that the loss of one positive charge in the peptide 
was sufficient to dampen the background signal. We assume that the PICs decorated with the 
CNleP peptides benefit even more from this loss in positive charge, because of the higher loading 
of peptides on the polymer. 
We indirectly showed that most or all PICs are still bound to the BCR, on the cell surface, within 
1 h of incubation at 37 °C. Therefore, the PICs are of potential relevance to function as a scaffold 
to target B cells and to induce antigen selective toxicity by the additional conjugation of an 
inhibiting molecule. CD22 ligand is a good candidate, as it is already used to dampen the B cell 
activation by binding to Siglecs.14 Alternatively, the attachment of a Fas ligand, which trimerizes 
the Fas receptor on the B cell membrane, can induce cell selective apoptosis. Further research into 
the influence of polymer length and spacing between peptides will complement our understanding 
for future application possibilities.  
121
Multivalent Polymer Scaffolds for Targeting of ACPA-Selective B cells
529590-L-bw-Lelieveldt
Processed on: 13-3-2019 PDF page: 122
Summarizing, the work described in this Chapter represents a new polymer scaffold which can 
be readily functionalized and shows promising results in the targeting of ACPA positive cells 
compared to the often used SA scaffold. The PICs show a low background signal for all cell types, 
while this is significantly higher for SA. Functionalization with a variety of antigen peptides and 
the attachment of an apoptosis inducer may become an interesting application for this PIC scaffold 
in future research. 
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5.5 Materials and Methods 
 
For general methods, see the materials and methods section of Chapter 2 (paragraph 2.4). 
 
CCP-biotin (1). CCP-biotin was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.753 min. LCMS (ESI+) m/z calcd for 
C100H171N41O34S22+ [M+2H]2+ 1277.61, found 1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 
852.68. C100H173N41O34S24+ [M+4H]4+ 639.31, found 641.16 
 
CArgP-biotin (2). CArgP-biotin was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in 
the general cyclization method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for 
C100H172N42O33S22+ [M+2H]2+ 1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 
852.28. C100H173N41O34S24+ [M+4H]4+ 639.06, found 640.20. 
 
CNleP-biotin (3). CNleP-biotin was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in 
the general cyclization method. The biotin moiety was not attached on resin as described for CCP 
and CArgP, but functionalized using NHS-biotin (10 µL of a 100mM stock solution in DMSO) as 
described for the DBCO functionalization above. HPLC: Rt. 13.432 min. LCMS (ESI+) m/z calcd 
for C100H171N39O33S22+ [M+2H]2+ 1255.12, found 1255.88. C100H172N39O33S23+ [M+3H]3+ 837.08, 
found 837.64. C100H173N39O33S24+ [M+4H]4+ 628.06, found 628.60. 
 
Lysine-peptides: 
 
CCP-Lys (7). CCP-Lys was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 10.209 min. LCMS (ESI+) m/z calcd for C90H157N39O32S2+ 
[M+2H]2+ 1164.08, found 1163.00. C90H158N39O32S3+ [M+3H]3+ 776.39, found 776.92. 
C90H159N39O32S4+ [M+4H]4+ 582.54, found 583.00. 
 
CArgP-Lys (8). CArgP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 10.310 min. LCMS (ESI+) m/z calcd for C90H159N40O31S3+ 
[M+3H]3+ 776.06, found 776.64. C90H160N40O31S4+ [M+4H]4+ 582.30, found 582.68. 
 
CNleP-Lys (9). CNleP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.054 min. LCMS (ESI+) m/z calcd for C90H157N37O31S2+ 
[M+2H]2+ 1142.08, found 1142.88. C90H158N37O31S3+ [M+3H]3+ 761.72, found 762.68. 
C90H159N37O31S4+ [M+4H]4+ 571.54, found 573.68. 
 
DBCO-peptide functionalization. All peptides with a C-terminal lysine were functionalized with 
a NHS-PEG4-DBCO after cleavage and cyclization. The lysine-containing peptides (2.0 µmol) 
were dissolved in DMF (2.0 mL) and DIPEA (204 µmol, 35.5 µL, 100 equiv.) was added. NHS-
PEG4-DBCO (16.2 mg, 25µmol) was dissolved in DMSO (100 µL, 250 mM) and 20 µL of the 
stock solution was added (resulting in a final concentration of 2.5 mM, 2.5 equiv.). The reaction 
was stirred for 5 hours at r.t. before the product was precipitated in Et2O. The pellet was washed 
three times and dried afterwards. 
 
CCP-DBCO (4). CCP-DBCO was synthesized following the procedures described in the general 
DBCO-peptide functionalization. CCP-Lys (7) was used as starting material. HPLC: Rt. 16.551 
min. LCMS (ESI+) m/z calcd for C120H191N41O39S2+ [M+2H]2+ 1431.20, found 1432.08. 
C120H192N41O39S3+ [M+3H]3+ 954.47, found 955.36. C120H193N41O39S4+ [M+4H]4+ 716.10, found 
718.36. 
 
CArgP-DBCO (5). CArgP-DBCO was synthesized following the procedures described in the 
general DBCO-peptide functionalization. CArgP-Lys (8) was used as starting material. HPLC: Rt. 
16.367 min. LCMS (ESI+) m/z calcd for C120H192N42O38S2+ [M+2H]2+ 1430.70, found 1431.52. 
C120H193N42O38S3+ [M+3H]3+ 954.14, found 955.08. C120H194N42O38S4+ [M+4H]4+ 715.86, found 
717.48. 
 
CNleP-DBCO (6). CNleP-DBCO was synthesized following the procedures described in the 
general DBCO-peptide functionalization. CNleP-Lys (9) was used as starting material. HPLC: Rt. 
16.880 min. LCMS (ESI+) m/z calcd for C120H191N39O38S2+ [M+2H]2+ 1409.20, found 1410.08. 
C120H192N39O38S3+ [M+3H]3+ 939.80, found 940.88. C120H193N39O38S4+ [M+4H]4+ 705.10, found 
707.28. 
 
Modification of  PICs. The PICs were kept at ice at all times and stored in nonstick microfuge 
tubes. DIBO-AF647 was dissolved in DMSO (1 mM). 4.90 µL of  DIBO-AF647 stock solution 
was added to PICs (1.325 mL, 1 mg/mL), which were synthesized according to previously 
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Summarizing, the work described in this Chapter represents a new polymer scaffold which can 
be readily functionalized and shows promising results in the targeting of ACPA positive cells 
compared to the often used SA scaffold. The PICs show a low background signal for all cell types, 
while this is significantly higher for SA. Functionalization with a variety of antigen peptides and 
the attachment of an apoptosis inducer may become an interesting application for this PIC scaffold 
in future research. 
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PICs as a multivalent scaffold for (CEP-1) antigens. 
5.5 Materials and Methods 
 
For general methods, see the materials and methods section of Chapter 2 (paragraph 2.4). 
 
CCP-biotin (1). CCP-biotin was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.753 min. LCMS (ESI+) m/z calcd for 
C100H171N41O34S22+ [M+2H]2+ 1277.61, found 1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 
852.68. C100H173N41O34S24+ [M+4H]4+ 639.31, found 641.16 
 
CArgP-biotin (2). CArgP-biotin was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in 
the general cyclization method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for 
C100H172N42O33S22+ [M+2H]2+ 1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 
852.28. C100H173N41O34S24+ [M+4H]4+ 639.06, found 640.20. 
 
CNleP-biotin (3). CNleP-biotin was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in 
the general cyclization method. The biotin moiety was not attached on resin as described for CCP 
and CArgP, but functionalized using NHS-biotin (10 µL of a 100mM stock solution in DMSO) as 
described for the DBCO functionalization above. HPLC: Rt. 13.432 min. LCMS (ESI+) m/z calcd 
for C100H171N39O33S22+ [M+2H]2+ 1255.12, found 1255.88. C100H172N39O33S23+ [M+3H]3+ 837.08, 
found 837.64. C100H173N39O33S24+ [M+4H]4+ 628.06, found 628.60. 
 
Lysine-peptides: 
 
CCP-Lys (7). CCP-Lys was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 10.209 min. LCMS (ESI+) m/z calcd for C90H157N39O32S2+ 
[M+2H]2+ 1164.08, found 1163.00. C90H158N39O32S3+ [M+3H]3+ 776.39, found 776.92. 
C90H159N39O32S4+ [M+4H]4+ 582.54, found 583.00. 
 
CArgP-Lys (8). CArgP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 10.310 min. LCMS (ESI+) m/z calcd for C90H159N40O31S3+ 
[M+3H]3+ 776.06, found 776.64. C90H160N40O31S4+ [M+4H]4+ 582.30, found 582.68. 
 
CNleP-Lys (9). CNleP-Lys was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the 
general cyclization method. HPLC: Rt. 12.054 min. LCMS (ESI+) m/z calcd for C90H157N37O31S2+ 
[M+2H]2+ 1142.08, found 1142.88. C90H158N37O31S3+ [M+3H]3+ 761.72, found 762.68. 
C90H159N37O31S4+ [M+4H]4+ 571.54, found 573.68. 
 
DBCO-peptide functionalization. All peptides with a C-terminal lysine were functionalized with 
a NHS-PEG4-DBCO after cleavage and cyclization. The lysine-containing peptides (2.0 µmol) 
were dissolved in DMF (2.0 mL) and DIPEA (204 µmol, 35.5 µL, 100 equiv.) was added. NHS-
PEG4-DBCO (16.2 mg, 25µmol) was dissolved in DMSO (100 µL, 250 mM) and 20 µL of the 
stock solution was added (resulting in a final concentration of 2.5 mM, 2.5 equiv.). The reaction 
was stirred for 5 hours at r.t. before the product was precipitated in Et2O. The pellet was washed 
three times and dried afterwards. 
 
CCP-DBCO (4). CCP-DBCO was synthesized following the procedures described in the general 
DBCO-peptide functionalization. CCP-Lys (7) was used as starting material. HPLC: Rt. 16.551 
min. LCMS (ESI+) m/z calcd for C120H191N41O39S2+ [M+2H]2+ 1431.20, found 1432.08. 
C120H192N41O39S3+ [M+3H]3+ 954.47, found 955.36. C120H193N41O39S4+ [M+4H]4+ 716.10, found 
718.36. 
 
CArgP-DBCO (5). CArgP-DBCO was synthesized following the procedures described in the 
general DBCO-peptide functionalization. CArgP-Lys (8) was used as starting material. HPLC: Rt. 
16.367 min. LCMS (ESI+) m/z calcd for C120H192N42O38S2+ [M+2H]2+ 1430.70, found 1431.52. 
C120H193N42O38S3+ [M+3H]3+ 954.14, found 955.08. C120H194N42O38S4+ [M+4H]4+ 715.86, found 
717.48. 
 
CNleP-DBCO (6). CNleP-DBCO was synthesized following the procedures described in the 
general DBCO-peptide functionalization. CNleP-Lys (9) was used as starting material. HPLC: Rt. 
16.880 min. LCMS (ESI+) m/z calcd for C120H191N39O38S2+ [M+2H]2+ 1409.20, found 1410.08. 
C120H192N39O38S3+ [M+3H]3+ 939.80, found 940.88. C120H193N39O38S4+ [M+4H]4+ 705.10, found 
707.28. 
 
Modification of  PICs. The PICs were kept at ice at all times and stored in nonstick microfuge 
tubes. DIBO-AF647 was dissolved in DMSO (1 mM). 4.90 µL of  DIBO-AF647 stock solution 
was added to PICs (1.325 mL, 1 mg/mL), which were synthesized according to previously 
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published methods.5-6 The reaction was kept at 4 °C overnight in a shaker. Afterwards, 50 µL was 
used for subsequent modification with a single antigen peptide. To this 50 µL, 8.50 µL of  antigen 
peptide (2 mg/mL in PBS, 1.5 equiv. compared to available azides) was added. Next, PBS (8.50 
µL) was added to have a final PIC concentration of  0.85 mg/mL. The reaction was again left 
overnight at 4°C.  
Before using these scaffold in flow cytometry measurements, stock solutions of  around 1 µM 
peptide concentration were prepared. Peptide concentrations were calculated starting with the 
initial concentration (mg/mL) and the molecular weight of  a monomer (360 Da, weight of  
monomers stays the same after polymerization). From this 2.36 mM of  monomer (0.85 𝑚𝑚𝑚𝑚/𝑚𝑚𝑚𝑚
360
×
1000), one every 83 monomers contains an azide. Maximal peptide concentration on the PICs is 
therefore 28.44µM (2.36 𝑚𝑚𝑚𝑚
83
× 1000). This mixture was then diluted to obtain the desired starting 
stock concentration for serial dilutions. 
 
Peptide loading onto SA. SA fluorophore conjugates were purchased from Thermo Fisher. The 
proteins were dissolved in PBS (2 mg/mL) and 116 µL biotinylated peptides (5 mg/mL in PBS, 
50 equiv.) were added to 125 µL of  SA. The reaction was left overnight at 4 °C and the mixtures 
were purified afterwards using 40K Zeba spin desalting column to remove the excess of  
biotinylated peptide added. Protein concentrations were determined afterwards using UV-Vis 
measurements. Absorbance was measured at 280 nm and 654 nm. Using Lambert-Beers law (Abs 
= c * ε * d), fluorophore concentration was calculated, ε for AF647 is 270000 M-1 cm-1, d is 0.1 cm. 
For SA the absorbance was first corrected for the fluorophore attached. The calculations were 
made using: AbsSA = Abs280 - Cf  * Absfluorophore ( in which Cf  is the correction factor for AF647 and 
is 0.03). Using this corrected absorbance, the concentration was calculated according to the law of  
Lambert-Beer, using ε for SA is 167000 M-1 cm-1. The correlation between the corrected SA 
concentration and the concentration at the wavelength of  the fluorophore depicts the ratio of  
SA:fluorophore. 
 
Flow cytometry measurements. The SA and PIC scaffolds were serial diluted and added to cell 
cultures containing either HEKACPA-TM, non-transfected HEK, ACPA-expressing or anti-TT-
expressing immortalized B cells in a 96 well plate. Subsequently, the cells were kept on ice for 30 
minutes unless described otherwise, washed, resuspended with 1% paraformaldehyde and 
measured by flow cytometry using BD LSRFortessa (BD Biosciences). 
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published methods.5-6 The reaction was kept at 4 °C overnight in a shaker. Afterwards, 50 µL was 
used for subsequent modification with a single antigen peptide. To this 50 µL, 8.50 µL of  antigen 
peptide (2 mg/mL in PBS, 1.5 equiv. compared to available azides) was added. Next, PBS (8.50 
µL) was added to have a final PIC concentration of  0.85 mg/mL. The reaction was again left 
overnight at 4°C.  
Before using these scaffold in flow cytometry measurements, stock solutions of  around 1 µM 
peptide concentration were prepared. Peptide concentrations were calculated starting with the 
initial concentration (mg/mL) and the molecular weight of  a monomer (360 Da, weight of  
monomers stays the same after polymerization). From this 2.36 mM of  monomer (0.85 𝑚𝑚𝑚𝑚/𝑚𝑚𝑚𝑚
360
×
1000), one every 83 monomers contains an azide. Maximal peptide concentration on the PICs is 
therefore 28.44µM (2.36 𝑚𝑚𝑚𝑚
83
× 1000). This mixture was then diluted to obtain the desired starting 
stock concentration for serial dilutions. 
 
Peptide loading onto SA. SA fluorophore conjugates were purchased from Thermo Fisher. The 
proteins were dissolved in PBS (2 mg/mL) and 116 µL biotinylated peptides (5 mg/mL in PBS, 
50 equiv.) were added to 125 µL of  SA. The reaction was left overnight at 4 °C and the mixtures 
were purified afterwards using 40K Zeba spin desalting column to remove the excess of  
biotinylated peptide added. Protein concentrations were determined afterwards using UV-Vis 
measurements. Absorbance was measured at 280 nm and 654 nm. Using Lambert-Beers law (Abs 
= c * ε * d), fluorophore concentration was calculated, ε for AF647 is 270000 M-1 cm-1, d is 0.1 cm. 
For SA the absorbance was first corrected for the fluorophore attached. The calculations were 
made using: AbsSA = Abs280 - Cf  * Absfluorophore ( in which Cf  is the correction factor for AF647 and 
is 0.03). Using this corrected absorbance, the concentration was calculated according to the law of  
Lambert-Beer, using ε for SA is 167000 M-1 cm-1. The correlation between the corrected SA 
concentration and the concentration at the wavelength of  the fluorophore depicts the ratio of  
SA:fluorophore. 
 
Flow cytometry measurements. The SA and PIC scaffolds were serial diluted and added to cell 
cultures containing either HEKACPA-TM, non-transfected HEK, ACPA-expressing or anti-TT-
expressing immortalized B cells in a 96 well plate. Subsequently, the cells were kept on ice for 30 
minutes unless described otherwise, washed, resuspended with 1% paraformaldehyde and 
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5.7 Supplementary Information 
 
Note SI-1.  
Both the SA concentration and the fluorophore  concentration were calculated using the equations 
and information below. Calculated values are used to determine the fluorophore:SA and 
fluorophore:peptide ratio.  
Equations: 
Absorbance correction for 280nm:  𝐴𝐴𝐴𝐴𝐴𝐴280,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝐴𝐴𝐴𝐴𝐴𝐴280 − 𝐶𝐶𝑓𝑓 × 𝐴𝐴𝐴𝐴𝐴𝐴654 
Lambert-Beer Law:    𝐶𝐶 = 𝐴𝐴𝐴𝐴𝐴𝐴
𝜀𝜀×𝑑𝑑
 
Fluorophore - protein ratio:  𝐶𝐶654
𝐶𝐶280
 
With:  
A = absorbance (average value) 
Cf = correction factor (0.03 for AF64716) 
C = concentration (µM) 
ε = extinction coefficient (M-1 cm-1, 167000 for SA17 and 270000 for AF64718) 
d = path length of the beam of light through the material sample (cm) 
 
 
Calculations: 
 
 Abs280 Abs654 Abs280, corr C280 C654 Ratio 
SA-CArgP 0.266 0.795 0.242 14.5 29.4 2.03 
SA-CCP 0.272 0.813 0.248 14.8 30.1 2.03 
 
Both SA conjugates contain approximately 2 fluorophores per SA molecule. Since in theory 4 
biotin peptides can be attached, the ratio of fluorophore to peptide is 2:4. 
 
 
Figure SI-2. Flow cytometric binding studies of scaffold background for HEKACPA-TM and non-
transfected HEK cells for A) PIC-AF647 for B) SA-AF647. 
 
Figure SI-3. Flow cytometric binding studies of scaffold background for ACPA-positive and anti-TT-
positive B cells for A) PIC-AF647 for B) SA-AF647. 
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Figure SI-4. Flow cytometric binding titration of HEKACPA-TM and non-transfected HEK cells for A) 
PIC-CCP and B) SA-CCP. 
 
Figure SI-5. Flow cytometric binding titration of ACPA-positive and anti-TT-positive B cells for A) PIC-
CCP and B) SA-CCP. 
 
Figure SI-6. Flow cytometric binding studies with of HEKACPA-TM and non-transfected HEK cells for 
comparison of PIC loaded with A) CArgP or B) CNleP. 
 
 
Figure SI-7. Flow cytometric binding studies with of ACPA-positive and anti-TT-positive B cells for 
comparison of PIC loaded with A) CArgP or B) CNleP. 
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Abstract 
 
Antigen-specific targeting and elimination of autoreactive B cells can be beneficial for the 
treatment of autoimmune diseases, including rheumatoid arthritis (RA). Antibodies against 
citrullinated proteins are present in the majority of RA patients. However, other posttranslational 
modifications, such as carbamylation, are also involved in the development of autoantibodies in 
RA. Approximately 45% of RA patients is positive for antibodies against carbamylated proteins 
(anti-CarP antibodies), and most of these patients are also positive for anti-citrullinated protein 
antibodies (ACPA). However, 20-30% of RA patients is ACPA-negative, and these are not likely 
affected by strategies aimed at the elimination of ACPA-positive B cells. A fraction of these 
patients (10-20%) is positive for anti-CarP. A major limitation for anti-CarP-positive B cell 
targeting, however, is the lack of knowledge on small anti-CarP antigens. Only full-length proteins 
are considered as anti-CarP antigens, whereas peptide structures have not been identified to date. 
In this Chapter, we study the binding of a homocitrulline-containing peptide antigen against anti-
CarP antibodies and we explore the translation of antigen-specific targeting of ACPA-positive B 
cells to anti-CarP-positive B cells. We show that the new homocitrulline-containing antigens, based 
on CCP, can be used as a targeting antigen for ACPA-negative but anti-CarP-positive sera. Anti-
CarP antibodies were shown to be produced in mice with collagen-induced arthritis, a widely used 
model for RA pathology. Hence, we suggest that the change from citrullinated to carbamylated 
antigens can also be interesting to study B cell targeting in anti-CarP positive mice. Finally, we 
show that we can make the antigen-caging and activation strategy demonstrated for ACPA in 
Chapters 2 and 3 work on anti-CarP antibodies. 
 
  
6.1 Introduction 
 
In the past few years, it has become clear that the antibody response in RA was specific to multiple 
recognition elements. Besides ACPA, directed to citrullinated proteins, antibodies to carbamylated 
proteins were found in patient sera. Some of these posttranslational modifications are introduced 
by enzymes (e.g. citrulline to arginine, by PAD enzymes, see Chapter 2), others result from non-
enzymatic conversions (e.g. carbamylation of lysines).1  
Carbamylation is a posttranslational modification resulting from the interaction between isocyanic 
acid and amines residing in proteins (α­NH2 or ε­NH2). When isocyanic acid reacts with the ε­NH2 
group of the lysine side chain, the amino acid homocitrulline is formed (Figure 1).2-3 Urea is a 
source of cyanate and is present in body fluids in equilibrium with ammonium cyanate at a 
suggested ratio of 1 to 500.0004. 
Increased protein carbamylation can be observed under certain conditions, for example in 
patients with enhanced levels of urea as a consequence of renal insufficiency.2 Isocyanic acid can 
also be formed by myeloperoxidase (MPO)-mediated transformation of thiocyanate (Figure 1B), 
a component in cigarette smoke,5 which is considered the most common environmental risk factor 
for RA.6 MPO is mainly stored in granules of neutrophils7 and is released during (chronic) 
inflammation. Chronic inflammation seen in RA patients can thus be a trigger to a higher level of 
cyanates and hence carbamylated proteins. Approximately 45% of RA patients have antibodies 
directed to carbamylated proteins and these anti-CarP antibodies were shown to display 96% 
specificity for RA patients compared to healthy controls.8 Anti-CarP antibodies are mainly found 
in ACPA-positive patients, which include 70-80% of the RA patients,9 but importantly also in 10-
20% of ACPA-negative patients.10-11 Similar to ACPA and rheumatoid factors, anti-CarP 
antibodies can be detected in the sera of RA patients many years before the onset of the disease. 
12-14  
 
 
Figure 1. Protein carbamylation. Cyanate is formed from either urea (A) or thiocyanate (B). When isocyanic 
acid reacts with the lysine side chain, homocitrulline is formed. 
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To our knowledge, only carbamylated proteins and no peptide antigens are known for anti-CarP 
recognition.10 To gain more information about anti-CarP antibodies, a peptide antigen (like CCP2 
used for ACPA studies) and can be advantageous over using a full protein. In this Chapter we 
explore the possibility of using a homocitrulline analogue of the CCP peptide designed in Chapter 
2, and test its binding capacity for anti-CarP antibodies. In Chapter 2 we also showed that we can 
selectively cage and activate citrulline-containing antigens to tune the binding to ACPA. We 
suggest that this strategy can interchangeably be used by carbamylated peptides, since the binding 
for both antibody types is dependent on the ureido group of citrulline and homocitrulline (HCit). 
If successful, this strategy might be of additional value for the 10-20% anti-CarP-positive and 
ACPA-negative RA patients.  
Interestingly, an immune response against carbamylated antigens was also observed in collagen-
induced arthritis (CIA) mice, the most frequently used animal model for arthritis.15 Previous 
reports in literature showed that in CIA mice no ACPA were detected,16 and that anti-CarP 
antibodies were already present prior to disease onset. The anti-CarP antibody response in these 
mice can be used as a model for immune responses to post-translationally modified proteins. 
Hence, we explore in this Chapter whether we can apply the caging and activation strategy, 
described in Chapter 2, on anti-CarP positive human sera and sera from an anti-CarP mouse 
model. 
 
6.2 Results and Discussion 
 
Anti-CarP antigen synthesis and recognition tests. To date, no specific carbamylated peptides 
have been identified that bind to anti-CarP antibodies. We were interested to see if we can modify 
the CCP antigen to bind to anti-CarP antibodies. Therefore, we synthesized the CCP peptide with 
homocitrulline instead of citrulline. Homocitrulline was protected with an Fmoc group (1) and 
subsequently used to synthesize the CHCitP peptide 2 using solid phase peptide synthesis (SPPS). 
All amino acids were coupled according to standard Fmoc SPPS procedures. The peptide was 
cyclized covalently, similar as in Chapter 2, and therefore the N-terminal cysteine was replaced by 
an alanine. The cyclization was achieved by reacting the N-terminus with chloroacetic anhydride 
and DIPEA. After deprotection of the full peptide, cyclization occurred in a basic buffer by 
nucleophilic addition of the cysteine onto the chloride.  
In addition to CHCitP (2), we synthesized CLysP (3) containing a lysine at the homocitrulline 
position, functioning as the negative control, and CAcLysP (4) containing an acetylated lysine to 
look at specificity and cross-reactivity of the anti-CarP antibodies. CCP (5) and CArgP (6) were 
taken along for the same purpose and for comparison with ACPA (see Figure 2A). 
To test these peptide antigens for anti-CarP recognition we used sera from mice immunized with 
carbamylated ovalbumin. Fibrinogen and carbamylated (Ca) fibrinogen were used as negative and 
positive controls, respectively, in an enzyme-linked immunosorbent assay (ELISA). In this ELISA, 
the different peptide antigens were attached to a streptavidin-coated well-plate and different 
concentrations of anti-CarP serum were added. After the incubation with a secondary antibody 
containing horseradish peroxidase and the addition of the substrate, a signal was measured 
corresponding to the binding of the primary antibody. Figure 2B shows that CHCitP (2) was 
indeed recognized by anti-CarP antibodies and resulted in signals of equal intensities as compared 
to carbamylated fibrinogen. This demonstrates that this peptide functions as a good antigen for 
the anti-CarP antibodies in this serum. Hence, this carbamylated peptide antigen might be of 
interest to replace full protein antigens in the detection of anti-CarP antibodies in general.  
 
 
Figure 2. Binding of anti-CarP antibodies to homocitrulline-containing CCP-like peptide. A) Structures of 
all CXP peptides used in the ELISA; B) ELISA with CXP peptides against anti-CarP and monoclonal 
ACPA, using fibrinogen and carbamylated fibrinogen as negative and positive control. The anti-CarP serum 
was used at dilutions as indicated and the monoclonal ACPA, derived from immortalized B cell supernatant, 
was not diluted.  
 
No anti-CarP binding was observed to fibrinogen, nor to the cyclic peptide containing a lysine 
residue, CLysP (3) (Figure 2B). The acetylated CLysP peptide (4), gave a significant signal, albeit 
with lower intensity as compared to carbamylated fibrinogen or CHCitP (2). This indicates that 
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the anti-CarP antibodies cross-react with CAcLysP (4). Furthermore, no binding of anti-CarP was 
observed for CCP (5) and CArgP (6), as expected. No cross-reactivity with any peptide was noted 
for the ACPA serum, as only CCP gave a positive signal. The cross-reactivity of the serum for 
carbamylated antigens might be due to the polyclonal nature of this serum; the ACPA used in this 
experiment are monoclonal antibodies derived from immortalized ACPA-expressing B cells.  
To show that CHCitP (2) was not only recognized by one specific immunized mouse serum, ten 
additional sera were tested (Figure 3). The ELISA experiment was performed as described above 
and the data showed that all mice positive for carbamylated fibrinogen were also positive for 
CHCitP. In most sera, cross-reactivity with CAcLysP was also observed. For all mouse sera tested, 
no reactivity with CLysP (3), CCP (5) and CArgP (6) was detected.  
 
 
Figure 3. Reactivity of anti-CarP-positive mouse sera with synthetic (carbamylated) peptides. Sera from 
mice (M) immunized with carbamylated ovalbumin were tested for reactivity with the peptide antigens 
defined in Figure 2A.  
 
These results strongly suggest that the carbamylated peptide is applicable for B cell targeting and 
isolation in this mouse model, but it may also be useful for targeting anti-CarP B cells in RA 
patients. To test whether CHCitP (2) is also recognized by anti-CarP antibodies in human serum, 
we analyzed a patient serum positive for both ACPA and anti-CarP antibodies by ELISA. Figure 
4 shows that both CCP (5) and CHCitP (2) bind to antibodies in the serum and that the absorbance 
is much higher than for carbamylated fibrinogen. Although anti-CarP antibodies in mice and 
humans are developed according to different triggers and therefore might recognize different 
epitopes, these data indicate that CHCitP (2) is readily recognized by both human and mouse anti-
CarP antibodies, while this is not the case for carbamylated fibrinogen. Since many patients do 
have anti-CarP antibodies, we next explored whether the antigen caging and activation strategy 
described in Chapter 2 can be applied to these carbamylated antigens. 
 
 
Figure 4. Reactivity of anti-CarP patient antibodies with CHCitP in ELISA. Microtiter plates were coated 
with (carbamylated) fibrinogen and peptide antigens 2-6 and incubated with an ACPA- and anti-CarP-
positive patient serum. ELISA was performed in duplo. 
 
CHCitP(CNBz) synthesis and activation. To examine whether we could apply the antigen 
caging and activation strategy as described in Chapter 2 on a carbamylated peptide, we synthesized 
Fmoc-HCit(CNBz)-OH (7) as shown in scheme 1 and used this amino acid in SPPS to synthesize 
CHCitP(CNBz) (8, Figure 5A).  
 
 
Scheme 1. Synthetic route to CNBz-caged Fmoc-HCit-OH (7). i) Fmoc-OSu, H2O, dioxane, r.t., 16 h, 
quant. ii) p-Nitrobenzyl chloroformate, THF, overnight, 40 °C, 68% yield based on recovered starting 
material. 
 
To test the antigen activation strategy, we used 0.3 equivalents of nitroreductase (NTR) for 1 h at 
37 °C with NADH as cofactor as these conditions gave complete activation of the CCP antigen 
in Chapter 2. Upon reduction of the nitro group by NTR, 1,6-elimination of the CNBz group 
yielded activated CHCitP (2). The reactivity with anti-CarP patient sera was assessed using three 
sera, two of which were both anti-CarP- and ACPA-positive, whereas the third was neither reactive 
with carbamylated nor with citrullinated antigens. Figure 5B shows the binding of CHCitP (2) by 
anti-CarP antibodies, while CNBz-caged CHCitP (8) did not yield any signal, like the CLysP. This 
demonstrates that the caging group also masked recognition of the anti-CarP antigen and that 
binding was restored after the addition of NTR for both human RA sera reactive with CHCitP (2).  
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the anti-CarP antibodies cross-react with CAcLysP (4). Furthermore, no binding of anti-CarP was 
observed for CCP (5) and CArgP (6), as expected. No cross-reactivity with any peptide was noted 
for the ACPA serum, as only CCP gave a positive signal. The cross-reactivity of the serum for 
carbamylated antigens might be due to the polyclonal nature of this serum; the ACPA used in this 
experiment are monoclonal antibodies derived from immortalized ACPA-expressing B cells.  
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epitopes, these data indicate that CHCitP (2) is readily recognized by both human and mouse anti-
CarP antibodies, while this is not the case for carbamylated fibrinogen. Since many patients do 
have anti-CarP antibodies, we next explored whether the antigen caging and activation strategy 
described in Chapter 2 can be applied to these carbamylated antigens. 
 
 
Figure 4. Reactivity of anti-CarP patient antibodies with CHCitP in ELISA. Microtiter plates were coated 
with (carbamylated) fibrinogen and peptide antigens 2-6 and incubated with an ACPA- and anti-CarP-
positive patient serum. ELISA was performed in duplo. 
 
CHCitP(CNBz) synthesis and activation. To examine whether we could apply the antigen 
caging and activation strategy as described in Chapter 2 on a carbamylated peptide, we synthesized 
Fmoc-HCit(CNBz)-OH (7) as shown in scheme 1 and used this amino acid in SPPS to synthesize 
CHCitP(CNBz) (8, Figure 5A).  
 
 
Scheme 1. Synthetic route to CNBz-caged Fmoc-HCit-OH (7). i) Fmoc-OSu, H2O, dioxane, r.t., 16 h, 
quant. ii) p-Nitrobenzyl chloroformate, THF, overnight, 40 °C, 68% yield based on recovered starting 
material. 
 
To test the antigen activation strategy, we used 0.3 equivalents of nitroreductase (NTR) for 1 h at 
37 °C with NADH as cofactor as these conditions gave complete activation of the CCP antigen 
in Chapter 2. Upon reduction of the nitro group by NTR, 1,6-elimination of the CNBz group 
yielded activated CHCitP (2). The reactivity with anti-CarP patient sera was assessed using three 
sera, two of which were both anti-CarP- and ACPA-positive, whereas the third was neither reactive 
with carbamylated nor with citrullinated antigens. Figure 5B shows the binding of CHCitP (2) by 
anti-CarP antibodies, while CNBz-caged CHCitP (8) did not yield any signal, like the CLysP. This 
demonstrates that the caging group also masked recognition of the anti-CarP antigen and that 
binding was restored after the addition of NTR for both human RA sera reactive with CHCitP (2).  
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Figure 5. Reactivity of anti-CarP patient and mouse antibodies with CNBz-caged antigens peptides and 
after activation using NTR. A) Overview of the peptides used in this experiment. CHCitP and CLysP were 
used as positive and negative controls, respectively and CHCitP(CNBz) as the caged anti-CarP antigen; B) 
Three RA patient sera and monoclonal ACPA antibodies were used. A positive signal was seen for the 
CHCitP positive control, but also after the activation of CHCitP(CNBz) with NTR, using 0.3 equiv., for 1 
h, at 37 °C and with NADH as a cofactor. The increasing signal was also observed after activation of 
CCP(CNBz); C) Four different mouse sera were tested against CHCitP and caged CHCitP(CNBz). All sera 
were positive for CHCitP, negative for the caged peptide antigen, and affinity was observed again after 
activation by NTR.  
 
Since these sera are double positive for anti-CarP antibodies and ACPA, CCP(CNBz) with and 
without NTR treatment was tested as a control. While CCP(CNBz) showed only weak signals for 
the two double positive human RA sera, no signal was seen for the monoclonal ACPA serum or 
the anti-CarP- and ACPA-negative serum (Patient 3). As soon as NTR was added, the signal 
increased showing the restored binding of ACPA, for the three ACPA-positive sera, to the free 
citrullinated peptide antigen.  
To substantiate the activation of homocitrulline by NTR, reactivity with the same antigens was 
analyzed for the mice sera described above. As shown in Figure 5C, the addition of the CNBz-
caging group to CHCitP completely masked anti-CarP antibody binding for all four mice sera 
tested. A similar negative signal was observed for the CLysP peptide. Treatment of CHCitP(CNBz) 
with NTR showed similar absorbance values as observed for the CHCitP positive control, 
demonstrating the successful restoration and recognition of the antigen by the mouse anti-CarP 
antibodies. 
 
6.3 Conclusions 
 
In this Chapter, we showed the design and synthesis of a carbamylated peptide, CHCitP (2), and 
its recognition by anti-CarP antibodies. We showed that CHCitP was recognized by both human 
and mice anti-CarP antibodies. Since no peptide antigens are known to date to detect anti-CarP 
antibodies, this finding can be advantageous for studies involving anti-CarP-producing B cells. 
Furthermore, we demonstrated that the antigen caging and activation strategy used for ACPA, as 
described in Chapter 2, can be applied to carbamylated peptides. Recognition of CHCitP (2) was 
proven to be selective to anti-CarP antibodies and dependent on the presence of the CNBz-caging 
group. 
The antigen activation strategy for anti-CarP antibodies can now be tested in carbamylated 
ovalbumin-immunized mice as an in vivo animal model. For this, we envision to conjugate anti-
mouse CD20 Fab fragments to an activating enzyme or chemical group to increase the local 
concentration of autoreactive antigens in close proximity to B cells. The carbamylated antigen can 
be further used as targeting antigen, for patients lacking ACPA but having anti-CarP antibodies. 
Finally, these anti-CarP antigens might be of use to isolate anti-CarP positive B cells, using 
streptavidin tetramers17 or PICs (Chapter 6), from either mouse or human to study them in more 
detail. 
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2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-6-ureidohexanoic acid (1). H-HCit-OH 
(1.00 g, 5.3 mmol, 1.0 equiv.) was suspended in dioxane (40 mL). NaHCO3 (2.22 
g, 26.4 mmol, 5 equiv.) was dissolved in H2O (40 mL) and added to the 
suspension. Fmoc-OSu (1.78 g, 5.29 mmol, 1.0 equiv.) was dissolved in dioxane 
(20 mL) and was added dropwise to the suspension on ice. The mixture was 
stirred for 16 h at r.t. and the dioxane was removed under reduced pressure. 1M 
HCl was added until a pH of 4 and this was extracted with EtOAc (3 x 40 mL). 
The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The product, a white 
solid (2.17 g, 5.3 mmol, 100%), was used without further purification. Rf = 0.10 (10% MeOH in 
DCM). 1H NMR (500 MHz, MeOH-d4) δ 7.81 (d, J = 7.5 Hz, 2H), 7.69 (t, J = 8.3 Hz, 2H), 7.62 
(s, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.9 Hz, 2H), 4.41 – 4.31 (m, 2H), 4.24 (t, J = 6.9 Hz, 
1H), 4.17 – 4.14 (m, 1H), 3.12 (t, J = 6.8 Hz, 2H), 1.95 – 1.64 (m, 2H), 1.54 (ddt, J = 18.8, 11.9, 
6.8 Hz, 2H), 1.49 – 1.39 (m, 2H). 13C NMR (126 MHz, MeOH-d4) δ 174.59, 173.46, 171.59, 160.88, 
157.32, 143.77, 141.18, 127.38, 126.77, 124.84, 119.50, 66.53, 60.14, 53.91, 47.02, 31.00, 29.33, 
24.88, 22.89, 19.46, 13.06. LRMS (ESI+) m/z calcd C22H26N3O5+ [M+H]+ 412.19, found: 411.92. 
C44H51N6O10+ [2M+H]+ 823.37, found 822.60. 
 
15-(9H-Fluoren-9-yl)-1-(4-nitrophenyl)-3,5,13-trioxo-2,14-dioxa-4,6,12-triazapentadecane-
11- carboxylic acid (7). Fmoc-HCit-OH (1) (2.18 g, 5.3 mmol, 1.0 
equiv.) was dissolved in THF (122 mL) and heated to 40 °C. 4-
nitrobenzyl chloroformate (1.71 g, 8.0 mmol, 1.5 equiv.) was 
dissolved in THF (5 mL) and added to Fmoc-HCit-OH. The 
reaction mixture was stirred overnight. The mixture was 
concentrated in vacuo and purified over silica (0-100% acetone in 
DCM), yielding a yellow solid product (2) (653 mg, 68% after 
regaining starting material). Rf = 0.14 (10% MeOH in DCM). 1H NMR (500 MHz, DMSO-d6) δ 
10.24 (s, 1H), 8.24 (d, J = 8.5 Hz, 2H), 7.89 (d, J = 7.4 Hz, 2H), 7.72 (d, J = 7.3 Hz, 1H), 7.67 (s, 
2H), 7.63 (d, J = 8.4 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.33 (t, J = 7.1 Hz, 2H), 5.34 (s, 1H), 5.26 
(s, 2H), 4.34 – 4.20 (m, 3H), 3.87 (q, J = 7.7 Hz, 1H), 3.21 – 3.06 (m, 2H), 1.76 – 1.54 (m, 2H), 
1.49 – 1.38 (m, 2H), 1.36 – 1.25 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.02, 154.05, 152.50, 
147.10, 143.86, 143.74, 140.68, 128.25, 127.59, 127.03, 125.28, 123.57, 120.07, 68.49, 65.52, 54.04, 
46.68, 39.00, 30.73, 28.94, 22.97. HRMS (ESI+) m/z calcd for C30H30N4NaO9+ [M+Na]+ 
613.19050, found: 613.19105 
 
CHCitP (2). CHCitP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, the peptides were cyclized as described in the general cyclization 
method. HPLC: Rt. 12.786 min. LCMS (ESI+) m/z calcd for C101H173N41O34S22+ [M+2H]2+ 
1284.62, found 1285.12. C101H174N41O34S23+ [M+3H]3+ 856.75, found 857.40. C101H175N41O34S24+ 
[M+4H]4+ 642.81, found 644.84. 
 
CLysP (3). CLysP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, the peptides were cyclized as described in the general cyclization 
method. HPLC: Rt. 12.596 min. LCMS (ESI+) m/z calcd for C100H172N40O33S22+ [M+2H]2+ 
1263.13, found 1263.56. C100H173N40O33S23+ [M+3H]3+ 842.42, found 843.12. C100H174N40O33S24+ 
[M+4H]4+ 632.07, found 634.52. C100H175N40O33S25+ [M+5H]5+ 505.85, found 507.00. 
CAcLysP (4). CAcLysP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, the peptides were cyclized as described in the general cyclization 
method. HPLC: Rt. 12.925 min. LCMS (ESI+) m/z calcd for C102H174N40O34S22+ [M+2H]2+ 
1284.13, found 1284.60. C102H175N40O34S23+ [M+3H]3+ 856.42, found 857.12. C102H176N40O34S24+ 
[M+4H]4+ 642.57, found 644.88. 
 
CCP (5). CCP was synthesized following the procedures described in the general peptide synthesis 
Section 2.4. Next, this peptide was cyclized and purified as described in the general cyclization 
method. HPLC: Rt. 12.753 min. LCMS (ESI+) m/z calcd for C100H171N41O34S22+ [M+2H]2+ 
1277.61, found 1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 852.68. C100H173N41O34S24+ 
[M+4H]4+ 639.31, found 641.16. 
 
CArgP (6). CArgP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for C100H172N42O33S22+ 
[M+2H]2+ 1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 852.28. 
C100H173N41O34S24+ [M+4H]4+ 639.06, found 640.20. 
 
CHCitP(CNBz) (8). CHCitP(CNBz) was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. This peptide was cyclized as described in the general 
cyclization method. HPLC: Rt. 14.923 min. LCMS (ESI+) m/z calcd for C109H178N42O38S22+ 
[M+2H]2+ 1374.14, found 1374.12 C109H179N42O38S23+ [M+3H]3+ 916.43, found 916.44. 
C109H180N42O38S24+ [M+4H]4+ 687.57, found 687.68.  
 
CCP(CNBz) (9). CCP(CNBz) was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. This peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 14.854 min. LCMS (ESI+) m/z calcd for C108H176N42O38S22+ 
[M+2H]2+ 1367.12, found 1367.52. C108H177N42O38S23+ [M+3H]3+ 911.75, found 912.20. 
C108H178N42O38S24+ [M+4H]4+ 684.06, found 685.20. 
 
Cell culture and monoclonal antibodies. See Section 2.4 
 
Anti-CarP-positive mouse serum. Carbamylated ovalbumin and alum were used to induce and 
boost anti-CarP production as described in literature.18 
 
RA plasma. Peripheral blood was obtained from ACPA- and anti-CarP-positive RA patients who 
visited the outpatient clinic of the Department of Rheumatology at Leiden University Medical 
Centre (LUMC). The patients met the 2010 ACR/EULAR criteria for RA at the time of diagnosis 
and gave written informed consent to participate in the study. Permission to conduct the study 
was obtained from the ethical review board of LUMC. Blood plasma was obtained by centrifuging 
heparin-treated peripheral blood.  
 
ELISA experiments. See Section 2.4.  
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2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-6-ureidohexanoic acid (1). H-HCit-OH 
(1.00 g, 5.3 mmol, 1.0 equiv.) was suspended in dioxane (40 mL). NaHCO3 (2.22 
g, 26.4 mmol, 5 equiv.) was dissolved in H2O (40 mL) and added to the 
suspension. Fmoc-OSu (1.78 g, 5.29 mmol, 1.0 equiv.) was dissolved in dioxane 
(20 mL) and was added dropwise to the suspension on ice. The mixture was 
stirred for 16 h at r.t. and the dioxane was removed under reduced pressure. 1M 
HCl was added until a pH of 4 and this was extracted with EtOAc (3 x 40 mL). 
The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The product, a white 
solid (2.17 g, 5.3 mmol, 100%), was used without further purification. Rf = 0.10 (10% MeOH in 
DCM). 1H NMR (500 MHz, MeOH-d4) δ 7.81 (d, J = 7.5 Hz, 2H), 7.69 (t, J = 8.3 Hz, 2H), 7.62 
(s, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.9 Hz, 2H), 4.41 – 4.31 (m, 2H), 4.24 (t, J = 6.9 Hz, 
1H), 4.17 – 4.14 (m, 1H), 3.12 (t, J = 6.8 Hz, 2H), 1.95 – 1.64 (m, 2H), 1.54 (ddt, J = 18.8, 11.9, 
6.8 Hz, 2H), 1.49 – 1.39 (m, 2H). 13C NMR (126 MHz, MeOH-d4) δ 174.59, 173.46, 171.59, 160.88, 
157.32, 143.77, 141.18, 127.38, 126.77, 124.84, 119.50, 66.53, 60.14, 53.91, 47.02, 31.00, 29.33, 
24.88, 22.89, 19.46, 13.06. LRMS (ESI+) m/z calcd C22H26N3O5+ [M+H]+ 412.19, found: 411.92. 
C44H51N6O10+ [2M+H]+ 823.37, found 822.60. 
 
15-(9H-Fluoren-9-yl)-1-(4-nitrophenyl)-3,5,13-trioxo-2,14-dioxa-4,6,12-triazapentadecane-
11- carboxylic acid (7). Fmoc-HCit-OH (1) (2.18 g, 5.3 mmol, 1.0 
equiv.) was dissolved in THF (122 mL) and heated to 40 °C. 4-
nitrobenzyl chloroformate (1.71 g, 8.0 mmol, 1.5 equiv.) was 
dissolved in THF (5 mL) and added to Fmoc-HCit-OH. The 
reaction mixture was stirred overnight. The mixture was 
concentrated in vacuo and purified over silica (0-100% acetone in 
DCM), yielding a yellow solid product (2) (653 mg, 68% after 
regaining starting material). Rf = 0.14 (10% MeOH in DCM). 1H NMR (500 MHz, DMSO-d6) δ 
10.24 (s, 1H), 8.24 (d, J = 8.5 Hz, 2H), 7.89 (d, J = 7.4 Hz, 2H), 7.72 (d, J = 7.3 Hz, 1H), 7.67 (s, 
2H), 7.63 (d, J = 8.4 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.33 (t, J = 7.1 Hz, 2H), 5.34 (s, 1H), 5.26 
(s, 2H), 4.34 – 4.20 (m, 3H), 3.87 (q, J = 7.7 Hz, 1H), 3.21 – 3.06 (m, 2H), 1.76 – 1.54 (m, 2H), 
1.49 – 1.38 (m, 2H), 1.36 – 1.25 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.02, 154.05, 152.50, 
147.10, 143.86, 143.74, 140.68, 128.25, 127.59, 127.03, 125.28, 123.57, 120.07, 68.49, 65.52, 54.04, 
46.68, 39.00, 30.73, 28.94, 22.97. HRMS (ESI+) m/z calcd for C30H30N4NaO9+ [M+Na]+ 
613.19050, found: 613.19105 
 
CHCitP (2). CHCitP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, the peptides were cyclized as described in the general cyclization 
method. HPLC: Rt. 12.786 min. LCMS (ESI+) m/z calcd for C101H173N41O34S22+ [M+2H]2+ 
1284.62, found 1285.12. C101H174N41O34S23+ [M+3H]3+ 856.75, found 857.40. C101H175N41O34S24+ 
[M+4H]4+ 642.81, found 644.84. 
 
CLysP (3). CLysP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, the peptides were cyclized as described in the general cyclization 
method. HPLC: Rt. 12.596 min. LCMS (ESI+) m/z calcd for C100H172N40O33S22+ [M+2H]2+ 
1263.13, found 1263.56. C100H173N40O33S23+ [M+3H]3+ 842.42, found 843.12. C100H174N40O33S24+ 
[M+4H]4+ 632.07, found 634.52. C100H175N40O33S25+ [M+5H]5+ 505.85, found 507.00. 
CAcLysP (4). CAcLysP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, the peptides were cyclized as described in the general cyclization 
method. HPLC: Rt. 12.925 min. LCMS (ESI+) m/z calcd for C102H174N40O34S22+ [M+2H]2+ 
1284.13, found 1284.60. C102H175N40O34S23+ [M+3H]3+ 856.42, found 857.12. C102H176N40O34S24+ 
[M+4H]4+ 642.57, found 644.88. 
 
CCP (5). CCP was synthesized following the procedures described in the general peptide synthesis 
Section 2.4. Next, this peptide was cyclized and purified as described in the general cyclization 
method. HPLC: Rt. 12.753 min. LCMS (ESI+) m/z calcd for C100H171N41O34S22+ [M+2H]2+ 
1277.61, found 1278.08. C100H172N41O34S23+ [M+3H]3+ 852.07, found 852.68. C100H173N41O34S24+ 
[M+4H]4+ 639.31, found 641.16. 
 
CArgP (6). CArgP was synthesized following the procedures described in the general peptide 
synthesis Section 2.4. Next, this peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 12.731 min. LCMS (ESI+) m/z calcd for C100H172N42O33S22+ 
[M+2H]2+ 1277.13, found 1277.56. C100H172N41O34S23+ [M+3H]3+ 851.75, found 852.28. 
C100H173N41O34S24+ [M+4H]4+ 639.06, found 640.20. 
 
CHCitP(CNBz) (8). CHCitP(CNBz) was synthesized following the procedures described in the 
general peptide synthesis Section 2.4. This peptide was cyclized as described in the general 
cyclization method. HPLC: Rt. 14.923 min. LCMS (ESI+) m/z calcd for C109H178N42O38S22+ 
[M+2H]2+ 1374.14, found 1374.12 C109H179N42O38S23+ [M+3H]3+ 916.43, found 916.44. 
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CCP(CNBz) (9). CCP(CNBz) was synthesized following the procedures described in the general 
peptide synthesis Section 2.4. This peptide was cyclized and purified as described in the general 
cyclization method. HPLC: Rt. 14.854 min. LCMS (ESI+) m/z calcd for C108H176N42O38S22+ 
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Cell culture and monoclonal antibodies. See Section 2.4 
 
Anti-CarP-positive mouse serum. Carbamylated ovalbumin and alum were used to induce and 
boost anti-CarP production as described in literature.18 
 
RA plasma. Peripheral blood was obtained from ACPA- and anti-CarP-positive RA patients who 
visited the outpatient clinic of the Department of Rheumatology at Leiden University Medical 
Centre (LUMC). The patients met the 2010 ACR/EULAR criteria for RA at the time of diagnosis 
and gave written informed consent to participate in the study. Permission to conduct the study 
was obtained from the ethical review board of LUMC. Blood plasma was obtained by centrifuging 
heparin-treated peripheral blood.  
 
ELISA experiments. See Section 2.4.  
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7.1 Summary 
 
Current B cell-directed therapies mainly induce generalized immune suppression by either 
inhibition or elimination of the complete B cell compartment, leaving patients at increased risk of 
infection.1 Ideally, therapeutics only target autoreactive B cells involved in disease pathogenesis, 
while leaving healthy B cells intact. In this thesis, we describe research to explore and develop new 
approaches to target autoreactive B cells selectively, making use of epitopes targeting the unique 
B cell receptor. As free circulating autoantibodies recognize and bind the same autoreactive 
epitopes, the unique recognition element is likely to be quenched during administration. We 
envisioned that by physically caging the autoantigen we could circumvent binding to 
autoantibodies and by selective removal of the caging group in close proximity of a B cell we can 
improve binding to the autoreactive B cell. 
In Chapter 1, we provided an overview of previously reported antigen-selective B cell targeting 
strategies in autoimmune diseases. We summarized the reported strategies to dampen a B cell 
response and we elaborated on the autoantigens used to target different diseases. Often, 
multivalent scaffolds were modified with an autoantigen combined with a functional molecule to 
induce anergy or apoptosis.  
In Chapter 2 we describe the caging of a cyclic citrullinated peptide (CCP) with a 
carboxynitrobenzyl (CNBz) group and the subsequent activation using the enzyme nitroreductase 
(NTR). We showed that we can fully retain the antigen from binding to both anti-citrullinated 
protein antibodies (ACPA) and ACPA-expressing B cells and that we can regain full binding only 
when removing CNBz using NTR. By conjugating the caged antigen peptide to a streptavidin-
toxin, we induced selective cytotoxicity using this caging and activation strategy towards CCP 
recognizing B cells. We showed that this strategy is antigen-dependent, since B cells recognizing 
tetanus toxoid were not affected by the antigen-toxin conjugate. 
In Chapter 3 we showed that besides using an enzymatic cleavage strategy, we could also use a 
chemical click-to-release reaction to selectively activate an autoantigen. We synthesized citrulline 
linked to an iminosydnone at the ureido side chain and showed that we could incorporate this 
amino acid into CCP. We showed that the iminosydnone-caged CCP fully retained binding to both 
ACPA and ACPA-expressing B cells. The click-to-release reaction using DBCO yielded free CCP 
and regained binding to both ACPA and ACPA-expressing B cells. We also conjugated the CCP 
and iminosydnone-protected CCP to a MMAE toxin and observed no selective cytotoxicity. No 
antigen dependency was found, when comparing the caged with the uncaged CCP, and therefore 
we hypothesize that a multivalent system is needed to increase the selectivity for the BCR.  
In Chapter 4 we described the development of a new click-to-release reaction that is based on a 
tetrazine ligation with a phenoxyvinyl boronic acid. We showed that this reaction is faster than the 
ligation with the corresponding vinyl ether due to the attachment of the boronic acid moiety. By 
the conjugation of a lymphocyte specific toxin, cladribine, we showed that we can induce cell death 
mainly when the drug is activated after the click-to-release reaction with a dipyridyl tetrazine. 
Although the cladribine-VBA conjugate seemed to degrade over time, significant difference in 
cytotoxicity was obtained between the caged cladribine and the liberated toxin. 
As we hypothesize that multivalency is important for BCR binding and we demonstrated this 
using tetravalent streptavidin (SA), in Chapter 5 we studied another multivalent scaffold with 
increased valence. The use of a scaffold with increased valence allows the introduction of multiple 
functionalities which may be beneficial for imaging or therapeutic purposes. We used 
poly(isocyanopeptides) (PICs) to attach both fluorophores and multiple antigen peptides to isolate 
CCP-recognizing B cells. We showed that the non-specific binding of this scaffold was lower 
compared to that of SA. In addition, we showed that the binding avidity of PIC and SA seemed 
comparable as demonstrated by a similar number of stained cells in a flow cytometric binding 
study. Furthermore, during our studies we found that the negative control peptide CArgP showed 
significant background binding to immortalized B cells. Replacing the positively charged arginine 
for a norleucine, however, diminished the background signal substantially. Lastly, we indirectly 
showed that it was not possible for the immortalized B cells to internalize the PIC scaffold. This 
is important information for future design of multivalent and multifunctional therapeutic 
structures based on the PIC scaffold.  
In Chapter 6 we show the discovery of a new synthetic antigen with affinity for anti-carbamylated 
protein antibodies (anti-CarP). We demonstrated that CHCitP, containing a homocitrulline, was 
efficiently bound by both human and mouse anti-CarP antibodies. We applied the 
carboxynitrobenzyl caging and activation mechanism, as described in Chapter 2, on CHCitP and 
established that similar results were obtained for both human and mouse sera. As mice cannot 
produce ACPA, this observation is an important step to allow the testing of the strategies described 
in this thesis in a mouse model, as well as in anti-CarP positive RA patient sera. 
 
7.2 Future Perspectives 
 
NTR modification and anti-CD20 Fab conjugation. To ensure that the activation of the caged 
antigen described in Chapter 2 occurs in close proximity of the B cell receptor (BCR), it is essential 
to target the nitroreductase (NTR) to the B cell membrane using a specific surface marker. Such a 
strategy, also described as antibody-directed enzyme prodrug therapy (ADEPT), has been explored 
extensively for local activation of cytotoxic prodrugs for tumor treatment.2 The marker of interest 
here is CD20, a non-internalizing membrane protein specific for B cells, including memory B cells. 
The natural ligand for this protein is not known, but it is thought that CD20 functions as a calcium 
channel. Also, CD20 knockout mice display an almost normal phenotype.1 CD20 is used as a 
therapeutic target for rituximab, which functions effectively as anti-cancer drug and has therapeutic 
benefit in RA. Here we specifically look at anti-CD20 Fab fragments, since they are known to be 
less immunogenic compared to a full antibody, since the Fc part is lacking.3 In order to attach 
NTR to this Fab fragment, chemical modifications at the NTR and Fab fragment are needed.  
 
 
Figure 1. General reaction scheme for N-terminal imidazolidinone formation. The reaction with the 
aldehyde first results in the imine, after which the stable imidazolidinone is formed.4  
 
As a first experiment, we tested a strategy using 2-pyridinecarboxyaldehyde (2-PCA) to modify 
NTR at the N-terminus only. This strategy was reported recently and allows the modification of 
the N-terminus of peptides and proteins without genetic engineering.4 The selectivity is due to the 
required nucleophilic attack of the neighboring amide nitrogen of the protein backbone on the 
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we hypothesize that a multivalent system is needed to increase the selectivity for the BCR.  
In Chapter 4 we described the development of a new click-to-release reaction that is based on a 
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ligation with the corresponding vinyl ether due to the attachment of the boronic acid moiety. By 
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As a first experiment, we tested a strategy using 2-pyridinecarboxyaldehyde (2-PCA) to modify 
NTR at the N-terminus only. This strategy was reported recently and allows the modification of 
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initially formed N-terminal imine (Figure 1) providing a stable cycloadduct. Because of this 
mechanism, other lysines present in the protein are unaffected.  
In order to attach an azide on the N-terminus, we synthesized two azide-containing 2-PCA 
analogues varying in linker length according to Scheme 1. We first synthesized the NHS-esters of 
both azidoacetic acid (1) and azido-PEG4-acetic acid (2), which are needed to obtain 2-PCA azides 
8 (without PEG tail) and 9 (with PEG tail, Scheme 1B). We started by oxidizing one of the alcohols 
of 2,6-pyridinedimethanol to the corresponding aldehyde 5. The second alcohol was mesylated 
yielding compound 6, and subsequently reacted with Boc-protected piperazine yielding the Boc-
protected 2-PCA 7. After Boc-deprotection using HCl in dioxane, NHS-esters 3 and 4 were used 
to yield 2-PCA azides 8 and 9, respectively.  
 
 
Scheme 1. Synthesis of azide-containing 2-PCA handles. A) Azide NHS synthesis without (3) and with 
PEG tail (4). i) EDC ּ HCl, NHS, DCM, r.t., 17 h, 3: 70%, 4: 65%; B) 2-PCA azide synthesis without (8) 
and with PEG tail (9). i) SeO2, dioxane, 65 °C, 24 h, 92%; ii) MsCl, Et3N, DCM, r.t., 30 min, 73%; iii) 
K2CO3, MeCN, 60 °C, 16 h, 87%; iv) 4M HCl in dioxane, DCM, r.t., 2 h; v) 3 or 4, Et3N, DMF, r.t., 2 h, 8: 
80%, 9: 11%.  
 
Next, we reacted NTR with 2-PCA azide 8 by incubating the reactants for 24 h in PBS buffer 
(Figure 2A). We performed the reaction at 4 °C, 21 °C and 37 °C to see if this affects the reaction 
efficiency of the conjugation. For two of the temperatures we used either no (only DMSO) or 100 
equivalents of 2-PCA azide 8. For the reaction at 4 °C we decided to also add 1000 equivalents as 
we expected the reaction to occur much slower at this temperature. After incubation, we tested 
the presence of the azide by reacting the alleged N3-NTR with either DBCO-Cy5.5 or DBCO-
PEG5000. On SDS-PAGE gel (Figure 2B) we observed the fluorescent band of the click-reaction 
with DBCO-Cy5.5 in varying intensities. Although there was some background observed for the 
NTR that was not functionalized with 2-PCA-azides, the intensity of the signal increased when 
azides were present. Especially at 21 °C and 37 °C a bright fluorescent signal was observed. We 
attempted to measure the efficiency of the modification conditions by reacting the NTR-azides 
with DBCO-PEG5000. However, no cycloaddition with DBCO-PEG5000 was observed for any of 
the conditions (Figure 2C). This might be due to steric hindrance of the enzyme, or to inefficient 
protein modification with the 2-PCA azide moiety.  
 
 
Figure 2. Strategy for the selective N-terminal modification of NTR. A) Reaction of 2-PCA-N3 (8) or 2-
PCA-PEG4-N3 (9) with NTR; B) The NTR modification using 0-1000 equiv. 2-PCA 8 was performed at 4 
°C, 21 °C and 37 °C and subsequently reacted with DBCO-Cy5.5 or DBCO-PEG5000, measured at 700 (red) 
and 800 nm (green); C) Coomassie Brilliant Blue staining of NTR reacted with 2-PCA 8; D) The NTR 
modification using 0 or 1000 equiv. 2-PCA 9 was performed at 4 °C and subsequently reacted with DBCO-
Cy5.5 or DBCO-PEG5000, measured at 700 (red) and 800nm (green); E) Coomassie Brilliant Blue staining 
of NTR reacted with 2-PCA 9.  
 
Next, we evaluated if NTR functionalization could be improved using 2-PCA 9, containing a short 
PEG tail. Incubating NTR with 2-PCA 9 at 4 °C followed by cycloaddition to DBCO-Cy5.5, 
provided a fluorescent signal for the modified NTR as expected (Figure 2D). Unfortunately, 
cycloaddition using DBCO-PEG5000 (Figure 2E) did not result in a protein shift as evidenced by 
Coomassie Brilliant Blue staining of the SDS-PAGE gel. Hence, reaction efficiency could not be 
determined. 
To test whether the reaction conditions of the N-terminal modification of NTR altered the 
enzyme activity, we tested the reaction efficiency of the 2-PCA-modified NTR. We used the 
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initially formed N-terminal imine (Figure 1) providing a stable cycloadduct. Because of this 
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PCA-PEG4-N3 (9) with NTR; B) The NTR modification using 0-1000 equiv. 2-PCA 8 was performed at 4 
°C, 21 °C and 37 °C and subsequently reacted with DBCO-Cy5.5 or DBCO-PEG5000, measured at 700 (red) 
and 800 nm (green); C) Coomassie Brilliant Blue staining of NTR reacted with 2-PCA 8; D) The NTR 
modification using 0 or 1000 equiv. 2-PCA 9 was performed at 4 °C and subsequently reacted with DBCO-
Cy5.5 or DBCO-PEG5000, measured at 700 (red) and 800nm (green); E) Coomassie Brilliant Blue staining 
of NTR reacted with 2-PCA 9.  
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PEG tail. Incubating NTR with 2-PCA 9 at 4 °C followed by cycloaddition to DBCO-Cy5.5, 
provided a fluorescent signal for the modified NTR as expected (Figure 2D). Unfortunately, 
cycloaddition using DBCO-PEG5000 (Figure 2E) did not result in a protein shift as evidenced by 
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To test whether the reaction conditions of the N-terminal modification of NTR altered the 
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CCP(CNBz) and monoclonal ACPA in a similar ELISA assay as described in Chapter 2. Besides 
using unmodified NTR, we tested all conditions, such as different incubation temperatures and 2-
PCA equivalents added, described earlier. The ELISA data showed that the enzyme was stable as 
there was no significant difference observed between the different incubation temperatures and 2-
PCA concentrations (Figure 3).  
 
 
Figure 3. Activity of modified NTR. The activity was tested by studying the deprotection efficiency of 
NTR on the CCP(CNBz) in ELISA. Non-patterned bars are negative controls (no 2-PCA) of NTR for 
each condition, dashed bars depict NTR reacted with 100 equiv. of 2-PCA azide and the horizontal striped 
bars corresponds to 1000 equiv. of 2-PCA azide. 
 
Next, we aimed to conjugate the anti-CD20 Fab fragment to one of the two different selectively 
modified NTR enzymes, with or without PEG chain. The Fab fragments with a LAETG and a 
histidine tag were produced using a hybridoma cell line. Fab fragments were excreted by cells and 
collected, after which they were purified by nickel affinity chromatography. The LAETG tag of 
the Fab fragments can be used in a sortase reaction. A sortase reaction using GGG-DBCO was 
performed at 4 °C for 24 h in sortase buffer (PBS + 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 
mM CaCl2). The strain promoted alkyne azide cycloaddition (SPAAC) between the Fab fragment 
and NTR was carried out overnight at 4 °C. The results were analyzed on SDS-PAGE gel (Figure 
4).  
We evaluated the results by non-reducing SDS-PAGE, so the heavy chain and the light chain of 
the Fab fragment remained connected. This simplifies the analysis as the molecular weight of both 
heavy and light chain is approximately 25.000 Da, similar to that of NTR. To test the reactivity of 
the DBCO on the Fab fragment, we reacted this with N3-PEG5000. In the third lane, a band shift 
was seen indicating the reaction between the Fab fragment and the PEG chain, meaning that the 
DBCO was active. Next, both modified NTRs were reacted and analyzed, but no reaction was 
observed. 
Up to this point, the modification of NTR was inefficient and the following cycloaddition with 
the DBCO-modified Fab fragment was unsuccessful. As the described cycloadditions were 
performed at 4 °C overnight, it would be interesting to investigate other conditions such as an 
increased temperature or reaction time.  
 
 
Figure 4. Analysis of SPAAC reactions with NTR and anti-CD20 Fab. Figure shows a SDS-PAGE gel 
under non-reducing conditions, to leave the heavy chain (HC) and light chain (LC) connected, of 8 or 9 
modified NTR reacted with anti-CD20 Fab-DBCO. Anti-CD20-His is shown in the first lane. The Fab 
fragment conjugated to DBCO is shown in the other lanes. Third lane shows the cycloaddition with 
N3PEG5000, in the fourth lane N3-NTR is added, in the fifth lane N3-PEG-NTR is added and in the final 
lane unmodified NTR is added. Gel was stained with Coomassie Brilliant Blue. 
 
Alternatively, another N-terminal modification strategy could be explored. Jensen et al. recently 
reported a general method for highly selective N-terminal acylation of proteins using 4-
methoxyphenyl esters as acylating agents.5 The authors showed that a N-terminal His tag, with the 
optimized sequence of GHHHn, was useful for these reactions. As the His-purification tag is often 
used to purify recombinant proteins, this labeling method could be applied to these proteins. For 
our research, NTR expressed with a N-terminal His-tag may be modified using 4-methoxyphenyl 
2-azidoacetate to yield the specific azide modification selectively on the N-terminus of NTR 
(Figure 5). 
 
Figure 5. N-terminal His tag acylation of Gly-Hisn-protein sequences. 4-Methoxyphenyl 2-azidoacetate 
acylation yields the N-terminal azide-labeled protein. This azide can subsequently be used in a SPAAC 
reaction. Protein depicted is enhanced green fluorescent protein. 
 
Lastly, to circumvent a chemical N-terminal modification procedure, it would be interesting to 
clone NTR containing a GGG-sortase motif directly at the N-terminus. As such, the NTR and the 
Fab fragment can be conjugated in one step using Sortase. It has to been seen if ligating these two 
proteins using the sortase approach is feasible, although the results of previous studies indicate 
that this could be achieved.6, 7 
 
Mono-functionalized iminosydnone caged antigen peptides. In Chapter 3 we described a 
strategy to retain antigen binding by introducing an iminosydnone at the citrulline side chain in 
CCP. We showed that activation of the antigen could be achieved via a click-to-release approach 
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CCP(CNBz) and monoclonal ACPA in a similar ELISA assay as described in Chapter 2. Besides 
using unmodified NTR, we tested all conditions, such as different incubation temperatures and 2-
PCA equivalents added, described earlier. The ELISA data showed that the enzyme was stable as 
there was no significant difference observed between the different incubation temperatures and 2-
PCA concentrations (Figure 3).  
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NTR on the CCP(CNBz) in ELISA. Non-patterned bars are negative controls (no 2-PCA) of NTR for 
each condition, dashed bars depict NTR reacted with 100 equiv. of 2-PCA azide and the horizontal striped 
bars corresponds to 1000 equiv. of 2-PCA azide. 
 
Next, we aimed to conjugate the anti-CD20 Fab fragment to one of the two different selectively 
modified NTR enzymes, with or without PEG chain. The Fab fragments with a LAETG and a 
histidine tag were produced using a hybridoma cell line. Fab fragments were excreted by cells and 
collected, after which they were purified by nickel affinity chromatography. The LAETG tag of 
the Fab fragments can be used in a sortase reaction. A sortase reaction using GGG-DBCO was 
performed at 4 °C for 24 h in sortase buffer (PBS + 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 
mM CaCl2). The strain promoted alkyne azide cycloaddition (SPAAC) between the Fab fragment 
and NTR was carried out overnight at 4 °C. The results were analyzed on SDS-PAGE gel (Figure 
4).  
We evaluated the results by non-reducing SDS-PAGE, so the heavy chain and the light chain of 
the Fab fragment remained connected. This simplifies the analysis as the molecular weight of both 
heavy and light chain is approximately 25.000 Da, similar to that of NTR. To test the reactivity of 
the DBCO on the Fab fragment, we reacted this with N3-PEG5000. In the third lane, a band shift 
was seen indicating the reaction between the Fab fragment and the PEG chain, meaning that the 
DBCO was active. Next, both modified NTRs were reacted and analyzed, but no reaction was 
observed. 
Up to this point, the modification of NTR was inefficient and the following cycloaddition with 
the DBCO-modified Fab fragment was unsuccessful. As the described cycloadditions were 
performed at 4 °C overnight, it would be interesting to investigate other conditions such as an 
increased temperature or reaction time.  
 
 
Figure 4. Analysis of SPAAC reactions with NTR and anti-CD20 Fab. Figure shows a SDS-PAGE gel 
under non-reducing conditions, to leave the heavy chain (HC) and light chain (LC) connected, of 8 or 9 
modified NTR reacted with anti-CD20 Fab-DBCO. Anti-CD20-His is shown in the first lane. The Fab 
fragment conjugated to DBCO is shown in the other lanes. Third lane shows the cycloaddition with 
N3PEG5000, in the fourth lane N3-NTR is added, in the fifth lane N3-PEG-NTR is added and in the final 
lane unmodified NTR is added. Gel was stained with Coomassie Brilliant Blue. 
 
Alternatively, another N-terminal modification strategy could be explored. Jensen et al. recently 
reported a general method for highly selective N-terminal acylation of proteins using 4-
methoxyphenyl esters as acylating agents.5 The authors showed that a N-terminal His tag, with the 
optimized sequence of GHHHn, was useful for these reactions. As the His-purification tag is often 
used to purify recombinant proteins, this labeling method could be applied to these proteins. For 
our research, NTR expressed with a N-terminal His-tag may be modified using 4-methoxyphenyl 
2-azidoacetate to yield the specific azide modification selectively on the N-terminus of NTR 
(Figure 5). 
 
Figure 5. N-terminal His tag acylation of Gly-Hisn-protein sequences. 4-Methoxyphenyl 2-azidoacetate 
acylation yields the N-terminal azide-labeled protein. This azide can subsequently be used in a SPAAC 
reaction. Protein depicted is enhanced green fluorescent protein. 
 
Lastly, to circumvent a chemical N-terminal modification procedure, it would be interesting to 
clone NTR containing a GGG-sortase motif directly at the N-terminus. As such, the NTR and the 
Fab fragment can be conjugated in one step using Sortase. It has to been seen if ligating these two 
proteins using the sortase approach is feasible, although the results of previous studies indicate 
that this could be achieved.6, 7 
 
Mono-functionalized iminosydnone caged antigen peptides. In Chapter 3 we described a 
strategy to retain antigen binding by introducing an iminosydnone at the citrulline side chain in 
CCP. We showed that activation of the antigen could be achieved via a click-to-release approach 
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using DBCO. After attachment of the MMAE toxin, with the aim to induce receptor-mediated 
cell death, we observed that the cytotoxicity was not dependent on the antigen. This result suggests 
that the use of a monovalent antigen-drug conjugate is insufficient to induce receptor 
internalization or that MMAE is unsuitable for inducing apoptosis in immortalized B cells.  
In Chapter 1 we reviewed research describing an approach to eliminate plasma cells using an 
affinity matrix (AM, Figure 6). This AM is an antibody-mediated coating of the surface of plasma 
cells with an autoantigen of interest. The secreted antibodies by the plasma cells are in close 
proximity of the AM antigen thereby binding directly onto the AM surface. As a result, the 
complement system is activated and the plasma cells are terminated via complement-mediated 
lysis.8 Anti-CD138 and anti-CD44 have already been used as antibody mediator for targeting the 
antigen of interest to the surface of plasma cells and it was shown that specific autoreactive long-
lived plasma cells were successfully depleted in vitro using this strategy.9  
A potential limitation of this approach in vivo is the presence of circulating autoantibodies. These 
antibodies may bind nonspecifically to the AM of protective plasma cells thereby inducing 
unwanted cytotoxicity.10 The authors suggest that this can be circumvented by the removal of these 
autoantibodies using plasma exchange or immunoadsorption. As this will be unpleasant for 
patients, they suggest otherwise to carefully titrate the affinity matrix, since plasma cells are spread 
throughout the bone marrow, but separated in niches.10 We suggest that by using our CCP-
iminosydnone caging strategy, we have the ability to circumvent binding of circulating 
autoantibodies to CCP before binding to the ACPA-producing plasma cells. The caged CCP is 
first localized to the plasma cell membrane, using for example an anti-CD138 directing antibody 
(Figure 6A), before DBCO is added. The autoantigens are protected from circulating antibodies 
and are mainly captured by the autoantibodies secreted by the autoreactive plasma cell due to 
increased local concentration (Figure 6B).  
 
 
Figure 6. Targeting of autoreactive long-lived plasma cells. A) Anti-CD138 is targeted to the cell membrane 
of an autoreactive plasma cell together with the iminosydnone-caged autoantigen. This conjugate cannot 
be cleared in circulation by autoreactive antibodies, due to the iminosydnone-caging group. As soon as 
plasma cells are coated with the caged autoantigen, DBCO can react and release the activated autoantigen; 
B) The autoantibodies secreted by the plasma cells are available in high local concentrations and will bind 
to the plasma cells own membrane after which the complement is activated. Due to complement-mediated 
lysis, this autoreactive plasma cell will be depleted whereas protective plasma cells, which do not secrete 
autoantibodies, will not be coated and hence not be lysed. 
 
Dual-functionalized iminosydnone caged antigen peptides. Recently, Bernard et al. reported 
the use of iminosydnones as a cleavable linker between an antibody and a fluorophore or a biotin 
moiety.11 Hence, they showed that after adding a DBCO, the linkage between two compounds was 
broken.  
To not only target the plasma cells, but also the memory B cells, a strategy in which a dual 
functionalized iminosydnone acts as a cleavable bridge between the CCP antigen peptide and an 
anti-CD20 Fab fragment was introduced in Chapter 3. Based on the strategy of Bernard et al., we 
envisioned that we could link the anti-CD20 Fab fragment using this iminosydnone to the CCP 
peptide. However, as we suspect that monovalent antigen binding to the BCR is not sufficient to 
induce receptor internalization, we propose a strategy to attach a biotin to CCP(Im) and link this 
Fab-CCP to streptavidin-toxin (such as saporin, a ribosome inactivator) conjugate (Figure 7). We 
have shown in Chapter 2 that such a construct can successfully induce antigen-selective cell death.  
 
 
Figure 7. Schematic representation of B cell targeting using the Fab-iminosydnone-CCP-SA conjugate. A) 
Antigen activation mechanism. The cycloaddition of the iminosydnone with DBCO results in a retro-Diels 
Alder reaction creating an isocyanate in situ at the citrulline side chain. When water reacts with this 
isocyanate this results in an instable carbamoyl carbamate. Liberation of CO2 restores the urea side chain 
of citrulline; B) Schematic representation of the targeting strategy. The Fab targets CD20 on the B cell 
membrane. Since the iminosydnone both binds and blocks the CCP peptide, this antigen is already localized 
to the B cell surface. If now DBCO is added, liberation of CCP-SA-ZAP can be bound to the neighboring 
BCR and be internalized, after which apoptosis is induced. 
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using DBCO. After attachment of the MMAE toxin, with the aim to induce receptor-mediated 
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In Chapter 1 we reviewed research describing an approach to eliminate plasma cells using an 
affinity matrix (AM, Figure 6). This AM is an antibody-mediated coating of the surface of plasma 
cells with an autoantigen of interest. The secreted antibodies by the plasma cells are in close 
proximity of the AM antigen thereby binding directly onto the AM surface. As a result, the 
complement system is activated and the plasma cells are terminated via complement-mediated 
lysis.8 Anti-CD138 and anti-CD44 have already been used as antibody mediator for targeting the 
antigen of interest to the surface of plasma cells and it was shown that specific autoreactive long-
lived plasma cells were successfully depleted in vitro using this strategy.9  
A potential limitation of this approach in vivo is the presence of circulating autoantibodies. These 
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unwanted cytotoxicity.10 The authors suggest that this can be circumvented by the removal of these 
autoantibodies using plasma exchange or immunoadsorption. As this will be unpleasant for 
patients, they suggest otherwise to carefully titrate the affinity matrix, since plasma cells are spread 
throughout the bone marrow, but separated in niches.10 We suggest that by using our CCP-
iminosydnone caging strategy, we have the ability to circumvent binding of circulating 
autoantibodies to CCP before binding to the ACPA-producing plasma cells. The caged CCP is 
first localized to the plasma cell membrane, using for example an anti-CD138 directing antibody 
(Figure 6A), before DBCO is added. The autoantigens are protected from circulating antibodies 
and are mainly captured by the autoantibodies secreted by the autoreactive plasma cell due to 
increased local concentration (Figure 6B).  
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of an autoreactive plasma cell together with the iminosydnone-caged autoantigen. This conjugate cannot 
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envisioned that we could link the anti-CD20 Fab fragment using this iminosydnone to the CCP 
peptide. However, as we suspect that monovalent antigen binding to the BCR is not sufficient to 
induce receptor internalization, we propose a strategy to attach a biotin to CCP(Im) and link this 
Fab-CCP to streptavidin-toxin (such as saporin, a ribosome inactivator) conjugate (Figure 7). We 
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As described above, an anti-CD20 Fab fragment containing a LAETG sortase tag was produced. 
We envision that we can conjugate a triple-Gly peptide containing an azide to the Fab fragment 
using sortase. Using this azide, we can react the Fab fragment with an alkyne attached to the 
iminosydnone-CCP and hence conjugate the iminosydnone-CCP to the Fab fragment.  
Our initial efforts to prepare a cleavable iminosydnone-containing linker are described. We aimed 
to introduce an alkyne handle for future conjugation as shown in Scheme 2, by following part of 
the synthetic route of the iodosydnone described by Bernard et. al.11  
 
 
Scheme 2. Reaction scheme for the synthesis of Fmoc-Cit(ImAlk)-OH (20). A) Synthesis of iminosydnone 
(17). i) chloroacetonitrile, acetonitrile, NaI, K2CO3, under Ar, 3 days, reflux, 82%; ii) amyl nitrite, dry THF, 
2 h, r.t.; ii) 4M HCl in dioxane, overnight, r.t., 95% over two steps; iv) Boc2O, NaHCO3, DMAP, dry THF, 
70 h, 0 °C   r.t., 59%; v) PdCl2(PPh3)2, EtOH, CO atmosphere, 2.5 h, 60 °C, 65%; vi) LiOH·H2O, 
THF/H2O, 2.5 h, r.t., 92%; vii) propargylamine, HATU, DIPEA, DMF, 2 h, r.t., 58%; viii) TFA/DCM 
(1:1), 4 h, r.t., 80%; B) Ornithine modification and Fmoc-Cit(ImAlk)-OH (20) synthesis. i) tert-butyl 2,2,2-
trichloroacetimidate, BF3 etherate, THF/hexane (1:1), overnight, 0 °C  r.t.; ii) Pd/C, H2, MeOH, 2 h, r.t., 
80% over two steps; iii) 1. triphosgene, sat. NaHCO3/DCM (1:1), 10 min, 0 °C; 2. 17 was added, 3 h, 0 °C, 
18% yield; iv). TFA/DCM (1:1), 2 h, r.t., quant.  
 
First, iodoaniline was reacted with chloroacetonitrile to obtain the nitrile product 10 in good yield. 
Next, iodophenylacetonitrile (10) was reacted in two steps; first with isoamyl nitrite and next with 
4M HCl in dioxane to induce ring closure to obtain iodosydnone 12. The free amine was protected 
with a Boc group, after which the iodide was reacted with ethanol and PdCl2(PPh3)2 under a CO 
atmosphere. The resulting ethyl ester (14) was hydrolyzed to the corresponding acid using LiOH. 
Next, propargylamine was reacted with the carboxylic acid (15) to form an amide bond and to 
attach a handle for a Cu-catalyzed Azide−Alkyne Cycloaddition (CuAAC). After Boc deprotection 
using TFA, iminosydnone 17 could be attached to ornithine. First, Fmoc-Orn(Cbz)-OH was tert-
butyl-protected on the free carboxylic acid. Then, Pd/C and H2 were used to deprotect the Cbz 
group. This modified ornithine 18 was treated with triphosgene before iminosydnone 17 was 
added. After the reaction and purification, the tert-butyl group of the ornithine was removed to 
yield the citrulline-iminosydnone 20. 
We next used Fmoc-Cit(ImAlk)-OH (20) in solid phase peptide synthesis (SPPS) to prepare 
CCP(ImAlk). No difficulties were observed during the synthesis, although we were not able to 
isolate the desired peptide using preparative HPLC. The mass value corresponding to the desired 
caged peptide was observed, but in a very small amount. Since we confirmed the stability of the 
building block under several conditions, including those used for general SPPS, peptide cyclization 
and the cleavage mixture for SPPS, we cannot explain why the synthesis of the CCP(ImAlk) was 
not successful. 
 
 
Figure 8. Overview of the targeting Fab-iminosydnone-CCP construct consisting of CCP conjugated to 
streptavidin-ZAP and caged by an iminosydnone linked anti-CD20 Fab fragment. R1 shows the Fab 
conjugation by first reacting the azide functionalized iminosydnone with the GGG-alkyne, and finally the 
conjugation to the anti-CD20 Fab fragment using sortase. R2 depicts the conjugation to streptavidin-ZAP.  
 
Bernard and coworkers showed recently that they were able to synthesize an iminosydnone 
containing an azide and that this modified iminosydnone could be used in CuAAC for antibody 
conjugation.11 Hence, future efforts should be directed to the synthesis of an azide-containing 
citrulline amino acid. Additionally, we aim to synthesize a triple-Gly peptide containing an alkyne 
154
Chapter 7
529590-L-bw-Lelieveldt
Processed on: 13-3-2019 PDF page: 155
7
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Figure 8. Overview of the targeting Fab-iminosydnone-CCP construct consisting of CCP conjugated to 
streptavidin-ZAP and caged by an iminosydnone linked anti-CD20 Fab fragment. R1 shows the Fab 
conjugation by first reacting the azide functionalized iminosydnone with the GGG-alkyne, and finally the 
conjugation to the anti-CD20 Fab fragment using sortase. R2 depicts the conjugation to streptavidin-ZAP.  
 
Bernard and coworkers showed recently that they were able to synthesize an iminosydnone 
containing an azide and that this modified iminosydnone could be used in CuAAC for antibody 
conjugation.11 Hence, future efforts should be directed to the synthesis of an azide-containing 
citrulline amino acid. Additionally, we aim to synthesize a triple-Gly peptide containing an alkyne 
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for conjugation to the CCP using CuAAC. Next, the GGG-modified CCP should be conjugated 
to the Fab fragment using sortase. Finally, to create a multivalent structure these Fab-antigen 
conjugates can be linked to streptavidin-ZAP as used in Chapter 2 (Figure 8). 
A limitation of the proposed strategy above, is that the Fab fragment and the CCP antigen peptide 
are directly linked and hence dual binding of both the Fab fragment and the antigen to the B cell, 
which would create a multivalent binding interaction, is hampered. Thereby, at least two 
iminosydnones should be deprotected to create a multivalent interaction with the BCR. Finally, a 
stoichiometric amount of DBCO is needed for antigen activation. In order to activate the antigen 
locally, high concentrations of DBCO might have to be administered to achieve this. So far, the 
maximum non-toxic dose of DBCO is not known.  
 
Use of DBCO-loaded cryogels for high local concentration of peptide antigens. Besides 
administering an excess of DBCO for local activation of caged antigens, we envision that DBCO 
can be localized to a specific inflamed region. One example is by using injectable hydrogels, for 
example using methacrylated (MA)-alginate cryogels,12 which are filled with DBCO. 
A cryogel is a hydrogel which is produced at subzero temperatures and used in many biomedical 
applications.12 These cryogels have pores that are produced by growing ice crystals. By melting of 
these crystals, a macroporous network is formed with enhanced mechanic stability.13 Cryogels used 
in cancer vaccination are made from alginate, which is a natural polymer that has been used in 
several applications, including drug delivery, cell delivery and tissue engineering.12 By crosslinking 
alginate, combining covalent and ionic bonds, a tough network is created. Upon compression the 
weaker ionic crosslinks will reversibly break, hence the tough MA-alginate cryogels can be used 
for needle-injections without sustaining damage.14 These cryogels loaded with tumor antigens are 
already in use and after implantation of these bio-based materials, dendritic cells are attracted and 
become activated after which they home to draining lymph nodes and present the antigen to T 
cells. This will subsequently lead to an anti-tumor response of the T cells. The release of large 
molecules, like proteins, from cryogels is often dependent on the diffusion rate, which is estimated 
to be between a few hours and a day.15 
If a cryogel linked to DBCO is locally injected into inflamed tissue with a high number of effector 
cells, or to the lymph nodes, it can locally activate iminosydnone-caged antigens (Figure 9). This is 
different from a local injection of DBCO alone, which would diffuse from the site of interest. This 
difference was shown for vascular endothelial growth factor (VEGF), which has been locally 
delivered in ischemic murine hindlimbs over a time of 15 days using alginate hydrogels, whereas 
all VEGF was already deprived after 72 hours with a direct injection.16  
The CCP antigens do not have to be administered locally, but will stay inactive until reaching the 
site of interest. The local induction of antigen-activation and thereby possible BCR binding for 
toxin uptake (Figure 9B) will decrease off-site activation of the antigen-drug conjugate. If small 
molecules are embedded in the gel and the release would be diffusion-dominated, all drugs would 
be released in a very short time period. Hence cleavable covalent linkages, including ester bonds 
or disulfide bonds, prolongs the drug release property.15  
There is no enzyme in humans or animals than can degrade alginate.12 Hence biodegradability 
may become an issue. Alternative to the MA-alginate, hyaluronic acid (HA) can be of interest. 
High molecular weight HA was used as a material for local regulation of wound healing and 
inflammatory response when conjugated to a cytokine-neutralizing antibody.17  
 
Figure 9. DBCO-containing hydrogel. A) DBCO (purple octagon) is linked to a hydrogel and can be 
injected locally; B) CCP(Im)-toxin (CCP - blue circle, Im – orange square, toxin – yellow star) is 
administered and only activated close to the hydrogel. Since the hydrogel will be injected in the inflamed 
tissue or lymph nodes, autoreactive B cells will be present and are targeted. A monovalent peptide is only 
depicted for clarity. 
 
Functionalization possibilities of multivalent PICs. In Chapter 5 we showed that PIC 
polymers can be used successfully to bind ACPA-expressing B cells comparably to the SA 
control.18 We further showed that not all, if any, PICs were internalized when incubated with the 
ACPA-expressing B cells at 37 °C for 1 hour.  
An advantage of using PIC over SA is that there are multiple sites available for cargo conjugation. 
For example, besides adding an antigen, we may conjugate a fluorophore for imaging purposes 
and/or a toxin to induce cell death. In order to decide on the most optimal cargo to induce antigen-
selective cell death, whether the cargo should either be effective inside the cell or on the cell 
surface, we should further characterize the binding and internalization behavior of PICs. We need 
to investigate at multiple time points and concentrations if PICs indeed remain on the cell surface, 
or are internalized under specific experimental conditions. 
The PIC polymer that we tested in Chapter 5 is approximately 400 nm in length. Although this 
polymer seems not to be internalized by B cells, it is possible that polymers being shorter in length 
can be internalized. Hence, it is interesting to test different polymer lengths for this purpose. The 
PIC polymers have to be internalized in case a potent toxin, like monomethyl auristatin E (MMAE, 
Chapter 3), is used to induce antigen specific cell death. The advantage of PICs that are not 
internalized is that external signals may be attached to induce cell death. Similar to Siglec-engaging 
tolerance-inducing antigenic liposomes (STALs, see Chapter 1 and Figure 10A), a CD22 ligand, 
dampening the function of B cells by binding to glycoprotein CD22, can be attached adjacent to 
the autoantigen onto the PIC.19 Previously, CD22 ligands with a 200-fold higher affinity than 
natural ligands were conjugated to STALs together with an autoantigen. Macauley et al. described 
that immunization of mice with these STALs showed a dramatically lower antibody response to 
the autoantigens than when immunogenic liposomes were used. They showed that tolerance 
induction was intrinsic to depletion of B cells, due to CD22-dependent apoptosis.19 By introducing 
an autoantigen, antigen-selective B cell signaling was inhibited. Unilamellar liposomes, however, 
are spherical structures with a lower surface area to volume ratio and the number of recognition 
domains (like antigens or ligands) participating simultaneously in interaction with a surface is 
therefore limited.20 Due to the higher surface to volume ratio and the semi-stiff characteristics of 
the PIC polymers, they may be more useful than liposomes because of the possibility of shaping 
around the cell surface to optimize receptor binding (Figure 10B). Indeed, it has been shown for 
the PICs that the combination of multivalency and an optimal flexible shape for interactions is 
beneficial.21 
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The PIC polymer that we tested in Chapter 5 is approximately 400 nm in length. Although this 
polymer seems not to be internalized by B cells, it is possible that polymers being shorter in length 
can be internalized. Hence, it is interesting to test different polymer lengths for this purpose. The 
PIC polymers have to be internalized in case a potent toxin, like monomethyl auristatin E (MMAE, 
Chapter 3), is used to induce antigen specific cell death. The advantage of PICs that are not 
internalized is that external signals may be attached to induce cell death. Similar to Siglec-engaging 
tolerance-inducing antigenic liposomes (STALs, see Chapter 1 and Figure 10A), a CD22 ligand, 
dampening the function of B cells by binding to glycoprotein CD22, can be attached adjacent to 
the autoantigen onto the PIC.19 Previously, CD22 ligands with a 200-fold higher affinity than 
natural ligands were conjugated to STALs together with an autoantigen. Macauley et al. described 
that immunization of mice with these STALs showed a dramatically lower antibody response to 
the autoantigens than when immunogenic liposomes were used. They showed that tolerance 
induction was intrinsic to depletion of B cells, due to CD22-dependent apoptosis.19 By introducing 
an autoantigen, antigen-selective B cell signaling was inhibited. Unilamellar liposomes, however, 
are spherical structures with a lower surface area to volume ratio and the number of recognition 
domains (like antigens or ligands) participating simultaneously in interaction with a surface is 
therefore limited.20 Due to the higher surface to volume ratio and the semi-stiff characteristics of 
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Figure 10. The influence of multivalent structures containing CD22 ligand and CCP on BCR-signaling in 
autoreactive B cells. A) Schematic representation of CCP-STALs; B) Schematic representation of PIC-
containing CCP and CD22 ligand.  
 
Since the PICs are known to be semi-flexible,21 they might facilitate the clustering of receptors. A 
receptor of interest, is the Fas receptor (CD95). The Fas receptor is involved in the regulation of 
apoptosis. Apoptosis induced by the interaction between Fas and Fas ligand (FasL, a cell surface 
molecule belonging to the tumor necrosis factor family) is the main route by which unwanted 
lymphocytes are eliminated during lymphocyte development and in the course of an immune 
response.22, 23 Also, cytotoxic T cells express FasL when activated to induce apoptosis of the target 
cell (for example, virus-infected cells or tumor cells).24 Activation of mature B cells causes 
expression of Fas and the cells become sensitive to Fas-mediated killing.25 It was shown before 
that an antibody to human Fas resulted in apoptosis of transformed mouse cells in 5 hours, 
indicating that this anti-Fas antibody works as an agonist.24 This anti-Fas or FasL can be attached 
to PICs together with autoantigens to induce antigen-selective apoptosis (Figure 11).  
Fas can also be activated by FasL, a protein with a molecular weight of 40 kDa, in solution 
(released from cell surfaces after cleavage by metalloproteinases).24 Large proteins have already 
been attached to the PIC polymers and showed to be functional.21 Hence we envision, that the 
conjugation of FasL to PIC together with the CCP antigen peptides allows for the antigen-selective 
induction of Fas trimerization on autoreactive B cells, followed by the initiation of apoptosis. 
 
 
Figure 11. Fas activation using PIC loaded with CCP and FasL. A) PIC is targeted towards the BCR by 
multivalent CCP binding; B) The Fas receptor is trimerized due to multiple ligands in the close proximity 
of the B cell membrane. This activation leads to antigen specific cell death. 
 
7.3 Concluding remarks 
 
In this thesis, we introduced several autoreactive B cell targeting strategies making use of ACPA 
autoantigens. By caging and selective activation of autoantigens, we showed that we can direct 
binding to the BCR. By developing a peptide for anti-CarP antibodies, we showed that the 
activation strategy is adoptable to other (homo)citrulline containing antigens, a feature which is 
important in RA, since autoantibodies recognizing varying antigens are in play. We showed that 
besides an enzymatic approach, a chemical click-to-release strategy may be used for caging and 
activation purposes. It was evident that a monovalent structure was not sufficient to induce BCR 
internalization and subsequent cytotoxicity. We showed that PIC scaffolds bind comparably to a 
specific BCR as a SA scaffold, but that it shows less background binding and there are more 
handles to modify. We further developed a new click-to-release reaction based on VBA tetrazine 
ligation, which can be further developed for antigen activation applications. 
The outlook and scope of the development of a new RA targeting strategy is promising. We 
showed that our caging and activation strategies can be applicable to several autoantigens for both 
human and mice serum in vitro and the next step will be to test this on B cells and finally in a mouse 
model. Using the anti-CarP antigen peptides, we observed that the caging and activation strategies 
can be used interchangeably between citrulline and homocitrulline. Although NTR is needed to 
activate the antigen in the strategy used for anti-CarP, which might be troublesome in vivo, we also 
expect that the click-to-release activation strategy will be possible for this antigen. We might, 
however, first need more information about the cytotoxicity of DBCO and the best way to achieve 
local antigen activation to continue this strategy. Doing so brings us another step closer to an 
effective and selective therapy towards autoreactive B cells in RA. 
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7.5 Materials and methods 
 
For general methods, see the materials and methods Section of Chapter 2 (paragraph 2.4). 
 
2,5-Dioxopyrrolidin-1-yl 2-azidoacetate (3). To a solution of 2-azido acetic acid (200 mg, 2.0 
mmol, 1.0 equiv.) in dry DCM (10 mL), N-hydroxysuccinamide (273 mg, 2.4 
mmol, 1.2 equiv.) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (455 mg, 2.4 mmol, 1.2 equiv.) were added and the reaction 
mixture was stirred at r.t. for 17 h. The reaction mixture was washed with H2O 
and brine, and dried over Na2SO4. Volatiles were removed under reduced pressure. The residue 
was purified by silica gel column chromatography (0-25% EtOAc in heptane) to yield title 
compound 3 as a white solid (274 mg, 1.4 mmol, 70%). Rf = 0.25 (EtOAc/heptane 1:1); IR (film) 
2113, 1818, 1786, 1736, 1426, 1366, 1283, 1202, 1095, 1066, 811, 647 cm-1; 1H NMR (400 MHz, 
chloroform-d) δ 4.24 (s, 2H), 2.88 (s, 4H). 13C NMR (126 MHz, chloroform-d) δ 168.40, 164.14, 
47.99, 25.56. Mass could not be found. 
 
2,5-Dioxopyrrolidin-1-yl 14-azido-3,6,9,12-tetraoxatetradecanoate (4). A solution of 14-
Azido-3,6,9,12-tetraoxatetradecanoic acid (50 mg, 0.18 
mmol, 361 µl, 1.0 equiv.) in tBME was added to dry 
DCM (2.5 mL). N-hydroxysuccinamide (25 mg, 0.22 
mmol, 1.2 equiv.) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (42 mg, 
0.22 mmol, 1.2 equiv.) were added and the reaction mixture was stirred at r.t. for 17 h. The reaction 
mixture was washed with H2O and brine, and dried over Na2SO4. Volatiles were removed under 
reduced pressure. The residue was purified by silica gel column chromatography (50-60% EtOAc 
in heptane) to yield title compound 4 as a white solid (44 mg, 0.12 mmol, 65%). Rf = 0.29 (60% 
EtOAc in heptane); IR (film) 2873, 2103, 1819, 1786, 1736, 1431, 1352, 1301, 1203, 1070, 814, 
648, 558 cm-1; 1H NMR (400 MHz, chloroform-d) δ 4.51 (s, 2H), 3.81 – 3.76 (m, 2H), 3.69 (dd, J 
= 4.0, 1.8 Hz, 2H), 3.68 – 3.66 (m, 2H), 3.65 (s, 8H), 3.40 – 3.35 (m, 2H), 2.84 (s, 4H). 13C NMR 
(101 MHz, chloroform-d) δ 171.95, 168.96, 166.13, 71.42, 70.75, 70.71, 70.63, 70.10, 66.62, 50.78, 
25.69, 25.48. Mass could not be found. 
 
6-(Hydroxymethyl)picolinaldehyde (5). 2,6-Pyridinedimethanol (500 mg, 3.6 mmol, 1.0 equiv.) 
and SeO2 (200 mg, 1.8 mmol, 0.5 equiv.) were added to a Schlenk tube and put 
under N2. 1,4-Dioxane (10 mL, not degassed or dried) was added, the mixture 
was sonicated for 2 min and then stirred at 65 °C for 24 h. After the mixture 
was cooled to r.t., it was diluted with DCM and filtered over celite. Then, the 
volatiles were removed under reduced pressure and the product was purified with column 
chromatography (2.5% MeOH in DCM) yielding aldehyde 5 (405 mg, 82%) as a slightly yellow oil. 
Rf = 0.17 (2.5% MeOH in DCM). 1H NMR (400 MHz, chloroform-d) δ 10.09 (s, 1H), 7.93 – 7.83 
(m, 2H), 7.56 – 7.47 (m, 1H), 4.88 (s, 2H). 13C NMR (100 MHz, chloroform-d) δ 193.2, 160.2, 
151.8, 137.9, 124.9, 120.6, 64.2. LRMS (ESI+) m/z calcd. for C7H7NNaO2+ [M+Na]+ 138.1, found: 
138.0. The obtained data agrees with literature.4 
 
(6-Formylpyridin-2-yl)methyl methanesulfonate (6). Alcohol 5 (350 mg 2.6 mmol, 1.0 equiv.) 
was dissolved in dry DCM, the solution was cooled to 0 °C and Et3N (1.1 mL, 
7.7 mmol, 3.0 equiv.) was added. Then, MsCl (237 µL, 3.1 mmol, 1.2 equiv.) 
was added dropwise and the mixture was stirred at r.t. for 30 min. The reaction 
was quenched with sat. NaHCO3, the layers were separated and the aqueous 
layer was extracted with DCM (3 x). The combined organic layers were dried over Na2SO4 and the 
volatiles were removed under reduced pressure. The brown oil was purified with column 
chromatography (60% EtOAc in heptane) yielding methanesulfonate 6 (399 mg, 73%) as a slightly 
yellow solid. Rf = 0.35 (EtOAc/heptane, 3:2). 1H NMR (400 MHz, chloroform-d) δ 10.05 (s, 1H), 
7.98 – 7.92 (m, 2H), 7.74 – 7.69 (m, 1H), 5.42 (s, 2H), 3.14 (s, 3H). 13C NMR (100 MHz, 
chloroform-d) δ 192.8, 154.8, 152.6, 138.5, 126.5, 121.7, 70.8, 38.2. LRMS (ESI+) m/z calcd. for 
C8H10NO4S+ [M+H]+ 216.0, found: 216.1. The obtained data agrees with literature.4 
 
tert-Butyl 4-((6-formylpyridin-2-yl)methyl)piperazine-1-carboxylate (7). Methanesulfonate 6 
(370 mg, 1.7 mmol, 1.0 equiv.) was dissolved in dry MeCN (10 mL) and 
1-Boc-piperazine (384 mg, 2.0 mmol, 1.2 equiv.) and K2CO3 (475 mg, 3.4 
mmol, 2.0 equiv.) were added. The mixture was stirred at 60 °C for 16 h, 
whereupon the solvent was evaporated. DCM and sat. NaHCO3 were 
added, the layers were separated and the aqueous layer was extracted with DCM (3 x). The 
combined organic layers were dried over Na2SO4 and the volatiles were removed using a rotary 
evaporator. Then, the product was purified using column chromatography (80% EtOAc in 
heptane) yielding tertiary amine 7 (456 mg, 87%) as a white solid. Rf = 0.26 (EtOAc/heptane, 4:1). 
1H NMR (400 MHz, chloroform-d) δ 10.07 (s, 1H), 7.88 – 7.82 (m, 2H), 7.73 – 7.66 (m, 1H), 3.77 
(s, 2H), 3.52 – 3.41 (m, 4H), 2.52 – 2.42 (m, 4H), 1.46 (s, 9H). 13C NMR (100 MHz, chloroform-
d) δ 193.7, 159.6, 154.9, 152.5, 137.6, 127.5, 120.4, 79.9, 64.3, 53.3, 28.6. LRMS (ESI+) m/z calcd. 
for C16H24N3O3+ [M+H]+ 306.2, found: 305.9. The obtained data agrees with literature.4 
 
6-((4-(2-Azidoacetyl)piperazin-1-yl)methyl)picolinaldehyde (8). tert-Butyl 4-((6-
formylpyridin-2-yl)methyl)piperazine-1-carboxylate 7 (25 mg, 82 
µmol, 1.0 equiv.) was dissolved in dry DCM (1 mL) under N2 and 4M 
HCl in dioxane (205 µL, 820 µmol, 10.0 equiv.) was added. The 
mixture was stirred for 2 h, whereupon the volatiles were evaporated. 
The solid was dissolved in DMF (1 mL) and 2,5-dioxopyrrolidin-1-yl 
2-azidoacetate (3) (19 mg, 98 µmol, 1.2 equiv.) was added. Then, Et3N (34 µL, 250 µmol, 3.0 equiv.) 
was added and the solution was stirred for 2 h. The volatiles were evaporated and the product was 
purified using column chromatography (50 to 100% EtOAc in heptane) yielding 2-PCA-N3 8 (19 
mg, 80%) as a white solid. Rf = 0.49 (5% MeOH in EtOAc). IR (film) 2107, 1711, 1657, 1592, 
1457, 1220, 1076, 1000, 788, 655 cm-1. 1H NMR (500 MHz, chloroform-d) δ 10.06 (s, 1H), 7.87 (d, 
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7.5 Materials and methods 
 
For general methods, see the materials and methods Section of Chapter 2 (paragraph 2.4). 
 
2,5-Dioxopyrrolidin-1-yl 2-azidoacetate (3). To a solution of 2-azido acetic acid (200 mg, 2.0 
mmol, 1.0 equiv.) in dry DCM (10 mL), N-hydroxysuccinamide (273 mg, 2.4 
mmol, 1.2 equiv.) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (455 mg, 2.4 mmol, 1.2 equiv.) were added and the reaction 
mixture was stirred at r.t. for 17 h. The reaction mixture was washed with H2O 
and brine, and dried over Na2SO4. Volatiles were removed under reduced pressure. The residue 
was purified by silica gel column chromatography (0-25% EtOAc in heptane) to yield title 
compound 3 as a white solid (274 mg, 1.4 mmol, 70%). Rf = 0.25 (EtOAc/heptane 1:1); IR (film) 
2113, 1818, 1786, 1736, 1426, 1366, 1283, 1202, 1095, 1066, 811, 647 cm-1; 1H NMR (400 MHz, 
chloroform-d) δ 4.24 (s, 2H), 2.88 (s, 4H). 13C NMR (126 MHz, chloroform-d) δ 168.40, 164.14, 
47.99, 25.56. Mass could not be found. 
 
2,5-Dioxopyrrolidin-1-yl 14-azido-3,6,9,12-tetraoxatetradecanoate (4). A solution of 14-
Azido-3,6,9,12-tetraoxatetradecanoic acid (50 mg, 0.18 
mmol, 361 µl, 1.0 equiv.) in tBME was added to dry 
DCM (2.5 mL). N-hydroxysuccinamide (25 mg, 0.22 
mmol, 1.2 equiv.) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (42 mg, 
0.22 mmol, 1.2 equiv.) were added and the reaction mixture was stirred at r.t. for 17 h. The reaction 
mixture was washed with H2O and brine, and dried over Na2SO4. Volatiles were removed under 
reduced pressure. The residue was purified by silica gel column chromatography (50-60% EtOAc 
in heptane) to yield title compound 4 as a white solid (44 mg, 0.12 mmol, 65%). Rf = 0.29 (60% 
EtOAc in heptane); IR (film) 2873, 2103, 1819, 1786, 1736, 1431, 1352, 1301, 1203, 1070, 814, 
648, 558 cm-1; 1H NMR (400 MHz, chloroform-d) δ 4.51 (s, 2H), 3.81 – 3.76 (m, 2H), 3.69 (dd, J 
= 4.0, 1.8 Hz, 2H), 3.68 – 3.66 (m, 2H), 3.65 (s, 8H), 3.40 – 3.35 (m, 2H), 2.84 (s, 4H). 13C NMR 
(101 MHz, chloroform-d) δ 171.95, 168.96, 166.13, 71.42, 70.75, 70.71, 70.63, 70.10, 66.62, 50.78, 
25.69, 25.48. Mass could not be found. 
 
6-(Hydroxymethyl)picolinaldehyde (5). 2,6-Pyridinedimethanol (500 mg, 3.6 mmol, 1.0 equiv.) 
and SeO2 (200 mg, 1.8 mmol, 0.5 equiv.) were added to a Schlenk tube and put 
under N2. 1,4-Dioxane (10 mL, not degassed or dried) was added, the mixture 
was sonicated for 2 min and then stirred at 65 °C for 24 h. After the mixture 
was cooled to r.t., it was diluted with DCM and filtered over celite. Then, the 
volatiles were removed under reduced pressure and the product was purified with column 
chromatography (2.5% MeOH in DCM) yielding aldehyde 5 (405 mg, 82%) as a slightly yellow oil. 
Rf = 0.17 (2.5% MeOH in DCM). 1H NMR (400 MHz, chloroform-d) δ 10.09 (s, 1H), 7.93 – 7.83 
(m, 2H), 7.56 – 7.47 (m, 1H), 4.88 (s, 2H). 13C NMR (100 MHz, chloroform-d) δ 193.2, 160.2, 
151.8, 137.9, 124.9, 120.6, 64.2. LRMS (ESI+) m/z calcd. for C7H7NNaO2+ [M+Na]+ 138.1, found: 
138.0. The obtained data agrees with literature.4 
 
(6-Formylpyridin-2-yl)methyl methanesulfonate (6). Alcohol 5 (350 mg 2.6 mmol, 1.0 equiv.) 
was dissolved in dry DCM, the solution was cooled to 0 °C and Et3N (1.1 mL, 
7.7 mmol, 3.0 equiv.) was added. Then, MsCl (237 µL, 3.1 mmol, 1.2 equiv.) 
was added dropwise and the mixture was stirred at r.t. for 30 min. The reaction 
was quenched with sat. NaHCO3, the layers were separated and the aqueous 
layer was extracted with DCM (3 x). The combined organic layers were dried over Na2SO4 and the 
volatiles were removed under reduced pressure. The brown oil was purified with column 
chromatography (60% EtOAc in heptane) yielding methanesulfonate 6 (399 mg, 73%) as a slightly 
yellow solid. Rf = 0.35 (EtOAc/heptane, 3:2). 1H NMR (400 MHz, chloroform-d) δ 10.05 (s, 1H), 
7.98 – 7.92 (m, 2H), 7.74 – 7.69 (m, 1H), 5.42 (s, 2H), 3.14 (s, 3H). 13C NMR (100 MHz, 
chloroform-d) δ 192.8, 154.8, 152.6, 138.5, 126.5, 121.7, 70.8, 38.2. LRMS (ESI+) m/z calcd. for 
C8H10NO4S+ [M+H]+ 216.0, found: 216.1. The obtained data agrees with literature.4 
 
tert-Butyl 4-((6-formylpyridin-2-yl)methyl)piperazine-1-carboxylate (7). Methanesulfonate 6 
(370 mg, 1.7 mmol, 1.0 equiv.) was dissolved in dry MeCN (10 mL) and 
1-Boc-piperazine (384 mg, 2.0 mmol, 1.2 equiv.) and K2CO3 (475 mg, 3.4 
mmol, 2.0 equiv.) were added. The mixture was stirred at 60 °C for 16 h, 
whereupon the solvent was evaporated. DCM and sat. NaHCO3 were 
added, the layers were separated and the aqueous layer was extracted with DCM (3 x). The 
combined organic layers were dried over Na2SO4 and the volatiles were removed using a rotary 
evaporator. Then, the product was purified using column chromatography (80% EtOAc in 
heptane) yielding tertiary amine 7 (456 mg, 87%) as a white solid. Rf = 0.26 (EtOAc/heptane, 4:1). 
1H NMR (400 MHz, chloroform-d) δ 10.07 (s, 1H), 7.88 – 7.82 (m, 2H), 7.73 – 7.66 (m, 1H), 3.77 
(s, 2H), 3.52 – 3.41 (m, 4H), 2.52 – 2.42 (m, 4H), 1.46 (s, 9H). 13C NMR (100 MHz, chloroform-
d) δ 193.7, 159.6, 154.9, 152.5, 137.6, 127.5, 120.4, 79.9, 64.3, 53.3, 28.6. LRMS (ESI+) m/z calcd. 
for C16H24N3O3+ [M+H]+ 306.2, found: 305.9. The obtained data agrees with literature.4 
 
6-((4-(2-Azidoacetyl)piperazin-1-yl)methyl)picolinaldehyde (8). tert-Butyl 4-((6-
formylpyridin-2-yl)methyl)piperazine-1-carboxylate 7 (25 mg, 82 
µmol, 1.0 equiv.) was dissolved in dry DCM (1 mL) under N2 and 4M 
HCl in dioxane (205 µL, 820 µmol, 10.0 equiv.) was added. The 
mixture was stirred for 2 h, whereupon the volatiles were evaporated. 
The solid was dissolved in DMF (1 mL) and 2,5-dioxopyrrolidin-1-yl 
2-azidoacetate (3) (19 mg, 98 µmol, 1.2 equiv.) was added. Then, Et3N (34 µL, 250 µmol, 3.0 equiv.) 
was added and the solution was stirred for 2 h. The volatiles were evaporated and the product was 
purified using column chromatography (50 to 100% EtOAc in heptane) yielding 2-PCA-N3 8 (19 
mg, 80%) as a white solid. Rf = 0.49 (5% MeOH in EtOAc). IR (film) 2107, 1711, 1657, 1592, 
1457, 1220, 1076, 1000, 788, 655 cm-1. 1H NMR (500 MHz, chloroform-d) δ 10.06 (s, 1H), 7.87 (d, 
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J = 3.9 Hz, 2H), 7.70 – 7.65 (m, 1H), 3.93 (s, 2H), 3.82 (s, 2H), 3.73 – 3.66 (m, 2H), 3.50 – 3.39 
(m, 2H), 2.60 (q, J = 5.9 Hz, 4H). 13C NMR (126 MHz, chloroform-d) δ 193.30, 172.07, 165.66, 
158.46, 152.43, 137.69, 127.57, 120.65, 76.78, 63.60, 52.71, 50.68, 44.93, 41.88, 25.41. HRMS 
(ESI+) m/z calcd. for C13H17N6O2 [M+H]+ 289.14075, found: 289.14130. m/z calcd. for 
C13H16N6NaO2 [M+Na]+ 311.12269, found 311.12324 
 
6-((4-(14-Azido-3,6,9,12-tetraoxatetradecanoyl)piperazin-1-yl)methyl)picolinaldehyde (9). 
tert-Butyl 4-((6-formylpyridin-2-yl)methyl) 
piperazine-1-carboxylate 7 (50 mg, 0.16 
mmol, 1.0 equiv.) was dissolved in dry 
DCM (2 mL) under N2 and 4M HCl in 
dioxane (410 µL, 1.6 mmol, 10.0 equiv.) was 
added. The mixture was stirred for 2 h, whereupon the volatiles were evaporated. The solid was 
dissolved in DMF (1 mL) and 2,5-dioxopyrrolidin-1-yl 14-azido-3,6,9,12-tetraoxatetradecanoate 
(4) (74 mg, 0.20 mmol, 1.2 equiv.) was added. Then, Et3N (69 µL, 0.49 mmol, 3.0 equiv.) was 
added and the solution was stirred for 2 h. The volatiles were evaporated and the product was 
purified using preparative HPLC (gradient: 5 to 100% MeCN in H2O in 55 minutes) yielding 2-
PCA-PEG4-N3 9 (8 mg, 11%) as a yellow oil. Rf = 0.45 (75% EtOAc in heptane). IR (film) 2104, 
1711, 1648, 1592, 1458, 1214, 1094, 799, 653 cm-1. 1H NMR (500 MHz, chloroform-d) δ 10.03 (s, 
1H), 7.99 (d, J = 7.8 Hz, 2H), 7.83 (d, J = 6.4 Hz, 1H), 4.41 (s, 2H), 4.21 (s, 2H), 3.98 – 3.87 (m, 
4H), 3.69 – 3.60 (m, 14H), 3.39 (q, J = 7.4, 4.9 Hz, 4H), 3.27 (s, 2H). 13C NMR (126 MHz, 
chloroform-d) δ 192.28, 167.85, 152.74, 150.53, 138.94, 129.88, 122.27, 70.63, 70.53, 70.52, 70.38, 
70.30, 70.28, 70.10, 69.94, 61.04, 52.29, 51.82, 50.59, 42.49, 39.05. HRMS (ESI+) m/z calcd. for 
C21H33N6O6 [M+H]+ 465.24561, found: 465.24616 m/z calcd. C21H32N6NaO6 [M+Na]+ 487.22755, 
found: 487.22607. 
 
2-((4-Iodophenyl)amino)acetonitrile (10). Iodoaniline (5.00 g, 23 mmol, 1 equiv.) was dissolved 
in dry acetonitrile (60 mL). To this solution was subsequently added K2CO3 
(3.80 g, 28 mmol, 1.2 equiv.) and NaI (3.40 g, 23 mmol, 1 equiv.). 
Chloroacetonitrile (2.89 mL, 46 mmol, 2 equiv.) was added dropwise and  
the mixture was then refluxed under argon for 3 days. Afterwards, the 
reaction was cooled down to room temperature and filtered over celite and rinsed with EtOAc. 
The organic layer was washed once with brine and dried over MgSO4. The volatiles were 
evaporated and the product (4.82 g, 82% yield) was obtained after purifying on a dry loaded 
column (20-50% EtOAc in heptane). Rf = 0.52 (50% EtOAc in heptane). 1H NMR (400 MHz, 
chloroform-d) δ 7.56 – 7.51 (m, 2H), 6.52 – 6.47 (m, 2H), 4.09 (d, J = 1.0 Hz, 1H), 4.07 (s, 2H). 
13C-NMR (100 MHz, chloroform-d): δ 144.76, 138.38 (2C), 116.55, 115.87 (2C), 81.76, 32.61. 
LRMS (ESI+): m/z calcd for C8H7IN2+ [M+H]+ 258.8, found 258.9. 
 
N-(Cyanomethyl)-N-(4-iodophenyl)nitrous amide (11). Compound 10 (740 mg, 2.9 mmol, 1 
equiv.) was dissolved in dry THF (3.8 mL) and isoamyl nitrite (1.19 mL, 8.6 
mmol, 3 equiv.) was added dropwise to the mixture. This was left to stir for 
2 hours at room temperature. Afterwards, the volatiles were removed 
yielding a crude product (821 mg, 2.9 mmol) with a high purity (>95%), so 
it was used in the next step without further purification. Rf = 0.62 (50% EtOAc in heptane). 1H-
NMR (400 MHz, chloroform-d): δ 7.89 (d, 2H, J = 8.8 Hz), 7.33 (d, 2H, J = 8.8 Hz), 4.77 (s, 2H). 
13C-NMR (100 MHz, chloroform-d): δ 139.59, 139.20 (2C), 121.42, 112.12 (2C), 93.74, 30.34. 
LRMS (ESI+): m/z calcd for C8H7IN3O+ [M+H]+ 288.0, found 288.1. 
 
5-Amino-3-(4-iodophenyl)-1,2,3-oxadiazol-3-ium chloride (12). Compound 11 was dissolved 
in 6 mL 4M HCl in dioxane and was stirred at room temperature 
overnight. The product was obtained by trituration in diethyl ether (95% 
yield over two steps). 1H-NMR (400 MHz, DMSO-d6): δ 9.97 (s, 2H), 8.66 
(s, 1H), 8.16 (d, 2H, J = 8.92 Hz), 7.84 (d, 2H, J = 8.93). 13C-NMR (100 
MHz, DMSO-d6): δ 169.45, 139.19 (2C), 132.44, 124.36 (2C), 101.43 (1C missing). LRMS (ESI+): 
m/z calcd for C8H7IN3O+ [M-Cl]+ 288.0, found 288.0  
 
 (tert-Butoxycarbonyl)(3-(4-iodophenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (13). 
Compound 12 (6.50 g, 20 mmol, 1 equiv.), NaHCO3 (1.90 g, 34 
mmol, 1.7 equiv.) and DMAP (276 mg, 2.3 mmol, 10 mol%) were 
dissolved in dry THF (100 mL). The mixture was cooled down to 0 
°C. To this mixture, Boc2O (7.40 g, 34 mmol, 1.7 equiv.) in THF (65 
mL) was added dropwise and the reaction was stirred for 70 hours. The reaction was then 
quenched with 165 mL of aq. sat. NH4Cl solution, THF was removed under reduced pressure and 
the product was extracted with EtOAC (3 x 80 mL). The organic layer was then dried and the 
product was obtained as an orange solid (4.79 g, 62% yield) after flash purification (0-50% EtOAc 
in heptane). Rf = 0.58 (50% EtOAc in heptane). 1H-NMR (400 MHz, chloroform-d): δ 8.09 (s, 
1H), 8.00 (d, 2H, J = 8.94), 7.54 (d, 2H, J = 8.94), 1.52 (s, 9H). 13C-NMR (100 MHz, chloroform-
d): δ 174.64, 160.72, 139.78, 139.75 (2C), 122.76, 122.74 (2C), 99.45, 79.24, 28.23 (3C). LRMS 
(ESI+): m/z calcd for C13H14IN3O3+ [M+H]+ 387.01, found 387.9 
 
(tert-Butoxycarbonyl)(3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide 
(14). Compound 13 (1.20 g, 3.1 mmol, 1 equiv.) was dissolved 
in dry ethanol (10 mL) and NEt3 (10 mL). To this, 
PdCl2(PPh3)2 (324 mg, 0.46 mmol, 15 mol%) was added. The 
compound was allowed to react in a CO atmosphere at 60 °C 
for 2.5 hours. The reaction mixture was then allowed to cool 
down and was filtered over celite. The mixture was then concentrated and purified using flash 
chromatography (0-50% EtOAc in heptane) to obtain an orange solid (668 mg, 65% yield). Rf = 
0.35 (50% EtOAc in heptane). 1H-NMR (400 MHz, chloroform-d): δ 8.32 (d, 2H, J = 8.87), 8.16 
(s, 1H), 7.89 (d, 2H, J = 8.87), 4.45 (q, 2H, J = 7.14), 1.52 (s, 9H), 1.43 (t, 3H, J = 7.14). 13C-NMR 
(100 MHz, chloroform-d): δ 174.88, 164.53, 160.95, 136.82, 134.93, 131.86 (2C), 121.63 (2C), 
102.62, 79.36, 62.20, 28.36 (3C), 14.39. LRMS (ESI+): m/z calcd for C16H20N3O5+ [M+H]+ 334.1, 
found 334.4. 
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J = 3.9 Hz, 2H), 7.70 – 7.65 (m, 1H), 3.93 (s, 2H), 3.82 (s, 2H), 3.73 – 3.66 (m, 2H), 3.50 – 3.39 
(m, 2H), 2.60 (q, J = 5.9 Hz, 4H). 13C NMR (126 MHz, chloroform-d) δ 193.30, 172.07, 165.66, 
158.46, 152.43, 137.69, 127.57, 120.65, 76.78, 63.60, 52.71, 50.68, 44.93, 41.88, 25.41. HRMS 
(ESI+) m/z calcd. for C13H17N6O2 [M+H]+ 289.14075, found: 289.14130. m/z calcd. for 
C13H16N6NaO2 [M+Na]+ 311.12269, found 311.12324 
 
6-((4-(14-Azido-3,6,9,12-tetraoxatetradecanoyl)piperazin-1-yl)methyl)picolinaldehyde (9). 
tert-Butyl 4-((6-formylpyridin-2-yl)methyl) 
piperazine-1-carboxylate 7 (50 mg, 0.16 
mmol, 1.0 equiv.) was dissolved in dry 
DCM (2 mL) under N2 and 4M HCl in 
dioxane (410 µL, 1.6 mmol, 10.0 equiv.) was 
added. The mixture was stirred for 2 h, whereupon the volatiles were evaporated. The solid was 
dissolved in DMF (1 mL) and 2,5-dioxopyrrolidin-1-yl 14-azido-3,6,9,12-tetraoxatetradecanoate 
(4) (74 mg, 0.20 mmol, 1.2 equiv.) was added. Then, Et3N (69 µL, 0.49 mmol, 3.0 equiv.) was 
added and the solution was stirred for 2 h. The volatiles were evaporated and the product was 
purified using preparative HPLC (gradient: 5 to 100% MeCN in H2O in 55 minutes) yielding 2-
PCA-PEG4-N3 9 (8 mg, 11%) as a yellow oil. Rf = 0.45 (75% EtOAc in heptane). IR (film) 2104, 
1711, 1648, 1592, 1458, 1214, 1094, 799, 653 cm-1. 1H NMR (500 MHz, chloroform-d) δ 10.03 (s, 
1H), 7.99 (d, J = 7.8 Hz, 2H), 7.83 (d, J = 6.4 Hz, 1H), 4.41 (s, 2H), 4.21 (s, 2H), 3.98 – 3.87 (m, 
4H), 3.69 – 3.60 (m, 14H), 3.39 (q, J = 7.4, 4.9 Hz, 4H), 3.27 (s, 2H). 13C NMR (126 MHz, 
chloroform-d) δ 192.28, 167.85, 152.74, 150.53, 138.94, 129.88, 122.27, 70.63, 70.53, 70.52, 70.38, 
70.30, 70.28, 70.10, 69.94, 61.04, 52.29, 51.82, 50.59, 42.49, 39.05. HRMS (ESI+) m/z calcd. for 
C21H33N6O6 [M+H]+ 465.24561, found: 465.24616 m/z calcd. C21H32N6NaO6 [M+Na]+ 487.22755, 
found: 487.22607. 
 
2-((4-Iodophenyl)amino)acetonitrile (10). Iodoaniline (5.00 g, 23 mmol, 1 equiv.) was dissolved 
in dry acetonitrile (60 mL). To this solution was subsequently added K2CO3 
(3.80 g, 28 mmol, 1.2 equiv.) and NaI (3.40 g, 23 mmol, 1 equiv.). 
Chloroacetonitrile (2.89 mL, 46 mmol, 2 equiv.) was added dropwise and  
the mixture was then refluxed under argon for 3 days. Afterwards, the 
reaction was cooled down to room temperature and filtered over celite and rinsed with EtOAc. 
The organic layer was washed once with brine and dried over MgSO4. The volatiles were 
evaporated and the product (4.82 g, 82% yield) was obtained after purifying on a dry loaded 
column (20-50% EtOAc in heptane). Rf = 0.52 (50% EtOAc in heptane). 1H NMR (400 MHz, 
chloroform-d) δ 7.56 – 7.51 (m, 2H), 6.52 – 6.47 (m, 2H), 4.09 (d, J = 1.0 Hz, 1H), 4.07 (s, 2H). 
13C-NMR (100 MHz, chloroform-d): δ 144.76, 138.38 (2C), 116.55, 115.87 (2C), 81.76, 32.61. 
LRMS (ESI+): m/z calcd for C8H7IN2+ [M+H]+ 258.8, found 258.9. 
 
N-(Cyanomethyl)-N-(4-iodophenyl)nitrous amide (11). Compound 10 (740 mg, 2.9 mmol, 1 
equiv.) was dissolved in dry THF (3.8 mL) and isoamyl nitrite (1.19 mL, 8.6 
mmol, 3 equiv.) was added dropwise to the mixture. This was left to stir for 
2 hours at room temperature. Afterwards, the volatiles were removed 
yielding a crude product (821 mg, 2.9 mmol) with a high purity (>95%), so 
it was used in the next step without further purification. Rf = 0.62 (50% EtOAc in heptane). 1H-
NMR (400 MHz, chloroform-d): δ 7.89 (d, 2H, J = 8.8 Hz), 7.33 (d, 2H, J = 8.8 Hz), 4.77 (s, 2H). 
13C-NMR (100 MHz, chloroform-d): δ 139.59, 139.20 (2C), 121.42, 112.12 (2C), 93.74, 30.34. 
LRMS (ESI+): m/z calcd for C8H7IN3O+ [M+H]+ 288.0, found 288.1. 
 
5-Amino-3-(4-iodophenyl)-1,2,3-oxadiazol-3-ium chloride (12). Compound 11 was dissolved 
in 6 mL 4M HCl in dioxane and was stirred at room temperature 
overnight. The product was obtained by trituration in diethyl ether (95% 
yield over two steps). 1H-NMR (400 MHz, DMSO-d6): δ 9.97 (s, 2H), 8.66 
(s, 1H), 8.16 (d, 2H, J = 8.92 Hz), 7.84 (d, 2H, J = 8.93). 13C-NMR (100 
MHz, DMSO-d6): δ 169.45, 139.19 (2C), 132.44, 124.36 (2C), 101.43 (1C missing). LRMS (ESI+): 
m/z calcd for C8H7IN3O+ [M-Cl]+ 288.0, found 288.0  
 
 (tert-Butoxycarbonyl)(3-(4-iodophenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (13). 
Compound 12 (6.50 g, 20 mmol, 1 equiv.), NaHCO3 (1.90 g, 34 
mmol, 1.7 equiv.) and DMAP (276 mg, 2.3 mmol, 10 mol%) were 
dissolved in dry THF (100 mL). The mixture was cooled down to 0 
°C. To this mixture, Boc2O (7.40 g, 34 mmol, 1.7 equiv.) in THF (65 
mL) was added dropwise and the reaction was stirred for 70 hours. The reaction was then 
quenched with 165 mL of aq. sat. NH4Cl solution, THF was removed under reduced pressure and 
the product was extracted with EtOAC (3 x 80 mL). The organic layer was then dried and the 
product was obtained as an orange solid (4.79 g, 62% yield) after flash purification (0-50% EtOAc 
in heptane). Rf = 0.58 (50% EtOAc in heptane). 1H-NMR (400 MHz, chloroform-d): δ 8.09 (s, 
1H), 8.00 (d, 2H, J = 8.94), 7.54 (d, 2H, J = 8.94), 1.52 (s, 9H). 13C-NMR (100 MHz, chloroform-
d): δ 174.64, 160.72, 139.78, 139.75 (2C), 122.76, 122.74 (2C), 99.45, 79.24, 28.23 (3C). LRMS 
(ESI+): m/z calcd for C13H14IN3O3+ [M+H]+ 387.01, found 387.9 
 
(tert-Butoxycarbonyl)(3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide 
(14). Compound 13 (1.20 g, 3.1 mmol, 1 equiv.) was dissolved 
in dry ethanol (10 mL) and NEt3 (10 mL). To this, 
PdCl2(PPh3)2 (324 mg, 0.46 mmol, 15 mol%) was added. The 
compound was allowed to react in a CO atmosphere at 60 °C 
for 2.5 hours. The reaction mixture was then allowed to cool 
down and was filtered over celite. The mixture was then concentrated and purified using flash 
chromatography (0-50% EtOAc in heptane) to obtain an orange solid (668 mg, 65% yield). Rf = 
0.35 (50% EtOAc in heptane). 1H-NMR (400 MHz, chloroform-d): δ 8.32 (d, 2H, J = 8.87), 8.16 
(s, 1H), 7.89 (d, 2H, J = 8.87), 4.45 (q, 2H, J = 7.14), 1.52 (s, 9H), 1.43 (t, 3H, J = 7.14). 13C-NMR 
(100 MHz, chloroform-d): δ 174.88, 164.53, 160.95, 136.82, 134.93, 131.86 (2C), 121.63 (2C), 
102.62, 79.36, 62.20, 28.36 (3C), 14.39. LRMS (ESI+): m/z calcd for C16H20N3O5+ [M+H]+ 334.1, 
found 334.4. 
 
163
Summary, Future Perspectives and Concluding Remarks
529590-L-bw-Lelieveldt
Processed on: 13-3-2019 PDF page: 164
 (tert-Butoxycarbonyl)(3-(4-carboxyphenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (15). 
Compound 14 (650 mg, 2.0 mmol, 1 equiv.) was dissolved in 
THF (15 mL) and LiOH·H2O (246 mg, 5.9 mmol, 3 equiv.) was 
added to water (15 mL). The two solutions were mixed for 2.5 
hours at room temperature. The reaction mixture was then 
diluted with water and extracted with EtOAc (3 x 30 mL). The 
water layer was then acidified to pH 2 with 1M HCl and again 
extracted with EtOAc (3 x 30 mL). The organic layers were combined and dried with MgSO4. The 
solvents were evaporated to yield a pure yellow compound (543 mg, 92% yield). Rf = 0.30 (10% 
MeOH, 0.5% AcOH in DCM). 1H-NMR (400 MHz, MeOH-d4): δ 8.46 (s, 1H), δ 8.32 (d, 2H, J = 
8.92), 8.11 (d, 2H, J = 8.92), 1.51 (s, 9H). 13C-NMR (100 MHz, MeOH-d4): δ 166.32, 159.21, 136.65, 
135.40, 131.29 (2C), 122.13 (2C), 108.99, 79.14, 27.11 (3C). HRMS (ESI+): m/z calcd for 
C14H15N3O5+ [M+H]+ 306.10900, found 306.10957 
 
 (tert-Butoxycarbonyl)(3-(4-(prop-2-yn-1-ylcarbamoyl)phenyl)-1,2,3-oxadiazol-3-ium-5-
yl)amide (16). Compound 15 (540 mg, 1.8 mmol, 1 equiv.) 
was dissolved in DMF (20 mL). To this mixture was added 
HATU (738 mg, 2.2 mmol, 1.1 equiv.) and DiPEA (620 µL, 
3.6 mmol, 2 equiv.) and was left to stir at room temperature 
for 5 minutes. Propargylamine (227 µL, 3.6 mmol, 2 equiv.) 
was added and stirred for 2 hours at room temperature. 
DMF was removed under reduced pressure and the product was obtained after flash 
chromatography (5% MeOH in DCM) to yield a yellow solid (349 mg, 58% yield). Rf = 0.24 (5% 
MeOH in DCM). 1H-NMR (400 MHz, MeOH-d4): δ 9.26 (t, 1H, J = 5.45), 8.60 (s, 1H), 8.21 (d, 
2H, J = 8.82), 8.14 (d, 2H, J = 8.82), 4.11 (dd, 2H, J = 5.45, 2.49), 3.18 (t, 1H, J = 2.49), 1.44 (s, 
9H). 13C-NMR (100 MHz, MeOH-d4): δ 174.72, 164.83, 160.13, 137.82, 136.01, 129.53 (2C), 122.90 
(2C), 81.34, 77.81, 73.67, 29.19, 28.48 (3C) (1C missing). HRMS (ESI+): m/z calcd for 
C17H19N4O4+ [M+H] 343.14008, found 343.14078. C17H18N4NaO4+ [M+Na]+ 365.12203, found, 
365.12403. 
 
5-Amino-3-(4-(prop-2-yn-1-ylcarbamoyl)phenyl)-1,2,3-oxadiazol-3-ium 2,2,2-trifluoro 
acetate (17). Compound 16 (349 mg, 1.1 mmol, 1 equiv.) was 
dissolved in DCM (20 mL). TFA (2 mL) was added dropwise. 
The mixture was left to stir for 4 hours at room temperature. 
The DCM was evaporated and the TFA was fully removed with 
co-evaporation with DCM (3 x) to yield a red/brown powder 
(259 mg, 80% yield, contaminated with a HATU remainder). 1H-NMR (400 MHz, MeOH-d4): δ 
8.41 (s, 1H), 8.17 (d, 2H, J = 8.99), 8.12 (d, 2H, J = 8.99), 4.20 (d, 2H, J = 2.54), 2.65 (t, 1H, J = 
2.54). 13C-NMR (100 MHz, MeOH-d4): δ 165.89, 140.19, 138.85, 129.28 (2C), 122.51 (2C), 78.91, 
71.02, 37.48, 28.77 (1C missing). HRMS (ESI+): m/z calcd for C12H11N4O2+ [M-TFA]+ 243.08820, 
found 243.08871. 
 
Fmoc-Orn(Cbz)-OtBu. Fmoc-Orn(Cbz)-OH (1.73 g, 3.7 mmol, 1.0 equiv.) was dissolved in 
THF/Hexane (30 mL, 1:1). This was cooled down to 0 °C and 
afterwards tert-butyl 2,2,2-trichloroacetimidate (1.32 mL, 7.4 mmol, 
2.0 equiv.) was added. This was stirred for 15 min and then BF3 
etherate (228 uL, 1.8 mmol, 0.5 equiv.) was added to the mixture and the reaction was stirred 
overnight at room temperature. The product was obtained via column chromatography in a 
gradient of EtOAc in heptane (0% to 40%). Rf = 0.30 (30% EtOAc in heptane). 1H NMR (500 
MHz, MeOH-d4) δ 7.79 (d, J = 7.5 Hz, 2H), 7.67 (t, J = 7.0 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.37 
– 7.26 (m, 7H), 5.49 (s, 2H), 5.08 (s, 2H), 4.37 (qd, J = 10.6, 7.1 Hz, 2H), 4.22 (t, J = 6.8 Hz, 1H), 
4.06 (dd, J = 8.6, 5.0 Hz, 1H), 3.15 (t, J = 6.7 Hz, 2H), 1.89 – 1.61 (m, 2H), 1.59 (d, J = 6.5 Hz, 
2H), 1.46 (s, 9H). 13C NMR (126 MHz, MeOH-d4) δ 171.88, 157.50, 157.19, 143.92, 143.76, 141.18 
(2C), 137.01, 128.06 (2C), 127.54 (2C), 127.38 (3C), 126.77 (2C), 124.86 (2C), 119.53 (2C), 81.36, 
66.49, 65.96, 54.57, 47.04, 39.92, 28.55, 26.90 (3C), 26.00. HRMS (ESI+) m/z calcd for 
C32H36N2NaO6+ [M+Na]+ 567.24711, found 567.24580. 
 
Fmoc-Orn-OtBu (18). Fmoc-Orn(Cbz)-OtBu was dissolved in methanol (40 mL). To this 
palladium on activated carbon (40 mg, 0.14 mmol) was added. The flask 
was then closed and H2 was bubbled through while stirring till 
completion. The product was filtrated over celite and obtained via 
column chromatography in 10% methanol in DCM (1.20 g, 80% yield over two steps). Rf = 0.23 
(10% MeOH in DCM). 1H NMR (500 MHz, MeOH-d4) δ 7.78 (d, J = 7.5 Hz, 2H), 7.66 (t, J = 7.8 
Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.25 (s, 1H), 4.89 (s, 2H), 4.42 (dd, J = 
10.6, 6.8 Hz, 1H), 4.31 (dd, J = 10.6, 6.8 Hz, 10H), 4.20 (t, J = 6.9 Hz, 1H), 4.06 (t, J = 8.8 Hz, 
1H), 2.95 (t, J = 7.1 Hz, 1H), 1.95 – 1.83 (m, 1H), 1.74 (dt, J = 16.6, 8.9 Hz, 3H), 1.46 (s, 9H). 13C 
NMR (126 MHz, MeOH-d4) δ 171.36, 157.29, 143.75 (2C), 141.20 (2C), 127.42 (2C), 126.79 (2C), 
124.80 (2C), 119.57 (2C), 81.66, 66.59, 54.28, 46.99, 38.92, 28.15, 26.89 (3C), 23.85. HRMS (ESI+) 
m/z calcd for C24H31N2O4+ [M+H]+ 411.228383, found 411.22757. C24H30N2NaO4+ [M+Na]+ 
433.21033, found 433.20943. 
 
Fmoc-Orn(Im-alkyne)-OtBu (19). Compound 18 (410 mg, 1.0 mmol, 1 equiv.) was dissolved in 
a mixture of DCM/sat. NaHCO3 (1:1, 20 
mL) and cooled down to 0 °C. While 
stirring vigorously, triphosgene (99 mg, 
0.33 mmol, 0.3 equiv.) dissolved in DCM 
(1 mL) was added dropwise. This was left 
to react for 10 min. Afterwards, 17 (356 
mg, 1.0 mmol, 1 equiv.) dissolved in DCM (1 mL) was added dropwise at 0 °C and stirred for 1 
hour. The reaction was then quenched with brine (20 mL) and extracted with EtOAc (3 x 30 mL). 
The product was obtained after purification with flash chromatography (2.5-5% MeOH in DCM) 
to yield an orange solid (122 mg, 18% yield). Rf = 0.22 (5% MeOH in DCM). 1H-NMR (400 MHz, 
DMSO-d6): δ 8.26 (s, 1H), 8.12 (d, 2H, J = 8.88), 8.05 (d, 2H, J = 8.88), 7.78 (d, 2H, J = 7.53), 7.71 
– 7.66 (m, 2H), 7.39 (t, 2H, J = 7.50), 7.32 (t, 2H, J = 7.39), 4.41 – 4.34 (m, 2H), 4.25 (d, J = 7.1 
Hz, 1H), 4.22 (d, J = 2.5 Hz, 2H), 4.10 (dd, J = 8.7, 4.9 Hz, 1H), 3.25 (t, J = 6.2 Hz, 2H), 2.67 (t, 
J = 2.5 Hz, 1H), 1.93 – 1.81 (m, 1H), 1.78 – 1.69 (m, 1H), 1.68 – 1.60 (m, 2H), 1.48 (s, 9H). HRMS 
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 (tert-Butoxycarbonyl)(3-(4-carboxyphenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (15). 
Compound 14 (650 mg, 2.0 mmol, 1 equiv.) was dissolved in 
THF (15 mL) and LiOH·H2O (246 mg, 5.9 mmol, 3 equiv.) was 
added to water (15 mL). The two solutions were mixed for 2.5 
hours at room temperature. The reaction mixture was then 
diluted with water and extracted with EtOAc (3 x 30 mL). The 
water layer was then acidified to pH 2 with 1M HCl and again 
extracted with EtOAc (3 x 30 mL). The organic layers were combined and dried with MgSO4. The 
solvents were evaporated to yield a pure yellow compound (543 mg, 92% yield). Rf = 0.30 (10% 
MeOH, 0.5% AcOH in DCM). 1H-NMR (400 MHz, MeOH-d4): δ 8.46 (s, 1H), δ 8.32 (d, 2H, J = 
8.92), 8.11 (d, 2H, J = 8.92), 1.51 (s, 9H). 13C-NMR (100 MHz, MeOH-d4): δ 166.32, 159.21, 136.65, 
135.40, 131.29 (2C), 122.13 (2C), 108.99, 79.14, 27.11 (3C). HRMS (ESI+): m/z calcd for 
C14H15N3O5+ [M+H]+ 306.10900, found 306.10957 
 
 (tert-Butoxycarbonyl)(3-(4-(prop-2-yn-1-ylcarbamoyl)phenyl)-1,2,3-oxadiazol-3-ium-5-
yl)amide (16). Compound 15 (540 mg, 1.8 mmol, 1 equiv.) 
was dissolved in DMF (20 mL). To this mixture was added 
HATU (738 mg, 2.2 mmol, 1.1 equiv.) and DiPEA (620 µL, 
3.6 mmol, 2 equiv.) and was left to stir at room temperature 
for 5 minutes. Propargylamine (227 µL, 3.6 mmol, 2 equiv.) 
was added and stirred for 2 hours at room temperature. 
DMF was removed under reduced pressure and the product was obtained after flash 
chromatography (5% MeOH in DCM) to yield a yellow solid (349 mg, 58% yield). Rf = 0.24 (5% 
MeOH in DCM). 1H-NMR (400 MHz, MeOH-d4): δ 9.26 (t, 1H, J = 5.45), 8.60 (s, 1H), 8.21 (d, 
2H, J = 8.82), 8.14 (d, 2H, J = 8.82), 4.11 (dd, 2H, J = 5.45, 2.49), 3.18 (t, 1H, J = 2.49), 1.44 (s, 
9H). 13C-NMR (100 MHz, MeOH-d4): δ 174.72, 164.83, 160.13, 137.82, 136.01, 129.53 (2C), 122.90 
(2C), 81.34, 77.81, 73.67, 29.19, 28.48 (3C) (1C missing). HRMS (ESI+): m/z calcd for 
C17H19N4O4+ [M+H] 343.14008, found 343.14078. C17H18N4NaO4+ [M+Na]+ 365.12203, found, 
365.12403. 
 
5-Amino-3-(4-(prop-2-yn-1-ylcarbamoyl)phenyl)-1,2,3-oxadiazol-3-ium 2,2,2-trifluoro 
acetate (17). Compound 16 (349 mg, 1.1 mmol, 1 equiv.) was 
dissolved in DCM (20 mL). TFA (2 mL) was added dropwise. 
The mixture was left to stir for 4 hours at room temperature. 
The DCM was evaporated and the TFA was fully removed with 
co-evaporation with DCM (3 x) to yield a red/brown powder 
(259 mg, 80% yield, contaminated with a HATU remainder). 1H-NMR (400 MHz, MeOH-d4): δ 
8.41 (s, 1H), 8.17 (d, 2H, J = 8.99), 8.12 (d, 2H, J = 8.99), 4.20 (d, 2H, J = 2.54), 2.65 (t, 1H, J = 
2.54). 13C-NMR (100 MHz, MeOH-d4): δ 165.89, 140.19, 138.85, 129.28 (2C), 122.51 (2C), 78.91, 
71.02, 37.48, 28.77 (1C missing). HRMS (ESI+): m/z calcd for C12H11N4O2+ [M-TFA]+ 243.08820, 
found 243.08871. 
 
Fmoc-Orn(Cbz)-OtBu. Fmoc-Orn(Cbz)-OH (1.73 g, 3.7 mmol, 1.0 equiv.) was dissolved in 
THF/Hexane (30 mL, 1:1). This was cooled down to 0 °C and 
afterwards tert-butyl 2,2,2-trichloroacetimidate (1.32 mL, 7.4 mmol, 
2.0 equiv.) was added. This was stirred for 15 min and then BF3 
etherate (228 uL, 1.8 mmol, 0.5 equiv.) was added to the mixture and the reaction was stirred 
overnight at room temperature. The product was obtained via column chromatography in a 
gradient of EtOAc in heptane (0% to 40%). Rf = 0.30 (30% EtOAc in heptane). 1H NMR (500 
MHz, MeOH-d4) δ 7.79 (d, J = 7.5 Hz, 2H), 7.67 (t, J = 7.0 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.37 
– 7.26 (m, 7H), 5.49 (s, 2H), 5.08 (s, 2H), 4.37 (qd, J = 10.6, 7.1 Hz, 2H), 4.22 (t, J = 6.8 Hz, 1H), 
4.06 (dd, J = 8.6, 5.0 Hz, 1H), 3.15 (t, J = 6.7 Hz, 2H), 1.89 – 1.61 (m, 2H), 1.59 (d, J = 6.5 Hz, 
2H), 1.46 (s, 9H). 13C NMR (126 MHz, MeOH-d4) δ 171.88, 157.50, 157.19, 143.92, 143.76, 141.18 
(2C), 137.01, 128.06 (2C), 127.54 (2C), 127.38 (3C), 126.77 (2C), 124.86 (2C), 119.53 (2C), 81.36, 
66.49, 65.96, 54.57, 47.04, 39.92, 28.55, 26.90 (3C), 26.00. HRMS (ESI+) m/z calcd for 
C32H36N2NaO6+ [M+Na]+ 567.24711, found 567.24580. 
 
Fmoc-Orn-OtBu (18). Fmoc-Orn(Cbz)-OtBu was dissolved in methanol (40 mL). To this 
palladium on activated carbon (40 mg, 0.14 mmol) was added. The flask 
was then closed and H2 was bubbled through while stirring till 
completion. The product was filtrated over celite and obtained via 
column chromatography in 10% methanol in DCM (1.20 g, 80% yield over two steps). Rf = 0.23 
(10% MeOH in DCM). 1H NMR (500 MHz, MeOH-d4) δ 7.78 (d, J = 7.5 Hz, 2H), 7.66 (t, J = 7.8 
Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.25 (s, 1H), 4.89 (s, 2H), 4.42 (dd, J = 
10.6, 6.8 Hz, 1H), 4.31 (dd, J = 10.6, 6.8 Hz, 10H), 4.20 (t, J = 6.9 Hz, 1H), 4.06 (t, J = 8.8 Hz, 
1H), 2.95 (t, J = 7.1 Hz, 1H), 1.95 – 1.83 (m, 1H), 1.74 (dt, J = 16.6, 8.9 Hz, 3H), 1.46 (s, 9H). 13C 
NMR (126 MHz, MeOH-d4) δ 171.36, 157.29, 143.75 (2C), 141.20 (2C), 127.42 (2C), 126.79 (2C), 
124.80 (2C), 119.57 (2C), 81.66, 66.59, 54.28, 46.99, 38.92, 28.15, 26.89 (3C), 23.85. HRMS (ESI+) 
m/z calcd for C24H31N2O4+ [M+H]+ 411.228383, found 411.22757. C24H30N2NaO4+ [M+Na]+ 
433.21033, found 433.20943. 
 
Fmoc-Orn(Im-alkyne)-OtBu (19). Compound 18 (410 mg, 1.0 mmol, 1 equiv.) was dissolved in 
a mixture of DCM/sat. NaHCO3 (1:1, 20 
mL) and cooled down to 0 °C. While 
stirring vigorously, triphosgene (99 mg, 
0.33 mmol, 0.3 equiv.) dissolved in DCM 
(1 mL) was added dropwise. This was left 
to react for 10 min. Afterwards, 17 (356 
mg, 1.0 mmol, 1 equiv.) dissolved in DCM (1 mL) was added dropwise at 0 °C and stirred for 1 
hour. The reaction was then quenched with brine (20 mL) and extracted with EtOAc (3 x 30 mL). 
The product was obtained after purification with flash chromatography (2.5-5% MeOH in DCM) 
to yield an orange solid (122 mg, 18% yield). Rf = 0.22 (5% MeOH in DCM). 1H-NMR (400 MHz, 
DMSO-d6): δ 8.26 (s, 1H), 8.12 (d, 2H, J = 8.88), 8.05 (d, 2H, J = 8.88), 7.78 (d, 2H, J = 7.53), 7.71 
– 7.66 (m, 2H), 7.39 (t, 2H, J = 7.50), 7.32 (t, 2H, J = 7.39), 4.41 – 4.34 (m, 2H), 4.25 (d, J = 7.1 
Hz, 1H), 4.22 (d, J = 2.5 Hz, 2H), 4.10 (dd, J = 8.7, 4.9 Hz, 1H), 3.25 (t, J = 6.2 Hz, 2H), 2.67 (t, 
J = 2.5 Hz, 1H), 1.93 – 1.81 (m, 1H), 1.78 – 1.69 (m, 1H), 1.68 – 1.60 (m, 2H), 1.48 (s, 9H). HRMS 
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(ESI+): m/z calcd for C37H39N6O7+ [M+H]+ 679.28802, found 679.28626. C37H38N6NaO7+ 
[M+Na]+ 701.26997, found 701.26923 
 
Fmoc-Orn(Im-alkyne)-OH (20). Compound 19 (316 mg, 0.47 mmol, 1 equiv.), was dissolved in 
DCM (7 mL). TFA (7 mL) was slowly 
added to the mixture. This was stirred for 
2.5 hours. The DCM was evaporated and 
the TFA removed by co-evaporation with 
DCM (3 x) to yield a yellow crystalline 
powder (280 mg, 96% yield). Rf = 0.27 (10% MeOH, 0.5% AcOH in DCM). 1H-NMR (400 MHz, 
MeOH-d4): δ 9.07 (s, 1H), 8.18 (s, 1H), 8.15 (d, 2H, J = 9.06), 8.12 (d, 2H, J = 9.06), 7.73 (d, 2H, 
J = 7.39), 7.64 (t, 2H, J = 6.41), 7.35 (t, 2H, J = 7.33), 7.28 (t, 2H, J = 7.34), 4.39 – 4.25 (m, 2H), 
4.23 (d, J = 7.6 Hz, 1H), 4.20 (d, J = 2.4 Hz, 2H), 3.36 – 3.32 (m, 1H), 2.66 (t, 1H, J = 2.50), 2.00 
– 1.89 (m, 1H), 1.81 – 1.75 (m, 1H), 1.75 – 1.65 (m, 2H).13C-NMR (100 MHz, MeOH-d4): δ 175.66, 
167.16, 158.63, 145.20 (2C), 142.46 (2C), 140.45, 136.23, 130.75 (2C), 128.77 (2C), 128.25 (2C), 
126.25 (2C), 124.03 (2C), 120.90 (2C), 111.37, 108.33, 80.32, 72.46, 67.96, 54.88, 40.82, 29.90, 
29.41, 27.11, 24.20. HRMS (ESI+): m/z calcd for C33H31N6O7+ [M+H]+ 623.22487, found 
623.22375. C33H30N6NaO7+ [M+Na]+ 645.20737, found 645.20802. 
 
Protein modification with 2-PCA 8 or 94. The protein (10 µM) and the indicated concentration 
of 2-PCA (500 mM stock in DMSO, 0 to 1000 equiv.) were combined in PBS buffer and 
incubated at 4, 21 or 37 °C for 24 h (400 rpm). The samples were purified by dialysis against PBS 
and were analyzed by SDS-PAGE (Figure 2). 
 
Modified-NTR activity tested with ELISA. All reactants were dissolved in PBS pH 7.4. 10 µM 
(1 equiv.) of biotinylated CCP(CNBz) was treated with 3 µM (0.3 equiv.) NTR and 50 equiv. 
NADH (both from Sigma Aldrich) to test the NTR capacity for 1 hour at 37 oC. Next, biotinylated 
CCP(CNBz) and NTR-pretreated CCP(CNBz) were coupled to streptavidin-coated ELISA plates 
(C96 Maxisorp Nunc-immuno plate, Thermo-Scientific). Undiluted supernatants of the 
immortalized B cell clones were incubated with the respective antigens; antigen-bound IgG was 
detected by polyclonal rabbit anti-human IgG HRP (DAKO) and stained with TMB-UP 
(Biomerieux). The absorbance of the colorimetric signal was measured with iMark TM Microplate 
Reader (BioRad) at 450 nm. 
 
Anti-CD20 Fab fragment isolation. The NKI-B20/1 hybridoma cell line, kindly provided by 
Ferenc A. Scheeren, was genetically engineered to secrete Fab fragments, with a heavy chain HC-
LAETGG-Hisx6 and WT light chain. Cells were maintained at 37 °C with 5% CO2, and cultured 
in complete RPMI1640 medium, supplemented with 2 mM ultraglutamine, 50 μM Gibco 2-
Mercaptoethanol, 1 x penicilin/streptomycin and 10% heat inactivated fetal bovine serum (FBS). 
Hybridoma supernatant containing antibodies was harvested and filtered through a 20 μm filter. 
Supernatant was run through a Ni-NTA column which was subsequently washed with 10 column 
volumes of PBS with 10 mM imidazole, and Fab fragments were eluted in PBS containing 500 
mM imidazole. Buffer exchange to PBS was performed via ultracentrifugation with amicon Ultra-
15 Centrifugal filter units. 
 
Sortase reaction. eSrtA(2A-9) pET29b was a gift from David Liu (Addgene plasmid # 75145) 
and produced according to literature procedure.26 The His-tag purified Fab fragments were 
transferred to sortase buffer (PBS + 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 100 mM CaCl2). 
Sortase (1 equiv.) and the triple-Gly peptide (50 equiv.) was added. The reaction was incubated for 
1 h at 37 °C and quenched afterwards using 0.5 M EDTA. Purification was performed using Fast 
Protein Liquid Chromatography on a NGC system 5BioRad using a SEC70 ENrich 10 x 300 
column (Bio-Rad, 7801070), and 100 µL fractions collected in a 96 well plate. Fractions containing 
the sortagged protein were collected and run on 12% SDS gel to confirm purity, pooled and 
concentrated by ultracentrifugation with amicon Ultra-15 Centrifugal filter units (Sigma, 717185). 
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Ferenc A. Scheeren, was genetically engineered to secrete Fab fragments, with a heavy chain HC-
LAETGG-Hisx6 and WT light chain. Cells were maintained at 37 °C with 5% CO2, and cultured 
in complete RPMI1640 medium, supplemented with 2 mM ultraglutamine, 50 μM Gibco 2-
Mercaptoethanol, 1 x penicilin/streptomycin and 10% heat inactivated fetal bovine serum (FBS). 
Hybridoma supernatant containing antibodies was harvested and filtered through a 20 μm filter. 
Supernatant was run through a Ni-NTA column which was subsequently washed with 10 column 
volumes of PBS with 10 mM imidazole, and Fab fragments were eluted in PBS containing 500 
mM imidazole. Buffer exchange to PBS was performed via ultracentrifugation with amicon Ultra-
15 Centrifugal filter units. 
 
Sortase reaction. eSrtA(2A-9) pET29b was a gift from David Liu (Addgene plasmid # 75145) 
and produced according to literature procedure.26 The His-tag purified Fab fragments were 
transferred to sortase buffer (PBS + 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 100 mM CaCl2). 
Sortase (1 equiv.) and the triple-Gly peptide (50 equiv.) was added. The reaction was incubated for 
1 h at 37 °C and quenched afterwards using 0.5 M EDTA. Purification was performed using Fast 
Protein Liquid Chromatography on a NGC system 5BioRad using a SEC70 ENrich 10 x 300 
column (Bio-Rad, 7801070), and 100 µL fractions collected in a 96 well plate. Fractions containing 
the sortagged protein were collected and run on 12% SDS gel to confirm purity, pooled and 
concentrated by ultracentrifugation with amicon Ultra-15 Centrifugal filter units (Sigma, 717185). 
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Reumatoïde artritis (afgekort als RA) is een auto-immuunziekte die wordt gekenmerkt door 
chronische ontstekingen van gewrichten en slijmvliezen. Door deze ontstekingen kan kraakbeen 
en/of het onderliggende bot afgebroken worden. Ongeveer 1% van de wereldpopulatie lijdt aan 
RA, wat neerkomt op meer dan 17.6 miljoen mensen wereldwijd.  
Een auto-immuunziekte wordt gekenmerkt doordat het immuunsysteem (het afweersysteem) 
lichaamseigen cellen en stoffen als lichaamsvreemd ziet. Deze stoffen worden dan herkend door 
antilichamen en afgebroken door immuuncellen, ondanks dat het lichaamseigen stoffen zijn en 
geen ziekteverwekkers.  Bij RA is ook bekend dat ongeveer 80% van de patiënten specifieke 
antilichamen aanmaken voor gecitrullineerde eiwitten (gevormd door een post translationele 
modificatie). Deze antilichamen worden ook wel ACPA genoemd en zorgen er onder andere voor 
dat de ontsteking aanblijft. Gecitrullineerde eiwitten komen voor bij elke ontsteking en vormen op 
zich geen probleem. Het ontwikkelen van een antilichaam tegen deze eiwitten daarentegen, is 
specifiek voor de RA patiënten. Omdat deze antilichamen zo specifiek zijn voor het ziektebeeld, 
zijn ze tegelijkertijd interessant voor diagnostiek en uiteindelijk voor nieuwe therapieën. 
ACPA worden geproduceerd door B-cellen, een type witte bloedcellen. Omdat de ACPA 
specifiek zijn voor RA patiënten, zijn deze ACPA-producerende B-cellen dit ook. Huidige 
therapieën zijn er op gericht om deze B-cellen op te sporen en te doden. Doordat alle B-cellen 
gedood worden, zijn de therapieën die nu op de markt zijn niet selectief en hebben zij veel 
bijwerkingen. De gezonde B-cellen zijn nodig voor het aanvechten van lichaamsvreemde stoffen, 
zoals bijvoorbeeld bacteriën en dus zal het doden van deze cellen zorgen voor een grotere kans op 
infecties.  
Om die reden hebben wij onderzoek gedaan naar nieuwe mogelijkheden om selectief de ACPA-
producerende B-cellen te doden, zonder daarbij de gezonde B-cellen aan te tasten. Op deze manier 
verwachten wij dat er een maximaal resultaat behaald kan worden met zo min mogelijk 
bijwerkingen. 
 
In Hoofdstuk 1 is een overzicht beschreven van de huidige mogelijkheden om B-cellen antigeen-
specifiek te kunnen opsporen en eventueel doden. Een antigeen is de stof die bindt aan 
antilichamen of aan B-cel-receptoren. Verschillende antigenen zijn in de literatuur beschreven in 
combinatie met functionele moleculen die via verschillende processen B-cellen kunnen stilleggen 
of uitschakelen.  
 
In Hoofdstuk 2 beschrijven we eerst de selectie en synthese van een autoantigeen, genaamd 
cyclisch gecitrullineerd peptide (CCP), wat echter ook bindt aan ACPA. Omdat we specifiek B-
cellen willen opsporen en niet gestoord willen worden door de circulerende ACPA (welke relatief 
veel meer aanwezig zijn dan B-cellen), wilden we CCP beschermen tegen binding aan circulerende 
ACPA. Daarom beschrijven we hoe we CCP hebben geblokkeerd met een carboxynitrobenzyl 
beschermgroep (CNBz) waardoor het niet meer kon binden aan ACPA. We hebben laten zien dat 
we met behulp van het enzym nitroreductase (NTR) de beschermgroep weer konden verwijderen 
en dat CCP weer kon binden aan ACPA. Het gebruik van deze selectieve binding werd 
gedemonstreerd door CCP ook te laten binden aan geïmmortaliseerde B-cellen. Er was geen 
binding te zien wanneer de CNBz groep werd geïntroduceerd en de binding werd hersteld zodra 
NTR was toegevoegd. Tot slot hebben we, door CCP vast te maken aan een streptavidine-toxine, 
laten zien dat we selectief ACPA-producerende B-cellen konden doden en niet B-cellen die 
specifiek zijn voor een tetanus antigeen. 
 
Omdat het gebruik van een enzym in een therapie moeilijkheden met zich mee zal brengen, hebben 
we ook onderzoek gedaan naar het gebruik van een beschermgroep die chemisch te verwijderen 
is. In Hoofdstuk 3 hebben we gekeken naar de iminosydnone klik-en-verwijder reactie. We 
hebben laten zien dat de iminosydnone op CCP goed functioneerde als een blokkade, waardoor 
binding van CCP aan ACPA en ACPA-producerende B-cellen niet meer mogelijk was. Door de 
reactie met de stof DBCO werd de CCP ontschermd en kon binding weer plaatsvinden. Daarnaast 
hebben we CCP direct aan een potent toxine (monomethyl auristatin E) gezet om te onderzoeken 
of we ook met deze methode selectieve celdood konden induceren. Door binding van CCP aan 
de B-cel receptoren zou het toxine geïnternaliseerd worden, waarna het geactiveerd wordt en de 
cel kan doden. Het verkregen resultaat liet echter geen verschil zien tussen de verschillende 
beschermde en ontschermde antigenen, net zo min als een verschil met de negatieve controle. In 
alle gevallen was het toxine giftig en was er geen antigen selectiviteit. Onze hypothese hiervoor is 
dat een enkel CCP antigeen niet voldoende is om aan een B-cel receptor te binden en/of voor de 
internalisatie van het toxine te zorgen. In hoofdstuk 2 hebben we namelijk gezien dat een 
streptavidine conjugaat (een tetrameer) wel werkt. 
 
In Hoofdstuk 4 hebben we de ontwikkeling van een nieuw klik-en-verwijder reactie beschreven. 
Bij deze reactie hebben we gebruik gemaakt van een tetrazine en een phenoxy-vinylboorzuur 
(afgekort als VBA). We hebben deze moleculen gesynthetiseerd en laten zien dat deze reactie 
dankzij het boorzuur sneller verliep dan de vergelijkbare reactie tussen een tetrazine en een 
vinylether. We hebben de toepasbaarheid van deze VBA gedemonstreerd door het te koppelen 
aan een toxine (cladribine), specifiek voor witte bloedcellen (waaronder ook B-cellen vallen). We 
hebben cladribine beschermd met VBA en aangetoond dat de toxiciteit hierdoor was afgenomen 
en werd hersteld zodra de reactie met tetrazine had plaatsgevonden. Helaas zagen we ook dat het 
conjugaat niet volledig stabiel was, waardoor toxiciteit over tijd ook toenam. Tot slot hebben we, 
zoals verwacht, laten zien dat deze strategie met cladribine inderdaad meer effect had op B-cellen 
dan op niet-witte bloedcellen, zoals bijvoorbeeld niercellen. 
 
Omdat wij verwachtten dat monovalentie niet genoeg zou zijn voor de binding van CCP aan B-
cel receptoren en de internalisatie van het CCP-conjugaat, hebben we gekeken naar een nieuw 
multivalent systeem. In Hoofdstuk 5 hebben we gebruik gemaakt van een langgerekt en semi-
flexibel polymeer, poly(isocyanopeptides) (PICs), als basis. Aan dit polymeer hebben we 
vervolgens fluoroforen en CCP vastgezet, vergelijkbaar met een eerder gepubliceerd streptavidine 
systeem. Streptavidine heeft echter maar 4 mogelijkheden om iets aan vast te zetten, waar PICs er 
ruim 100 hebben. We vergeleken streptavidine met PICs en we zagen dat beide ongeveer even 
efficiënt waren in het binden van B-cellen. Het voordeel van de PICs, naast de meerdere binding 
plaatsen, bleek het lage achtergrond signaal in vergelijking met streptavidine. Tot slot hebben we 
nog gekeken naar de internalisatie van de PICs door de B-cellen, iets wat van belang is voor 
toekomstig gebruik van de PICs om B-cellen te lokaliseren en mogelijk te doden. Met behulp van 
een indirecte celkleuringsstudie hebben we gezien dat de PICs niet of nauwelijks internaliseren.  
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Reumatoïde artritis (afgekort als RA) is een auto-immuunziekte die wordt gekenmerkt door 
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In Hoofdstuk 6 hebben we gekeken naar anti-CarP antilichamen en een bijbehorend antigeen. 
Niet alle RA patiënten hebben ACPA en sommige van deze patiënten hebben wel anti-CarP 
antilichamen. Het onderzoek in dit proefschrift is gericht op antigenen specifiek voor ACPA, maar 
het zou een toevoeging zijn als deze methoden kunnen worden gebruikt voor andere RA specifieke 
antigenen, zoals voor anti-CarP antilichamen. Om deze reden modificeerden we het antigeen 
peptide CCP met een homocitrulline (resulterende in CHCitP) en dit bleek goed te binden aan 
zowel anti-CarP antilichamen geproduceerd door mensen als door muizen. Dit laatste is extra 
interessant omdat er geen muizen bestaan met ACPA en dus muisexperimenten niet gebruikt 
kunnen worden om strategieën ontworpen voor ACPA te testen voor de ontwikkeling van een 
nieuwe therapie. We hebben laten zien dat de CNBz beschermgroep, zoals gebruikt in Hoofdstuk 
2, ook als beschermgroep kan dienen voor CHCitP en inderdaad zorgde voor de verminderde 
binding aan anti-CarP antilichamen. Tot slot demonstreren we dat we gebruik kunnen maken van 
NTR om deze bescherming ongedaan te maken en dus de binding aan anti-CarP antilichamen 
weer te kunnen herstellen. Hiermee hebben we laten zien dat we in staat zijn om een strategie 
ontworpen voor ACPA kunnen toepassen op anti-CarP antilichamen en dit biedt mogelijkheden 
voor dierstudies in de toekomst. 
 
In Hoofdstuk 7 worden, naast de Engelse samenvatting, de reikwijdte en de veelbelovende 
vooruitzichten van de specifieke B-cel lokalisatie strategieën beschreven, inclusief het gebruik van 
een dubbele lokalisatie techniek en andere antigeen activatie mogelijkheden. 
 
Hopelijk zijn hiermee de grote lijnen van dit onderzoek duidelijk geworden. Houd er rekening mee dat deze 
samenvatting op een aantal punten gesimplificeerd is omwille van de begrijpelijkheid. Meer details zijn te vinden in 
de Engelstalige samenvatting in Hoofdstuk 7, en natuurlijk in de overige hoofdstukken van dit proefschrift. 
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mij heel waardevol geweest, bedankt! 
I would like to thank the doctoral thesis committee, consisting of Daniela Wilson, Sander van 
Kasteren and Jan van Hest, for critically reading the thesis manuscript. Jan jou wil ik graag ook 
nog bedanken voor het in contact brengen van Kim en mij ruim 4 jaar geleden! 
 
Mijn eerste master stage is al een lange tijd terug, maar heel erg waardevol gebleken tijdens mijn 
carrière in de chemie. Marjoke ik wil jou nog heel graag bedanken voor die tijd. Ik heb echt veel 
geleerd en dat is mij later goed van pas gekomen, daar ben ik je erg dankbaar voor! 
 
Dear Hendy, I am very grateful for having you as my partner in crime all this time! I think we did 
a great job combining chemistry and immunology. I wish you all the best! Ook René Toes en Uli 
Scherer wil ik graag bedanken voor deze vruchtbare samenwerking. 
 
Dan wil ik graag Lise en Bastiaan bedanken dat jullie mijn paranimfen willen zijn! Met jullie beiden 
begon dit avontuur al ruim 10 jaar geleden. Lise we zaten al snel samen in een practicum groepje, 
maar nog belangrijker ook samen op Pinkpop. We hadden verschillende vriendengroepen en 
daardoor waren we altijd aan elkaar gewaagd tijdens de playbackshow borrels (althans, zo ziet onze 
groep dat graag ;)). Tijdens onze stages liepen we al rond (soms op hakken) op de derde verdieping 
en daardoor hebben we veel lief en leed in het onderzoek gedeeld, maar natuurlijk ook alle 
streepjesborrels. Waar ik zelf toch het meeste van heb genoten zijn alle concerten en festivals 
(knakworsten met goldstrike!!). Ik vind het heel bijzonder dat we deze traditie al zo lang hebben 
en dat de groep alleen maar groter is geworden. Dat we dit mogen blijven doen! Lieve Bastiaan, 
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of liever, Beebz, ook wij hebben elkaar (schijnbaar tijdens wiskunde..) in het eerste jaar al ontmoet. 
Het hoogtepunt uit onze bachelor moet toch wel W&J zijn! De Fratparties, het reizen langs de 
Eastcoast en uiteraard het harde studeren daar was echt een top tijd. Toen je na aandringen van 
veel mensen eindelijk je positie bij Jan aannam, werd je gelukkig ook nog mijn collega! Het was 
fijn om af en toe even te kunnen ouwehoeren tijdens lunch of even te kunnen zeuren tijdens een 
van onze ‘frustratie’ koffie pauzes ;) Ik vind het nog steeds heel erg jammer dat je halverwege 
moest verhuizen naar Eindhoven, ik heb je echt gemist! Heel veel succes met de afronding van 
jouw PhD en hopelijk zijn de frustratiekoffies daarna niet meer nodig en kunnen we allebei lekker 
genieten van biertjes, festivals en reizen!  
 
Gelukkig heb ik ook erg leuk gezelschap gehad aan de Bonger groep. Selma jij was al voor mij 
begonnen en dat zorgde voor een warm welkom, ondanks dat ik al bekend was op de afdeling. We 
hebben al snel samen een student begeleid en een project opgestart. Ik heb je altijd bewondert om 
je chemische kennis en wil je graag bedanken voor het helpen bij het oplossen van synthetische 
vragen. Behalve dat je mijn collega was, heb ik ook genoten van de activiteiten buiten werk; 
weekendjes weg, een lekker biertje of de stapavonden aan het begin van onze samenwerking. Fleur 
jij werkte in het begin nog op het RIMLS, maar gelukkig heb je de oversteek gemaakt. Ik wil je erg 
bedanken dat ik bij je terecht kon met mijn bio-gerelateerde vragen! Vooral de laatste maanden 
hebben wij lief en leed gedeeld, dit was niet de leukste periode, maar ik was blij dat jij er was om 
me op de been te houden of om tegen te klagen ;) Gelukkig is er waardige opvolging gekomen. 
Yvonne jij was natuurlijk al bekend in onze groep vanwege stages, maar het was erg leuk dat je 
besloot om weer terug te komen. In het begin was je vooral in het RIMLS, maar ik ben blij dat je 
de laatste tijd steeds vaker aan onze kant van de weg te vinden was. Bedankt voor je gezelligheid 
en ik wens je heel veel succes met je PhD, maar dat komt vast goed want je kunt meer dan je zelf 
denkt! Bob, we hebben maar kort samen gewerkt maar je was een gezellige nieuwe aanwinst en je 
bracht een fijne nieuwe positieve energie met je mee. Bedankt voor je gezelligheid en ik wens je 
veel succes met je PhD! 
 
Tijdens mijn promotie heb ik met veel studenten mogen samenwerken. Ik ben jullie erg dankbaar 
voor de gezelligheid op het lab en de inzet in jullie verschillende projecten. Abel, jij werkte onder 
de supervisie van Selma en mijzelf, wat vanwege onze stress van het laatste jaar niet altijd even 
makkelijk en leuk is geweest. Ik wil je graag bedanken voor de hoeveelheid synthese die je hebt 
gedaan en ook je geduld en precisie voor de optimalisatie hiervan. Dit zal resulteren in een mooie 
publicatie. Angelina, jij hebt gewerkt aan het PAD project, niet altijd makkelijk maar evengoed 
tot een leuk einde gebracht. Bedankt voor je inzet en zelfstandige werkhouding, jij komt er wel! 
Kevin, heel fijn dat jij me nog bent komen helpen om het iminosydnone project nog een stap 
verder te brengen! Naast je skills op het lab werd ook je bier brouwkunst zeer gewaardeerd. Veel 
succes met je PhD die geheid gaat volgen. Laura, ondanks dat jouw project niet de makkelijkste 
was heb je je er echt in vastgebeten en je best gedaan om het tot een goed einde te brengen. 
Ontzettend bedankt voor je doorzettingsvermogen, ik wens je het allerbeste voor de toekomst! 
Lieke, ondanks dat het snel duidelijk was dat onderzoek niet jouw interesse had, hebben we een 
gezellige tijd gehad! Mike, jou wil ik graag bedanken voor je hulp aan het iminosydnone project. 
Zoals je ziet is veel daarvan in dit proefschrift belandt en dat was nooit zover gekomen als jij in 
mijn laatste jaar niet was bijgesprongen. Succes met de laatste loodjes van je studie en alvast veel 
succes met je PhD. Selina, jij was de eerste student op het VBA click-to-release project van Selma 
en mij. Ondanks dat de start van dit project soms wat moeizaam ging, heeft het toch een goede 
basis gelegd voor het hoofdstuk in dit proefschrift, bedankt! Wilke, jou wil ik graag bedanken voor 
een super literatuur scriptie die ervoor heeft gezorgd dat de introductie van dit proefschrift een 
volledig overzicht van de huidige literatuur beslaat. Echt super gedaan, dankjewel! Yvonne, jij hebt 
een mooi fundament gelegd voor het werk beschreven in hoofdstuk 5. Bedankt voor je motivatie 
en je kritische blik op het onderzoek! 
 
Ik ben me ervan bewust dat het werk wat ik heb gedaan niet had gekund zonder de ondersteuning 
van de niet altijd zichtbare, maar zeker erg belangrijke krachten achter de schermen. Marieke, jou 
wil ik graag vooral bedanken voor alle gezelligheid! Voor officiële regel dingen kwam ik natuurlijk 
niet zo vaak bij jou, op de laatste maanden na, maar al die kerstborrels over de jaren heen hebben 
we maar mooi voor elkaar gekregen. Ik heb je interesse altijd erg gewaardeerd en ik zal je missen! 
Els, hartelijk dank voor alle hulp bij administratieve zaken. Ook was ik altijd blij verrast als ik een 
dag voor mijn vakantie een email van je kreeg om me veel plezier te wensen. Heel attent en het 
zijn vaak de kleine dingen die het ‘m doen, bedankt! Peter van Dijk, hartelijk bedankt voor alle 
hulp op veel verschillende vlakken. Naast allerlei praktische dingen, wil ik je ook bedanken voor 
je positiviteit en interesse over de jaren. Heb je het toch nog van me gewonnen en zit een 
gezamenlijk afscheidsfeestje er niet in. Voor nu wens ik je nog veel plezier op de werkvloer en 
voor erna alle geluk en gezondheid met je pensioen. Behalve voor alle hulp bij bestellingen en het 
vinden van epjes en puntjes, wil ik graag Jan Dommerholt bedanken voor de gezellige praatjes en 
alle fijne F1 analyses op de maandag ochtend na een race weekend. Deze nabeschouwing was 
uiteraard leuker als Max een race op zijn naam wist te schrijven of als de Duitse zender zelf Vettel 
had uitgescholden. Peter van Galen bedankt voor het draaiende houden van de mass-spec 
faciliteiten, ook als de apparatuur al van streek was zodra ik de massa kamer binnen kwam (volgens 
jou dan ;)). Helene, bedankt voor jouw hulp met de verschillende HPLCs. Paul White many 
thanks for the increased possibilities concerning NMR, I have greatly enjoyed your enthusiasm 
(and of course your BBQ skills)! Hans Adams, altijd gezellig als jij op een gegeven moment even 
een praatje kwam maken. Dan wel over peptide chemie of over alles wat er mis was ;) Ik ben je 
erg dankbaar voor de goede achtergrond die ik heb gekregen over peptide chemie (al tijdens mijn 
master stage 7 jaar geleden!). 
 
Het leuke van werken in een interdisciplinair veld is dat je veel mensen uit verschillende groepen 
leert kennen. Natuurlijk BMC, ondanks dat ik voornamelijk in het Huygens heb gewerkt, wil ik 
jullie allemaal, Ger, Amrah, Annemarie, Bas, Carla, Cynthia, Els, Fleur, Ilmar, Marina, 
Mathijs, Merel, Selma, Wilbert, en Wilma bedanken dat ik altijd mocht komen voor een ELISA 
en voor het welkome gevoel als ik er was. Ook voor de gezelligheid en hulp wil graag de BOC 
groep: Jan van Hest, Annika (erg leuk dat wij nog u-tje buren zijn geweest!), Anika, Bastiaan, 
Britta, Dave, David, Dennis, Emilia, Hans, Henan, Imke & Pascal (beide zeer gewaardeerde 
leden van de pineapple bende, jullie zijn schatten!), Jan Pille (bedankt voor de ELP samenwerking, 
wie weet krijgt dit nog een vervolg in de toekomst), Joep, Lise, Loai, Marcel, Mark, Marlies, 
Mathijs, Morten, Nanda, Ruud, Sanne (vi ses i København!), Saskia, Stijn, Zhipeng, en SOC 
groep: Floris Rutjes, Abbas (thanks for your enthusiasm and of course the linzensoep!), 
Alejandra (you deserved how everything came together!), Bram, Claudia, Dani, Danny (we zien 
mekaar nog op feestjes en etentjes!), Emiel, Freek, Henri, Hidde (mede bierfanaat, of beter nog 
specifiek Mikkellers!), Ivan, Johan, Jona, Jorgen, Marjoke, Rens, Sam, Stefan (het is weer eens 
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hebben al snel samen een student begeleid en een project opgestart. Ik heb je altijd bewondert om 
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hebben wij lief en leed gedeeld, dit was niet de leukste periode, maar ik was blij dat jij er was om 
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jou dan ;)). Helene, bedankt voor jouw hulp met de verschillende HPLCs. Paul White many 
thanks for the increased possibilities concerning NMR, I have greatly enjoyed your enthusiasm 
(and of course your BBQ skills)! Hans Adams, altijd gezellig als jij op een gegeven moment even 
een praatje kwam maken. Dan wel over peptide chemie of over alles wat er mis was ;) Ik ben je 
erg dankbaar voor de goede achtergrond die ik heb gekregen over peptide chemie (al tijdens mijn 
master stage 7 jaar geleden!). 
 
Het leuke van werken in een interdisciplinair veld is dat je veel mensen uit verschillende groepen 
leert kennen. Natuurlijk BMC, ondanks dat ik voornamelijk in het Huygens heb gewerkt, wil ik 
jullie allemaal, Ger, Amrah, Annemarie, Bas, Carla, Cynthia, Els, Fleur, Ilmar, Marina, 
Mathijs, Merel, Selma, Wilbert, en Wilma bedanken dat ik altijd mocht komen voor een ELISA 
en voor het welkome gevoel als ik er was. Ook voor de gezelligheid en hulp wil graag de BOC 
groep: Jan van Hest, Annika (erg leuk dat wij nog u-tje buren zijn geweest!), Anika, Bastiaan, 
Britta, Dave, David, Dennis, Emilia, Hans, Henan, Imke & Pascal (beide zeer gewaardeerde 
leden van de pineapple bende, jullie zijn schatten!), Jan Pille (bedankt voor de ELP samenwerking, 
wie weet krijgt dit nog een vervolg in de toekomst), Joep, Lise, Loai, Marcel, Mark, Marlies, 
Mathijs, Morten, Nanda, Ruud, Sanne (vi ses i København!), Saskia, Stijn, Zhipeng, en SOC 
groep: Floris Rutjes, Abbas (thanks for your enthusiasm and of course the linzensoep!), 
Alejandra (you deserved how everything came together!), Bram, Claudia, Dani, Danny (we zien 
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tijd voor een motor tourtochtje!), Thomas, Toni, Torben en Victor (de goedzak van de afdeling, 
bedankt voor je gezelligheid tijdens de vele lunches, borrels en etentjes!) bedanken! Andere mensen 
die ik graag nog in het zonnetje wil zetten voor gezelligheid en samenwerkingen komen van de 
TIL groep: Bas, Camille (many thanks for help with the Fab fragments and our collaboration), 
Floris van Dalen (bedankt voor je goede en soms interessante muzikale contributie aan ons lab. 
Ik ben blij dat je ons team kwam versterken!), Iris, Jorieke, Loek, Martijn en Roel (bedankt voor 
je hulp met de PICs en onze samenwerking. Ik heb je kritische blik altijd erg gewaardeerd en het 
blijft me verbazen dat ik je vaak ‘even’ iets wilde komen vragen en pas een uur later op mijn plek 
terug kwam ;) ). Ook wil ik graag Sjoerd Postma bedanken voor je positiviteit en gekke 
uitspattingen, dit heeft voor veel slappe lach gezorgd tijdens mijn PhD maar ook al tijdens mijn 
studie. Britta Helwig, ook jou wil ik bedanken voor de gezellige praatjes op de gang en de 
organisatie van verschillende borrels! Veel succes nog met je PhD! 
 
Morten Meldal, tak for sjov tiden og for vores samarbejde, den sidste resulterede i en god artikel. 
 
I would like to thank dr. Anupama Shanmuganathan for your great drill in immunology at W&J. 
Ever since your lectures I have been motivated to work in the field of immunology. 
 
Tijdens de afgelopen vier jaar heb ik samen met de piketploeg en BHVers ervoor mogen zorgen 
dat de werkplek veilig bleef. Naast serieuze incidenten werd er altijd veel gelachen en waren we 
een goed team. Allereerst, Ricardo de meest verstandige van het hele stel (…), bedankt voor veel 
leerzame momenten en de organisatie van het realistisch oefenen. Daarnaast wil ik graag Christel, 
Danny, Geert-jan, Gerben, Lars, Michel, Mirjam, Rene, Serge, Stefan en Victor bedanken 
voor de goede samenwerking. 
 
Ik ben dankbaar voor het feit dat ik bij de groep van het ICI mocht horen. Ik heb zo veel leuke 
mensen leren kennen en we hebben met zijn allen zeker een (persoonlijke) groei doorstaan. 
Bedankt Hendy, Berend, Dennis, Dion, Elko, Eveline, Jorieke, Joost, Jorick, Laurent, Loek, 
Martje, Sebastiaan, Tim en alle anderen voor alle diepgaande gesprekken en eerlijkheid, maar 
ook voor alle gezellige etentjes en avonden! 
 
Buiten het werk om was er gelukkig ook tijd om te ontspannen en met wie kan je dit beter doen 
dan met je lieve vrienden? Ook al heb ik misschien niet altijd evenveel tijd voor jullie gehad als ik 
zou willen, ik ben blij dat we elkaar met enige regelmaat nog zien! Vooral mijn oude studiegenoten, 
Anneloes, Bastiaan (Basti buddy!), dr. Daniël (en gelukkig ook mijn collega gedurende deze 4 
jaren), Ian, Leoni, Peter (Heenbam! Gezellig dat je me in de laatste maanden kwam vergezellen 
met schrijven!), Pjotr en Shane bedankt voor jullie regelmatige interesse in mijn onderzoek en 
juist voor de ontspanning daaromheen! In het speciaal wil ik jou graag bedanken, Frank, dat je me 
altijd gesteund hebt en me maar vaak genoeg verteld hebt dat stress niet helpt (dit geldt natuurlijk 
ook voor jou ;) ). Ik koester onze waardevolle vriendschap en ik weet zeker dat er nog veel biertjes 
en reisverhalen uitgewisseld zullen worden! 
 
Martijn jou wil ik ook graag bedanken voor de gezellige avonden onder het genot van een biertje 
en ook voor je nuchtere kijk. Mats bedankt voor de ontspannende tour tochten op de motor, dat 
we nog maar op veel zonnige dagen en gas mogen opentrekken! 
Mange tak til min kære ven Daniel! Jeg er glad for, at vi kan dele vores passion for øl med 
hinanden. Jeg vil gerne takke dig for den store tid i København og for lytte til min klage over 'The 
machine'. Jeg er meget glad for at du bor nu i Holland. Rob ook wij hebben veel tijd doorgebracht 
in het mooie Kopenhagen en de nodige dansjes gedaan op een van onze vele stapavonden (en 
Distortion!). Bedankt voor je gezelligheid en vrolijkheid! Sanne en Morten, ook jullie wil ik graag 
bedanken voor de gezelligheid in Kopenhagen en natuurlijk ook in Nijmegen!  
 
Graag wil ik ook Evie, mijn kleine zusje en grote vriendin bedanken. Ik ben ontzettend blij met 
het mooie ontwerp van mijn kaft en vind het heel speciaal dat jij deze voor mij wilde maken. Ik 
vind het ook erg bijzonder dat wij zoveel interesses met elkaar delen en veel leuke dingen samen 
doen, een beter zusje had ik me niet kunnen wensen! 
Lieve pap en mam, ik ben jullie heel dankbaar voor alle steun de afgelopen jaren. Het was niet 
altijd rozengeur en maneschijn, maar jullie stonden altijd voor me klaar. Ik ben heel blij dat ik mijn 
verdriet maar vooral ook mijn geluk met jullie kan delen. Laten we blijven genieten van alle leuke 
dingen die we samen doen. Of het nou een bierfestival, een concert of een avondje stappen met 
de vierdaagse is, ik ben trots dat wij ook deze dingen allemaal samen kunnen doen! 
Ik wil ook graag mijn lieve oma’s bedanken voor hun interesse en warmte. Het is niet voor niks 
dat ik dit werk aan jullie heb opgedragen. Een hele dikke knuffel voor jullie oma Beestjes en oma 
Klok!  
 
Tot slot wil ik graag dr. Rens bedanken. Mijn PhD heeft dit proefschrift als resultaat, maar nog 
belangrijker ons samenzijn! Ik wil je heel erg bedanken voor je hulp tijdens mijn PhD en ook je 
geduld in de laatste maanden. Ik vind het bijzonder dat we dit allebei van mekaar hebben mogen 
meemaken! Nog veel belangrijker, ik wil je graag bedanken voor de fijne tijd die we samen hebben. 
Het is super om de passie voor bier, Formule 1 en reizen met jou te kunnen delen. Ons grote 
avontuur gaat nu echt bijna beginnen, samen de grote wereld in. Ik kan niet wachten! Ik hou van 
jou! 
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